FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Silveira, MF
   Barros, AJD
   Horta, BL
   Pellanda, LC
   Victora, GD
   Dellagostin, OA
   Struchiner, CJ
   Burattini, MN
   Valim, ARM
   Berlezi, EM
   Mesa, JM
   Ikeda, MLR
   Mesenburg, MA
   Mantesso, M
   Dall'Agnol, MM
   Bittencourt, RA
   Hartwig, FP
   Menezes, AMB
   Barros, FC
   Hallal, PC
   Victora, CG
AF Silveira, Mariangela F.
   Barros, Aluisio J. D.
   Horta, Bernardo L.
   Pellanda, Lucia C.
   Victora, Gabriel D.
   Dellagostin, Odir A.
   Struchiner, Claudio J.
   Burattini, Marcelo N.
   Valim, Andreia R. M.
   Berlezi, Evelise M.
   Mesa, Jeovany M.
   Ikeda, Maria Leticia R.
   Mesenburg, Marilia A.
   Mantesso, Marina
   Dall'Agnol, Marinel M.
   Bittencourt, Raqueli A.
   Hartwig, Fernando P.
   Menezes, Ana M. B.
   Barros, Fernando C.
   Hallal, Pedro C.
   Victora, Cesar G.
TI Population-based surveys of antibodies against SARS-CoV-2 in Southern
   Brazil
SO NATURE MEDICINE
LA English
DT Article
AB Population-based data on COVID-19 are urgently needed. We report on three rounds of probability sample household surveys in the state of Rio Grande do Sul (Brazil), carried out in nine large municipalities using the Wondfo lateral flow point-of-care test for immunoglobulin M and G antibodies against SARS-CoV-2 (https://en.wondfo.com.cn/product/ wondfo-sars-cov-2-antibody-test-lateral-flow-method-2/). Before survey use, the assay underwent four validation studies with pooled estimates of sensitivity (84.8%; 95% confidence interval (CI) = 81.4-87.8%) and specificity (99.0%; 95% CI = 97.8-99.7%). We calculated that the seroprevalence was 0.048% (2/4,151; 95% CI = 0.006-0.174) on 11-13 April (round 1), 0.135% (6/4,460; 95% CI = 0.049-0.293%) on 25-27 April (round 2) and 0.222% (10/4,500; 95% CI = 0.107-0.408) on 9-11 May (round 3), with a significant upward trend over the course of the surveys. Of 37 family members of positive individuals, 17 (35%) were also positive. The epidemic is at an early stage in the state, and there is high compliance with social distancing, unlike in other parts of Brazil. Periodic survey rounds will continue to monitor trends until at least the end of September, and our population-based data will inform decisions on preventive policies and health system preparedness at the state level.
C1 [Silveira, Mariangela F.; Barros, Aluisio J. D.; Horta, Bernardo L.; Dellagostin, Odir A.; Hartwig, Fernando P.; Menezes, Ana M. B.; Barros, Fernando C.; Hallal, Pedro C.; Victora, Cesar G.] Univ Fed Pelotas, Pelotas, RS, Brazil.
   [Pellanda, Lucia C.; Mesenburg, Marilia A.] Fundacao Univ Fed Ciencias Saude Porto Alegre, Porto Alegre, RS, Brazil.
   [Victora, Gabriel D.] Rockefeller Univ, Lab Lymphocyte Dynam, 1230 York Ave, New York, NY 10021 USA.
   [Struchiner, Claudio J.] Fundacao Getulio Vargas, Rio De Janeiro, Brazil.
   [Burattini, Marcelo N.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Valim, Andreia R. M.] Univ Santa Cruz, Santa Cruz Do Sul, RS, Brazil.
   [Berlezi, Evelise M.] Univ Ijui, Ijui, Brazil.
   [Mesa, Jeovany M.] IMED Passo Fundo, Passo Fundo, RS, Brazil.
   [Ikeda, Maria Leticia R.] Univ Vale Rio dos Sinos, Sao Leopoldo, Brazil.
   [Mantesso, Marina] Univ Caxias Sul, Caxias Do Sul, RS, Brazil.
   [Dall'Agnol, Marinel M.] Univ Fed Santa Maria, Santa Maria, RS, Brazil.
   [Bittencourt, Raqueli A.] Secretaria Municipal Saude Uruguaiana, Uruguaiana, Brazil.
RP Hallal, PC (corresponding author), Univ Fed Pelotas, Pelotas, RS, Brazil.
EM prchallal@gmail.com
RI Pellanda, Lucia/ABC-1687-2020; Pellanda, Lucia C/B-4701-2010; Rosane de
   Moura Valim, Andreia/L-1009-2018
OI Pellanda, Lucia C/0000-0002-8776-2248; Reis,
   AlessanRSS/0000-0001-8486-7469; Rosane de Moura Valim,
   Andreia/0000-0001-9611-3103
FU UNIMED Porto Alegre; Instituto Cultural Floresta; Instituto
   Serrapilheira
FX This work was started through the Data Committee created by the State of
   Rio Grande do Sul government to fight the COVID-19 pandemics. The tests
   used in the study have been provided by the Brazilian Ministry of
   Health. Funding for data collection was provided by UNIMED Porto Alegre,
   Instituto Cultural Floresta and Instituto Serrapilheira.
CR [Anonymous], 2020, INF PREL 13 MAY 2020
   [Anonymous], 2016, PESQ NAC AM DOM SINT
   [Anonymous], 2019, PROJ POP
   [Anonymous], 2020, COM TECN INQ EP SARS
   [Anonymous], 2020, COR DIS 19 REP S KOR
   Barreto Mauricio Lima, 2020, Rev. bras. epidemiol., V23, pe200032, DOI 10.1590/1980-549720200032
   Bendavid E, 2020, COVID 19 ANTIBODY SE, DOI [10.1101/2020.04.14.20062463, DOI 10.1101/2020.04.14.20062463]
   Campos Pellanda L, 2020, SENSITIVITY SPECIFIC, DOI [10.1101/2020.05.06.20093476, DOI 10.1101/2020.05.06.20093476]
   County of Los Angeles Public Health, 2020, USC LA COUNT STUD EA
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Diggle PJ, 2011, EPIDEMIOL RES INT, V2011, P608719, DOI [10.1155/2011/608719, DOI 10.1155/2011/608719]
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Hallal PC, 2020, CIENC SAUDE COLETIVA, V25, P2395, DOI 10.1590/1413-81232020256.1.09632020
   Horta BL, 2015, INT J EPIDEMIOL, V44, P441, DOI 10.1093/ije/dyv017
   Lumley T., 2004, J STAT SOFTW, V9, P1, DOI DOI 10.18637/JSS.V009.I08
   Ogris G, 2020, COVID 19 PREVALENCE
   Pearce N, 2020, AM J PUBLIC HEALTH, V110, P949, DOI 10.2105/AJPH.2020.305708
   Public Health Agency of Sweden, 2020, NYA RES FRAN UND FOR
   R Core Development Team, 2018, R LANG ENV STAT COMP
   Regalado A., 2020, MIT TECHNOLOGY REV
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Whitman Jeffrey D, 2020, medRxiv, DOI 10.1101/2020.04.25.20074856
   WHO, 2020, IMM PASSP CONT COVID
   World Health Organization (WHO), 2020, ADV US POINT OF CAR
NR 24
TC 7
Z9 7
U1 1
U2 1
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD AUG
PY 2020
VL 26
IS 8
BP 1196
EP +
DI 10.1038/s41591-020-0992-3
EA JUL 2020
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA MX8ZF
UT WOS:000546536800001
PM 32641783
OA Bronze
DA 2020-12-08
ER

PT J
AU Hallal, PC
   Horta, BL
   Barros, AJD
   Dellagostin, OA
   Hartwig, FP
   Pellanda, LC
   Struchiner, CJ
   Burattini, MN
   da Silveira, MF
   Menezes, AMB
   Barros, FC
   Victora, CG
AF Hallal, Pedro Curi
   Horta, Bernardo L.
   Barros, Aluisio J. D.
   Dellagostin, Odir A.
   Hartwig, Fernando P.
   Pellanda, Lucia C.
   Struchiner, Claudio Jose
   Burattini, Marcelo N.
   da Silveira, Mariangela Freitas
   Menezes, Ana M. B.
   Barros, Fernando C.
   Victora, Cesar Gomes
TI Trends in the prevalence of COVID-19 infection in Rio Grande do Sul,
   Brazil: repeated serological surveys
SO CIENCIA & SAUDE COLETIVA
LA English
DT Article
DE COVID-19; Infection; Prevalence; Population-based study; Brazil
AB COVID-19, the disease produced by the virus SARS-CoV-2, has spread quickly throughout the world, leading the World Health Organization to first classify it as an international health emergency and, subsequently, declaring it pandemic. The number of confirmed cases, as April 11, surpassed 1,700,000, but this figure does not reflect the prevalence of COVID-19 in the population as, in many countries, tests are almost exclusively performed in people with symptoms, particularly severe cases. To properly assess the magnitude of the problem and to contribute to the design of evidence-based policies for fighting COVID-19, one must accurately estimate the population prevalence of infection. Our study is aimed at estimating the prevalence of infected individuals in the state of Rio Grande do Sul, Brazil, to document how fast the infection spreads, and to estimate the proportion of infected persons who present or presented symptoms, as well as the proportion of asymptomatic infections. Four repeated serological surveys will be conducted in probability samples of nine sentinel cities every two weeks. Tests will be performed in 4,500 participants in each survey, totaling18,000 interviews. Interviews and tests will be conducted at the participants' household. A rapid test for the detection of antibodies will be used; the test was validated prior to the beginning of the fieldwork.
C1 [Hallal, Pedro Curi; Horta, Bernardo L.; Barros, Aluisio J. D.; Dellagostin, Odir A.; Hartwig, Fernando P.; da Silveira, Mariangela Freitas; Menezes, Ana M. B.; Barros, Fernando C.; Victora, Cesar Gomes] Univ Fed Pelotas, Programa Posgrad Epidemiol, R Marechal Deodoro 1160, BR-96020220 Pelotas, RS, Brazil.
   [Pellanda, Lucia C.] Fundacao Univ Fed Ciencias Saude Porto Alegre, Porto Alegre, RS, Brazil.
   [Struchiner, Claudio Jose] Univ Estado Rio de Janeiro, Rio De Janeiro, RJ, Brazil.
   [Burattini, Marcelo N.] Univ Sao Paulo, Sao Paulo, SP, Brazil.
RP Hallal, PC (corresponding author), Univ Fed Pelotas, Programa Posgrad Epidemiol, R Marechal Deodoro 1160, BR-96020220 Pelotas, RS, Brazil.
EM prchallal@gmail.com
RI Pellanda, Lucia C/B-4701-2010; Pellanda, Lucia/ABC-1687-2020;
   Struchiner, Claudio/M-9360-2013; Dellagostin, Odir/C-2331-2009; Victora,
   Cesar/D-4476-2013; Burattini, Marcelo Nascimento/J-9272-2014
OI Pellanda, Lucia C/0000-0002-8776-2248; Struchiner,
   Claudio/0000-0003-2114-847X; Reis, AlessanRSS/0000-0001-8486-7469;
   Dellagostin, Odir/0000-0003-2803-4088; Menezes, Ana M
   B/0000-0002-2996-9427; Victora, Cesar/0000-0002-2465-2180; da Silveira,
   Mariangela Freitas/0000-0002-2861-7139; Burattini, Marcelo
   Nascimento/0000-0002-5407-6890; Barros, Aluisio/0000-0002-2022-8729
CR [Anonymous], 2020, POP BAS AG STRAT SER
   [Anonymous], SARS COV 2 ANTIBODY
   [Anonymous], 2020, COR DIS COVID 19 SIT
   Banerjee A, 2017, CATALOGUE BIAS 2017
   Castelfranco S., HARD LESSONS ITALYS
   Gudbjartsson D. F., 2020, EARLY SPREAD SARS CO, DOI DOI 10.1101/2020.03.26.20044446V2
   Nature, 2020, COV COR INF COULD BE
   Roser M, 2020, CORONAVIRUS DIS COVI
   Streeck H., 2020, VORLAUFIGES ERGEBNIS
   VICTORA CG, 1993, LANCET, V342, P97, DOI 10.1016/0140-6736(93)91291-S
   World Health Organization, 2019, COR DIS COVID 19 PAN
NR 11
TC 6
Z9 8
U1 2
U2 2
PU ABRASCO-ASSOC BRASILEIRA POS-GRADUACAO & SAUDE COLETIVA
PI RIO DE JANEIRO
PA AVENIDA BRASIL, 4036, SALA 700 MANGUINHOS-1, RIO DE JANEIRO, 21040-36,
   BRAZIL
SN 1413-8123
EI 1678-4561
J9 CIENC SAUDE COLETIVA
JI Cienc. Saude Coletiva
PD JUN
PY 2020
VL 25
SU 1
BP 2395
EP 2401
DI 10.1590/1413-81232020256.1.09632020
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA LX1WX
UT WOS:000539630300002
PM 32520284
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Maier, SB
   Massad, E
   Amaku, M
   Burattini, MN
   Greenhalgh, D
AF Maier, Sandra B.
   Massad, Eduardo
   Amaku, Marcos
   Burattini, Marcelo N.
   Greenhalgh, David
TI The Optimal Age of Vaccination Against Dengue with an Age-Dependent
   Biting Rate with Application to Brazil
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Dengue; Vaccination; Optimal vaccination age; Age-structured model;
   Biting rate; Hospitalisation
ID HEMORRHAGIC-FEVER; YELLOW-FEVER; DYNAMICS; INFECTIONS; ANTIBODIES;
   DISEASES; INFANTS; BURDEN; MODELS; RISKS
AB In this paper we introduce a single serotype transmission model, including an age-dependent mosquito biting rate, to find the optimal vaccination age against dengue in Brazil with Dengvaxia. The optimal vaccination age and minimal lifetime expected risk of hospitalisation are found by adapting a method due to Hethcote (Math Biosci 89:29-52). Any number and combination of the four dengue serotypes DENv1-4 is considered. Successful vaccination against a serotype corresponds to a silent infection. The effects of antibody-dependent enhancement (ADE) and permanent cross-immunity after two heterologous infections are studied. ADE is assumed to imply risk-free primary infections, while permanent cross-immunity implies risk-free tertiary and quaternary infections. Data from trials of Dengvaxia indicate vaccine efficacy to be age and serostatus dependent and vaccination of seronegative individuals to induce an increased risk of hospitalisation. Some of the scenarios are therefore reconsidered taking these findings into account. The optimal vaccination age is compared to that achievable under the current age restriction of the vaccine. If vaccination is not considered to induce risk, optimal vaccination ages are very low. The assumption of ADE generally leads to a higher optimal vaccination age in this case. For a single serotype vaccination is not recommended in the case of ADE. Permanent cross-immunity results in a slightly lower optimal vaccination age. If vaccination induces a risk, the optimal vaccination ages are much higher, particularly for permanent cross-immunity. ADE has no effect on the optimal vaccination age when permanent cross-immunity is considered; otherwise, it leads to a slight increase in optimal vaccination age.
C1 [Maier, Sandra B.; Greenhalgh, David] Univ Strathclyde, Dept Math & Stat, Glasgow G1 1XH, Lanark, Scotland.
   [Massad, Eduardo; Amaku, Marcos; Burattini, Marcelo N.] Univ Sao Paulo, Fac Med, Hosp Clin, LIM01, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo N.] Univ Fed Sao Paulo, Escola Paulista Med, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
   [Massad, Eduardo] Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, RJ, Brazil.
RP Greenhalgh, D (corresponding author), Univ Strathclyde, Dept Math & Stat, Glasgow G1 1XH, Lanark, Scotland.
EM david.greenhalgh@strath.ac.uk
RI Amaku, Marcos/D-5252-2012
OI Amaku, Marcos/0000-0003-4752-6774
FU University of Strathclyde; Leverhulme TrustLeverhulme Trust
   [RF-2015-88]; British Council Malaysia [DTC 16022]; Science Without
   Borders Program for a Special Visiting Fellowship (CNPq) [30098/2014/7]
FX DG and SM are grateful to the University of Strathclyde for support for
   a Ph.D. studentship. DG is grateful to the Leverhulme Trust for support
   from a Leverhulme Fellowship (RF-2015-88) and the British Council
   Malaysia for funding from the Dengue Tech Challenge (Application
   Reference DTC 16022). EM and DG are grateful to the Science Without
   Borders Program for a Special Visiting Fellowship (CNPq Grant
   30098/2014/7).
CR Aguiar M, 2018, CLIN INFECT DIS, V66, P641, DOI 10.1093/cid/cix882
   Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179
   Aguiar M, 2016, LANCET INFECT DIS, V16, P882, DOI 10.1016/S1473-3099(16)30168-2
   Anderson KB, 2014, J INFECT DIS, V209, P360, DOI 10.1093/infdis/jit436
   ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   [Anonymous], 2009, DENG GUID DIAGN TREA
   Martinez-Vega RA, 2017, VACCINE, V35, P3910, DOI 10.1016/j.vaccine.2017.06.004
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Billings L, 2008, MATH BIOSCI, V211, P265, DOI 10.1016/j.mbs.2007.08.004
   Burattini MN, 2016, CLINICS, V71, P455, DOI 10.6061/clinics/2016(08)08
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Coudeville L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051244
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Durham DP, 2013, VACCINE, V31, P3957, DOI 10.1016/j.vaccine.2013.06.036
   Esteva L, 1998, MATH BIOSCI, V150, P131, DOI 10.1016/S0025-5564(98)10003-2
   Favier C, 2006, TROP MED INT HEALTH, V11, P332, DOI 10.1111/j.1365-3156.2006.01560.x
   Feng ZL, 1997, J MATH BIOL, V35, P523, DOI 10.1007/s002850050064
   Ferguson NM, 2016, SCIENCE, V353, P1033, DOI 10.1126/science.aaf9590
   Flasche S., 2016, COMP MODELLING DENGU
   Fredericks AC, 2014, ANN GLOB HEALTH, V80, P466, DOI 10.1016/j.aogh.2015.02.006
   Fried JR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000617
   Garba SM, 2008, MATH BIOSCI, V215, P11, DOI 10.1016/j.mbs.2008.05.002
   Gibbons RV, 2007, AM J TROP MED HYG, V77, P910, DOI 10.4269/ajtmh.2007.77.910
   Gibbons RV, 2002, BRIT MED J, V324, P1563, DOI 10.1136/bmj.324.7353.1563
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   Halstead SB, 2016, J INFECT DIS, V214, P1793, DOI 10.1093/infdis/jiw340
   Halstead SB, 2016, TRAVEL MED INFECT DI, V14, P378, DOI 10.1016/j.tmaid.2016.06.005
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Halstead SB, 2009, ANN NY ACAD SCI, V1171, pE48, DOI 10.1111/j.1749-6632.2009.05052.x
   HETHCOTE HW, 1988, MATH BIOSCI, V89, P29, DOI 10.1016/0025-5564(88)90111-3
   Jain A, 2010, FEMS IMMUNOL MED MIC, V59, P119, DOI 10.1111/j.1574-695X.2010.00670.x
   Knipl D, 2015, B MATH BIOL, V77, P2212, DOI 10.1007/s11538-015-0120-6
   Leong ASY, 2007, SEMIN DIAGN PATHOL, V24, P227, DOI 10.1053/j.semdp.2007.07.002
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Massad E, 2015, COMMUNICATION
   Reiner RC, 2014, P NATL ACAD SCI USA, V111, pE2694, DOI 10.1073/pnas.1314933111
   SAGE/World Health Organization, 2016, BACKGR PAP DENG VACC
   Stephenson JR, 2005, B WORLD HEALTH ORGAN, V83, P308
   United States Central Intelligence Agency, 2016, BRAZ WORLD FACTB
   van Panhuis WG, 2011, AM J TROP MED HYG, V85, P355, DOI 10.4269/ajtmh.2011.11-0125
   World Health Organization, 2012, GLOB STRAT DENG PREV
NR 45
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JAN 14
PY 2020
VL 82
IS 1
AR 12
DI 10.1007/s11538-019-00690-1
PG 32
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA KM9LV
UT WOS:000514463600005
PM 31933012
OA Green Accepted, Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Barros, AJD
   Victora, CG
   Menezes, AMB
   Horta, BL
   Hartwig, F
   Victora, G
   Pellanda, LC
   Dellagostin, OA
   Struchiner, CJ
   Burattini, MN
   Goncalves, MR
   Possuelo, LG
   Weber, LP
   Estima, SL
   Jacques, N
   Harter, J
   Silva, SG
   Frizzo, M
   Lima, RC
   Barros, FC
   Silveira, MF
   Hallal, PC
AF Barros, Aluisio J. D.
   Victora, Cesar G.
   Menezes, Ana M. B.
   Horta, Bernardo L.
   Hartwig, Fernando
   Victora, Gabriel
   Pellanda, Lucia C.
   Dellagostin, Odir A.
   Struchiner, Claudio J.
   Burattini, Marcelo N.
   Goncalves, Marcelo R.
   Possuelo, Lia G.
   Weber, Liliana P.
   Estima, Sonara Lucia
   Jacques, Nadege
   Harter, Jenifer
   Silva, Shana G.
   Frizzo, Matias
   Lima, Rosangela C.
   Barros, Fernando C.
   Silveira, Mariangela F.
   Hallal, Pedro C.
TI Social distancing patterns in nine municipalities of Rio Grande do Sul,
   Brazil: the Epicovid19/RS study
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE Coronavirus Infections, prevention & control; Health Knowledge,
   Attitudes, Practice; Health Risk Behaviors; Socioeconomic Factors
AB OBJECTIVE: To describe social distancing practices in nine municipalities of the state of Rio Grande do Sul, Brazil, stratified by gender, age, and educational attainment.
   METHODS: Two sequential cross-sectional studies were conducted in the municipalities of Canoas, Caxias do Sul, Ijui, Passo Fundo, Pelotas, Porto Alegre, Santa Cruz do Sul, Santa Maria, and Uruguaiana to estimate the population prevalence of COVID-19. The study was designed to be representative of the urban population of these municipalities. A questionnaire including three questions about social distancing was also administered to the participants. Here, we present descriptive analyses of social distancing practices by subgroups and use chi-square tests for comparisons.
   RESULTS: In terms of degree of social distancing, 25.8% of the interviewees reported being essentially isolated and 41.1% reported being quite isolated. 20.1% of respondents reported staying at home all the time, while 44.5% left only for essential activities. More than half of households reported receiving no visits from non-residents. Adults aged 20 to 59 reported the least social distancing, while more than 80% of participants aged 60 years or older reported being essentially isolated or quite isolated. Women reported more stringent distancing than men. Groups with higher educational attainment reported going out for daily activities more frequently.
   CONCLUSIONS: The extremes of age are more protected by social distancing, but some groups remain highly exposed. This can be an important limiting factor in controlling progression of the COVID-19 pandemic.
C1 [Barros, Aluisio J. D.; Victora, Cesar G.; Menezes, Ana M. B.; Horta, Bernardo L.; Hartwig, Fernando; Jacques, Nadege; Barros, Fernando C.; Silveira, Mariangela F.; Hallal, Pedro C.] Univ Fed Pelotas, Ctr Pesquisas Epidemiol, Pelotas, RS, Brazil.
   [Victora, Gabriel] Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.
   [Pellanda, Lucia C.] Fundacao Univ Fed Ciencias Saude Porto, Porto Alegre, RS, Brazil.
   [Dellagostin, Odir A.] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Pelotas, RS, Brazil.
   [Struchiner, Claudio J.] Fundacao Getulio Vargas, Escola Matemat Aplicada, Rio De Janeiro, RJ, Brazil.
   [Burattini, Marcelo N.] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo N.] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
   [Goncalves, Marcelo R.] Univ Fed Rio Grande do Sul, Porto Alegre, RS, Brazil.
   [Possuelo, Lia G.] Univ Santa Cruz do Sul, Santa Cruz Do Sul, RS, Brazil.
   [Weber, Liliana P.] Univ Caxias do Sul, Caxias Do Sul, RS, Brazil.
   [Estima, Sonara Lucia] Univ La Salle Unilasalle, Canoas, RS, Brazil.
   [Harter, Jenifer] Univ Fed Pampa, Uruguaiana, RS, Brazil.
   [Silva, Shana G.] Univ Fed Fronteira Sul, Passo Fundo, RS, Brazil.
   [Frizzo, Matias] Univ Reg Noroeste Estado Rio Grande Sul UNIJUI, Ijui, RS, Brazil.
   [Lima, Rosangela C.] Univ Fed Santa Maria, Santa Maria, RS, Brazil.
   [Silveira, Mariangela F.] Univ Catolica Pelotas, Fac Med, Pelotas, RS, Brazil.
RP Barros, AJD (corresponding author), R Mal Deodoro 1160,3 Piso, BR-96020220 Pelotas, RS, Brazil.
EM abarros.epi@gmail.com
RI Pellanda, Lucia C/B-4701-2010; Pellanda, Lucia/ABC-1687-2020;
   Dellagostin, Odir/C-2331-2009; Struchiner, Claudio/M-9360-2013; Victora,
   Cesar/D-4476-2013; Burattini, Marcelo Nascimento/J-9272-2014
OI Pellanda, Lucia C/0000-0002-8776-2248; Dellagostin,
   Odir/0000-0003-2803-4088; Reis, AlessanRSS/0000-0001-8486-7469; Barros,
   Aluisio/0000-0002-2022-8729; Menezes, Ana M B/0000-0002-2996-9427;
   Struchiner, Claudio/0000-0003-2114-847X; Victora,
   Cesar/0000-0002-2465-2180; Burattini, Marcelo
   Nascimento/0000-0002-5407-6890
FU Brazilian Ministry of Health; Health Department of the State of Rio
   Grande do Sul; Instituto Serrapilheira; Unimed Porto Alegre; Instituto
   Cultural Floresta
FX The rapid rests used in the research were provided by the Brazilian
   Ministry of Health and the Health Department of the State of Rio Grande
   do Sul. Funding for hiring the company responsible for data collection
   was obtained from Instituto Serrapilheira, Unimed Porto Alegre, and
   Instituto Cultural Floresta.
CR Baumgartner MT, 2020, SOCIAL DISTANCING MO, DOI [10.1101/2020.05.02.20088013, DOI 10.1101/2020.05.02.20088013]
   Campos Pellanda L, 2020, SENSITIVITY SPECIFIC, DOI [10.1101/2020.05.06.20093476, DOI 10.1101/2020.05.06.20093476]
   Chu DK, 2020, LANCET
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Hallal PC, 2020, CIENC SAUDE COLETIVA, V25, P2395, DOI 10.1590/1413-81232020256.1.09632020
   Li X, 2020, NAT CELL BIOL, V2020, P1, DOI DOI 10.1016/J.JACI.2020.04.006
   Moraes RF, 2020, 16 IPEA
   Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574
   Oliveira CA, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3593947, DOI 10.2139/SSRN.3593947]
   Oliveira SB, 2020, MONITORING SOCIAL DI, DOI [10.1101/2020.04.30.20082172, DOI 10.1101/2020.04.30.20082172]
   Silveira M., 2020, REPEATED POPULATION, DOI [10.1101/2020.05.01.20087205, DOI 10.1101/2020.05.01.20087205]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 12
TC 0
Z9 0
U1 2
U2 2
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PY 2020
VL 54
BP 29
EP 42
AR 75
DI 10.11606/s1518-8787.2020054002810
PG 14
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA MX6EF
UT WOS:000557813300004
PM 32725098
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Klautau, GB
   da Mota, NVF
   Salles, MJC
   Burattini, MN
   Rodrigues, DS
AF Klautau, Giselle Burlamaqui
   Ferreira da Mota, Nadijane Valeria
   Costa Salles, Mauro Jose
   Burattini, Marcelo Nascimento
   Rodrigues, Denise Silva
TI Interferon-gamma release assay as a sensitive diagnostic tool of latent
   tuberculosis infection in patients with HIV: a cross-sectional study
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE HIV; Latent tuberculosis infection; Tuberculin skin testing;
   Interferon-gamma release assay; AIDS
ID AREAS; CD4; TB
AB In developing countries, tuberculosis (TB) is a major public health problem and the leading cause of death among patients with HIV (Human Immunodeficiency Virus). Until 2001, the tuberculin skin test (TST) was the only available tool for the diagnosis of latent tuberculosis infection (LTBI), but false-negative TST results are frequently reported. Recently, the interferon-gamma (IFN-gamma) release assay (IGRA) has gained ground because it can detect the IFN-gamma secreted by circulating lymphocytes T cells when stimulated by specific TB antigens. However, the role of IGRA in the diagnosis of LTBI in HIV-infected patients has not been well established.
   This cross-sectional study compared the accuracy of TST (performed by the Mantoux method) and IGRA (QuantiFERON-TB Gold In-Tube, Cellestis, Carnegie, Australia) on the diagnosis of LTBI among patients with HIV. LTBI is defined by LTBI risk and at least one positive test (TST or IGRA), without clinical evidence of active TB. We also assessed the accuracy of TST and IGRA among HIV patients with high and low risk for LTBI.
   Among 90 HIV patients, 80 met the study criteria for LTBI, fifty-nine (73.7%) patients were TST positive, 21 (26.2%) were negative, whereas 75 patients (93.7%) were IGRA positive, and five (6.2%) were negative. TST showed poor agreement with the diagnosis of LTBI (Kappa: 0.384), while IGRA demonstrated good agreement (Kappa: 0.769). Among 69 patients with high risk and 21 with low risk for LTBI, TST was positive in 48 (69.5%) and 11 (52.4%), while IGRA was positive in 68 (98.5%) and 7 (33.3%) patients, respectively. There were no association between TST and the level of risk (P = 0,191). Conversely, we observed a strong association between the IGRA and risk for LTBI (p < 0.001).
   Compared to TST, IGRA positivity is consistent with the risk of TB infection and seems to be a better diagnostic tool for LTBI in HIV-infected patients.
C1 [Klautau, Giselle Burlamaqui; Costa Salles, Mauro Jose] Hosp Irmandade Santa Casa Misericordia Sao Paulo, Santa Casa Sao Paulo Sch Med Sci, Dept Internal Med, Div Infect Dis, Rua Dr Cesareo Mota Jr 112, BR-01303060 Sao Paulo, SP, Brazil.
   [Rodrigues, Denise Silva] Clemente Ferreira Inst, Rua Consolacao 717, BR-01221020 Sao Paulo, SP, Brazil.
   [Klautau, Giselle Burlamaqui] Emilio Ribas Inst Infectol, Av Dr Arnaldo 165, BR-01246900 Sao Paulo, SP, Brazil.
   [Ferreira da Mota, Nadijane Valeria; Burattini, Marcelo Nascimento; Rodrigues, Denise Silva] Fed Univ Sao Paulo UNIFESP, Rua Sena Madureira 1500, BR-04021001 Sao Paulo, Brazil.
RP Klautau, GB; Salles, MJC (corresponding author), Hosp Irmandade Santa Casa Misericordia Sao Paulo, Santa Casa Sao Paulo Sch Med Sci, Dept Internal Med, Div Infect Dis, Rua Dr Cesareo Mota Jr 112, BR-01303060 Sao Paulo, SP, Brazil.
EM gisellebk@hotmail.com; salles.infecto@gmail.com
RI Salles, Mauro/K-4760-2012; Burattini, Marcelo N/J-9272-2014; Salles,
   Mauro/R-9256-2019
OI Salles, Mauro/0000-0002-5443-6024; Burattini, Marcelo
   N/0000-0002-5407-6890; Salles, Mauro/0000-0002-5443-6024
FU Sao Paulo Research Foundation (Fundacao Amparo a Pesquisa do Estado de
   Sao Paulo - FAPESP) [2011/05805-1]; National Council for Scientific and
   Technological Development (Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico - CNPq)National Council for Scientific and
   Technological Development (CNPq) [141705/2011-6]
FX This project was funded by the Sao Paulo Research Foundation (Fundacao
   Amparo a Pesquisa do Estado de Sao Paulo - FAPESP) Process no.
   2011/05805-1 (Regular Research Project) and the National Council for
   Scientific and Technological Development (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - CNPq) Process no.
   141705/2011-6. Neither FAPESP nor CNPq interfered in the study design,
   collection, analysis and interpretation of data and in writing this
   manuscript.
CR Agresti A., 2007, INTRO CATEGORICAL DA, P244
   Akolo C, 2010, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD000171.PUB3)
   Barbesti S, 2005, CYTOM PART B-CLIN CY, V68B, P43, DOI 10.1002/cyto.b.20068
   Brasil. Ministerio da Saude, 2013, PROT CLIN DIR TER MA
   Cattamanchi A, 2011, JAIDS-J ACQ IMM DEF, V56, P230, DOI 10.1097/QAI.0b013e31820b07ab
   Chee CBE, 2013, RESPIROLOGY, V18, P205, DOI 10.1111/resp.12002
   Conde MB, 2009, J BRAS PNEUMOL, V35, P1018, DOI 10.1590/S1806-37132009001000011
   del Corral H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008257
   Field SK, 2018, CHEST, V153, P467, DOI 10.1016/j.chest.2017.11.018
   Fujita A, 2011, CLIN DEV IMMUNOL
   Getahun H, 2015, NEW ENGL J MED, V372, P2127, DOI 10.1056/NEJMra1405427
   International Agency for Research on Center, 2018, LAT TUB INF UPD CONS, P1, DOI DOI 10.1016/S1473-3099(14)70780-7
   JONES BE, 1993, AM REV RESPIR DIS, V148, P1292, DOI 10.1164/ajrccm/148.5.1292
   Kabeer BSA, 2010, AIDS, V24, P323, DOI 10.1097/QAD.0b013e328334895e
   Klautau Giselle Burlamaqui, 2005, Braz J Infect Dis, V9, P464, DOI 10.1590/S1413-86702005000600004
   MANTOUX MC, 1912, PRESSE MED, V20, P146
   Mazurek Gerald H., 2010, Morbidity and Mortality Weekly Report, V59, P1
   Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006
   Ministerio da Saude (BR), 2018, 112018DIAHVSVSMS BR
   Ministerio da Saude (BR), 2011, NORMAS MANUAIS TEC A
   Ministerio de Saude (MS), 2015, B EPIDEMIOL, V46, P1
   Rangaka MX, 2007, AM J RESP CRIT CARE, V175, P514, DOI 10.1164/rccm.200610-1439OC
   ROSE CE, 1979, AM REV RESPIR DIS, V119, P603
   Sester M, 2011, EUR RESPIR J, V37, P100, DOI 10.1183/09031936.00114810
   Sharma SK, 2012, CHEST, V142, P761, DOI 10.1378/chest.12-0142
   Smith Kim Connelly, 2003, Expert Rev Anti Infect Ther, V1, P483, DOI 10.1586/14787210.1.3.483
   Wang L, 2003, THORAX, V58, P188
   WHO, 2011, WHOHTMTB201116
   World Health Organization, 2011, WHOHTMTB201118
   World Health Organization, 2018, WHOCDSTB201020
   World Health Organization, 2015, WHOHTMTB201501
   World Health Organization, 2012, GLOB ACT PLAN CONTR, P1, DOI DOI 10.1016/S0968-8080(12)40660-7
   World Health Organization, 2011, GUID INT TUB CAS FIN, P52
   Zumla A, 2013, NEW ENGL J MED, V368, P745, DOI 10.1056/NEJMra1200894
NR 34
TC 4
Z9 5
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD NOV 19
PY 2018
VL 18
AR 585
DI 10.1186/s12879-018-3508-8
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA HB8BF
UT WOS:000451308200004
PM 30453903
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Massad, E
   Amaku, M
   Coutinho, FAB
   Struchiner, CJ
   Lopez, LF
   Coelho, G
   Wilder-Smith, A
   Burattini, MN
AF Massad, Eduardo
   Amaku, Marcos
   Bezerra Coutinho, Francisco Antonio
   Struchiner, Claudio Jose
   Lopez, Luis Fernandez
   Coelho, Giovanini
   Wilder-Smith, Annelies
   Burattini, Marcelo Nascimento
TI The risk of urban yellow fever resurgence in Aedes-infested American
   cities
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Aedes aegypti; dengue; mathematical models; risk; yellow fever
ID RIO-DE-JANEIRO; DENGUE; VIRUS; VISITORS; OUTBREAK; AEGYPTI; SPREAD
AB Aedes aegypti, historically known as yellow fever (YF) mosquito, transmits a great number of other viruses such as Dengue, West Nile, Chikungunya, Zika, Mayaro and perhaps Oropouche, among others. Well established in Africa and Asia, Aedes mosquitoes are now increasingly invading large parts of the American continent, and hence the risk of urban YF resurgence in the American cities should because of great concern to public health authorities. Although no new urban cycle of YF was reported in the Americas since the end of an Aedes eradication programme in the late 1950s, the high number of non-vaccinated individuals that visit endemic areas, that is, South American jungles where the sylvatic cycle of YF is transmitted by canopy mosquitoes, and return to Aedes-infested urban areas, increases the risk of resurgence of the urban cycle of YF. We present a method to estimate the risk of urban YF resurgence in dengue-endemic cities. This method consists in (1) to estimate the number of Aedes mosquitoes that explains a given dengue outbreak in a given region; (2) calculate the force of infection caused by the introduction of one infective individual per unit area in the endemic area under study; (3) using the above estimates, calculate the probability of at least one autochthonous YF case per unit area produced by one single viraemic traveller per unit area arriving from a YF endemic or epidemic sylvatic region at the city studied. We demonstrate that, provided the relative vector competence, here defined as the capacity to being infected and disseminate the virus, of Ae. aegypti is greater than 0.7 (with respect to dengue), one infected traveller can introduce urban YF in a dengue endemic area.
C1 [Massad, Eduardo; Amaku, Marcos; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Massad, Eduardo; Wilder-Smith, Annelies] London Sch Hyg & Trop Med, London, England.
   [Massad, Eduardo] Univ Derby, Coll Life & Nat Sci, Derby, England.
   [Massad, Eduardo; Struchiner, Claudio Jose] Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, Brazil.
   [Struchiner, Claudio Jose] Fundacao Oswaldo Cruz, Programme Sci Computat, Rio De Janeiro, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, Ctr Internet Augmented Res & Assessment, Miami, FL 33199 USA.
   [Coelho, Giovanini] CHA VT PAHO WHO, Neglected Trop & Vector Borne Dis Program, Washington, DC USA.
   [Wilder-Smith, Annelies] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.
   [Wilder-Smith, Annelies] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London, England.; Massad, E (corresponding author), Univ Derby, Coll Life & Nat Sci, Derby, England.; Massad, E (corresponding author), Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Struchiner,
   Claudio J/M-9360-2013; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Lopez, Luis
   F/0000-0003-4097-6887; Struchiner, Claudio J/0000-0003-2114-847X; Amaku,
   Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [LIM01-HCFMUSP]; Brazilian Ministry of Health [777588/2012]; ZikaPLAN
   through the European Union [734584]; Canadian Institutes of Health
   Research (CIHR)Canadian Institutes of Health Research (CIHR) [372512]
FX This work has been funded by LIM01-HCFMUSP, CNPq, by the Brazilian
   Ministry of Health (grant #777588/2012), by ZikaPLAN through the
   European Union's Horizon 2020 research and innovation programme under
   grant agreement No. 734584, and the Canadian Institutes of Health
   Research (CIHR), consortium Canada-Latin/America-Caribean Zika Virus
   Program (Grant no. 372512). Data used in this paper are available at
   http://portalsinan.saude.gov.br/dengue, accessed in January 2017.
CR Amaku M, 2016, EPIDEMIOLOGY INFECT, V19, P1
   Amaku M, 2011, BIOSYSTEMS, V106, P111, DOI 10.1016/j.biosystems.2011.07.004
   Bailey NT, 2006, ELEMENTS STOCHASTIC
   Bryan CS, 2004, INFECT DIS CLIN N AM, V18, P275, DOI 10.1016/j.idc.2004.01.007
   Bryant JE, 2007, PLOS PATHOG, V3, P668, DOI 10.1371/journal.ppat.0030075
   CDC, 2016, ZIK VIR POT RANG US
   Chernick M., 2008, BOOTSTRAP METHODS GU
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Couto-Lima D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05186-3
   Dick OB, 2012, AM J TROP MED HYG, V87, P584, DOI 10.4269/ajtmh.2012.11-0770
   Gardner CL, 2010, CLIN LAB MED, V30, P237, DOI 10.1016/j.cll.2010.01.001
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Johansson MA, 2012, AM J TROP MED HYG, V86, P349, DOI 10.4269/ajtmh.2012.11-0432
   Johnson BW, 2002, T ROY SOC TROP MED H, V96, P611, DOI 10.1016/S0035-9203(02)90326-3
   Kraemer MUG, 2017, LANCET INFECT DIS, V17, P330, DOI [10.1016/S1473-3099(16)30513-8, 10.1016/s1473-3099(16)30513-8]
   Maciel-De-Freitas R, 2008, CAD SAUDE PUBLICA, V24, P2747, DOI 10.1590/S0102-311X2008001200003
   Magalhaes R. C. S, 2016, ERRADICACAO AEDES AE
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Massad Eduardo, 2017, Infect Dis Model, V2, P441, DOI 10.1016/j.idm.2017.12.001
   Massad E, 2016, LANCET, V388, P25, DOI 10.1016/S0140-6736(16)30842-X
   PAHO, EP UPD YELL FEV
   Strode WK, 1951, YELLOW FEVER
   WHO, YELL FEV ANG
   Ximenes R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1517-z
NR 25
TC 8
Z9 8
U1 0
U2 16
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2018
VL 146
IS 10
BP 1219
EP 1225
DI 10.1017/S0950268818001334
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA GO3YN
UT WOS:000439936400003
PM 29843824
OA Bronze, Green Accepted
DA 2020-12-08
ER

PT J
AU Brunialti, MKC
   Cerqueira, N
   Maestri, A
   Chaves, L
   Levi, JE
   Pannuti, CS
   Kallas, EG
   Burattini, MN
   Salomao, R
AF Brunialti, Milena K. C.
   Cerqueira, Natalia
   Maestri, Alvino
   Chaves, Lucas
   Levi, Jose E.
   Pannuti, Claudio S.
   Kallas, Esper G.
   Burattini, Marcelo N.
   Salomao, Reinaldo
TI TOLL-LIKE RECEPTOR SIGNALING PATHWAY IS DIFFERENTIALLY MODULATED IN
   PATIENTS WITH DENGUE WITHOUT WARNING SIGNS AND DENGUE WITH WARNING SIGNS
SO SHOCK
LA English
DT Meeting Abstract
CT 41st Annual Conference on Shock
CY JUN 09-12, 2018
CL Scottsdale, AZ
SP Shock Soc
C1 [Brunialti, Milena K. C.; Burattini, Marcelo N.; Salomao, Reinaldo] Univ Fed Sao Paulo, Hosp Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil.
   [Cerqueira, Natalia; Maestri, Alvino; Chaves, Lucas; Kallas, Esper G.] Univ Sao Paulo, Hosp Clin, Div Clin Immunol & Allergy, Sao Paulo, Brazil.
   [Levi, Jose E.; Pannuti, Claudio S.] Univ Sao Paulo, Inst Trop Med, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1073-2322
EI 1540-0514
J9 SHOCK
JI Shock
PD JUN
PY 2018
VL 49
IS 6
SU 1
MA P120
BP 90
EP 91
PG 2
WC Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease
SC General & Internal Medicine; Hematology; Surgery; Cardiovascular System
   & Cardiology
GA GQ0XL
UT WOS:000441343800190
DA 2020-12-08
ER

PT J
AU Massad, E
   Amaku, M
   Coutinho, FAB
   Struchiner, CJ
   Burattini, MN
   Khan, K
   Liu-Helmersson, J
   Rocklov, J
   Kraemer, MUG
   Wilder-Smith, A
AF Massad, Eduardo
   Amaku, Marcos
   Bezerra Coutinho, Francisco Antonio
   Struchiner, Claudio Jose
   Burattini, Marcelo Nascimento
   Khan, Kamran
   Liu-Helmersson, Jing
   Rocklov, Joacim
   Kraemer, Moritz U. G.
   Wilder-Smith, Annelies
TI Estimating the probability of dengue virus introduction and secondary
   autochthonous cases in Europe
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RIO-DE-JANEIRO; TEMPERATURE-FLUCTUATIONS; AEDES-ALBOPICTUS; FOREIGN
   VISITORS; OLYMPIC GAMES; IMPORTATIONS; OUTBREAK; SPREAD; TRAVEL; RISK
AB Given the speed of air travel, diseases even with a short viremia such as dengue can be easily exported to dengue naive areas within 24 hours. We set out to estimate the risk of dengue virus introductions via travelers into Europe and number of secondary autochthonous cases as a result of the introduction. We applied mathematical modeling to estimate the number of dengue-viremic air passengers from 16 dengue-endemic countries to 27 European countries, taking into account the incidence of dengue in the exporting countries, travel volume and the probability of being viremic at the time of travel. Our models estimate a range from zero to 167 air passengers who are dengue-viremic at the time of travel from dengue endemic countries to each of the 27 receiving countries in one year. Germany receives the highest number of imported dengue-viremic air passengers followed by France and the United Kingdom. Our findings estimate 10 autochthonous secondary asymptomatic and symptomatic dengue infections, caused by the expected 124 infected travelers who arrived in Italy in 2012. The risk of onward transmission in Europe is reassuringly low, except where Aedes aegypti is present.
C1 [Massad, Eduardo; Amaku, Marcos; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
   [Massad, Eduardo] Univ Derby, Coll Nat & Life Sci, Derby, England.
   [Massad, Eduardo] Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, Brazil.
   [Struchiner, Claudio Jose] Fundacao Oswaldo Cruz, Programme Sci Computat, Rio De Janeiro, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Khan, Kamran] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Liu-Helmersson, Jing; Rocklov, Joacim; Wilder-Smith, Annelies] Umea Univ, Dept Publ Hlth & Clin Med Epidemiol & Global Hlth, SE-90185 Umea, Sweden.
   [Kraemer, Moritz U. G.] Harvard Med Sch, Boston, MA USA.
   [Kraemer, Moritz U. G.] Boston Childrens Hosp, Boston, MA USA.
   [Kraemer, Moritz U. G.] Univ Oxford, Dept Zool, Oxford, England.
   [Wilder-Smith, Annelies] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.
   [Wilder-Smith, Annelies] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London, England.; Massad, E (corresponding author), Univ Derby, Coll Nat & Life Sci, Derby, England.; Massad, E (corresponding author), Fundacao Getulio Vargas, Sch Appl Math, Rio De Janeiro, Brazil.
EM edmassad@dim.fm.usp.br
RI Massad, Eduardo/B-1169-2012; Amaku, Marcos/D-5252-2012; Burattini,
   Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011; Struchiner,
   Claudio J/M-9360-2013
OI Massad, Eduardo/0000-0002-7200-2916; Amaku, Marcos/0000-0003-4752-6774;
   Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; Struchiner, Claudio J/0000-0003-2114-847X;
   Rocklov, Joacim/0000-0003-4030-0449; Helmersson,
   Jing/0000-0001-9647-1015
FU HealthTheme of the Seventh Framework Programme of the European Community
   [282589]; project ZikaPLAN - European Union's Horizon research and
   innovation programme [734584]; International Research Consortium on
   Dengue Risk Assessment Management and Surveillance (IDAMS) (European
   Commission) [21803]
FX The study was funded under the HealthTheme of the Seventh Framework
   Programme of the European Community (DengueTools, Grant No. 282589), and
   by the project ZikaPLAN, funded by European Union's Horizon 2020
   research and innovation programme under Grant Agreement No. 734584. MK
   was funded at the time through the International Research Consortium on
   Dengue Risk Assessment Management and Surveillance (IDAMS, Grant No.
   21803, European Commission).
CR Amaku M, 2014, B MATH BIOL, V76, P697, DOI 10.1007/s11538-014-9939-5
   Astrom C, 2012, ECOHEALTH, V9, P448, DOI 10.1007/s10393-012-0808-0
   Burattini MN, 2016, EPIDEMIOL INFECT, V144, P1904, DOI 10.1017/S0950268816000649
   Carrington LB, 2013, J MED ENTOMOL, V50, P43, DOI 10.1603/ME11242
   Duong V, 2015, P NATL ACAD SCI USA, V112, P14688, DOI 10.1073/pnas.1508114112
   Glaesser D, 2017, J TRAVEL MED, V24, DOI 10.1093/jtm/tax007
   Hamer DH, 2016, ANN INTERN MED
   Khan K., 2014, PLOS CURRENTS, V6
   Khan K., 2013, PLOS CURRENTS, V5
   Khan K, 2009, NEW ENGL J MED, V361, P212, DOI 10.1056/NEJMc0904559
   Kraemer MUG, 2015, ELIFE, V4, DOI 10.7554/eLife.08347
   Kraemer MUG, 2015, SCI DATA, V2, DOI 10.1038/sdata.2015.35
   La Ruche G, 2010, EUROSURVEILLANCE, V15, P2
   Lambrechts L, 2011, P NATL ACAD SCI USA, V108, P7460, DOI 10.1073/pnas.1101377108
   Liu-Helmersson J, 2016, EBIOMEDICINE, V7, P267, DOI 10.1016/j.ebiom.2016.03.046
   Liu-Helmersson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089783
   Lopez LF, 2016, B MATH BIOL, V78, P185, DOI 10.1007/s11538-015-0135-z
   Massad E, 2016, GLOBAL HEALTH ACTION, V9, P1, DOI 10.3402/gha.v9.31669
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Medlock JM, 2017, LANCET INFECT DIS, V17, P140, DOI 10.1016/S1473-3099(17)30024-5
   Neumayr A, 2017, EURO SURVEILL, V22
   Quam MB, 2016, J TRAVEL MED, V23, DOI 10.1093/jtm/taw059
   Quam MB, 2016, AM J TROP MED HYG, V94, P409, DOI 10.4269/ajtmh.15-0468
   Quam MB, 2015, J TRAVEL MED, V22, P186, DOI 10.1111/jtm.12192
   Quam MB, 2015, J TRAVEL MED, V22, P72, DOI 10.1111/jtm.12177
   Reiter P, 1998, J AM MOSQUITO CONTR, V14, P83
   Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6
   Schaffner F, 2014, LANCET INFECT DIS, V14, P1044, DOI 10.1016/S1473-3099(14)70925-9
   Semenza JC, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003278
   Stanaway JD, 2016, LANCET INFECT DIS, V16, P712, DOI 10.1016/S1473-3099(16)00026-8
   Wilder-Smith A, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.8.20718
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, P1109, DOI 10.1016/S1473-3099(17)30494-2
   Wilder-Smith A, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0363-y
   Ximenes R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1517-z
   Zhou YP, 2014, J TRAVEL MED, V21, P272, DOI 10.1111/jtm.12133
NR 35
TC 21
Z9 21
U1 1
U2 13
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 15
PY 2018
VL 8
AR 4629
DI 10.1038/s41598-018-22590-5
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FZ3DF
UT WOS:000427465800009
PM 29545610
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Amaku, M
   Burattini, MN
   Chaib, E
   Coutinho, FAB
   Greenhalgh, D
   Lopez, LF
   Massad, E
AF Amaku, Marcos
   Burattini, Marcelo Nascimento
   Chaib, Eleazar
   Bezerra Coutinho, Francisco Antonio
   Greenhalgh, David
   Lopez, Luis Fernandez
   Massad, Eduardo
TI Estimating the prevalence of infectious diseases from under-reported
   age-dependent compulsorily notification databases
SO THEORETICAL BIOLOGY AND MEDICAL MODELLING
LA English
DT Article
DE Hepatitis C; Mathematical models; Notifications system incidence;
   Prevalence
ID UNITED-STATES; COMPLETENESS; SURVEILLANCE
AB Background: National or local laws, norms or regulations (sometimes and in some countries) require medical providers to report notifiable diseases to public health authorities. Reporting, however, is almost always incomplete. This is due to a variety of reasons, ranging from not recognizing the diseased to failures in the technical or administrative steps leading to the final official register in the disease notification system. The reported fraction varies from 9 to 99% and is strongly associated with the disease being reported.
   Methods: In this paper we propose a method to approximately estimate the full prevalence (and any other variable or parameter related to transmission intensity) of infectious diseases. The model assumes incomplete notification of incidence and allows the estimation of the non-notified number of infections and it is illustrated by the case of hepatitis C in Brazil. The method has the advantage that it can be corrected iteratively by comparing its findings with empirical results.
   Results: The application of the model for the case of hepatitis C in Brazil resulted in a prevalence of notified cases that varied between 163,902 and 169,382 cases; a prevalence of non-notified cases that varied between 1,433,638 and 1,446,771; and a total prevalence of infections that varied between 1,597,540 and 1,616,153 cases.
   Conclusions: We conclude that the model proposed can be useful for estimation of the actual magnitude of endemic states of infectious diseases, particularly for those where the number of notified cases is only the tip of the iceberg. In addition, the method can be applied to other situations, such as the well-known underreported incidence of criminality (for example rape), among others.
C1 [Amaku, Marcos; Burattini, Marcelo Nascimento; Chaib, Eleazar; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Greenhalgh, David] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland.
   [Lopez, Luis Fernandez] Florida Int Univ, Ctr Internet Augmented Res & Assessment, Miami, FL 33199 USA.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, SP, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London, England.
EM edmassad@dim.fm.usp.br
RI Lopez, Luis F/C-4721-2012; Burattini, Marcelo N/J-9272-2014; Coutinho,
   Francisco A B/H-5644-2011; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/B-1169-2012
OI Lopez, Luis F/0000-0003-4097-6887; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Amaku, Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916
FU LIM01-HCFMUSP; CNPqNational Council for Scientific and Technological
   Development (CNPq); Brazilian Ministry of Health [TED 27/2015];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Leverhulme Trust from a Leverhulme Research Fellowship [RF-2015-88];
   British Council, Malaysia from the Dengue Tech Challenge [DTC 16022];
   Science Without Borders Program for a Special Visiting Fellowship (CNPq)
   [30098/2014-7]
FX This work was partially funded by LIM01-HCFMUSP, CNPq, Brazilian
   Ministry of Health (Grant TED 27/2015) and FAPESP. DG is grateful to the
   Leverhulme Trust for support from a Leverhulme Research Fellowship
   (RF-2015-88) and the British Council, Malaysia for funding from the
   Dengue Tech Challenge (Application Reference DTC 16022). EM and DG are
   grateful to the Science Without Borders Program for a Special Visiting
   Fellowship (CNPq grant 30098/2014-7).
CR Aguiar M, 2015, SCI REP-UK, V5, DOI 10.1038/srep08462
   Amaku M, 2016, B MATH BIOL, V78, P970, DOI 10.1007/s11538-016-0170-4
   American Liver Foundation, PROGR LIV DIS
   Brabazon ED, 2008, EPIDEMIOL INFECT, V136, P241, DOI 10.1017/S0950268807008230
   Chaib E, 2005, TRANSPLANT P, V37, P4329, DOI 10.1016/j.transproceed.2005.11.014
   Chaib E, 2014, J TRANSPLANT, V2014, DOI 10.1155/2014/219789
   Doyle TJ, 2002, AM J EPIDEMIOL, V155, P866, DOI 10.1093/aje/155.9.866
   Gibbons CL, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-147
   Gibney KB, 2016, EPIDEMIOL INFECT, V144, P3263, DOI 10.1017/S0950268816001072
   Keramarou M, 2012, J INFECTION, V64, P555, DOI 10.1016/j.jinf.2012.03.005
   KONOWITZ PM, 1984, PUBLIC HEALTH REP, V99, P31
   Lopez LF, 2016, B MATH BIOL, V78, P185, DOI 10.1007/s11538-015-0135-z
   Mann Jonathan, 1996, Health Hum Rights, V2, P1, DOI 10.2307/4065231
   MMWR - Summary of notifiable diseases United States, 1998, MMWR-MORBID MORTAL W, V47, P92
   NHS Choices, HEP C
   Roberts EA, 2002, HEPATOLOGY, V36, pS106, DOI 10.1053/jhep.2002.36792
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   ROSENBERG ML, 1977, J INFECT DIS, V136, P458, DOI 10.1093/infdis/136.3.458
   Roush S, 1999, JAMA-J AM MED ASSOC, V282, P164, DOI 10.1001/jama.282.2.164
   Rowe SL, 2016, AUST NZ J PUBL HEAL, V40, P148, DOI 10.1111/1753-6405.12434
   Schiffman EK, 2016, UNDER REPORTING LYME
   Serra I, 1999, REV MED CHILE, V127, P485
   THACKER SB, 1983, JAMA-J AM MED ASSOC, V249, P1181
   TRUCCO E, 1965, B MATH BIOPHYS, V27, P285, DOI 10.1007/BF02478406
   Ximenes R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1517-z
NR 25
TC 2
Z9 2
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4682
J9 THEOR BIOL MED MODEL
JI Theor. Biol. Med. Model.
PD DEC 12
PY 2017
VL 14
AR 23
DI 10.1186/s12976-017-0069-2
PG 18
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA FP8CO
UT WOS:000417868000001
PM 29228966
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Maier, SB
   Huang, X
   Massad, E
   Amaku, M
   Burattini, MN
   Greenhalgh, D
AF Maier, Sandra B.
   Huang, Xiao
   Massad, Eduardo
   Amaku, Marcos
   Burattini, Marcelo N.
   Greenhalgh, David
TI Analysis of the optimal vaccination age for dengue in Brazil with a
   tetravalent dengue vaccine
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
DE Dengue; Vaccination; Optimal vaccination age; Age-structured model;
   Serotype; Risk function; Mortality; Hospitalisation; Mathematical model
ID ANTIBODY-DEPENDENT ENHANCEMENT; HEMORRHAGIC-FEVER; TRANSMISSION
   DYNAMICS; YELLOW-FEVER; SAO-PAULO; RISK; DISEASE; PERSISTENCE;
   SEROTYPES; INFECTION
AB In this paper we study a mathematical model to analyse the optimal vaccination age against Dengue in Brazil. Data from Brazil are used to estimate the basic reproduction numbers for each of the four Dengue serotypes and then the optimal vaccination age is calculated using a method due to Hethcote [1]. The vaccine has different efficacies against each serotype. Vaccination that is too early is ineffective as individuals are protected by maternal antibodies but leaving vaccination until later may allow the disease to spread.
   First of all the optimal vaccination ages ate calculated where there is just one serotype in circulation and then when there are multiple serotypes. The calculations are done using data both assuming constant vaccine efficacy and age-dependent vaccine efficacy against a given serotype. The multiple serotype calculations are repeated assuming that the first infection is a risky infection and that it is not (to model Dengue Antibody Enhancement). The calculations are then repeated when any third or fourth Dengue infections are asymptomatic, so that two Dengue infections with different serotypes provide effective permanent immunity. The calculations are also repeated when the age-dependent risk function (fitted to Brazilian data) is hospitalisation from Dengue and when it is mortality due to Dengue. We find a wide variety of optimal vaccination ages depending on both the serotypes in circulation and the assumptions of the model. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Maier, Sandra B.; Huang, Xiao; Greenhalgh, David] Univ Strathclyde, Dept Math & Stat, Glasgow G1 1XH, Lanark, Scotland.
   [Massad, Eduardo; Amaku, Marcos; Burattini, Marcelo N.] Univ Sao Paulo, LIM01 Hosp Clin, Fac Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo N.] Univ Fed Sao Paulo, Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.
RP Greenhalgh, D (corresponding author), Univ Strathclyde, Dept Math & Stat, Glasgow G1 1XH, Lanark, Scotland.
EM david.greenhalgh@strath.ac.uk
RI Amaku, Marcos/D-5252-2012; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Amaku, Marcos/0000-0003-4752-6774; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916
FU University of Strathclyde; Leverhulme TrustLeverhulme Trust
   [RF-2015-88]; British Council Malaysia from the Dengue Tech Challenge
   [DTC 16022]; Science Without Borders Program (CNPq) [30098/2014/7]
FX DG and SM are grateful to the University of Strathclyde for support for
   a Ph.D. studentship. DG is grateful to the Leverhulme Trust for support
   from a Leverhulme Fellowship (RF-2015-88) and the British Council
   Malaysia for funding from the Dengue Tech Challenge (Application
   reference DTC 16022). EM and DG are grateful to the Science Without
   Borders Program for a Special Visiting Fellowship (CNPq grant
   30098/2014/7).
CR Adams B, 2006, P NATL ACAD SCI USA, V103, P14234, DOI 10.1073/pnas.0602768103
   Aguiar M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005179
   Aguiar M, 2016, LANCET INFECT DIS, V16, P882, DOI 10.1016/S1473-3099(16)30168-2
   Amaku M, 2012, REV INST MED TROP SP, V54, pS18, DOI 10.1590/S0036-46652012000700008
   ANDERSON R M, 1991
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Billings L, 2008, MATH BIOSCI, V211, P265, DOI 10.1016/j.mbs.2007.08.004
   Burattini M.N., 2017, COMMUNICATION
   Burattini MN, 2016, CLINICS, V71, P455, DOI 10.6061/clinics/2016(08)08
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Carrington LB, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00290
   Chen SC, 2012, SCI TOTAL ENVIRON, V431, P385, DOI 10.1016/j.scitotenv.2012.05.012
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Coudeville L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051244
   Derouich M, 2006, APPL MATH COMPUT, V177, P528, DOI 10.1016/j.amc.2005.11.031
   Durham DP, 2013, VACCINE, V31, P3957, DOI 10.1016/j.vaccine.2013.06.036
   Esteva L, 1998, MATH BIOSCI, V150, P131, DOI 10.1016/S0025-5564(98)10003-2
   Esteva L, 2003, J MATH BIOL, V46, P31, DOI 10.1007/s00285-002-0168-4
   Favier C, 2006, TROP MED INT HEALTH, V11, P332, DOI 10.1111/j.1365-3156.2006.01560.x
   Ferguson N, 1999, P NATL ACAD SCI USA, V96, P790, DOI 10.1073/pnas.96.2.790
   Flasche S., 2016, COMP MODELLING DENGU
   Fried JR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000617
   Friedrich MJ, 2016, JAMA-J AM MED ASSOC, V315, P242, DOI 10.1001/jama.2015.18460
   Garba SM, 2008, MATH BIOSCI, V215, P11, DOI 10.1016/j.mbs.2008.05.002
   Gibbons RV, 2007, AM J TROP MED HYG, V77, P910, DOI 10.4269/ajtmh.2007.77.910
   Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480
   Guzman MG, 2013, ARCH VIROL, V158, P1445, DOI 10.1007/s00705-013-1645-3
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   HALSTEAD SB, 1980, B WORLD HEALTH ORGAN, V58, P1
   Halstead SB, 2016, J INFECT DIS, V214, P1793, DOI 10.1093/infdis/jiw340
   Halstead SB, 2016, AM J TROP MED HYG, V95, P741, DOI 10.4269/ajtmh.16-0222
   Halstead SB, 2016, TRAVEL MED INFECT DI, V14, P378, DOI 10.1016/j.tmaid.2016.06.005
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Halstead SB, 2009, ANN NY ACAD SCI, V1171, pE48, DOI 10.1111/j.1749-6632.2009.05052.x
   HETHCOTE HW, 1988, MATH BIOSCI, V89, P29, DOI 10.1016/0025-5564(88)90111-3
   Knipl D, 2015, B MATH BIOL, V77, P2212, DOI 10.1007/s11538-015-0120-6
   Macdonald G., 1957, EPIDEMIOLOGY CONTROL
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Nagao Y, 2008, P NATL ACAD SCI USA, V105, P2238, DOI 10.1073/pnas.0709029105
   Olkowski S, 2013, J INFECT DIS, V208, P1026, DOI 10.1093/infdis/jit273
   Reich NG, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0414
   Reiner RC, 2014, P NATL ACAD SCI USA, V111, pE2694, DOI 10.1073/pnas.1314933111
   Reiner RC, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0921
   Supriatna AK, 2008, MATH BIOSCI, V216, P114, DOI 10.1016/j.mbs.2008.08.011
   Nunes MRT, 2012, EMERG INFECT DIS, V18, P1858, DOI 10.3201/eid1811.120217
   van Panhuis WG, 2011, AM J TROP MED HYG, V85, P355, DOI 10.4269/ajtmh.2011.11-0125
   World Health Organization, 2012, GLOB STRAT DENG PREV
   World Health Organization, 2016, SUMM APR 2016 M STRA
   Zanetta RAC, 2001, VACCINE, V20, P226, DOI 10.1016/S0264-410X(01)00267-5
NR 51
TC 9
Z9 9
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD DEC
PY 2017
VL 294
BP 15
EP 32
DI 10.1016/j.mbs.2017.09.004
PG 18
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA FR9SU
UT WOS:000419414200002
PM 28935561
OA Green Accepted
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Khan, K
   Struchiner, CJ
   Coutinho, FAB
   Wilder-Smith, A
AF Massad, E.
   Nascimento Burattini, M.
   Khan, K.
   Struchiner, C. J.
   Coutinho, F. A. B.
   Wilder-Smith, A.
TI On the origin and timing of Zika virus introduction in Brazil
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Force of infection; French Polynesia; mathematical models; risk; Zika
   virus
ID RIO-DE-JANEIRO; OLYMPIC GAMES; FOREIGN VISITORS; WORLD CUP; DENGUE;
   RISK; INFECTION; TRAVELERS; AMERICA
AB The timing and origin of Zika virus (ZIKV) introduction in Brazil has been the subject of controversy. Initially, it was assumed that the virus was introduced during the FIFA World Cup in June-July 2014. Then, it was speculated that ZIKV may have been introduced by athletes from French Polynesia (FP) who competed in a canoe race in Rio de Janeiro in August 2014. We attempted to apply mathematical models to determine the most likely time window of ZIKV introduction in Brazil. Given that the timing and origin of ZIKV introduction in Brazil may be a politically sensitive issue, its determination (or the provision of a plausible hypothesis) may help to prevent undeserved blame. We used a simple mathematical model to estimate the force of infection and the corresponding individual probability of being infected with ZIKV in FP. Taking into account the air travel volume from FP to Brazil between October 2013 and March 2014, we estimated the expected number of infected travellers arriving at Brazilian airports during that period. During the period between December 2013 and February 2014, 51 individuals travelled from FP airports to 11 Brazilian cities. Basing on the calculated force of ZIKV infection (the per capita rate of new infections per time unit) and risk of infection (probability of at least one new infection), we estimated that 18 (95% CI 12-22) individuals who arrived in seven of the evaluated cities were infected. When basic ZIKV reproduction numbers greater than one were assumed in the seven evaluated cities, ZIKV could have been introduced in any one of the cities. Based on the force of infection in FP, basic reproduction ZIKV number in selected Brazilian cities, and estimated travel volume, we concluded that ZIKV was most likely introduced and established in Brazil by infected travellers arriving from FP in the period between October 2013 and March 2014, which was prior to the two aforementioned sporting events.
C1 [Massad, E.; Nascimento Burattini, M.; Coutinho, F. A. B.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Massad, E.] London Sch Hyg & Trop Med, London, England.
   [Nascimento Burattini, M.] Univ Fed Sao Paulo, Sao Paulo, Brazil.
   [Khan, K.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.
   [Struchiner, C. J.] Fundacao Oswaldo Cruz, Programme Sci Computat, Rio De Janeiro, Brazil.
   [Wilder-Smith, A.] Heidelberg Univ, Inst Publ Hlth, Heidelberg, Germany.
   [Wilder-Smith, A.] Umea Univ, Dept Publ Hlth & Clin Med Epidemiol & Global Hlth, SE-90185 Umea, Sweden.
   [Wilder-Smith, A.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London, England.
EM edmassad@usp.br
RI Wilder-Smith, Annelies/F-8751-2015; Struchiner, Claudio J/M-9360-2013;
   Burattini, Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011;
   Massad, Eduardo/B-1169-2012
OI Struchiner, Claudio J/0000-0003-2114-847X; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Massad, Eduardo/0000-0002-7200-2916
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); ZikaPLAN through the European Union's Horizon 2020 Research and
   Innovation Programme [734584]; Canadian Institutes of Health Research
   (CIHR)Canadian Institutes of Health Research (CIHR); consortium
   Canada-Latin/America-Caribbean Zika Virus Program [372512]; 
   [LIM01-HCFMUSP]
FX This work has been funded by LIM01-HCFMUSP; CNPq; ZikaPLAN through the
   European Union's Horizon 2020 Research and Innovation Programme under
   grant agreement No. 734584; and Canadian Institutes of Health Research
   (CIHR), consortium Canada-Latin/America-Caribbean Zika Virus Program
   (Grant 372512).
CR Amaku M, 2016, B MATH BIOL, V78, P970, DOI 10.1007/s11538-016-0170-4
   Brasil P., 2016, NEW ENGLAND J MED
   Burattini MN, 2016, EPIDEMIOL INFECT, V144, P1904, DOI 10.1017/S0950268816000649
   Enserink M., 2015, INFECT DIS OBSCURE M, P1012
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Funk S, 2016, BIORXIV, DOI [10.1101/043265, DOI 10.1101/043265]
   Lednicky J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004687
   Lopez LF, 2016, B MATH BIOL, V78, P185, DOI 10.1007/s11538-015-0135-z
   Massad E, 2013, EPIDEMIOL INFECT, V141, P412, DOI 10.1017/S0950268812000507
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Massad E, 2016, LANCET, V388, P658, DOI 10.1016/S0140-6736(16)31228-4
   Massad E, 2016, LANCET, V388, P25, DOI 10.1016/S0140-6736(16)30842-X
   Massad E, 2016, GLOBAL HEALTH ACTION, V9, P1, DOI 10.3402/gha.v9.31669
   Massad E, 2014, LANCET INFECT DIS, V14, P552, DOI 10.1016/S1473-3099(14)70807-2
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Massad E, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-130
   Massad E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-296
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2015, LANCET, V386, P243, DOI 10.1016/S0140-6736(15)61273-9
   Tabatabaei S, 2015, INT J INFECT, V2
   World Health Organization, HIST ZIK VIR
   Ximenes R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1517-z
   Zanluca C, 2015, MEM I OSWALDO CRUZ, V110, P569, DOI 10.1590/0074-02760150192
   Zinszer K, 2017, EMERG INFECT DIS, V23, P92, DOI 10.3201/eid2301.161274
NR 25
TC 19
Z9 20
U1 0
U2 19
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD AUG
PY 2017
VL 145
IS 11
BP 2303
EP 2312
DI 10.1017/S0950268817001200
PG 10
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA FF6MC
UT WOS:000409124100015
PM 28675351
OA Bronze
DA 2020-12-08
ER

PT J
AU Amaku, M
   Azevedo, F
   Burattini, MN
   Coelho, GE
   Coutinho, FAB
   Greenhalgh, D
   Lopez, LF
   Motitsuki, RS
   Wilder-Smith, A
   Massad, E
AF Amaku, M.
   Azevedo, F.
   Burattini, M. N.
   Coelho, G. E.
   Coutinho, F. A. B.
   Greenhalgh, D.
   Lopez, L. F.
   Motitsuki, R. S.
   Wilder-Smith, A.
   Massad, E.
TI Magnitude and frequency variations of vector-borne infection outbreaks
   using the Ross-Macdonald model: explaining and predicting outbreaks of
   dengue fever
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Dengue; geo-spatial epidemiology; mathematical models; outbreak
   patterns; vectorborne infections
ID THRESHOLD CONDITIONS; TRANSMISSION
AB The classical Ross-Macdonald model is often utilized to model vector-borne infections; however, this model fails on several fronts. First, using measured (or estimated) parameters, which values are accepted from the literature, the model predicts a much greater number of cases than what is usually observed. Second, the model predicts a single large outbreak that is followed by decades of much smaller outbreaks, which is not consistent with what is observed. Usually towns or cities report a number of recurrences for many years, even when environmental changes cannot explain the disappearance of the infection between the peaks. In this paper, we continue to examine the pitfalls in modelling this class of infections, and explain that, if properly used, the Ross-Macdonald model works and can be used to understand the patterns of epidemics and even, to some extent, be used to make predictions. We model several outbreaks of dengue fever and show that the variable pattern of yearly recurrence (or its absence) can be understood and explained by a simple Ross-Macdonald model modified to take into account human movement across a range of neighbourhoods within a city. In addition, we analyse the effect of seasonal variations in the parameters that determine the number, longevity and biting behaviour of mosquitoes. Based on the size of the first outbreak, we show that it is possible to estimate the proportion of the remaining susceptible individuals and to predict the likelihood and magnitude of the eventual subsequent outbreaks. This approach is described based on actual dengue outbreaks with different recurrence patterns from some Brazilian regions.
C1 [Amaku, M.; Azevedo, F.; Burattini, M. N.; Coutinho, F. A. B.; Lopez, L. F.; Motitsuki, R. S.; Massad, E.] Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, SP, Brazil.
   [Burattini, M. N.] Univ Fed Sao Paulo, Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Coelho, G. E.] Minist Saude, Brasilia, DF, Brazil.
   [Greenhalgh, D.] Univ Strathclyde, Dept Math & Stat, Glasgow, Lanark, Scotland.
   [Lopez, L. F.] Florida Int Univ, Ctr Internet Augmented Res & Assessment, Miami, FL 33199 USA.
   [Wilder-Smith, A.] Nanyang Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Massad, E.] London Sch Hyg & Trop Med, London, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Amaku,
   Marcos/D-5252-2012; Wilder-Smith, Annelies/F-8751-2015; Coutinho,
   Francisco A B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Lopez, Luis
   F/0000-0003-4097-6887; Amaku, Marcos/0000-0003-4752-6774; Coutinho,
   Francisco A B/0000-0003-3127-3071
FU LIM01 HCFMUSP, Fapesp [2014/26229-7, 2014/26327-9]; CNPqNational Council
   for Scientific and Technological Development (CNPq); Dengue Tools under
   the Seventh Framework Programme of the European Community [282589];
   MS/FNS [777588/2012]
FX This work was partially supported by LIM01 HCFMUSP, Fapesp (2014/26229-7
   and 2014/26327-9), CNPq, Dengue Tools under the Seventh Framework
   Programme of the European Community, grant agreement no. 282589, and
   MS/FNS (grant no. 777588/2012).
CR Amaku M, 2015, EPIDEMIOL INFECT, V143, P1803, DOI 10.1017/S0950268814002660
   Amaku M, 2014, B MATH BIOL, V76, P697, DOI 10.1007/s11538-014-9939-5
   Amaku M, 2010, B MATH BIOL, V72, P1294, DOI 10.1007/s11538-009-9495-6
   Ball F, 2015, EPIDEMICS-NETH, V10, P63, DOI 10.1016/j.epidem.2014.08.001
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Braga C, 2010, ACTA TROP, V113, P234, DOI 10.1016/j.actatropica.2009.10.021
   Burattini M. N., 2008, BIOSCI HYPOTHESES, V1, P168, DOI DOI 10.1016/J.BIHY.2008.05.003
   Chastel C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00070
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Garba SM, 2008, MATH BIOSCI, V215, P11, DOI 10.1016/j.mbs.2008.05.002
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Li J, 2011, COMPUT MATH METHOD M, DOI 10.1155/2011/527610
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Massad E, 2004, MED HYPOTHESES, V63, P911, DOI 10.1016/j.mehy.2004.03.028
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Monath TP, 1996, FIELD VIROL, V3, P961
NR 16
TC 7
Z9 7
U1 0
U2 26
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 2016
VL 144
IS 16
BP 3435
EP 3450
DI 10.1017/S0950268816001448
PG 16
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA ED1QY
UT WOS:000388621200010
PM 27538702
OA Green Accepted, Bronze
DA 2020-12-08
ER

PT J
AU Macciocchi, D
   Lanini, S
   Vairo, F
   Zumla, A
   Figueiredo, LTM
   Lauria, FN
   Strada, G
   Brouqui, P
   Puro, V
   Krishna, S
   Kremsner, P
   Scognamiglio, P
   Kohler, C
   Nicastri, E
   Di Caro, A
   Cieri, RM
   Ioannidis, JPA
   Kobinger, G
   Burattini, MN
   Ippolito, G
AF Macciocchi, Daniele
   Lanini, Simone
   Vairo, Francesco
   Zumla, Alimuddin
   Moraes Figueiredo, Luiz Tadeu
   Lauria, Francesco Nicola
   Strada, Gino
   Brouqui, Philippe
   Puro, Vincenzo
   Krishna, Sanjeev
   Kremsner, Peter
   Scognamiglio, Paola
   Kohler, Carsten
   Nicastri, Emanuele
   Di Caro, Antonino
   Cieri, Rodolfo Maria
   Ioannidis, John P. A.
   Kobinger, Gary
   Burattini, Marcelo Nascimento
   Ippolito, Giuseppe
TI Short-term economic impact of the Zika virus outbreak
SO NEW MICROBIOLOGICA
LA English
DT Article
DE Zika Virus Infection; Disease Outbreaks; Latin America; Economics;
   Behavioral
ID HEALTH; AMERICA
AB Zika virus (ZIKV) is mainly transmitted by mosquitoes bites. However, transmission by sexual contacts has been reported in 11 non endemic countries. The rapid spread of ZIKV in Latin American and Caribbean Countries (LCR), person-to-person transmission and perceived risk on people's well being can affect the emerging economies of LCR which historically dependent on truism. Here we present an analysis on economic outputs for assessing the current impact of ZIKV on markets. Our analysis show an unexpected resilience of LCR markets to international alerts. This positive response represents an opportunity to scale-up interventions for preventing the further spreading of the ZIKV epidemic.
C1 [Macciocchi, Daniele] Univ Utah, David Eccles Sch Business, Salt Lake City, UT USA.
   [Lanini, Simone; Vairo, Francesco; Lauria, Francesco Nicola; Puro, Vincenzo; Scognamiglio, Paola; Nicastri, Emanuele; Di Caro, Antonino; Ippolito, Giuseppe] Lazzaro Spallanzani Natl Inst Infect Dis IRCCS, Rome, Italy.
   [Zumla, Alimuddin; Krishna, Sanjeev] UCL, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] UCL Hosp Natl Hlth Serv Fdn Trust, UK Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Moraes Figueiredo, Luiz Tadeu] Univ Sao Paulo, FMRP, CPV, Ribeirao Preto, SP, Brazil.
   [Strada, Gino] Emergency NGO, Milan, Italy.
   [Brouqui, Philippe] Inst Hosp Univ Mediterranee, Serv Malad Infect & Trop, Marseille, France.
   [Kremsner, Peter; Kohler, Carsten] Univ Klinikum Tubingen, Inst Tropenmed, Tubingen, Germany.
   [Kremsner, Peter; Kohler, Carsten] Ctr Rech Med Lambarene, Lambarene, Gabon.
   [Lanini, Simone; Vairo, Francesco; Zumla, Alimuddin; Di Caro, Antonino; Cieri, Rodolfo Maria; Kobinger, Gary; Ippolito, Giuseppe] Int Publ Hlth Crisis Grp, Rome, Italy.
   [Ioannidis, John P. A.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Stanford, CA 94305 USA.
   [Kobinger, Gary] Quebec Laval Univ, Infect Dis Res Ctr, Fac Med, Dept Microbiol & Immunol, Quebec City, PQ, Canada.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] LIM01 HCFMUSP, Sao Paulo, SP, Brazil.
RP Lanini, S (corresponding author), Lazzaro Spallanzani Natl Inst Infect Dis IRCCS, Rome, Italy.; Lanini, S (corresponding author), Int Publ Hlth Crisis Grp, Rome, Italy.
EM simone.lanini@inmi.it
RI Burattini, Marcelo N/J-9272-2014; Brouqui, Philippe/P-5771-2016;
   Ippolito, Giuseppe/J-7207-2017; Di Caro, Antonino/K-6854-2016; ZUMLA,
   Alimuddin/ABA-8208-2020; nicastri, emanuele/K-7780-2016; Lanini,
   Simone/C-7523-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Di Caro,
   Antonino/0000-0001-6027-3009; nicastri, emanuele/0000-0002-5606-8712;
   Lanini, Simone/0000-0002-6743-4001; Ippolito,
   Giuseppe/0000-0002-1076-2979; Zumla, Professor Sir
   Alimuddin/0000-0002-5111-5735
FU Italian Ministry of Health (Ricerca Corrente)Ministry of Health, Italy
FX the Italian Ministry of Health (Ricerca Corrente).
CR Attaran A, 2016, COMMUNICATION
   Gostin L. O, 2016, JAMA-J AM MED ASSOC, V15, P2395
   Hoyt K, 2016, NAT BIOTECHNOL, V34, P384, DOI 10.1038/nbt.3532
   Ippolito G, 2015, NEW MICROBIOL, V38, P1
   Kieny MP, 2016, LANCET, V387, P1509, DOI 10.1016/S0140-6736(16)00686-3
   Liuzzi G, 2016, EUR J INTERN MED, P30091
   Liuzzi G, 2016, NEW MICROBIOL, V39, P83
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Nicastri E, 2016, LANCET INFECT DIS, V16, P771, DOI 10.1016/S1473-3099(16)30074-3
   Petersen E, 2016, INT J INFECT DIS, V44, P11, DOI 10.1016/j.ijid.2016.02.001
   Rasmussen SA, 2016, NEW ENGL J MED, V374, P1981, DOI 10.1056/NEJMsr1604338
   Roa M, 2016, LANCET, V387, P843, DOI 10.1016/S0140-6736(16)00331-7
   Turrini F, 2016, NEW MICROBIOL, V39, P86
   WHO, 2016, WHO ZIK SIT REP 11 A
   WHO, 2016, WHO ZIK SIT REP 10 M
   WHO, 2016, 1 M INT HLTH REG 200
   World Bank, 2016, SHORT TERM EC COSTS
   World Health Organisation, 2016, WHO DIR GEN SUMM OUT
   Zumla A, 2016, INT J INFECT DIS, V47, P1, DOI 10.1016/j.ijid.2016.06.010
   Zumla A, 2016, INT J INFECT DIS, V47, P5, DOI 10.1016/j.ijid.2016.06.012
NR 20
TC 11
Z9 11
U1 0
U2 7
PU EDIZIONI INT SRL
PI PAVIA
PA DIV EDIMES, EDIZIONI MEDICO SCIENTIFICHE PAVIA, VIA RIVIERA, PAVIA,
   39-27100, ITALY
SN 1121-7138
J9 NEW MICROBIOL
JI New Microbiol.
PD OCT
PY 2016
VL 39
IS 4
BP 287
EP 289
PG 3
WC Microbiology
SC Microbiology
GA EI4NB
UT WOS:000392469400007
PM 28004846
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Coutinho, FAB
   Lopez, LF
   Ximenes, R
   Quam, M
   Wilder-Smith, A
   Massad, E
AF Burattini, M. N.
   Coutinho, F. A. B.
   Lopez, L. F.
   Ximenes, R.
   Quam, M.
   Wilder-Smith, A.
   Massad, E.
TI Potential exposure to Zika virus for foreign tourists during the 2016
   Carnival and Olympic Games in Rio de Janeiro, Brazil
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
C1 [Burattini, M. N.; Coutinho, F. A. B.; Lopez, L. F.; Ximenes, R.; Massad, E.] Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
   [Burattini, M. N.] Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Lopez, L. F.] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Quam, M.] Umea Univ, Epidemiol & Global Hlth, Umea, Sweden.
   [Wilder-Smith, A.] Lee Kong Chian Sch Med, Nanyang, Singapore.
   [Wilder-Smith, A.] Nanyang Technol Univ, Singapore 639798, Singapore.
   [Massad, E.] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Ximenes, Raphael/G-2881-2014;
   Massad, Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014;
   Wilder-Smith, Annelies/F-8751-2015; Lopez, Luis F/C-4721-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Ximenes,
   Raphael/0000-0003-2536-951X; Massad, Eduardo/0000-0002-7200-2916;
   Burattini, Marcelo N/0000-0002-5407-6890; Lopez, Luis
   F/0000-0003-4097-6887
FU HSP/ UNIFESP; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2012/18463-4]; Ministry of Health (Fundo Nacional de
   Saude) [27835/2012]; DengueTools under Health theme of Seventh Framework
   Programme of the European Community [282589]; DengueTools: innovative
   tools and strategies for the surveillance and control of dengue; 
   [LIM01-HCFMUSP]
FX This study received partial funding from LIM01-HCFMUSP, HSP/ UNIFESP,
   CNPq, FAPESP (grant no. 2012/18463-4), Ministry of Health (Fundo
   Nacional de Saude, grant no. 27835/2012), and was also partially funded
   by DengueTools under the Health theme of the Seventh Framework Programme
   of the European Community (grant agreement no. 282589), DengueTools:
   innovative tools and strategies for the surveillance and control of
   dengue.
CR Delatte H, 2010, VECTOR-BORNE ZOONOT, V10, P249, DOI 10.1089/vbz.2009.0026
   European Centre for Disease Prevention and Control, 2015, RAP RISK ASS ZIK VIR
   Lopez LF, 2016, B MATH BIOL, V78, P185, DOI 10.1007/s11538-015-0135-z
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   WHO, DENGUE
   World Health Organization, ZIK VIR POT COMPL
NR 7
TC 18
Z9 18
U1 0
U2 41
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2016
VL 144
IS 9
BP 1904
EP 1906
DI 10.1017/S0950268816000649
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA DO5JV
UT WOS:000377820300013
PM 27040593
OA Bronze
DA 2020-12-08
ER

PT J
AU Amaku, M
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
   Mesquita, F
   Naveira, MCM
   Pereira, GFM
   Santos, ME
   Massad, E
AF Amaku, Marcos
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
   Lopez, Luis Fernandez
   Mesquita, Fabio
   Moscoso Naveira, Marcelo Contardo
   Mendes Pereira, Gerson Fernando
   Santos, Melina Erica
   Massad, Eduardo
TI Estimating the Size of the HCV Infection Prevalence: A Modeling Approach
   Using the Incidence of Cases Reported to an Official Notification System
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Hepatitis C; Mathematical models; Notification system incidence;
   Prevalence
ID HEPATITIS-C-VIRUS; GLOBAL EPIDEMIOLOGY; BRAZILIAN PRISONERS; HIV;
   TRANSMISSION; PROGRESSION
AB In this paper we propose two methods to give a first rough estimate of the actual number of hepatitis C virus (HCV)-infected individuals (prevalence) taking into account the notification rate of newly diagnosed infections (incidence of notification) and the size of the liver transplantation waiting list (LTWL) of patients with liver failure due to chronic HCV infection. Both approaches, when applied to the Brazilian HCV situation converge to the same results, that is, the methods proposed reproduce both the prevalence of reported cases and the LTWL with reasonable accuracy. We use two methods to calculate the prevalence of HCV that, as a first, and very crude approximation, assumes that the actual prevalence of HCV in Brazil is proportional to the reported incidence to the official notification system with a constant denoted . In the paper we discuss the limitations and advantages of this assumption. With the two methods we calculated , which reproduces both the reported incidence and the size of the LTWL. With the value of we calculated the prevalence I(a) (the integral of which resulted in 1.6 million people living with the infection in Brazil, most of whom unidentified). Other variables related to HCV infection (e.g., the distribution of the proportion of people aged a who got infected n years ago) can be easily calculated from this model. These new variables can then be measured and the model can be recursively updated, improving its accuracy.
C1 [Amaku, Marcos; Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
   [Amaku, Marcos; Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] LIM01 HCFMUSP, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, Miami, FL 33199 USA.
   [Mesquita, Fabio; Moscoso Naveira, Marcelo Contardo; Mendes Pereira, Gerson Fernando; Santos, Melina Erica] Minist Saude Brazil, Dept DST AIDS & Hepatites Virais, Brasilia, DF, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.; Massad, E (corresponding author), LIM01 HCFMUSP, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London WC1, England.
EM edmassad@dim.fm.usp.br
RI Amaku, Marcos/D-5252-2012; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Mesquita, Fabio/AAZ-7021-2020; Burattini,
   Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012
OI Amaku, Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916;
   Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Lopez, Luis F/0000-0003-4097-6887; Naveira,
   Marcelo/0000-0002-0555-5254; Mesquita, Fabio/0000-0002-8297-0224
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Ministry of Health of Brazil;  [LIM01-HCFMUSP]
FX This work was partially supported by grants from LIM01-HCFMUSP, FAPESP,
   CNPq and Ministry of Health of Brazil.
CR Ackerman Z, 2000, J VIRAL HEPATITIS, V7, P93
   Amaku M, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051907
   Burattini MN, 2000, REV SAUDE PUBL, V34, P431, DOI 10.1590/S0034-89102000000500001
   Chaib E, 2013, ABCD-ARQ BRAS CIR DI, V26, P324, DOI 10.1590/S0102-67202013000400014
   Chaib E, 2010, MED HYPOTHESES, V75, P324, DOI 10.1016/j.mehy.2010.03.013
   Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076
   Cox AL, 2015, SCIENCE, V349, P790, DOI 10.1126/science.aad1302
   CROFTS N, 1999, TECHNICAL REPORT SER, V3
   Custer B, 2004, J CLIN GASTROENTEROL, V38, pS158, DOI 10.1097/00004836-200411003-00008
   Giannini C, 2003, CELL DEATH DIFFER, V10, pS27, DOI 10.1038/sj.cdd.4401121
   Gower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027
   Hill A, 2014, SCIENCE, V345, P141, DOI 10.1126/science.1257737
   Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227
   Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107
   Lawrence S P, 2000, Adv Intern Med, V45, P65
   Massad E, 2009, EPIDEMIOL INFECT, V137, P241, DOI 10.1017/S0950268808000873
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   Nakano T, 2012, LIVER INT, V32, P339, DOI 10.1111/j.1478-3231.2011.02684.x
   Romano CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011170
   Rosen HR, 2011, NEW ENGL J MED, V364, P2429, DOI 10.1056/NEJMcp1006613
   Shepard CW, 2005, LANCET INFECT DIS, V5, P558, DOI 10.1016/S1473-3099(05)70216-4
   Simmonds P, 2013, CURR TOP MICROBIOL, V369, P1, DOI 10.1007/978-3-642-27340-7_1
   Strazza L, 2007, CAD SAUDE PUBLICA, V23, P197, DOI 10.1590/S0102-311X2007000100021
   Thein HH, 2008, HEPATOLOGY, V48, P418, DOI 10.1002/hep.22375
   VANDENHOEK JAR, 1990, J INFECT DIS, V162, P823, DOI 10.1093/infdis/162.4.823
   Reiche EMV, 2008, INT J MOL MED, V21, P387
NR 26
TC 7
Z9 7
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD MAY
PY 2016
VL 78
IS 5
BP 970
EP 990
DI 10.1007/s11538-016-0170-4
PG 21
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA DO7AF
UT WOS:000377933900006
PM 27160282
DA 2020-12-08
ER

PT J
AU Ximenes, R
   Amaku, M
   Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Greenhalgh, D
   Wilder-Smith, A
   Struchiner, CJ
   Massad, E
AF Ximenes, Raphael
   Amaku, Marcos
   Lopez, Luis Fernandez
   Bezerra Coutinho, Francisco Antonio
   Burattini, Marcelo Nascimento
   Greenhalgh, David
   Wilder-Smith, Annelies
   Struchiner, Claudio Jose
   Massad, Eduardo
TI The risk of dengue for non-immune foreign visitors to the 2016 summer
   olympic games in Rio de Janeiro, Brazil
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE Dengue; Mathematical models; Risk assessment; Olympic games; Travel
   medicine
ID FIFA WORLD CUP; REEMERGENCE; VIRUSES
AB Background: Rio de Janeiro in Brazil will host the Summer Olympic Games in 2016. About 400,000 non-immune foreign tourists are expected to attend the games. As Brazil is the country with the highest number of dengue cases worldwide, concern about the risk of dengue for travelers is justified.
   Methods: A mathematical model to calculate the risk of developing dengue for foreign tourists attending the Olympic Games in Rio de Janeiro in 2016 is proposed. A system of differential equation models the spread of dengue amongst the resident population and a stochastic approximation is used to assess the risk to tourists. Historical reported dengue time series in Rio de Janeiro for the years 2000-2015 is used to find out the time dependent force of infection, which is then used to estimate the potential risks to a large tourist cohort. The worst outbreak of dengue occurred in 2012 and this and the other years in the history of Dengue in Rio are used to discuss potential risks to tourists amongst visitors to the forthcoming Rio Olympics.
   Results: The individual risk to be infected by dengue is very much dependent on the ratio asymptomatic/symptomatic considered but independently of this the worst month of August in the period studied in terms of dengue transmission, occurred in 2007.
   Conclusions: If dengue returns in 2016 with the pattern observed in the worst month of August in history (2007), the expected number of symptomatic and asymptomatic dengue cases among tourists will be 23 and 206 cases, respectively. This worst case scenario would have an incidence of 5.75 (symptomatic) and 51.5 (asymptomatic) per 100,000 individuals.
C1 [Ximenes, Raphael; Amaku, Marcos; Lopez, Luis Fernandez; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento; Greenhalgh, David; Massad, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.
   [Ximenes, Raphael; Amaku, Marcos; Lopez, Luis Fernandez; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento; Greenhalgh, David; Massad, Eduardo] HCFMUSP LIM01, Sao Paulo, SP, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, Ctr Internet Augmented Res & Assessment, Miami, FL 33199 USA.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Greenhalgh, David] Univ Strathclyde, Glasgow, Lanark, Scotland.
   [Wilder-Smith, Annelies] Nanyang Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Struchiner, Claudio Jose] Fundacao Oswaldo Cruz, Programme Sci Computat, Rio De Janeiro, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, SP, Brazil.; Massad, E (corresponding author), HCFMUSP LIM01, Sao Paulo, SP, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London WC1, England.
EM edmassad@usp.br
RI Wilder-Smith, Annelies/F-8751-2015; Coutinho, Francisco A B/H-5644-2011;
   Burattini, Marcelo N/J-9272-2014; Struchiner, Claudio J/M-9360-2013;
   Lopez, Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012; Ximenes,
   Raphael/G-2881-2014; Amaku, Marcos/D-5252-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Struchiner, Claudio J/0000-0003-2114-847X; Lopez,
   Luis F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916;
   Ximenes, Raphael/0000-0003-2536-951X; Amaku, Marcos/0000-0003-4752-6774
FU LIM01-HCFMUSP; CNPqNational Council for Scientific and Technological
   Development (CNPq) [300981/2014-7]; FAPESPFundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2012/18463-4]; Brazilian Ministry of
   Health (Fundo Nacional de Saude) [777588/2012]; Dengue Tools under the
   Health theme of the Seventh Framework Programme of the European
   Community [282589]; Leverhulme Trust Research FellowshipLeverhulme Trust
   [RF-2015-88]
FX Funding This study received partial funding from LIM01-HCFMUSP, CNPq
   (grant 300981/2014-7), FAPESP (grant 2012/18463-4), Brazilian Ministry
   of Health (Fundo Nacional de Saude, grant 777588/2012), Dengue Tools
   under the Health theme of the Seventh Framework Programme of the
   European Community (Grant Agreement Number 282589) and was also
   partially funded by Leverhulme Trust Research Fellowship grant
   (RF-2015-88) (DG).
CR Aguiar M, 2015, SCI REP-UK, V5, DOI 10.1038/srep10570
   Aguiar M, 2015, LANCET INFECT DIS, V15, P765, DOI 10.1016/S1473-3099(15)00073-0
   Amaku M, 2015, EPIDEMIOL INFECT, V143, P1803, DOI 10.1017/S0950268814002660
   [Anonymous], COORD GER PROGR NAC
   Barcellos C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003022
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Chastel C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00070
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Duong V, 2015, PNAS, P1
   Earnest A, 2012, EPIDEMIOL INFECT, V140, P1244, DOI 10.1017/S095026881100183X
   Harley D, 2014, LANCET INFECT DIS, V14, P543, DOI 10.1016/S1473-3099(14)70797-2
   Hay S, 2013, NATURE, V503, P439, DOI 10.1038/503439a
   Heringer M, 2015, T ROY SOC TROP MED H, V109, P268, DOI 10.1093/trstmh/trv006
   Khan K, 2010, CAN MED ASSOC J, V182, P579, DOI 10.1503/cmaj.100093
   Liu-Helmersson J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089783
   Lowe R, 2014, LANCET INFECT DIS, V14, P619, DOI 10.1016/S1473-3099(14)70781-9
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Rodriguez-Barraquer I, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000935
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Wilder-Smith Annelies, 2010, Curr Infect Dis Rep, V12, P157, DOI 10.1007/s11908-010-0102-7
   Wilson ME, 2014, CLIN INFECT DIS, V58, P1347, DOI 10.1093/cid/ciu122
   Woolhouse M, 2011, PHILOS T R SOC B, V366, P2045, DOI 10.1098/rstb.2010.0387
NR 26
TC 20
Z9 20
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD APR 29
PY 2016
VL 16
AR 186
DI 10.1186/s12879-016-1517-z
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA DK7BU
UT WOS:000375080600001
PM 27129407
OA DOAJ Gold, Green Accepted, Green Published
DA 2020-12-08
ER

PT J
AU Burattini, MN
AF Burattini, Marcelo Nascimento
TI Infectious diseases in the XXI century
SO ACTA PAULISTA DE ENFERMAGEM
LA English
DT Editorial Material
ID RIO-DE-JANEIRO; FOREIGN VISITORS; OLYMPIC GAMES; DENGUE; BRAZIL; RISK
C1 [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Minist Hlth, Brasilia, DF, Brazil.
RP Burattini, MN (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.; Burattini, MN (corresponding author), Univ Sao Paulo, Sao Paulo, SP, Brazil.; Burattini, MN (corresponding author), Minist Hlth, Brasilia, DF, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR Attaran A., 2016, HARVARD PUBLIC HLTH
   Burattini MN, 2016, EPIDEMIOL INFECT, V144, P1904, DOI 10.1017/S0950268816000649
   Codeco C, 2016, MEM I OSWALDO CRUZ, V111, P414, DOI 10.1590/0074-02760160003
   Hay S, 2013, NATURE, V503, P439, DOI 10.1038/503439a
   Johnson-Hanks J, 2008, ANNU REV ANTHROPOL, V37, P301, DOI 10.1146/annurev.anthro.37.081407.085138
   Lopez LF, 2016, B MATH BIOL, V78, P185, DOI 10.1007/s11538-015-0135-z
   Massad E., 2014, LANCET ID, V14, P619
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Porter R, 2006, CAMBRIDGE HISTORY OF MEDICINE, P1
   Ximenes R, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1517-z
NR 10
TC 0
Z9 0
U1 0
U2 1
PU UNIV FED SAO PAULO, DEPT ENFERMAGEN
PI SAO PAULO
PA RUA NAPOLEAO DE BARROS, 754 VILA CLEMENTINO, SAO PAULO, CEP04024-002,
   BRAZIL
SN 0103-2100
EI 1982-0194
J9 ACTA PAUL ENFERM
JI Acta Paul. Enferm.
PD MAR-APR
PY 2016
VL 29
IS 2
BP III
EP VI
DI 10.1590/1982-0194201600018
PG 4
WC Nursing
SC Nursing
GA EE7AH
UT WOS:000389765800001
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Amaku, M
   Coutinho, FAB
   Quam, M
   Burattini, MN
   Struchiner, CJ
   Wilder-Smith, A
   Massad, E
AF Lopez, Luis Fernandez
   Amaku, Marcos
   Bezerra Coutinho, Francisco Antonio
   Quam, Mikkel
   Burattini, Marcelo Nascimento
   Struchiner, Claudio Jose
   Wilder-Smith, Annelies
   Massad, Eduardo
TI Modeling Importations and Exportations of Infectious Diseases via
   Travelers
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Infectious disease importation; Infectious disease exportation;
   Travelers; Modeling; Risk
ID RISK; DENGUE; TRANSMISSION; SPREAD; TRENDS; VIRUS; EBOLA
AB This paper is an attempt to estimate the risk of infection importation and exportation by travelers. Two countries are considered: one disease-free country and one visited or source country with a running endemic or epidemic infectious disease. Two models are considered. In the first model (disease importation), susceptible individuals travel from their disease-free home country to the endemic country and come back after some weeks. The risk of infection spreading in their home country is then estimated supposing the visitors are submitted to the same force of infection as the local population but do not contribute to it. In the second model (disease exportation), it is calculated the probability that an individual from the endemic (or epidemic) country travels to a disease-free country in the condition of latent infected and eventually introduces the infection there. The input of both models is the force of infection at the visited/source country, assumed known. The models are deterministic, but a preliminary stochastic formulation is presented as an appendix. The models are exemplified with two distinct real situations: the risk of dengue importation from Thailand to Europe and the risk of Ebola exportation from Liberia to the USA.
C1 [Lopez, Luis Fernandez; Amaku, Marcos; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento; Massad, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Quam, Mikkel] Umea Univ, Epidemiol & Global Hlth, Umea, Sweden.
   [Burattini, Marcelo Nascimento] Hosp Sao Paulo, Escola Paulista Med, Sao Paulo, SP, Brazil.
   [Struchiner, Claudio Jose] Fiocruz MS, PROCC, BR-21045900 Rio De Janeiro, Brazil.
   [Wilder-Smith, Annelies] Lee Kong Chian Sch Med, Nanyang, Singapore.
   [Wilder-Smith, Annelies] Technol Univ, Singapore, Singapore.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.; Massad, E (corresponding author), London Sch Hyg & Trop Med, London WC1, England.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Amaku, Marcos/D-5252-2012; Lopez, Luis
   F/C-4721-2012; Wilder-Smith, Annelies/F-8751-2015; Burattini, Marcelo
   N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011; Struchiner, Claudio
   J/M-9360-2013
OI Massad, Eduardo/0000-0002-7200-2916; Amaku, Marcos/0000-0003-4752-6774;
   Lopez, Luis F/0000-0003-4097-6887; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Struchiner, Claudio J/0000-0003-2114-847X
FU HSP/UNIFESP; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); Ministry of Health (Fundo Nacional de Saude)
   [27835/2012]; DengueTools [282589];  [LIM01-HCFMUSP]
FX This study received partial funding from LIM01-HCFMUSP, HSP/UNIFESP,
   CNPq, FAPESP, Ministry of Health (Fundo Nacional de Saude, grant
   27835/2012), and was also partially funded by DengueTools (22) under the
   Health theme of the Seventh Framework Programme of the European
   Community (Grant Agreement Number 282589), DengueTools: innovative tools
   and strategies for the surveillance and control of dengue.
   <http://www.ncbi.nlm.nih.gov/pubmed/22451836> (Wilder-Smith et al.
   2012).
CR Amaku M, 2015, EPIDEMIOL INFECT, V143, P1803, DOI 10.1017/S0950268814002660
   ANDERSON R M, 1991
   Bossak BH, 2009, MED HYPOTHESES, V72, P749, DOI 10.1016/j.mehy.2008.12.045
   Caley P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000143
   Cox D. R., 1965, THEORY STOCHASTIC PR
   Gomes Marcelo F C, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.cd818f63d40e24aef769dda7df9e0da5
   Jones KE, 2008, NATURE, V451, P990, DOI 10.1038/nature06536
   Khan K, 2010, J TRAVEL MED, V17, P75, DOI 10.1111/j.1708-8305.2010.00397.x
   Khan K, 2009, NEW ENGL J MED, V361, P212, DOI 10.1056/NEJMc0904559
   Leder K, 2008, J TRAVEL MED, V15, P263, DOI 10.1111/j.1708-8305.2008.00218.x
   Leder K, 2013, EMERG INFECT DIS, V19, P1049, DOI 10.3201/eid1907.121573
   Lewnard JA, 2014, LANCET INFECT DIS, V14, P1189, DOI [10.1016/s1473-3099(14)70995-8, 10.1016/S1473-3099(14)70995-8]
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2005, MED HYPOTHESES, V65, P17, DOI 10.1016/j.mehy.2004.09.029
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 2004, MED HYPOTHESES, V63, P911, DOI 10.1016/j.mehy.2004.03.028
   Massad E, 2013, EPIDEMIOL INFECT, V141, P412, DOI 10.1017/S0950268812000507
   Massad E, 2007, MED HYPOTHESES, V68, P442, DOI 10.1016/j.mehy.2006.07.041
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Massad E, 2010, MEM I OSWALDO CRUZ, V105, P179, DOI 10.1590/S0074-02762010000200012
   Massad E, 2009, J TRAVEL MED, V16, P191, DOI 10.1111/j.1708-8305.2009.00310.x
   Pandey A, 2014, SCIENCE, V346, P991, DOI 10.1126/science.1260612
   Quam M, 2014, LANCET, V383, P1632, DOI 10.1016/S0140-6736(14)60537-7
   Tatem AJ, 2012, PARASITOLOGY, V139, P1816, DOI 10.1017/S0031182012000352
   WHO World Health Organization, 2014, WHO WHO EB RESP ROAD
   Wilder-Smith A, 2007, TROP MED INT HEALTH, V12, P1137, DOI 10.1111/j.1365-3156.2007.01912.x
   Wilder-Smith A, 2003, J TRAVEL MED, V10, P257
   Wilder-Smith Annelies, 2006, Travel Med Infect Dis, V4, P53, DOI 10.1016/j.tmaid.2005.04.004
   Wilder-Smith A, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.17273
NR 29
TC 28
Z9 28
U1 0
U2 22
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD FEB
PY 2016
VL 78
IS 2
BP 185
EP 209
DI 10.1007/s11538-015-0135-z
PG 25
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA DF3LG
UT WOS:000371244900001
PM 26763222
OA Green Published
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Lopez, LF
   Coutinho, FAB
   Siqueira, JB
   Homsani, S
   Sarti, E
   Massad, E
AF Burattini, Marcelo N.
   Lopez, Luis F.
   Coutinho, Francisco A. B.
   Siqueira-, Joao B., Jr.
   Homsani, Sheila
   Sarti, Elsa
   Massad, Eduardo
TI Age and regional differences in clinical presentation and risk of
   hospitalization for dengue in Brazil, 2000-2014
SO CLINICS
LA English
DT Article
DE Dengue; Morbidity; Epidemiology; Surveillance System; Hospitalization;
   Brazil
ID HEMORRHAGIC-FEVER; CASE DEFINITIONS; CLASSIFICATION; COUNTRIES
AB OBJECTIVES: Dengue cases range from asymptomatic to severe, eventually leading to hospitalization and death. Timely and appropriate management is critical to reduce morbidity. Since 1980, dengue has spread throughout Brazil, affecting an increasing number of individuals. This paper describes age and regional differences in dengue's clinical presentation and associated risk of hospitalization based on more than 5 million cases reported to the Brazilian Ministry of Health from 2000-2014.
   METHODS: We performed a retrospective analysis of similar to 5,450,000 dengue cases, relating clinical manifestations and the risk of hospitalization to age, gender, previous infection by dengue, dengue virus serotype, years of formal education, delay to first attendance and the occurrence of dengue during outbreaks and in different Brazilian regions.
   RESULTS: Complicated forms of dengue occurred more frequently among those younger than 10 years (3.12% vs 1.92%) and those with dengue virus 2 infection (7.65% vs 2.42%), with a delay to first attendance >2 days (3.18% vs 0.82%) and with <= 4 years of formal education (2.02% vs 1.46%). The risk of hospitalization was higher among those aged 6-10 years old (OR 4.57; 95% CI 1.43-29.96) and those who were infected by dengue virus 2 (OR 6.36; 95% CI 2.52-16.06), who lived in the Northeast region (OR 1.38; 95% CI 1.11-2.10) and who delayed first attendance by >5 days (composite OR 3.15; 95% CI 1.33-8.9).
   CONCLUSIONS: In Brazil, the occurrence of severe dengue and related hospitalization is associated with being younger than 10 years old, being infected by dengue virus 2 or 3, living in the Northeast region (the poorest and the second most populated) and delaying first attendance for more than 2 days.
C1 [Burattini, Marcelo N.; Lopez, Luis F.; Coutinho, Francisco A. B.; Massad, Eduardo] Univ Sao Paulo, Fac Med, Div Informat Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo N.] Escola Paulista Med, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
   [Lopez, Luis F.] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Siqueira-, Joao B., Jr.] Univ Fed Goias, Inst Trop Patol & Saude Publ, Goiania, Go, Brazil.
   [Homsani, Sheila] Sanofi Pasteur, Sao Paulo, SP, Brazil.
   [Sarti, Elsa] Sanofi Pasteur Latinoamer, Mexico City, DF, Mexico.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Fac Med, Div Informat Med, Sao Paulo, SP, Brazil.; Burattini, MN (corresponding author), Escola Paulista Med, Hosp Sao Paulo, Sao Paulo, SP, Brazil.
EM mnburatt@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014;
   Lopez, Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Lopez, Luis F/0000-0003-4097-6887; Massad,
   Eduardo/0000-0002-7200-2916
FU Fundo Nacional de Saude of the Brazilian Ministry of Health (FNS)
   [777588/2012]; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Hospital Sao Paulo (HSP); EPM-UNIFESP; Sanofi Pasteur; Dengue
   TOOLS (under the health theme of the Seven Framework Program of the
   European Community) [282589];  [LIM 01-HCFMUSP]
FX This work was partially supported by Fundo Nacional de Saude of the
   Brazilian Ministry of Health (FNS, Grant#777588/2012); Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP): MNB, LFL, EM;
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq):
   MNB, LFL, EM; LIM 01-HCFMUSP: MNB, LFL, EM; Hospital Sao Paulo (HSP) and
   EPM-UNIFESP: MNB; Sanofi Pasteur: SH & ES; and Dengue TOOLS (under the
   health theme of the Seven Framework Program of the European Community,
   Grant #282589): EM. The sponsors did not participate in the data
   collection, data analysis, or data interpretation or in the writing of
   the manuscript.
CR Alexander N, 2011, TROP MED INT HEALTH, V16, P936, DOI 10.1111/j.1365-3156.2011.02793.x
   [Anonymous], 2009, DENG GUID DIAGN TREA
   Bandyopadhyay S, 2006, TROP MED INT HEALTH, V11, P1238, DOI 10.1111/j.1365-3156.2006.01678.x
   Castillo VMS, 2011, REV CLIN MED FAM, V4, P25
   Cattand P, 2006, DIS CONTROL PRIORITI
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Cordeiro R, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-355
   Teixeira TRD, 2008, CAD SAUDE PUBLICA, V24, P2160, DOI 10.1590/S0102-311X2008000900022
   Deen JL, 2006, LANCET, V368, P170, DOI 10.1016/S0140-6736(06)69006-5
   Dom NC, 2013, PROCD SOC BEHV, V105, P183, DOI 10.1016/j.sbspro.2013.11.019
   Guha-Sapir D, 2005, EMERG THEMES EPIDEMI, V2, DOI 10.1186/1742-7622-2-1
   Lima FR, 2013, CLINICS, V68, P1299, DOI 10.6061/clinics/2013(10)02
   Margolis HS, 2014, 2014 YELLOW BOOK
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Ministerio da Saude, 2013, DENG DIAGN MAN CLIN
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Rigau-Perez JG, 2006, LANCET INFECT DIS, V6, P297, DOI 10.1016/S1473-3099(06)70465-0
   Rogers DJ, 2014, ACTA TROP, V129, P1, DOI 10.1016/j.actatropica.2013.08.008
   Siqueira JB, 2005, EMERG INFECT DIS, V11, P48, DOI 10.3201/eid1101.031091
   Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Viana Dione Viero, 2013, Rev. bras. epidemiol., V16, P240, DOI 10.1590/S1415-790X2013000200002
NR 22
TC 14
Z9 15
U1 0
U2 6
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2016
VL 71
IS 8
BP 455
EP 463
DI 10.6061/clinics/2016(08)08
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA DV4CK
UT WOS:000382872200008
PM 27626476
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Nunes, CM
   de Lima, VMF
   de Melo, GD
   de Paula, HB
   Pereira, MEG
   Tronco, CDT
   Hiramoto, RM
   Laurenti, MD
   Burattini, MN
AF Nunes, Caris Maroni
   Felix de Lima, Valeria Marcal
   de Melo, Guilherme Dias
   de Paula, Henrique Borges
   Goncalves Pereira, Maria Esther
   Trinconi Tronco, Cristiana de Melo
   Hiramoto, Roberto Mitsuyoshi
   Laurenti, Marcia Dalastra
   Burattini, Marcelo Nascimento
TI Serological, parasitological and molecular tests for canine visceral
   leishmaniosis diagnosis in a longitudinal study
SO REVISTA BRASILEIRA DE PARASITOLOGIA VETERINARIA
LA English
DT Article
DE Cohort studies; diagnosis; Leishmania infantum chagasi; parasitological
   evaluation; PCR; serology
ID POLYMERASE-CHAIN-REACTION; INFANTUM INFECTION; IMMUNE-RESPONSE;
   IMMUNOCHROMATOGRAPHIC-DIPSTICK; BRAZILIAN DOGS; ENDEMIC AREA; COHORT;
   TRANSMISSION; PCR
AB One of the measures to control visceral leishmaniosis (VL) in Brazil is the identification and culling of the canine reservoir. There is much controversy concerning this strategy, including the proper identification of positive dogs and the fact that the host-parasite relationship changes over time make it more challenging. A dynamic cohort of 62 dogs was followed every three months using serological and parasitological examinations and PCR. Positivity by PCR was higher than by serology and by parasitological examinations and showed a tendency to decrease over time, while serology tended to increase after six months. Concomitant positivity in all tests was observed in 10.4% of the samples, and negativity in 29.1%. Overall sensitivity ranged from 43.6 to 64.1%, and was not uniform over time. The proportion of dogs with or without clinical signs was not different by cytology or PCR but PCR was able to identify a larger number of asymptomatic dogs compared to ELISA and immunochromatography. PCR can be useful for surveillance of areas where cases of canine VL have not yet been detected and in which control strategies can be implemented to limit the spread of the disease. Despite the advance in diagnostic tools CVL diagnosis remains a challenge.
C1 [Nunes, Caris Maroni; Felix de Lima, Valeria Marcal; de Melo, Guilherme Dias] Univ Estadual Paulista UNESP, Fac Med Vet, Aracatuba, SP, Brazil.
   [Goncalves Pereira, Maria Esther] Co Integrada Desenvolvimento Agr St Catarina, Florianopolis, SC, Brazil.
   [Trinconi Tronco, Cristiana de Melo] Univ Sao Paulo, Inst Ciencias Biomed, Sao Paulo, SP, Brazil.
   [Hiramoto, Roberto Mitsuyoshi] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Laurenti, Marcia Dalastra; Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
RP Nunes, CM (corresponding author), Univ Estadual Paulista Julio de Mesquita Filho UN, Fac Med Vet, Dept Apoio Prod & Saude Anim, Rua Clovis Pestana 793, BR-16050680 Aracatuba, SP, Brazil.
EM caris@fmva.unesp.br
RI de Melo, Guilherme Dias/E-1691-2012; Nunes, Caris M/R-9337-2016; de
   Lima, Valeria M.F./B-7867-2013; Burattini, Marcelo N/J-9272-2014;
   Laurenti, Marcia Dalastra/C-4734-2012
OI de Melo, Guilherme Dias/0000-0003-0747-7760; Nunes, Caris
   M/0000-0002-5463-3845; de Lima, Valeria M.F./0000-0002-0954-5045;
   Burattini, Marcelo N/0000-0002-5407-6890; 
CR Almeida MAO, 2005, VET PARASITOL, V127, P227, DOI 10.1016/j.vetpar.2004.10.010
   Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X
   [Anonymous], 2006, MAN VIG CONTR LEISHM
   ASHFORD DA, 1995, AM J TROP MED HYG, V53, P251, DOI 10.4269/ajtmh.1995.53.251
   Barbieri CL, 2006, PARASITE IMMUNOL, V28, P329, DOI 10.1111/j.1365-3024.2006.00840.x
   Carson C, 2009, VET PARASITOL, V162, P207, DOI 10.1016/j.vetpar.2009.03.037
   Conraths FJ, 2006, VET PARASITOL, V136, P91, DOI 10.1016/j.vetpar.2005.12.004
   Costa C H, 2001, Rev Soc Bras Med Trop, V34, P223
   Coura-Vital W, 2013, VET PARASITOL, V197, P411, DOI 10.1016/j.vetpar.2013.07.031
   Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312
   da Silva DA, 2013, VET J, V195, P252, DOI 10.1016/j.tvjl.2012.06.010
   de Arruda MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069988
   de Lima VMF, 2005, PESQUISA VET BRASIL, V25, P215, DOI 10.1590/S0100-736X2005000400005
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   do Rosario EY, 2005, MEM I OSWALDO CRUZ, V100, P197, DOI 10.1590/S0074-02762005000200015
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   Falqueto A, 2009, AM J TROP MED HYG, V80, P559, DOI 10.4269/ajtmh.2009.80.559
   Franca-Silva JC, 2005, VET PARASITOL, V131, P213, DOI 10.1016/j.vetpar.2005.05.006
   Gontijo Célia Maria Ferreira, 2004, Rev. bras. epidemiol., V7, P338
   Grimaldi G, 2012, AM J TROP MED HYG, V86, P966, DOI 10.4269/ajtmh.2012.12-0040
   Grimaldi G, 2012, T ROY SOC TROP MED H, V106, P54, DOI 10.1016/j.trstmh.2011.10.001
   Instituto Brasileiro de Geografia e Estatistica-IBGE, 2013, EST POP MUN BRAS 01
   Laurenti MD, 2009, B EPIDEMIOLOGICO PAU, V6, P13
   Maia C, 2008, VET PARASITOL, V158, P274, DOI 10.1016/j.vetpar.2008.07.028
   Mettler M, 2005, J CLIN MICROBIOL, V43, P5515, DOI 10.1128/JCM.43.11.5515-5519.2005
   Moreira MAB, 2007, VET PARASITOL, V145, P245, DOI 10.1016/j.vetpar.2006.12.012
   Costa CHN, 2011, REV SOC BRAS MED TRO, V44, P232, DOI [10.1590/S0037-86822011005000014, 10.1590/s0037-86822011005000014]
   Nunes CM, 2007, REV BRAS PARASITOL V, V16, P5
   Nunes CM, 2008, VET PARASITOL, V153, P19, DOI 10.1016/j.vetpar.2008.01.005
   Oliva G, 2006, J CLIN MICROBIOL, V44, P1318, DOI 10.1128/JCM.44.4.1318-1322.2006
   Otranto D, 2013, TRENDS PARASITOL, V29, P339, DOI 10.1016/j.pt.2013.05.003
   Palatnik-de-Sousa CB, 2001, AM J TROP MED HYG, V65, P510, DOI 10.4269/ajtmh.2001.65.510
   Paradies P, 2010, VET J, V186, P370, DOI 10.1016/j.tvjl.2009.09.011
   Quinnell RJ, 2003, VET IMMUNOL IMMUNOP, V91, P161, DOI 10.1016/S0165-2427(02)00311-2
   Quinnell RJ, 1997, PARASITOLOGY, V115, P143, DOI 10.1017/S0031182097001200
   Quinnell RJ, 2001, PARASITOLOGY, V122, P253, DOI 10.1017/S0031182001007363
   Quinnell RJ, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001992
   Reis AB, 2006, RES VET SCI, V81, P68, DOI 10.1016/j.rvsc.2005.09.011
   Reis AB, 2009, VET IMMUNOL IMMUNOP, V128, P87, DOI 10.1016/j.vetimm.2008.10.307
   Reithinger R, 2002, J CLIN MICROBIOL, V40, P2352, DOI 10.1128/JCM.40.7.2352-2356.2002
   Rolim Glauco de Souza, 2007, Bragantia, V66, P711, DOI 10.1590/S0006-87052007000400022
   *SES SP, 2006, MAN VIG CONTR LEISHM
   Solano-Gallego L, 2001, J CLIN MICROBIOL, V39, P560, DOI 10.1128/JCM.39.2.560-563.2001
   Solano-Gallego L, 2009, VET PARASITOL, V165, P1, DOI 10.1016/j.vetpar.2009.05.022
NR 44
TC 4
Z9 4
U1 0
U2 9
PU BRAZILIAN COLL VETERINARY PARASITOLOGY
PI SAO PAULO
PA VIA ACESSO PROF PAULO DONATO CASTELLANS, S-Z, ZONA RURAL, JABOTICABAL,
   SAO PAULO, CEP14884-900, BRAZIL
SN 1984-2961
J9 REV BRAS PARASITOL V
JI Rev. Bras. Parasitol. Vet.
PD OCT-DEC
PY 2015
VL 24
IS 4
BP 402
EP 409
DI 10.1590/S1984-29612015073
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA CZ8JE
UT WOS:000367345200003
PM 26689179
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Massad, E
   Lopez, LF
   Amaku, M
   Coutinho, FAB
   Quam, M
   Burattini, MN
   Struchiner, CJ
   Wilder-Smith, A
AF Massad, E.
   Lopez, L. F.
   Amaku, M.
   Coutinho, F. A. B.
   Quam, M.
   Burattini, M. N.
   Struchiner, C. J.
   Wilder-Smith, A.
TI The risk of infectious diseases introduction into non-infected countries
   by travelers visiting endemic countries
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Massad, E.; Lopez, L. F.; Amaku, M.; Coutinho, F. A. B.; Burattini, M. N.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Quam, M.] Umea Univ, Umea, Sweden.
   [Struchiner, C. J.] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
   [Wilder-Smith, A.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 639798, Singapore.
RI Burattini, Marcelo N/J-9272-2014; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/B-1169-2012; Coutinho, Francisco A B/H-5644-2011; Struchiner,
   Claudio J/M-9360-2013; Lopez, Luis F/C-4721-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Amaku,
   Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916;
   Coutinho, Francisco A B/0000-0003-3127-3071; Struchiner, Claudio
   J/0000-0003-2114-847X; Lopez, Luis F/0000-0003-4097-6887
NR 0
TC 0
Z9 0
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD SEP
PY 2015
VL 20
SU 1
SI SI
MA PS2.098
BP 340
EP 340
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA CQ7BW
UT WOS:000360758802088
DA 2020-12-08
ER

PT J
AU Amaku, M
   Azevedo, F
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
   Massad, E
AF Amaku, M.
   Azevedo, F.
   Burattini, M. N.
   Coutinho, F. A. B.
   Lopez, L. F.
   Massad, E.
TI Interpretations and pitfalls in modelling vector-transmitted infections
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Dengue; mathematical modelling; vector-borne infections
ID THRESHOLD CONDITIONS; DENGUE; DYNAMICS; COMPLEX; SPREAD; NUMBER; FEVER;
   RISK
AB In this paper we propose a debate on the role of mathematical models in evaluating control strategies for vector-borne infections. Mathematical models must have their complexity adjusted to their goals, and we have basically two classes of models. At one extreme we have models that are intended to check if our intuition about why a certain phenomenon occurs is correct. At the other extreme, we have models whose goals are to predict future outcomes. These models are necessarily very complex. There are models in between these classes. Here we examine two models, one of each class and study the possible pitfalls that may be incurred. We begin by showing how to simplify the description of a complicated model for a vector-borne infection. Next, we examine one example found in a recent paper that illustrates the dangers of basing control strategies on models without considering their limitations. The model in this paper is of the second class. Following this, we review an interesting paper (a model of the first class) that contains some biological assumptions that are inappropriate for dengue but may apply to other vector-borne infections. In conclusion, we list some misgivings about modelling presented in this paper for debate.
C1 [Amaku, M.] Univ Sao Paulo, Sch Vet Med, Sao Paulo, Brazil.
   [Azevedo, F.; Burattini, M. N.; Coutinho, F. A. B.; Lopez, L. F.; Massad, E.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Azevedo, F.; Burattini, M. N.; Coutinho, F. A. B.; Lopez, L. F.; Massad, E.] LIM 01 HCFMUSP, Sao Paulo, Brazil.
   [Lopez, L. F.] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Massad, E.] Univ London, London Sch Hyg & Trop Med, London, England.
RP Coutinho, FAB (corresponding author), Ave Doutor Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM coutinho@dim.fm.usp.br
RI Amaku, Marcos/D-5252-2012; Coutinho, Francisco A B/H-5644-2011; Lopez,
   Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012; Burattini, Marcelo
   N/J-9272-2014
OI Amaku, Marcos/0000-0003-4752-6774; Coutinho, Francisco A
   B/0000-0003-3127-3071; Lopez, Luis F/0000-0003-4097-6887; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890
FU FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); Dengue Tools [282589]; MS/FNS [27835/2012];  [LIM01 HCFMUSP]
FX This work was partially supported by LIM01 HCFMUSP, Fapesp, CNPq, Dengue
   Tools under the Seventh Framework Programme of the European Community,
   grant agreement no. 282589, and MS/FNS (grant no. 27835/2012).
CR Amaku M, 2013, COMP MATH MATH PHYS, V2013
   Amaku M, 2014, B MATH BIOL, V76, P697, DOI 10.1007/s11538-014-9939-5
   ANDERSON R M, 1991
   Burattini MN, 2009, MED HYPOTHESES, V73, P110, DOI 10.1016/j.mehy.2009.01.036
   Coudeville L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051244
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Favier C, 2006, TROP MED INT HEALTH, V11, P332, DOI 10.1111/j.1365-3156.2006.01560.x
   Garba SM, 2008, MATH BIOSCI, V215, P11, DOI 10.1016/j.mbs.2008.05.002
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Lopez LF, 1999, MATH COMPUT MODEL, V29, P55, DOI 10.1016/S0895-7177(99)00062-X
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2010, TROP MED INT HEALTH, V15, P120, DOI 10.1111/j.1365-3156.2009.02413.x
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Massad E, 2011, LANCET, V377, P1630, DOI 10.1016/S0140-6736(11)60470-4
   Massad E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-296
   MAY RM, 1988, PHILOS T ROY SOC B, V321, P565, DOI 10.1098/rstb.1988.0108
   Mazilu DA, 2012, EUR J PHYS, V33, P793, DOI 10.1088/0143-0807/33/4/793
   Pinho STR, 2010, PHILOS T R SOC A, V368, P5679, DOI 10.1098/rsta.2010.0278
   Postnikov EB, 2007, MATH BIOSCI, V208, P205, DOI 10.1016/j.mbs.2006.10.004
   Riley S, EPIDEMICS IN PRESS
   Ross R., 1911, PREVENTION MALARIA
NR 22
TC 5
Z9 5
U1 0
U2 24
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2015
VL 143
IS 9
BP 1803
EP 1815
DI 10.1017/S0950268814002660
PG 13
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA CJ8NU
UT WOS:000355760600002
PM 25417817
DA 2020-12-08
ER

PT J
AU Laporta, GZ
   Burattini, MN
   Levy, D
   Fukuya, LA
   de Oliveira, TMP
   Maselli, LMF
   Conn, JE
   Massad, E
   Bydlowski, SP
   Sallum, MAM
AF Laporta, Gabriel Zorello
   Burattini, Marcelo Nascimento
   Levy, Debora
   Fukuya, Linah Akemi
   Porangaba de Oliveira, Tatiane Marques
   Ferreira Maselli, Luciana Morganti
   Conn, Jan Evelyn
   Massad, Eduardo
   Bydlowski, Sergio Paulo
   Mureb Sallum, Maria Anice
TI Plasmodium falciparum in the southeastern Atlantic forest: a challenge
   to the bromeliad-malaria paradigm?
SO MALARIA JOURNAL
LA English
DT Article
DE Atlantic forest; Anopheles; Forest fragment; Landscape; Malaria;
   Plasmodium falciparum; Transmission dynamics
ID ASYMPTOMATIC BLOOD-DONORS; SOUTH-EASTERN BRAZIL; SAO-PAULO;
   AUTOCHTHONOUS MALARIA; UNEXPECTED DETECTION; INFECTIOUS-DISEASES;
   NATURAL INFECTION; HOWLER MONKEYS; RAIN-FOREST; VIVAX
AB Background: Recently an unexpectedly high prevalence of Plasmodium falciparum was found in asymptomatic blood donors living in the southeastern Brazilian Atlantic forest. The bromeliad-malaria paradigm assumes that transmission of Plasmodium vivax and Plasmodium malariae involves species of the subgenus Kerteszia of Anopheles and only a few cases of Plasmodium vivax malaria are reported annually in this region. The expectations of this paradigm are a low prevalence of Plasmodium vivax and a null prevalence of Plasmodium falciparum. Therefore, the aim of this study was to verify if Plasmodium falciparum is actively circulating in the southeastern Brazilian Atlantic forest remains.
   Methods: In this study, anophelines were collected with Shannon and CDC-light traps in seven distinct Atlantic forest landscapes over a 4-month period. Field-collected Anopheles mosquitoes were tested by real-time PCR assay in pools of ten, and then each mosquito from every positive pool, separately for Plasmodium falciparum and Plasmodium vivax. Genomic DNA of Plasmodium falciparum or Plasmodium vivax from positive anophelines was then amplified by traditional PCR for sequencing of the 18S ribosomal DNA to confirm Plasmodium species. Binomial probabilities were calculated to identify non-random results of the Plasmodium falciparum-infected anopheline findings.
   Results: The overall proportion of anophelines naturally infected with Plasmodium falciparum was 4.4% (21/480) and only 0.8% (4/480) with Plasmodium vivax. All of the infected mosquitoes were found in intermixed natural and human-modified environments and most were Anopheles cruzii (22/25 = 88%, 18 Plasmodium falciparum plus 4 Plasmodium vivax). Plasmodium falciparum was confirmed by sequencing in 76% (16/21) of positive mosquitoes, whereas Plasmodium vivax was confirmed in only 25% (1/4). Binomial probabilities suggest that Plasmodium falciparum actively circulates throughout the region and that there may be a threshold of the forested over human-modified environment ratio upon which the proportion of Plasmodium falciparum-infected anophelines increases significantly.
   Conclusions: These results show that Plasmodium falciparum actively circulates, in higher proportion than Plasmodium vivax, among Anopheles mosquitoes of fragments of the southeastern Brazilian Atlantic forest. This finding challenges the classical bromeliad-malaria paradigm, which considers Plasmodium vivax circulation as the driver for the dynamics of residual malaria transmission in this region.
C1 [Laporta, Gabriel Zorello; Porangaba de Oliveira, Tatiane Marques; Mureb Sallum, Maria Anice] Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, BR-01246904 Sao Paulo, SP, Brazil.
   [Laporta, Gabriel Zorello; Burattini, Marcelo Nascimento; Massad, Eduardo] Univ Sao Paulo, Fac Med, Lab Informat Med LIM 01, BR-05405000 Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Hosp Sao Paulo, Div Doencas Infecc, BR-04024002 Sao Paulo, Brazil.
   [Levy, Debora; Ferreira Maselli, Luciana Morganti; Bydlowski, Sergio Paulo] Univ Sao Paulo, Fac Med, Lab Genet & Hematol Mol LIM 31, BR-05403000 Sao Paulo, SP, Brazil.
   [Fukuya, Linah Akemi; Ferreira Maselli, Luciana Morganti] Univ Sao Paulo, Fac Med, Fundacao Prosangue Hemoctr Sao Paulo, Divisao Pesquisa, BR-05403000 Sao Paulo, SP, Brazil.
   [Conn, Jan Evelyn] Wadsworth Ctr, Dept Hlth, Slingerlands, NY 12159 USA.
   [Conn, Jan Evelyn] SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12222 USA.
RP Laporta, GZ (corresponding author), Univ Sao Paulo, Fac Saude Publ, Dept Epidemiol, BR-01246904 Sao Paulo, SP, Brazil.
EM gabrielzorelo@usp.br
RI Laporta, Gabriel/P-3621-2019; Levy, Debora/G-8208-2014; Sallum, Maria
   Anice Mureb/B-8537-2012; Laporta, Gabriel/B-8662-2012; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012
OI Laporta, Gabriel/0000-0001-7412-9390; Levy, Debora/0000-0001-7492-997X;
   Sallum, Maria Anice Mureb/0000-0002-7051-2891; Laporta,
   Gabriel/0000-0001-7412-9390; Burattini, Marcelo N/0000-0002-5407-6890;
   Massad, Eduardo/0000-0002-7200-2916; Conn, Jan/0000-0002-5301-7020
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/20397-7];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [301666/2011-3]; FAPESPFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2009/53141-5, 2012/09939-5, 2014/09774-1];
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX We are in debited to Marcelo Jacobs-Lorena for providing Anopheles
   mosquitoes infected with Plasmodium; Marcelo Urbano Ferreira for
   Plasmodium samples used as positive controls for the PCRs; financial
   support from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP Grant 2011/20397-7) and Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq no. 301666/2011-3) to MAMS; financial
   support from FAPESP (Grant 2009/53141-5) and CNPq to SBP. GZL had a
   postdoctorate fellowship from FAPESP (Grant 2012/09939-5), and is
   currently supported by FAPESP (Grant 2014/09774-1).
CR Araujo MS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-180
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Branquinho M S, 1997, Rev Panam Salud Publica, V2, P189, DOI 10.1590/S1020-49891997000900004
   Cerutti C, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-33
   Costa DC, 2014, MEM I OSWALDO CRUZ, V109, P641, DOI 10.1590/0074-0276130578
   Couto RD, 2010, REV SOC BRAS MED TRO, V43, P52, DOI 10.1590/S0037-86822010000100012
   Curado I, 2006, ACTA TROP, V100, P54, DOI 10.1016/j.actatropica.2006.09.010
   de Duarte AMR, 2006, J MED PRIMATOL, V35, P87, DOI 10.1111/j.1600-0684.2006.00148.x
   de Pina-Costa A, 2014, MEM I OSWALDO CRUZ, V109, P618, DOI 10.1590/0074-0276140228
   DEANE LM, 1992, MEM I OSWALDO CRUZ, V87, P1, DOI 10.1590/S0074-02761992000700001
   Duarte AMRC, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-58
   Foley DH, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-145
   Forattini OP, 1996, REV SAUDE PUBL, V30, P107, DOI 10.1590/S0034-89101996000200001
   Forattini OP, 2002, CULICIDOLOGIA MEDICA, VII
   Foster PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054063
   Gadelha P., 1994, Parassitologia (Rome), V36, P175
   Kar NP, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-265
   Krief S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000765
   Lambin EF, 2010, INT J HEALTH GEOGR, V9, DOI 10.1186/1476-072X-9-54
   Laporta GZ, 2011, MEM I OSWALDO CRUZ, V106, P239, DOI 10.1590/S0074-02762011000900029
   Liu WM, 2010, NATURE, V467, P420, DOI 10.1038/nature09442
   LUTZ Adolpho, 2005, CENTRALBLATT BAKTERI, P733
   Marques TC, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-41
   Marrelli MT, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-127
   Maselli LMF, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-224
   Mendrone A, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-336
   Miguel RB, 2014, MEM I OSWALDO CRUZ, V109, P634, DOI 10.1590/0074-0276130558
   Miller SA, 1998, NUCLEIC ACIDS RES, V16, P1215, DOI DOI 10.1093/NAR/16.3.1215
   Sallum MAM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-337
   Neves A, 2013, ACTA TROP, V125, P102, DOI 10.1016/j.actatropica.2012.08.014
   Norman GR, 1994, BARE ESSENTIALS
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004
   Rayner JC, 2011, TRENDS PARASITOL, V27, P222, DOI 10.1016/j.pt.2011.01.006
   Rezende HR, 2009, NEOTROP ENTOMOL, V38, P272, DOI 10.1590/S1519-566X2009000200017
   Ribeiro AF, 2012, J VECTOR ECOL, V37, P316, DOI 10.1111/j.1948-7134.2012.00233.x
   Duarte AMRD, 2008, ACTA TROP, V107, P179, DOI 10.1016/j.actatropica.2008.05.020
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   SERVICE MW, 1993, MOSQUITO ECOLOGY
   Sharp PM, 2013, SCIENCE, V340, P284, DOI 10.1126/science.1236958
   Smith LB, 1952, ANN REP SMITHSON I, V1952, P385
   Sundararaman SA, 2013, P NATL ACAD SCI USA, V110, P7020, DOI 10.1073/pnas.1305201110
   Wayant NM, 2010, GEOSPATIAL HEALTH, V4, P179, DOI 10.4081/gh.2010.199
   Wolfe ND, 2007, NATURE, V447, P279, DOI 10.1038/nature05775
   Yamasaki T, 2011, J MED PRIMATOL, V40, P392, DOI 10.1111/j.1600-0684.2011.00498.x
   Zavortink T.J., 1973, CONTRIBUTIONS AM ENT, V9, P1
NR 46
TC 15
Z9 15
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD APR 25
PY 2015
VL 14
AR 181
DI 10.1186/s12936-015-0680-9
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA CH0CI
UT WOS:000353686200001
PM 25909655
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ribeiro, AF
   Tengan, C
   Sato, HK
   Spinola, R
   Mascheretti, M
   Franca, ACC
   Port-Carvalho, M
   Pereira, M
   de Souza, RP
   Amaku, M
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
   Massad, E
AF Ribeiro, Ana Freitas
   Tengan, Cilea
   Sato, Helena Keico
   Spinola, Roberta
   Mascheretti, Melissa
   Costa Franca, Ana Cecilia
   Port-Carvalho, Marcio
   Pereira, Mariza
   de Souza, Renato Pereira
   Amaku, Marcos
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
   Lopez, Luis Fernandez
   Massad, Eduardo
TI A public health risk assessment for yellow fever vaccination: a model
   exemplified by an outbreak in the state of Sao Paulo, Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE yellow fever; vaccination; side-effects; mathematical models;
   optimisation; risk estimation
ID REEMERGENCE
AB We propose a method to analyse the 2009 outbreak in the region of Botucatu in the state of Sao Paulo (SP), Brazil, when 28 yellow fever (YF) cases were confirmed, including 11 deaths. At the time of the outbreak, the Secretary of Health of the State of Sao Paulo vaccinated one million people, causing the death of five individuals, an unprecedented number of YF vaccine-induced fatalities. We apply a mathematical model described previously to optimise the proportion of people who should be vaccinated to minimise the total number of deaths. The model was used to calculate the optimum proportion that should be vaccinated in the remaining, vaccine-free regions of SP, considering the risk of vaccine-induced fatalities and the risk of YF outbreaks in these regions.
C1 [Ribeiro, Ana Freitas; Tengan, Cilea; Sato, Helena Keico; Spinola, Roberta; Mascheretti, Melissa; Costa Franca, Ana Cecilia] Ctr Vigilancia Epidemiol, Sao Paulo, SP, Brazil.
   [Port-Carvalho, Marcio] Inst Florestal, Sao Paulo, SP, Brazil.
   [Pereira, Mariza] Superintendencia Controle Endemias Estado Sao Paul, Sao Paulo, SP, Brazil.
   [de Souza, Renato Pereira] Adolfo Lutz Inst, Sao Paulo, SP, Brazil.
   [Amaku, Marcos] Univ Sao Paulo, Fac Med Vet & Zootecnia, Sao Paulo, SP, Brazil.
   [Amaku, Marcos; Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Escola Paulista Med, Hosp Sao Paulo, BR-04023 Sao Paulo, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, Ctr Internet Augmented Res & Assessment, Miami, FL 33199 USA.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Lopez, Luis F/C-4721-2012; Ribeiro, Ana Freitas/P-6862-2015; Amaku,
   Marcos/D-5252-2012; Massad, Eduardo/B-1169-2012; Burattini, Marcelo
   N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011
OI Lopez, Luis F/0000-0003-4097-6887; Amaku, Marcos/0000-0003-4752-6774;
   Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Pereira de Souza, Renato/0000-0003-1315-7085
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); LIM01-HCFMUSP
FX LIM01-HCFMUSP, CNPq, FAPESP
CR Barnett ED, 2007, CLIN INFECT DIS, V44, P850, DOI 10.1086/511869
   Bauch CT, 2003, P NATL ACAD SCI USA, V100, P10564, DOI 10.1073/pnas.1731324100
   Costa ZGA, 2011, REV PAN AMAZ SAUDE, V2, P11, DOI DOI 10.5123/S2176-62232011000100002
   DALKEY N, 1963, MANAGE SCI, V9, P458, DOI 10.1287/mnsc.9.3.458
   Fortaleza CMCB, 2009, J VENOM ANIM TOXINS, V15, P186, DOI 10.1590/S1678-91992009000200002
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Monath T, 1991, HUNTERS TROPICAL MED, P233
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   Moreno ES, 2011, REV INST MED TROP SP, V53, P335, DOI 10.1590/S0036-46652011000600007
   Moreno ES, 2011, REV SOC BRAS MED TRO, V44, P290, DOI [10.1590/s0037-86822011005000041, 10.1590/S0037-86822011005000041]
   Ortega N, 2003, KYBERNETES, V32, P460, DOI 10.1108/03684920310463876
   Sao-Joao TM, 2013, REV SAUDE PUBL, V47, P1
   Zanotto PMD, 1996, P NATL ACAD SCI USA, V93, P548, DOI 10.1073/pnas.93.2.548
NR 14
TC 3
Z9 4
U1 0
U2 14
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD APR
PY 2015
VL 110
IS 2
BP 230
EP 234
DI 10.1590/0074-02760140345
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA CH5HN
UT WOS:000354066400010
PM 25946247
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Lima-Stein, ML
   Alkmim, WT
   Bizinoto, MCD
   Lopez, LF
   Burattini, MN
   Maricato, JT
   Giron, L
   Sucupira, MCA
   Diaz, RS
   Janini, LM
AF de Lima-Stein, Mariana Leao
   Alkmim, Wagner Tadeu
   de Souza Bizinoto, Maria Clara
   Lopez, Luis Fernandez
   Burattini, Marcelo Nascimento
   Maricato, Juliana Terzi
   Giron, Leila
   Araripe Sucupira, Maria Cecilia
   Diaz, Ricardo Sobhie
   Janini, Luiz Mario
TI In Vivo HIV-1 Hypermutation and Viral Loads Among Antiretroviral-Naive
   Brazilian Patients
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BLOOD MONONUCLEAR-CELLS; CD4(+) T-CELLS;
   REVERSE-TRANSCRIPTASE; APOBEC3G EXPRESSION; ELITE SUPPRESSORS;
   MUTATION-RATE; A MUTATIONS; VIF PROTEIN; DNA
AB Hypermutation alludes to an excessive number of specific guanine-to-adenine (G- > A) substitutions in proviral DNA and this phenomenon is attributed to the catalytic activity of cellular APOBECs. Population studies relating hypermutation and the progression of infection by human immunodeficiency virus type 1 (HIV-1) have been performed to elucidate the effect of hypermutation on the natural course of HIV-1 infection. However, the many different approaches employed to assess hypermutation in nucleotide sequences render the comparison of results difficult. This study selected 157 treatment-naive patients and sought to correlate the hypermutation level of the proviral sequences in clinical samples with demographic variables, HIV-1 RNA viral load, and the level of CD4(+) T cells. Nested touchdown polymerase chain reaction (PCR) was performed with specific primers to detect hypermutation in the region of HIV-1 integrase, and the amplified sequences were run in agarose gels with HA-Yellow. The analysis of gel migration patterns using the k-means clustering method was validated by its agreement with the results obtained with the software Hypermut. Hypermutation was found in 31.2% of the investigated samples, and a correlation was observed between higher hypermutation levels and higher viral load levels. These findings suggest a high frequency of hypermutation detection in a Brazilian cohort, which can reflect a particular characteristic of this population, but also can result from the method approach by aiming at hypermutation-sensitive sites. Furthermore, we found that hypermutation events are pervasive during HIV-1 infection as a consequence of high viral replication, reflecting its role during disease progression.
C1 [de Lima-Stein, Mariana Leao; Alkmim, Wagner Tadeu; de Souza Bizinoto, Maria Clara; Maricato, Juliana Terzi; Giron, Leila; Araripe Sucupira, Maria Cecilia; Diaz, Ricardo Sobhie; Janini, Luiz Mario] Univ Fed Sao Paulo, BR-04039032 Sao Paulo, Brazil.
   [Lopez, Luis Fernandez; Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Janini, LM (corresponding author), Univ Fed Sao Paulo, Rua Pedro de Toledo,781,16 Andar, BR-04039032 Sao Paulo, Brazil.
EM janini@unifesp.br
RI Lopez, Luis F/C-4721-2012; Burattini, Marcelo N/J-9272-2014; Giron,
   Leila B/A-9642-2015
OI Lopez, Luis F/0000-0003-4097-6887; Burattini, Marcelo
   N/0000-0002-5407-6890; Giron, Leila B/0000-0002-3898-5680; Janini, Luiz
   Mario/0000-0002-6186-6284
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/50650-0]; Infectious Diseases Department of the Federal University
   of Sao Paulo (UNIFESP)
FX This study was supported by the FAPESP research grant (2007/50650-0) and
   by the Infectious Diseases Department of the Federal University of Sao
   Paulo (UNIFESP).
CR An P, 2004, J VIROL, V78, P11070, DOI 10.1128/JVI.78.20.11070-11076.2004
   An P, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030019
   Armitage AE, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002550
   Bizinoto MC, 2011, AIDS RES HUM RETROV, V27, P137, DOI 10.1089/aid.2010.0146
   Chang J, 1996, J VIROL, V70, P7792, DOI 10.1128/JVI.70.11.7792-7803.1996
   Chaudhary Monica, 2008, J Int Assoc Physicians AIDS Care (Chic), V7, P259, DOI 10.1177/1545109708322302
   Cho SJ, 2006, J VIROL, V80, P2069, DOI 10.1128/JVI.80.4.2069-2072.2006
   Dinoso JB, 2008, CLIN INFECT DIS, V47, P102, DOI 10.1086/588791
   Egger S, 2009, JAIDS-J ACQ IMM DEF, V50, P513, DOI 10.1097/QAI.0b013e31819906d3
   Eigen M, 2002, P NATL ACAD SCI USA, V99, P13374, DOI 10.1073/pnas.212514799
   Fourati S, 2012, J ANTIMICROB CHEMOTH, V67, P2323, DOI 10.1093/jac/dks219
   Fourati S, 2012, AIDS, V26, P1619, DOI 10.1097/QAD.0b013e3283560703
   GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992
   Gaddis NC, 2003, J VIROL, V77, P5810, DOI 10.1128/JVI.77.10.5810-5820.2003
   Gandhi SK, 2008, J VIROL, V82, P3125, DOI 10.1128/JVI.01533-07
   GOODENOW M, 1989, J ACQ IMMUN DEF SYND, V2, P344
   Janini M, 2001, J VIROL, V75, P7973, DOI 10.1128/JVI.75.17.7973-7986.2001
   Johnston R, 2010, AIDS RES HUM RETROV, V26, P943, DOI 10.1089/aid.2010.0087
   Julias JG, 1998, J VIROL, V72, P7941, DOI 10.1128/JVI.72.10.7941-7949.1998
   Kieffer TL, 2005, J VIROL, V79, P1975, DOI 10.1128/JVI.79.3.1975-1980.2005
   Kijak GH, 2008, VIROLOGY, V376, P101, DOI 10.1016/j.virol.2008.03.017
   Kijak GH, 2007, AIDS RES HUM RETROV, V23, P554, DOI 10.1089/aid.2006.0279
   Komninakis SV, 2012, J CLIN MICROBIOL, V50, P2132, DOI 10.1128/JCM.00393-12
   Kourteva Y, 2012, VIROLOGY, V430, P1, DOI 10.1016/j.virol.2012.03.018
   Land AM, 2008, J VIROL, V82, P8172, DOI 10.1128/JVI.01115-08
   LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992
   Macqueen JB, 1967, P 5 BERK S MATH STAT, V1, P281, DOI DOI 10.1007/S11665-016-2173-6
   Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709
   MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995
   MARTINEZ MA, 1994, P NATL ACAD SCI USA, V91, P11787, DOI 10.1073/pnas.91.25.11787
   Mbisa JL, 2007, J VIROL, V81, P7099, DOI 10.1128/JVI.00272-07
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Min W, 2004, AIDS, V18, P1863, DOI 10.1097/00002030-200409030-00023
   MULLER W, 1981, NUCLEIC ACIDS RES, V9, P95, DOI 10.1093/nar/9.1.95
   Naif HM, 1999, J VIROL, V73, P4866, DOI 10.1128/JVI.73.6.4866-4881.1999
   Opi S, 2007, J VIROL, V81, P8236, DOI 10.1128/JVI.02694-06
   Pace C, 2006, J VIROL, V80, P9259, DOI 10.1128/JVI.00888-06
   Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582
   Piantadosi A, 2009, J VIROL, V83, P7805, DOI 10.1128/JVI.00280-09
   Pimenta JR, 2006, HUM HERED, V62, P190, DOI 10.1159/000096872
   Rathore A, 2008, GENET TEST, V12, P453, DOI 10.1089/gte.2008.0017
   Reddy K, 2010, AIDS, V24, P195, DOI 10.1097/QAD.0b013e3283353bba
   Ribeiro AC, 2005, J VIROL, V79, P823, DOI 10.1128/JVI.79.2.823-833.2005
   Rose PP, 2000, BIOINFORMATICS, V16, P400, DOI 10.1093/bioinformatics/16.4.400
   Russell RA, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-16
   Sanabani S, 2006, INFECT GENET EVOL, V6, P368, DOI 10.1016/j.meegid.2006.01.003
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schuurman R, 1999, J CLIN MICROBIOL, V37, P2291, DOI 10.1128/JCM.37.7.2291-2296.1999
   Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569
   Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939
   Simao LNAW, 2009, BRASILIA VIRUS REV R, P14
   Simon V, 2005, PLOS PATHOG, V1, P20, DOI 10.1371/journal.ppat.0010006
   Skinner LM, 1998, J ACQ IMMUN DEF SYND, V19, P99, DOI 10.1097/00042560-199810010-00001
   Smith RJ, 2010, SCIENCE, V327, P697, DOI 10.1126/science.1180556
   Sousa MML, 2007, MOL ASPECTS MED, V28, P276, DOI 10.1016/j.mam.2007.04.006
   Suspene R, 2006, NUCLEIC ACIDS RES, V34, P4677, DOI 10.1093/nar/gkl555
   Thompson Julie D, 2002, Curr Protoc Bioinformatics, VChapter 2, DOI 10.1002/0471250953.bi0203s00
   Ulenga NK, 2008, AIDS RES HUM RETROV, V24, P1285, DOI 10.1089/aid.2008.0072
   VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092
   WAINHOBSON S, 1995, VIROLOGY, V209, P297, DOI 10.1006/viro.1995.1261
   Xu HZ, 2007, VIROLOGY, V360, P247, DOI 10.1016/j.virol.2006.10.036
NR 61
TC 5
Z9 5
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD SEP
PY 2014
VL 30
IS 9
BP 867
EP 880
DI 10.1089/aid.2013.0241
PG 14
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AO7IO
UT WOS:000341526800009
PM 25065371
OA Green Published
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Ximenes, R
   Amaku, M
   Wilder-Smith, A
AF Massad, Eduardo
   Burattini, Marcelo N.
   Ximenes, Raphael
   Amaku, Marcos
   Wilder-Smith, Annelies
TI Dengue outlook for the World Cup in Brazil
SO LANCET INFECTIOUS DISEASES
LA English
DT Letter
C1 [Massad, Eduardo; Burattini, Marcelo N.; Ximenes, Raphael] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
   [Amaku, Marcos] Univ Sao Paulo, Fac Vet Med, Sao Paulo, Brazil.
   [Burattini, Marcelo N.] Univ Fed Sao Paulo, Paulista Sch Med, Sao Paulo, Brazil.
   [Wilder-Smith, Annelies] Umea Univ, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden.
   [Wilder-Smith, Annelies] Nanyang Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
EM anneleisws@gmail.com
RI Massad, Eduardo/B-1169-2012; Wilder-Smith, Annelies/F-8751-2015;
   Ximenes, Raphael/G-2881-2014; Burattini, Marcelo N/J-9272-2014; Amaku,
   Marcos/D-5252-2012
OI Massad, Eduardo/0000-0002-7200-2916; Ximenes,
   Raphael/0000-0003-2536-951X; Burattini, Marcelo N/0000-0002-5407-6890;
   Amaku, Marcos/0000-0003-4752-6774; Wilder-Smith,
   Annelies/0000-0003-0362-5375
CR Lowe R, 2014, LANCET INFECT DIS, V14, P619, DOI 10.1016/S1473-3099(14)70781-9
   Massad E, 2014, MEM I OSWALDO CRUZ, V109, P394, DOI 10.1590/0074-0276140133
   Wilson ME, 2014, CLIN INFECT DIS, V58, P1347, DOI 10.1093/cid/ciu122
   Wilson ME, 2014, TRAVEL MED INFECT DI
NR 4
TC 7
Z9 7
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD JUL
PY 2014
VL 14
IS 7
BP 552
EP 553
DI 10.1016/S1473-3099(14)70807-2
PG 2
WC Infectious Diseases
SC Infectious Diseases
GA AJ8XG
UT WOS:000337990800016
PM 24929925
DA 2020-12-08
ER

PT J
AU Massad, E
   Wilder-Smith, A
   Ximenes, R
   Amaku, M
   Lopez, LF
   Coutinho, FAB
   Coelho, GE
   da Silva, JB
   Struchiner, CJ
   Burattini, MN
AF Massad, Eduardo
   Wilder-Smith, Annelies
   Ximenes, Raphael
   Amaku, Marcos
   Lopez, Luis Fernandez
   Bezerra Coutinho, Francisco Antonio
   Coelho, Giovanini Evelim
   da Silva, Jarbas Barbosa, Jr.
   Struchiner, Claudio Jose
   Burattini, Marcelo Nascimento
TI Risk of symptomatic dengue for foreign visitors to the 2014 FIFA World
   Cup in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Editorial Material
DE dengue; risk; foreign travellers; probabilistic; modelling; World Cup
ID TRAVELERS; FEVER; CHIKUNGUNYA; OUTBREAK; ILLNESS; TRENDS; AREAS
AB Brazil will host the FIFA World Cup T, the biggest single-event competition in the world, from June 12-July 13 2014 in 12 cities. This event will draw an estimated 600,000 international visitors. Brazil is endemic for dengue. Hence, attendees of the 2014 event are theoretically at risk for dengue. We calculated the risk of dengue acquisition to non-immune international travellers to Brazil, depending on the football match schedules, considering locations and dates of such matches for June and July 2014. We estimated the average per-capita risk and expected number of dengue cases for each host-city and each game schedule chosen based on reported dengue cases to the Brazilian Ministry of Health for the period between 2010-2013. On the average, the expected number of cases among the 600,000 foreigner tourists during the World Cup is 33, varying from 3-59. Such risk estimates will not only benefit individual travellers for adequate pre-travel preparations, but also provide valuable information for public health professionals and policy makers worldwide. Furthermore, estimates of dengue cases in international travellers during the World Cup can help to anticipate the theoretical risk for exportation of dengue into currently non-infected areas.
C1 [Massad, Eduardo; Ximenes, Raphael; Lopez, Luis Fernandez; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, Brazil.
   [Massad, Eduardo] Univ Sao Paulo, Fac Med Vet, Sao Paulo, Brazil.
   [Wilder-Smith, Annelies] Univ Sao Paulo, Nucleo Anal Interdisciplinares Polit Publ & Estra, Sao Paulo, Brazil.
   [Amaku, Marcos] London Sch Hyg & Trop Med, London WC1, England.
   [Lopez, Luis Fernandez] Nanyang Univ, Lee Kong Chian Sch Med, Singapore, Singapore.
   [Lopez, Luis Fernandez; Bezerra Coutinho, Francisco Antonio; Burattini, Marcelo Nascimento] Florida Int Univ, Ctr Internet Augmented Res & Assesssment, Miami, FL 33199 USA.
   [Coelho, Giovanini Evelim; da Silva, Jarbas Barbosa, Jr.] Minist Saude, Brasilia, DF, Brazil.
   [Struchiner, Claudio Jose] Fiocruz MS, Programa Comp Cient, Rio De Janeiro, RJ, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Escola Paulista Med, Hosp Sao Paulo, Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin LIM01, Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Ximenes, Raphael/G-2881-2014; Amaku, Marcos/D-5252-2012; Coutinho,
   Francisco A B/H-5644-2011; Wilder-Smith, Annelies/F-8751-2015;
   Burattini, Marcelo N/J-9272-2014; Struchiner, Claudio J/M-9360-2013;
   Massad, Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012
OI Ximenes, Raphael/0000-0003-2536-951X; Amaku, Marcos/0000-0003-4752-6774;
   Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Struchiner, Claudio J/0000-0003-2114-847X;
   Massad, Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Wilder-Smith, Annelies/0000-0003-0362-5375
FU FNS-SVS; MS [27835/2012]; CNPqNational Council for Scientific and
   Technological Development (CNPq); LIM01-HCFMUSP; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); DengueTools/Seventh
   Framework Programme of the European Community [282589]
FX FNS-SVS, MS, CNPq, LIM01-HCFMUSP, FAPESP, MS (27835/2012),
   DengueTools/Seventh Framework Programme of the European Community
   (282589)
CR Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Hay S, 2013, NATURE, V503, P439, DOI 10.1038/503439a
   Leder K, 2013, EMERG INFECT DIS, V19, P1049, DOI 10.3201/eid1907.121573
   Luz PM, 2003, MEM I OSWALDO CRUZ, V98, P871, DOI 10.1590/S0074-02762003000700002
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2008, J TRAVEL MED, V15, P147, DOI 10.1111/j.1708-8305.2008.00186.x
   Massad E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-296
   Massad E, 2009, J TRAVEL MED, V16, P191, DOI 10.1111/j.1708-8305.2009.00310.x
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Napoli C, 2012, J TRAVEL MED, V19, P294, DOI 10.1111/j.1708-8305.2012.00640.x
   Oliver L, 2014, J ENVIRON HEALTH, V76, P66
   Nogueira RMR, 2007, REV PANAM SALUD PUBL, V22, P358, DOI 10.1590/S1020-49892007001000009
   Schwartz E, 2008, EMERG INFECT DIS, V14, P1081, DOI 10.3201/eid1407.071412
   Sessions OM, 2013, GLOBAL HEALTH ACTION, V6, DOI 10.3402/gha.v6i0.21822
   Seyler T, 2009, EPIDEMICS-NETH, V1, P175, DOI 10.1016/j.epidem.2009.06.003
   Teixeira MG, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002520
   Teixeira MG, 2009, CAD SAUDE PUBLICA, V25, pS7, DOI 10.1590/S0102-311X2009001300002
   Viana Dione Viero, 2013, Rev. bras. epidemiol., V16, P240, DOI 10.1590/S1415-790X2013000200002
   Wilder-Smith A, 2005, NEW ENGL J MED, V353, P924, DOI 10.1056/NEJMra041927
   Wilder-Smith A, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.8.20718
   Wilder-Smith Annelies, 2010, Curr Infect Dis Rep, V12, P157, DOI 10.1007/s11908-010-0102-7
   Wilson ME, 2014, CLIN INFECT DIS, V58, P1347, DOI 10.1093/cid/ciu122
   Ximenes R, 2013, STUDY RISK DENGUE TO
NR 24
TC 22
Z9 22
U1 0
U2 24
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAY
PY 2014
VL 109
IS 3
BP 394
EP +
DI 10.1590/0074-0276140133
PG 7
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AJ7VV
UT WOS:000337909100022
PM 24863976
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Guerra, JCD
   Mourao, MA
   Franca, CN
   da Rosa, CDP
   Burattini, MN
AF de Campos Guerra, J. C.
   Mourao, M. A.
   Franca, C. N.
   da Rosa, C. D. P.
   Burattini, M. N.
TI Impact of coagulation in the development of thromboembolic events in
   patients with spinal cord injury
SO SPINAL CORD
LA English
DT Article
DE thromboembolism; spinal cord injury; Leiden factor V;
   hyperhomocysteinemia
ID DEEP VENOUS THROMBOSIS; VEIN THROMBOSIS; RISK; MUTATION
AB Study design: Although the knowledge described about risk factors and venous thromboembolism (VT) in the general population, the impact of these factors in the development of thromboembolic events in patients with spinal injury (SI) caused by spinal cord injury (SCI) is poorly understood.
   Objective: Evaluate the impact of risk factors in the development of thromboembolic events in patients with SCI. Setting: Brazil, Sao Paulo.
   Methods: Observational, prospective and cross-study. Eligible patients (n = 100) had SI by SCI, > 18 years. The degree of motor and sensory lesion was evaluated based on American Spinal Injury Association (ASIA) Impairment Scale (AIS). Blood samples were collected for coagulation exams, hemogram, laboratory and biochemical analyses. Ultrasonography analyzes were performed from deep and superficial venous systems of lower limbs. Quantitative real-time PCR experiments were performed in order to investigate mutations in the prothrombin (G20210A) and Leiden factor V (G1691A) genes.
   Results: The main finding of this study was the higher occurrence of deep venous thrombosis (DVT) in patients with Leiden factor V and hyperhomocysteinemia. There was no association between SI for DVT, VT and thrombophilia. Also, there was no relation between lupus anticoagulant and anti-cardiolipin.
   Conclusion: There is an important difference in the incidence of DVT in patients with SI by acute and chronic SCI. Therefore, the conduct of the investigation for thrombophilia should be based on clinical factors, risk factors for DVT and family history of thrombosis.
C1 [de Campos Guerra, J. C.; Burattini, M. N.] Univ Sao Paulo, Dept Pathol, Sao Paulo, Brazil.
   [de Campos Guerra, J. C.] Hosp Israelita Albert Einstein, Dept Clin Pathol, Sao Paulo, Brazil.
   [Mourao, M. A.] Univ Sao Paulo, Clin Hosp, Sao Paulo, Brazil.
   [Franca, C. N.] Univ Fed Sao Paulo, Dept Med, Div Cardiol, Sao Paulo, Brazil.
   [Franca, C. N.] Univ Santo Amaro, Sao Paulo, Brazil.
   [da Rosa, C. D. P.] Univ Sao Paulo, Inst Phys Med & Rehabil, Sao Paulo, Brazil.
   [Burattini, M. N.] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
RP Guerra, JCD (corresponding author), Albert Einstein Ave,627-701 2nd Floor Block E, BR-05652901 Sao Paulo, Brazil.
EM jcguerra@einstein.br
RI Franca, Carolina Nunes/J-2429-2015; Rached, Chennyfer Dobbins
   Abi/M-3406-2014; Burattini, Marcelo N/J-9272-2014
OI Franca, Carolina Nunes/0000-0002-4167-4293; Rached, Chennyfer Dobbins
   Abi/0000-0002-4499-3716; Burattini, Marcelo N/0000-0002-5407-6890
FU Clinical Pathology Laboratory of Israelita Albert Einstein Hospital;
   Instituto Israelita de Ensino e Pesquisa do Hospital Albert Einstein
   H-IIEP-HIAE; Haematology Center of Sao Paulo, Physical Medicine and
   Rehabilitation Institute from Clinics Hospital of University of Sao
   Paulo
FX The authors gratefully acknowledge the Clinical Pathology Laboratory of
   Israelita Albert Einstein Hospital, Haematology Center of Sao Paulo,
   Physical Medicine and Rehabilitation Institute from Clinics Hospital of
   University of Sao Paulo, for the support in the development of this
   study. The study was sponsored by The Instituto Israelita de Ensino e
   Pesquisa do Hospital Albert Einstein H-IIEP-HIAE. Tubes for collecting
   blood were donated by Sarstedt LTDA and coolers for transporting samples
   were courtesy of Adarve Group.
CR American Spinal Injury Association, INT STAND NEUR CLASS
   American Spinal Injury Association/International Medical Society of Paraplegia (ASIA/IMSOP), 1992, INT STAND NEUR FUNCT
   BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0
   Boudaoud L, 1997, SPINAL CORD, V35, P151, DOI 10.1038/sj.sc.3100373
   Chung SB, 2011, J TRAUMA, V71, P867, DOI 10.1097/TA.0b013e31822dd3be
   Ersoz G, 1999, SPINAL CORD, V37, P644, DOI 10.1038/sj.sc.3100903
   Franco RF, 1999, BRIT J HAEMATOL, V104, P50, DOI 10.1046/j.1365-2141.1999.01149.x
   GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401
   Green D, 2003, AM J PHYS MED REHAB, V82, P950, DOI 10.1097/01.PHM.0000098043.88979.BA
   Guyatt GH, 2012, CHEST S, V141
   Iversen PO, 2002, BRIT J HAEMATOL, V119, P1011, DOI 10.1046/j.1365-2141.2002.03953.x
   KIM SW, 1994, ARCH PHYS MED REHAB, V75, P965
   MERLI GJ, 1993, ARCH PHYS MED REHAB, V74, P1199
   Miranda AR, 2000, HEMATOL ONCOL CLIN N, V14, P401, DOI 10.1016/S0889-8588(05)70141-6
   MYLLYNEN P, 1985, J TRAUMA, V25, P541, DOI 10.1097/00005373-198506000-00013
   Paffrath T, 2010, INJURY, V41, P97, DOI 10.1016/j.injury.2009.06.010
   WARING WP, 1991, PARAPLEGIA, V29, P8, DOI 10.1038/sc.1991.2
   YAO JST, 1992, CHEST, V102, pS645, DOI 10.1378/chest.102.6.645S
   Zoller B, 1999, HAEMATOLOGICA, V84, P59
NR 19
TC 4
Z9 4
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1362-4393
EI 1476-5624
J9 SPINAL CORD
JI Spinal Cord
PD APR
PY 2014
VL 52
IS 4
BP 327
EP 332
DI 10.1038/sc.2013.170
PG 6
WC Clinical Neurology; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA AE9PZ
UT WOS:000334341500017
PM 24513719
OA Bronze
DA 2020-12-08
ER

PT J
AU Boccia, TMQR
   Burattini, MN
   Coutinho, FAB
   Massad, E
AF Boccia, T. M. Q. R.
   Burattini, M. N.
   Coutinho, F. A. B.
   Massad, E.
TI Will people change their vector-control practices in the presence of an
   imperfect dengue vaccine?
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE epidemiology; health policy; infectious disease control; Dengue fever;
   vaccines
ID THRESHOLD CONDITIONS; SAO-PAULO; IMMUNOGENICITY; RECOMBINANT;
   POPULATION; SAFETY; IMPACT; STATE
AB Human behaviours, which are influenced by social, cultural, economic and political factors, can increase or decrease the risk of dengue infection, depending on the relationship with the insect vector. Because no vaccine is currently available, the spread of dengue can only be curtailed by controlling vector populations (Aedes aegypti and others) and by protecting individuals. This study tested the hypothesis that dengue-affected populations are likely to relax their vector-control habits if a potentially protective vaccine becomes available. The hypothesis was tested using two approaches: a mathematical model designed to describe dengue transmission and an empirical field test in which the local population of an endemic area was interviewed about their vector-control habits given the presence of a theoretical vaccine. The model demonstrated that depending on the level of vector-control reduction, there is a threshold in vaccine efficacy below which it is better not to introduce the vaccine. The interview showed that people who were informed that a very effective vaccine is available would reduce their vector-control habits significantly compared to a group that was informed that the vaccine is not very effective.
C1 [Boccia, T. M. Q. R.; Burattini, M. N.; Coutinho, F. A. B.; Massad, E.] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Boccia, T. M. Q. R.; Burattini, M. N.; Coutinho, F. A. B.; Massad, E.] LIM01 HC FMUSP, Sao Paulo, Brazil.
   [Massad, E.] Univ London, London Sch Hyg & Trop Med, London, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A B/0000-0003-3127-3071
FU European Union from LIM01 HCFMUSP [282589]; CNPqNational Council for
   Scientific and Technological Development (CNPq)
FX This research received funding from the European Union's Seventh
   Framework Programme (FP7/2007-2013) under grant agreement no. 282589
   from LIM01 HCFMUSP and CNPq. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amaku M, REV I MED TROPIC S18, V54, pS18
   Bland M., 2000, INTRO MED STAT
   Buchbinder S., 1999, IAVI REPORT, V4, P9
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   Chao DL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001876
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0
   Heggenhougen K, 2003, TDRSTRSEBVOL031 WHO
   Heintze C, 2007, T ROY SOC TROP MED H, V101, P317, DOI 10.1016/j.trstmh.2006.08.007
   Kanesa-thasan N, 2001, VACCINE, V19, P3179, DOI 10.1016/S0264-410X(01)00020-2
   Kay BH, 2002, AM J TROP MED HYG, V66, P40, DOI 10.4269/ajtmh.2002.66.40
   Leo YS, 2012, HUM VACC IMMUNOTHER, V8, P1259, DOI 10.4161/hv.21224
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Massad E, 2001, MATH COMPUT MODEL, V34, P345, DOI 10.1016/S0895-7177(01)00066-8
   Moreno ES, 2011, REV SOC BRAS MED TRO, V44, P290, DOI [10.1590/s0037-86822011005000041, 10.1590/S0037-86822011005000041]
   NETO RSD, 1994, EPIDEMIOL INFECT, V113, P161, DOI 10.1017/S095026880005158X
   Perez Gonzalez K, 1999, Gac Sanit, V13, P7
   Sabchareon A, 2012, LANCET, V380, P1559, DOI 10.1016/S0140-6736(12)61428-7
   Wilder-Smith A, 2008, MED CLIN N AM, V92, P1377, DOI 10.1016/j.mcna.2008.07.002
   Wilder-Smith Annelies, 2010, Curr Infect Dis Rep, V12, P157, DOI 10.1007/s11908-010-0102-7
   YASUNO M, 1970, B WORLD HEALTH ORGAN, V43, P319
NR 22
TC 7
Z9 7
U1 0
U2 24
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD MAR
PY 2014
VL 142
IS 3
BP 625
EP 633
DI 10.1017/S0950268813001350
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AD0PZ
UT WOS:000332937900020
PM 23735007
DA 2020-12-08
ER

PT J
AU Amaku, M
   Coutinho, FAB
   Raimundo, SM
   Lopez, LF
   Burattini, MN
   Massad, E
AF Amaku, Marcos
   Bezerra Coutinho, Francisco Antonio
   Raimundo, Silvia Martorano
   Lopez, Luis Fernandez
   Burattini, Marcelo Nascimento
   Massad, Eduardo
TI A Comparative Analysis of the Relative Efficacy of Vector-Control
   Strategies Against Dengue Fever
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Dengue; Basic reproduction number; Force of infection; Sensitivity
   analysis; Vector control
ID POPULATION-DYNAMICS; SENSITIVITY-ANALYSIS; THRESHOLD CONDITIONS;
   AEDES-AEGYPTI; TRANSMISSION; PARAMETERS; DISEASES; MALARIA; SYSTEM; COST
AB Dengue is considered one of the most important vector-borne infection, affecting almost half of the world population with 50 to 100 million cases every year. In this paper, we present one of the simplest models that can encapsulate all the important variables related to vector control of dengue fever. The model considers the human population, the adult mosquito population and the population of immature stages, which includes eggs, larvae and pupae. The model also considers the vertical transmission of dengue in the mosquitoes and the seasonal variation in the mosquito population. From this basic model describing the dynamics of dengue infection, we deduce thresholds for avoiding the introduction of the disease and for the elimination of the disease. In particular, we deduce a Basic Reproduction Number for dengue that includes parameters related to the immature stages of the mosquito. By neglecting seasonal variation, we calculate the equilibrium values of the model's variables. We also present a sensitivity analysis of the impact of four vector-control strategies on the Basic Reproduction Number, on the Force of Infection and on the human prevalence of dengue. Each of the strategies was studied separately from the others. The analysis presented allows us to conclude that of the available vector control strategies, adulticide application is the most effective, followed by the reduction of the exposure to mosquito bites, locating and destroying breeding places and, finally, larvicides. Current vector-control methods are concentrated on mechanical destruction of mosquitoes' breeding places. Our results suggest that reducing the contact between vector and hosts (biting rates) is as efficient as the logistically difficult but very efficient adult mosquito's control.
C1 [Amaku, Marcos] Univ Sao Paulo, Sch Vet Med, BR-05508270 Sao Paulo, Brazil.
   [Bezerra Coutinho, Francisco Antonio; Raimundo, Silvia Martorano; Lopez, Luis Fernandez; Burattini, Marcelo Nascimento; Massad, Eduardo] Univ Sao Paulo, Sch Med, LIM HCFMUSP 01, BR-01246903 Sao Paulo, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London W1C 7HT, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, LIM HCFMUSP 01, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012; Raimundo, Silvia
   Martorano/D-4624-2012; Coutinho, Francisco A B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Amaku,
   Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916; Lopez,
   Luis F/0000-0003-4097-6887; Raimundo, Silvia
   Martorano/0000-0002-9960-7341; Coutinho, Francisco A
   B/0000-0003-3127-3071
FU European UnionEuropean Union (EU) [282589]; LIM01 HCFMUSP; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX The research from which these results were obtained has received funding
   from the European Union's Seventh Framework Programme (FP7/2007-2013)
   under grant agreement no. 282589, from LIM01 HCFMUSP and CNPq. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams B, 2010, EPIDEMICS-NETH, V2, P1, DOI 10.1016/j.epidem.2010.01.001
   Aguiar M, 2013, ECOL COMPLEX, V16, P31, DOI 10.1016/j.ecocom.2012.09.001
   Amaku M., 2013, PHIL T R SOC A
   Amaku M, 2013, COMPUT MATH METHOD M, DOI 10.1155/2013/659038
   Amaku M, 2009, MEM I OSWALDO CRUZ, V104, P897, DOI 10.1590/S0074-02762009000600013
   Anguelov R, 2012, COMPUT MATH APPL, V64, P374, DOI 10.1016/j.camwa.2012.02.068
   Bacaer N, 2006, J MATH BIOL, V53, P421, DOI 10.1007/s00285-006-0015-0
   Beatty ME, 2011, AM J TROP MED HYG, V84, P473, DOI 10.4269/ajtmh.2011.10-0521
   Beatty ME, 2008, P 2 INT C DENG DENG
   Brownstin JS, 2003, J INVERTEBR PATHOL, V84, P24, DOI 10.1016/S0022-2011(03)00082-X
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   Chitnis N, 2008, B MATH BIOL, V70, P1272, DOI 10.1007/s11538-008-9299-0
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho F. A. B., 2004, AM J PHYS, V72, P1068
   Coutinho FAB, 2005, MATH COMPUT SIMULAT, V70, P149, DOI 10.1016/j.matcom.2005.06.003
   Dumont Y, 2010, MATH BIOSCI ENG, V7, P313, DOI 10.3934/mbe.2010.7.313
   Ellis AM, 2011, AM J TROP MED HYG, V85, P257, DOI 10.4269/ajtmh.2011.10-0516
   Erickson RA, 2010, ECOL MODEL, V221, P2899, DOI 10.1016/j.ecolmodel.2010.08.036
   Fegan GW, 2007, LANCET, V370, P1035, DOI 10.1016/S0140-6736(07)61477-9
   Forattini O. P., 1996, MED CULICIDOLOGY
   Garba SM, 2008, MATH BIOSCI, V215, P11, DOI 10.1016/j.mbs.2008.05.002
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8
   Gubler Duane J, 2011, Trop Med Health, V39, P3, DOI 10.2149/tmh.2011-S05
   Guy B, 2011, LANCET, V377, P381, DOI 10.1016/S0140-6736(11)60128-1
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   Khasnis AA, 2005, ARCH MED RES, V36, P689, DOI 10.1016/j.arcmed.2005.03.041
   Kooi BW, 2013, J COMPUT APPL MATH, V252, P148, DOI 10.1016/j.cam.2012.08.008
   Lambrechts L, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000646
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Luz PM, 2011, LANCET, V377, P1673, DOI 10.1016/S0140-6736(11)60246-8
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2011, PHYS LIFE REV, V8, P169, DOI 10.1016/j.plrev.2011.01.001
   Massad E, 2011, LANCET, V377, P1630, DOI 10.1016/S0140-6736(11)60470-4
   Massad E, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-296
   Ocampo CB, 2004, AM J TROP MED HYG, V71, P506, DOI 10.4269/ajtmh.2004.71.506
   Pinho STR, 2010, PHILOS T R SOC A, V368, P5679, DOI 10.1098/rsta.2010.0278
   Reiter P, 2001, DENGUE DENGUE HEMORR, P425
   Rodrigues H. S., 2012, ARXIV12040544V1
   Ross R., 1911, PREVENTION MALARIA
   Silverman MP, 2004, AM J PHYS, V72, P1068, DOI 10.1119/1.1738426
   Suaya JA, 2009, AM J TROP MED HYG, V80, P846, DOI 10.4269/ajtmh.2009.80.846
   UNWTO, 2011, TOUR HIGHL
   Wahl LM, 2000, P ROY SOC B-BIOL SCI, V267, P835, DOI 10.1098/rspb.2000.1079
   Wang WD, 2008, J DYN DIFFER EQU, V20, P699, DOI 10.1007/s10884-008-9111-8
   Wilder-Smith A, 2012, GLOBAL HEALTH ACTION, V5, P1, DOI 10.3402/gha.v5i0.17273
   Wilder-Smith Annelies, 2010, Curr Infect Dis Rep, V12, P157, DOI 10.1007/s11908-010-0102-7
   YASUNO M, 1970, B WORLD HEALTH ORGAN, V43, P319
NR 47
TC 28
Z9 29
U1 0
U2 44
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD MAR
PY 2014
VL 76
IS 3
BP 697
EP 717
DI 10.1007/s11538-014-9939-5
PG 21
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA AD3GD
UT WOS:000333125400008
PM 24619807
DA 2020-12-08
ER

PT B
AU Coutinho, FAB
   Chaib, E
   Amaku, M
   Burattini, MN
   Massad, E
AF Bezerra Coutinho, Francisco Antonio
   Chaib, Eleazar
   Amaku, Marcos
   Burattini, Marcelo Nascimento
   Massad, Eduardo
BE Mondaini, RP
TI THE MATHEMATICS OF LIVER TRANSPLANTATION
SO BIOMAT 2013: INTERNATIONAL SYMPOSIUM ON MATHEMATICAL AND COMPUTATIONAL
   BIOLOGY
SE BIOMAT-International Symposium on Mathematical and Computational Biology
LA English
DT Proceedings Paper
CT International Symposium on Mathematical and Computational Biology
   (BIOMAT)
CY NOV 04-08, 2013
CL Fields Inst Res Math Sci, Toronto, CANADA
HO Fields Inst Res Math Sci
DE Liver transplantation; hepatocellular carcinoma; expanded criteria;
   model
ID WAITING-LIST; SAO-PAULO; BRAZIL; STATE; DYNAMICS; NUMBER; IMPACT
AB Sao Paulo is the pioneer Brazilian state in transplantation surgery. The Brazilian model for organ sharing has developed a system that prioritizes liver transplantion (LT) for patients who have the highest risk of wait-list mortality. In this paper we present a brief review of the application of mathematical models to the problem of how to improve the speed with which patients with liver failure can receive a liver graft and how alternative criteria for prioritizing patients in the waiting list can be proposed.
C1 [Bezerra Coutinho, Francisco Antonio; Chaib, Eleazar; Amaku, Marcos; Burattini, Marcelo Nascimento; Massad, Eduardo] Univ Sao Paulo, HCFMUSP, Sch Med LIM 01 & LIM 37, BR-01246903 Sao Paulo, SP, Brazil.
RP Coutinho, FAB (corresponding author), Univ Sao Paulo, HCFMUSP, Sch Med LIM 01 & LIM 37, Ave Doutor Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM coutinho@dim.fm.usp.br
RI Coutinho, Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014;
   Amaku, Marcos/D-5252-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Amaku, Marcos/0000-0003-4752-6774
CR Chaib E, 2005, TRANSPLANT P, V37, P4329, DOI 10.1016/j.transproceed.2005.11.014
   Chaib E, 2009, TRANSPL P, V41, P3775, DOI 10.1016/j.transproceed.2009.05.035
   Chaib E, 2008, TRANSPL INT, V21, P290, DOI 10.1111/j.1432-2277.2007.00600.x
   Chaib E, 2007, TRANSPLANTATION, V84, P1209, DOI 10.1097/01.tp.0000287192.32090.2b
   Chaib E, 2010, MED HYPOTHESES, V75, P324, DOI 10.1016/j.mehy.2010.03.013
   Chaib E, 2008, LIVER TRANSPLANT, V14, P1732, DOI 10.1002/lt.21611
   deCarvalho HB, 1996, J ACQ IMMUN DEF SYND, V12, P84, DOI 10.1097/00042560-199605010-00012
   Massad E, 2009, EPIDEMIOL INFECT, V137, P241, DOI 10.1017/S0950268808000873
NR 8
TC 0
Z9 0
U1 0
U2 3
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE
BN 978-981-4602-21-1
J9 BIOMAT INT S MATH CO
JI BIOMAT-Int. S. Math. Comput. Biol.
PY 2014
BP 234
EP 249
PG 16
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA BD1LK
UT WOS:000358137000014
DA 2020-12-08
ER

PT J
AU Oliver, L
   Burattini, MN
   Coutinho, FAB
   Coelho, GE
   Struchiner, CJ
   Massad, E
AF Oliver, Leuda
   Burattini, Marcelo N.
   Coutinho, Francisco A. B.
   Coelho, Giovanini E.
   Struchiner, Claudio J.
   Massad, Eduardo
TI A Negative Correlation Between Dengue and Bushfires in Brazil
SO JOURNAL OF ENVIRONMENTAL HEALTH
LA English
DT Editorial Material
C1 [Oliver, Leuda; Burattini, Marcelo N.; Coutinho, Francisco A. B.; Massad, Eduardo] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Coelho, Giovanini E.] Minist Hlth Brazil, Natl Program Dengue Control, Porto Alegre, RS, Brazil.
   [Struchiner, Claudio J.] Fiocruz MS, Program Sci Computat, Rio De Janeiro, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Dept Med, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Coutinho, Francisco A B/H-5644-2011;
   Burattini, Marcelo N/J-9272-2014; Struchiner, Claudio J/M-9360-2013;
   OLIVEIRA, LEUDA/C-5578-2016
OI Massad, Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; Burattini, Marcelo N/0000-0002-5407-6890;
   Struchiner, Claudio J/0000-0003-2114-847X; OLIVEIRA,
   LEUDA/0000-0002-2762-3705
CR Ciencia e Technologia e Meio Ambiente, 2010, VEG FIR FIR MON
   Massad E, 2010, EPIDEMIOL INFECT, V138, P951, DOI 10.1017/S0950268809990501
   Wilder-Smith A, 2010, EPIDEMIOL INFECT, V138, P962, DOI 10.1017/S0950268810000683
NR 3
TC 3
Z9 3
U1 0
U2 14
PU NATL ENVIRON HEALTH ASSOC
PI DENVER
PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA
SN 0022-0892
J9 J ENVIRON HEALTH
JI J. Environ. Health
PD JAN-FEB
PY 2014
VL 76
IS 6
SI SI
BP 66
EP 67
PG 2
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA AO7NQ
UT WOS:000341540300009
PM 24645415
DA 2020-12-08
ER

PT J
AU Chaib, E
   Amaku, M
   Coutinho, FAB
   Lopez, LF
   Burattini, MN
   D'Albuquerque, LAC
   Massad, E
AF Chaib, Eleazar
   Amaku, Marcos
   Coutinho, Francisco A. B.
   Lopez, Luis F.
   Burattini, Marcelo N.
   D'Albuquerque, Luiz A. C.
   Massad, Eduardo
TI A mathematical model for optimizing the indications of liver
   transplantation in patients with hepatocellular carcinoma
SO THEORETICAL BIOLOGY AND MEDICAL MODELLING
LA English
DT Article
DE Liver transplantation; Hepatocellular carcinoma; Expanded criteria;
   Modelling
ID WAITING-LIST; SAO-PAULO; RESECTION; STATE; VACCINATION; DYNAMICS;
   NUMBER; IMPACT
AB Background: The criteria for organ sharing has developed a system that prioritizes liver transplantation (LT) for patients with hepatocellular carcinoma (HCC) who have the highest risk of wait-list mortality. In some countries this model allows patients only within the Milan Criteria (MC, defined by the presence of a single nodule up to 5 cm, up to three nodules none larger than 3 cm, with no evidence of extrahepatic spread or macrovascular invasion) to be evaluated for liver transplantation. This police implies that some patients with HCC slightly more advanced than those allowed by the current strict selection criteria will be excluded, even though LT for these patients might be associated with acceptable long-term outcomes.
   Methods: We propose a mathematical approach to study the consequences of relaxing the MC for patients with HCC that do not comply with the current rules for inclusion in the transplantation candidate list. We consider overall 5-years survival rates compatible with the ones reported in the literature. We calculate the best strategy that would minimize the total mortality of the affected population, that is, the total number of people in both groups of HCC patients that die after 5 years of the implementation of the strategy, either by post-transplantation death or by death due to the basic HCC. We illustrate the above analysis with a simulation of a theoretical population of 1,500 HCC patients with tumor size exponentially. The parameter. obtained from the literature was equal to 0.3. As the total number of patients in these real samples was 327 patients, this implied in an average size of 3.3 cm and a 95% confidence interval of [2.9; 3.7]. The total number of available livers to be grafted was assumed to be 500.
   Results: With 1500 patients in the waiting list and 500 grafts available we simulated the total number of deaths in both transplanted and non-transplanted HCC patients after 5 years as a function of the tumor size of transplanted patients. The total number of deaths drops down monotonically with tumor size, reaching a minimum at size equals to 7 cm, increasing from thereafter. With tumor size equals to 10 cm the total mortality is equal to the 5 cm threshold of the Milan criteria.
   Conclusion: We concluded that it is possible to include patients with tumor size up to 10 cm without increasing the total mortality of this population.
C1 [Chaib, Eleazar; D'Albuquerque, Luiz A. C.] Univ Sao Paulo, Liver & Pancreas Transplantat Surg Unit, Dept Gastroenterol, LIM 37,Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Amaku, Marcos; Coutinho, Francisco A. B.; Lopez, Luis F.; Burattini, Marcelo N.; Massad, Eduardo] Univ Sao Paulo, Dept Med Informat, LIM 01, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Dept Med Informat, LIM 01, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012; Burattini,
   Marcelo N/J-9272-2014; D'Albuquerque, Luiz Augusto Carneiro/A-8812-2013;
   D'ALBUQUERQUE, Luiz Carneiro Augusto/I-4011-2012; Amaku,
   Marcos/D-5252-2012; Coutinho, Francisco A B/H-5644-2011
OI Massad, Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Burattini, Marcelo N/0000-0002-5407-6890; D'Albuquerque, Luiz Augusto
   Carneiro/0000-0001-7607-7168; Amaku, Marcos/0000-0003-4752-6774;
   Coutinho, Francisco A B/0000-0003-3127-3071
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); LIMS [01, 37 HCFMUSP]
FX This work is supported by grants FAPESP, CNPq and LIMS 01 and 37
   HCFMUSP.
CR BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005
   Chaib E, 2005, TRANSPLANT P, V37, P4329, DOI 10.1016/j.transproceed.2005.11.014
   Chaib E, 2012, CLIN TRANSPLANT, V26, pE590, DOI 10.1111/ctr.12030
   Chaib E, 2008, TRANSPL INT, V21, P704, DOI 10.1111/j.1432-2277.2008.00661.x
   Chaib E, 2008, TRANSPL INT, V21, P290, DOI 10.1111/j.1432-2277.2007.00600.x
   Chaib E, 2007, TRANSPLANTATION, V84, P1209, DOI 10.1097/01.tp.0000287192.32090.2b
   Chaib E, 2008, LIVER TRANSPLANT, V14, P1732, DOI 10.1002/lt.21611
   Chawla YK, 2011, J CLIN EXP HEPATOL, V1, P161, DOI 10.1016/S0973-6883(11)60233-8
   Figueras J, 2000, J AM COLL SURGEONS, V190, P580, DOI 10.1016/S1072-7515(00)00251-9
   FREIRE J.G.C., 1968, REV ASSOC MED BRAS, V14, P133
   IWATSUKI S, 1991, ANN SURG, V214, P221, DOI 10.1097/00000658-199109000-00005
   Machado M C, 1972, Rev Hosp Clin Fac Med Sao Paulo, V27, P1
   Marsh JW, 2000, CANCER, V88, P538, DOI 10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO;2-H
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Massad E, 2008, STUD FUZZ SOFT COMP, V232, P1
   Mazzaferro V, 2009, LANCET ONCOL, V10, P35, DOI 10.1016/S1470-2045(08)70284-5
   Onaca N, 2007, LIVER TRANSPLANT, V13, P391, DOI 10.1002/lt.21095
   Ortega N, 2003, KYBERNETES, V32, P460, DOI 10.1108/03684920310463876
   RINGE B, 1991, WORLD J SURG, V15, P270, DOI 10.1007/BF01659064
   Roayaie S, 2002, ANN SURG, V235, P533, DOI 10.1097/00000658-200204000-00012
   Ryckman FC, 2008, SEMIN PEDIATR SURG, V17, P123, DOI 10.1053/j.sempedsurg.2008.02.008
   Samuel D, 2011, LIVER TRANSPLANT, V17, pS6, DOI 10.1002/lt.22423
   Thuluvath PJ, 2010, AM J TRANSPLANT, V10, P1003, DOI 10.1111/j.1600-6143.2010.03037.x
   Toso C, 2012, HEPATOLOGY, V56, P149, DOI 10.1002/hep.25603
   Volk ML, 2008, AM J TRANSPLANT, V8, P839, DOI 10.1111/j.1600-6143.2007.02138.x
   Yao FY, 2001, HEPATOLOGY, V33, P1394, DOI 10.1053/jhep.2001.24563
NR 27
TC 0
Z9 0
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1742-4682
J9 THEOR BIOL MED MODEL
JI Theor. Biol. Med. Model.
PD OCT 20
PY 2013
VL 10
AR 60
DI 10.1186/1742-4682-10-60
PG 12
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 267QT
UT WOS:000328113400001
PM 24139285
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Amaku, M
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
   Massad, E
AF Amaku, Marcos
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
   Lopez, Luis Fernandez
   Massad, Eduardo
TI Maximum Equilibrium Prevalence of Mosquito-Borne Microparasite
   Infections in Humans
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID THRESHOLD; DISEASES; SYSTEM; TRANSMISSION; STRATEGIES; DYNAMICS; DENGUE
AB To determine the maximum equilibrium prevalence of mosquito-borne microparasitic infections, this paper proposes a general model for vector-borne infections which is flexible enough to comprise the dynamics of a great number of the known diseases transmitted by arthropods. From equilibrium analysis, we determined the number of infected vectors as an explicit function of the model's parameters and the prevalence of infection in the hosts. From the analysis, it is also possible to derive the basic reproduction number and the equilibrium force of infection as a function of those parameters and variables. From the force of infection, we were able to conclude that, depending on the disease's structure and the model's parameters, there is a maximum value of equilibrium prevalence for each of the mosquito-borne microparasitic infections. The analysis is exemplified by the cases of malaria and dengue fever. With the values of the parameters chosen to illustrate those calculations, the maximum equilibrium prevalence found was 31% and 0.02% for malaria and dengue, respectively. The equilibrium analysis demonstrated that there is a maximum prevalence for the mosquito-borne microparasitic infections.
C1 [Amaku, Marcos] Univ Sao Paulo, Sch Vet Med, BR-05508270 Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Lopez, Luis Fernandez; Massad, Eduardo] LIM 01 HCFMUSP, BR-05405000 Sao Paulo, Brazil.
   [Lopez, Luis Fernandez] Florida Int Univ, CIARA, Miami, FL 33199 USA.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Amaku, M (corresponding author), Univ Sao Paulo, Sch Vet Med, Ave Prof Dr Orlando Marques de Paiva 87, BR-05508270 Sao Paulo, Brazil.
EM amaku@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Lopez, Luis F/C-4721-2012; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Amaku,
   Marcos/D-5252-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Lopez, Luis
   F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916; Burattini,
   Marcelo N/0000-0002-5407-6890; Amaku, Marcos/0000-0003-4752-6774
FU European UnionEuropean Union (EU) [282589]; LIM01 HCFMUSP; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX The research from which these results were obtained has received funding
   from the European Union's Seventh Framework Programme (FP7/2007-2013)
   under Grant agreement no. 282589, from LIM01 HCFMUSP and CNPq. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the paper.
CR Adams B, 2010, EPIDEMICS-NETH, V2, P1, DOI 10.1016/j.epidem.2010.01.001
   Amaku M., COMP ANAL RELATIVE E
   ANDERSON R M, 1991
   [Anonymous], 2004, GLOB STRAT FRAM INT
   Bacaer N, 2006, J MATH BIOL, V53, P421, DOI 10.1007/s00285-006-0015-0
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   CDC (Centers for Diseases Control), 2005, INF ARB ENC
   CIESIN (Center for International Earth Science Information Network), 2012, CHANG INC VECT BORN
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho FAB, 2005, MATH COMPUT SIMULAT, V70, P149, DOI 10.1016/j.matcom.2005.06.003
   Erickson RA, 2010, ECOL MODEL, V221, P2899, DOI 10.1016/j.ecolmodel.2010.08.036
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P227, DOI 10.1590/S0034-89101993000400001
   Gray SM, 1999, MICROBIOL MOL BIOL R, V63, P128, DOI 10.1128/MMBR.63.1.128-148.1999
   Gubler D. J., 2005, INTEGRATION PUBLIC H, P44
   GUBLER DJ, 1989, AM J TROP MED HYG, V40, P571
   Gubler DJ, 1998, EMERG INFECT DIS, V4, P442, DOI 10.3201/eid0403.980326
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Gubler DJ, 2002, ARCH MED RES, V33, P330, DOI 10.1016/S0188-4409(02)00378-8
   IOM (Institute of Medicine), 1992, EM INF MICR THREATS
   Karunamoorthi K., 2012, J SOCIALOMICS, V1
   Lemon S.M., 2008, VECTOR BORNE DIS UND
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2012, MEM I OSWALDO CRUZ, V107, P564, DOI 10.1590/S0074-02762012000400022
   Massad E, 2011, PHYS LIFE REV, V8, P169, DOI 10.1016/j.plrev.2011.01.001
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Smith DL, 2005, NATURE, V438, P492, DOI 10.1038/nature04024
   Wahl LM, 2000, P ROY SOC B-BIOL SCI, V267, P835, DOI 10.1098/rspb.2000.1079
   Wang WD, 2008, J DYN DIFFER EQU, V20, P699, DOI 10.1007/s10884-008-9111-8
   *WHO, 2005, STAT ART VACC RES DE
   Wilder-Smith A., 2012, GLOBAL HLTH ACTION, V5
   Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338
NR 32
TC 1
Z9 1
U1 0
U2 19
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PY 2013
AR 659038
DI 10.1155/2013/659038
PG 7
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 289HA
UT WOS:000329671300001
PM 24454539
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Bellei, NCJ
   Cabeca, TK
   Carraro, E
   Goto, JM
   Cuba, GT
   Hidalgo, SR
   Burattini, MN
AF Junqueira Bellei, Nancy Cristina
   Cabeca, Tatiane Karen
   Carraro, Emerson
   Goto, Janaina Midori
   Cuba, Gabriel Trova
   Hidalgo, Sonia Regina
   Burattini, Marcelo Nascimento
TI Pandemic H1N1 illness prognosis: evidence from clinical and
   epidemiological data from the first pandemic wave in Sao Paulo, Brazil
SO CLINICS
LA English
DT Article
DE Influenza; Pandemic H1N1; Epidemiology; Clinical Outcome; Treatment
ID INFLUENZA A(H1N1) INFECTION; CRITICALLY-ILL PATIENTS; VIRUS-INFECTION;
   RISK
AB OBJECTIVES: The pandemic of 2009 H1N1 influenza A emerged in February 2009, with high morbidity and mortality, and rapidly spread globally. Sao Paulo was among the most affected areas in Brazil. This study compares the clinical and epidemiological characteristics of influenza-like illness between outpatients and hospitalized patients and evaluates the impact of oseltamivir therapy on the outcome of 2009 H1N1 influenza A patients.
   METHODS: This is a case series study comparing the clinical and epidemiological characteristics of influenza-like illness between outpatients attended at Hospital Sao Paulo in August 2009 (the peak of the first pandemic wave) and those patients hospitalized between May and September 2009 (the entire first pandemic wave).
   RESULTS: The 1651 patients evaluated were predominantly female (927x686, p<0.001) and aged 31.71 +/- 16.42 years, with 148 reporting chronic pulmonary disease. Dyspnea was presented by 381 (23.4%) patients and was more frequent among those aged 30 years or more (p<0.001). Hospitalization occurred at 3.73 +/- 2.85 days, and antiviral treatment started 2.27 +/- 2.97 days after the onset of first symptoms. A delay of more than 5 days in starting oseltamivir therapy was independently associated with hospitalization (p<0.001), a stay in the ICU (p<0.001) and a higher risk of dying (OR = 28.1, 95% CI 2.81-280.2, p = 0.007).
   CONCLUSION: The 2009 pandemic of H1N1 influenza A affected young adults, presented a significant disease burden and produced severe cases with a significant fatality rate. However, promptly starting specific therapy improved the outcome.
C1 [Junqueira Bellei, Nancy Cristina; Cabeca, Tatiane Karen; Carraro, Emerson] Univ Fed Sao Paulo, Escola Paulista Med, Lab Virol Clin, Sao Paulo, Brazil.
   [Goto, Janaina Midori; Cuba, Gabriel Trova; Hidalgo, Sonia Regina] Univ Fed Sao Paulo, Escola Paulista Med, Dept Med, Disciplina Infectol, Sao Paulo, Brazil.
   [Junqueira Bellei, Nancy Cristina; Goto, Janaina Midori; Cuba, Gabriel Trova; Hidalgo, Sonia Regina; Burattini, Marcelo Nascimento] Hosp Sao Paulo, Unidade Doencas Infecciosas, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Disciplina Informat Med, Sao Paulo, Brazil.
RP Bellei, NCJ (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Lab Virol Clin, Sao Paulo, Brazil.
EM mnburattini@unifesp.br
RI Carraro, Emerson/G-7954-2012; Bellei, Nancy/D-8641-2016; Burattini,
   Marcelo N/J-9272-2014
OI Bellei, Nancy/0000-0001-6080-5693; Burattini, Marcelo
   N/0000-0002-5407-6890; Carraro, Emerson/0000-0001-5420-2300
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX We would like to acknowledge the members of the Influenza Working Group
   of Hospital Sao Paul, Eduardo Medeiros, Odair Marson (in memory), Celso
   Granato, Suely Yashiro, Katsumi Osiro, Enfermeira Nazare, Ana Luiza
   Fernandes, Luis Eduardo Nery and Nivia Pissaya and the medical staff of
   the emergency ward for their contribution to the preparedness of the
   hospital and to the treatment of the patients attended at Hospital Sao
   Paulo during the first 2009 H1N1 pandemic wave. We also acknowledge the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and
   the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) for
   partially supporting this work.
CR Armstrong GL, 2011, CLIN INFECT DIS, V52, pS83, DOI 10.1093/cid/ciq013
   Bautista E, 2010, NEW ENGL J MED, V362, P1708, DOI 10.1056/NEJMra1000449
   Bellei N, 2008, J MED VIROL, V80, P1824, DOI 10.1002/jmv.21295
   Brazilian Ministry of Health, 2009, B EL EP INFL, V02
   Brazilian Ministry of Health, 2011, PROT TRAT INFL 2011
   Brazilian Ministry of Health, 2009, INF EP INFL PAND H1N, V11
   Brazilian Ministry of Health, 2009, PROT VIG EP INFL PAN
   Carraro E, 2008, DIAGN MICR INFEC DIS, V60, P445, DOI 10.1016/j.diagmicrobio.2007.11.012
   Center for Disease Control and Prevention (CDC), PROT REAL TIM RTPCR
   Chan MCW, 2010, AM J PATHOL, V176, P1828, DOI 10.2353/ajpath.2010.091087
   Donaldson LJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5213
   Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Kawai N, 2011, J INFECT CHEMOTHER, V17, P375, DOI 10.1007/s10156-010-0179-9
   Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496
   Louie JK, 2009, JAMA-J AM MED ASSOC, V302, P1896, DOI 10.1001/jama.2009.1583
   Massad E, 2010, MEM I OSWALDO CRUZ, V105, P179, DOI 10.1590/S0074-02762010000200012
   Qi L, 2011, VIROLOGY, V412, P426, DOI 10.1016/j.virol.2011.01.029
   Rodriguez A, 2011, J ANTIMICROB CHEMOTH, V66, P1140, DOI 10.1093/jac/dkq511
   Shun-Shin M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3172
   Slopen M. E., 2010, Morbidity and Mortality Weekly Report, V58, P1436
   Ugarte S, 2010, CRIT CARE MED, V38, pE133, DOI 10.1097/CCM.0b013e3181c87716
   Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481
   World Health Organization (WHO) - Western pacific region, INFL PAND H1N1 2009
   Yu HJ, 2011, CLIN INFECT DIS, V52, P457, DOI 10.1093/cid/ciq144
   Yu HJ, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4779
   Zhang GL, 2011, INTERVIROLOGY, V54, P164, DOI 10.1159/000319930
NR 26
TC 3
Z9 3
U1 0
U2 15
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2013
VL 68
IS 6
BP 840
EP 845
DI 10.6061/clinics/2013(06)19
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 165DS
UT WOS:000320463800019
PM 23778481
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Souza, PML
   Burattini, MN
   Jacob, W
   Santarem, JM
AF Souza, Paula M. L.
   Burattini, Marcelo N.
   Jacob Filho, Wilson
   Santarem, Jose Maria
TI PROGRESSIVE RESISTANCE TRAINING IN ELDERLY LIVING WITH HIV
SO JOURNAL OF AGING AND PHYSICAL ACTIVITY
LA English
DT Meeting Abstract
C1 [Souza, Paula M. L.; Burattini, Marcelo N.; Jacob Filho, Wilson; Santarem, Jose Maria] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 2
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1063-8652
J9 J AGING PHYS ACTIV
JI J. Aging Phys. Act.
PD AUG
PY 2012
VL 20
SU S
BP S290
EP S290
PG 1
WC Geriatrics & Gerontology; Gerontology; Sport Sciences
SC Geriatrics & Gerontology; Sport Sciences
GA 987QZ
UT WOS:000307433500502
DA 2020-12-08
ER

PT J
AU Souza, PML
   Jacob, W
   Santarem, JM
   Burattini, MN
AF Souza, Paula M. L.
   Jacob Filho, Wilson
   Santarem, Jose Maria
   Burattini, Marcelo Nascimento
TI Effect of progressive resistance training on strength evolution of
   ageing people living with HIV compared to healthy controls
SO JOURNAL OF AGING AND PHYSICAL ACTIVITY
LA English
DT Meeting Abstract
DE Resistance Training; HIV; Body Mass Index; Strength Evolution
C1 [Souza, Paula M. L.; Jacob Filho, Wilson; Santarem, Jose Maria; Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 7
PU HUMAN KINETICS PUBL INC
PI CHAMPAIGN
PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA
SN 1063-8652
J9 J AGING PHYS ACTIV
JI J. Aging Phys. Act.
PD AUG
PY 2012
VL 20
SU S
BP S255
EP S255
PG 1
WC Geriatrics & Gerontology; Gerontology; Sport Sciences
SC Geriatrics & Gerontology; Sport Sciences
GA 987QZ
UT WOS:000307433500440
DA 2020-12-08
ER

PT J
AU de Souza, PML
   Jacob, W
   Santarem, JM
   Zomignan, AA
   Burattini, MN
AF Loiola de Souza, Paula Maria
   Jacob-Filho, Wilson
   Santarem, Jose Maria
   Zomignan, Adriana Almeida
   Burattini, Marcelo Nascimento
TI Effect of progressive resistance exercise on strength evolution of
   elderly patients living with HIV compared to healthy controls
SO CLINICS
LA English
DT Article
DE Exercise; HIV; Elderly adults; Muscular strength; Resistance exercise
ID MUSCLE; MASS; MEN; AGE
AB OBJECTIVES: Human Immunodeficiency Virus (HIV) infection worsens the frailty of elderly people, compromising their quality of life. In this study we prospectively evaluated eleven patients living with HIV and 21 controls older than 60 years and without prior regular physical activity, who engaged in a one-year progressive resistance exercise program to compare its effects on muscular strength, physical fitness and body composition.
   METHODS: Exercises for major muscular groups were performed 2 times/week, under professional supervision. Strength increase was evaluated bimonthly, while body composition, lipid and glycaemic profiles (only of those living with HIV) and physical fitness were evaluated before and after the one-year training.
   RESULTS: The participants living with HIV were lighter, had smaller Body Mass Index and were initially much weaker than controls. However, their strength increased more (1.52-2.33 times the baseline values for those living with HIV x 1.21-1.48 times for controls, p<0.01), nullifying the differences initially seen. These effects were seen independently of gender, age or baseline physical activity. In addition, those living with HIV improved their fasting glucose levels and showed a tendency to improve their lipids after the one year training program. These effects were slightly more pronounced among those not using protease inhibitors, although not significantly.
   CONCLUSIONS: Resistance exercise safely increased the strength of older patients living with HIV adults, allowing them to achieve performance levels observed among otherwise healthy controls. These findings favor the recommendation of resistance exercise for elderly adults living with HIV adults.
C1 [Loiola de Souza, Paula Maria; Burattini, Marcelo Nascimento] Univ Sao Paulo FMUSP, Discipline Med Informat, Fac Med, Hosp Clin, Sao Paulo, Brazil.
   [Loiola de Souza, Paula Maria; Burattini, Marcelo Nascimento] Univ Sao Paulo FMUSP, LIM Dept Pathol 01, Hosp Clin, Fac Med, Sao Paulo, Brazil.
   [Jacob-Filho, Wilson; Santarem, Jose Maria] Univ Sao Paulo, Fac Med, Dept Clin Med, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Discipline Infect Dis, Sao Paulo, Brazil.
   [Jacob-Filho, Wilson; Santarem, Jose Maria; Zomignan, Adriana Almeida] Univ Sao Paulo, Fac Med, Ctr Estudos Ciencias Atividade Fis CECAFI, Sao Paulo, Brazil.
RP de Souza, PML (corresponding author), Univ Sao Paulo FMUSP, Discipline Med Informat, Fac Med, Hosp Clin, Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR Bhasin S, 2000, JAMA-J AM MED ASSOC, V283, P763, DOI 10.1001/jama.283.6.763
   Bhasin S, 2000, JAMA-J AM MED ASSOC, V284, P175, DOI 10.1001/jama.284.2.175
   Calloway C., 1988, ANTHROPOMETRIC STAND, P39
   Guadalupe-Grau A, 2009, SPORTS MED, V39, P439, DOI 10.2165/00007256-200939060-00002
   GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902
   HARRISON GG, 1988, ANTHROPOMETRIC STAND, P55
   Hunter GR, 2004, SPORTS MED, V34, P329, DOI 10.2165/00007256-200434050-00005
   Hurley BF, 2000, SPORTS MED, V30, P249, DOI 10.2165/00007256-200030040-00002
   KLITGAARD H, 1990, ACTA PHYSIOL SCAND, V140, P41, DOI 10.1111/j.1748-1716.1990.tb08974.x
   Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027
   de Souza PML, 2008, CLINICS, V63, P619, DOI 10.1590/S1807-59322008000500009
   Lox CL, 1996, INT J BEHAV MED, V3, P55, DOI 10.1207/s15327558ijbm0301_5
   MASCOLINI M, 2010, RES INITIATIVE TREAT, V15, P5
   Mazzeo RS, 1998, MED SCI SPORT EXER, V30, P992, DOI 10.1097/00005768-199806000-00033
   MCCARTNEY N, 1995, J GERONTOL A-BIOL, V50, pB97, DOI 10.1093/gerona/50A.2.B97
   O'Brien K, 2008, AIDS CARE, V20, P631, DOI 10.1080/09540120701661708
   O'Brien K, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001796.pub3
   Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032
   Roubenoff R, 2000, AM J MANAG CARE, V6, P1003
   Roubenoff R, 1999, AIDS, V13, P231, DOI 10.1097/00002030-199902040-00011
   Shaw C E, 1995, J Cardiopulm Rehabil, V15, P283, DOI 10.1097/00008483-199507000-00005
   Srinivasan S, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000924
   Suominen H, 2006, AGING CLIN EXP RES, V18, P85, DOI 10.1007/BF03327422
   Whiteford J, 2010, OSTEOPOROSIS INT, V21, P1529, DOI 10.1007/s00198-009-1132-6
   Winett RA, 2001, PREV MED, V33, P503, DOI 10.1006/pmed.2001.0909
NR 25
TC 30
Z9 32
U1 0
U2 13
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PY 2011
VL 66
IS 2
BP 261
EP 266
DI 10.1590/S1807-59322011000200014
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 748BO
UT WOS:000289365200014
PM 21484044
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT B
AU Ribas, CE
   Francisco, AJF
   Yamamoto, JF
   Burattini, MN
AF Ribas, Carlos Eduardo
   Ferreira Francisco, Antonio Joao
   Yamamoto, Jorge Futoshi
   Burattini, Marcelo Nascimento
BE Callaos, N
   Goncalves, R
   Hashimoto, S
   Jastroch, N
   Marlowe, TJ
   Nousala, S
TI A New Approach to Information Security Assessment: a case study in a
   Brazilian healthcare organization
SO WMSCI 2011: 15TH WORLD MULTI-CONFERENCE ON SYSTEMICS, CYBERNETICS AND
   INFORMATICS, VOL II
LA English
DT Proceedings Paper
CT 15th World Multi-Conference on Systematics, Cybernetics and Informatics
   (WMSCI 2011)
CY JUL 19-22, 2011
CL Orlando, FL
SP Int Inst Informat & Syst
DE information security; information system; ISO standards; assessment;
   health informatics
AB Information security is an important issue in today's business. Information has become a vital asset of organizations and it is necessary to protect it, ensuring its confidentiality, integrity and availability (CIA). The ISO 27000 family of standards related to information security is designed to help organizations to keep their information securely. Risk management, comprising its identification, analysis and assessment is extremely important and can be crucial to the success or failure of an organization. However, the proper management of risks is not easily achieved. The aim of this study is to present an information system designed to help organizations in assessing their information security level based on ISO standards. The system proposed is named Information Security Assessment (ISA) and uses a scoring scheme that assigns a value to each control. ISA was used during the implementing process of an Information Security Management System (ISMS) in a Brazilian hospital. The case studied has shown that ISA yielded consistent results and that it helped to identify priorities in the institutional information risks treatment.
C1 [Ribas, Carlos Eduardo; Ferreira Francisco, Antonio Joao; Yamamoto, Jorge Futoshi] ANSP, Located Dr Ovidio Pires de Campos 215, BR-05403010 Sao Paulo, SP, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, SP, Brazil.
RP Ribas, CE (corresponding author), ANSP, Located Dr Ovidio Pires de Campos 215, BR-05403010 Sao Paulo, SP, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR ABNT-Associacao Brasileira de Normas Tecnicas, 2005, 270022005 ABNT NBR I
   Boehmer Wolfgang, 2008, 2008 Second International Conference on Emerging Security Information, Systems and Technologies (SECUREWARE), P224, DOI 10.1109/SECURWARE.2008.7
   Gilbert Miller H., 2009, IT PROFESSIONAL, V11, P60
   Ramos A, 2008, SECURITY OFFICER GUI
   Tong CKS, 2003, INT CONGR SER, V1256, P311, DOI 10.1016/S0531-5131(03)00518-1
   Xu CH, 2009, WISM: 2009 INTERNATIONAL CONFERENCE ON WEB INFORMATION SYSTEMS AND MINING, PROCEEDINGS, P497, DOI 10.1109/WISM.2009.106
   Zhao I, 2007, ICEMI 07, p2296 99
NR 7
TC 0
Z9 0
U1 0
U2 0
PU INT INST INFORMATICS & SYSTEMICS
PI ORLANDO
PA 14269 LORD BARCLAY DR, ORLANDO, FL 32837 USA
BN 978-1-936338-30-6
PY 2011
BP 219
EP 223
PG 5
WC Computer Science, Cybernetics; Computer Science, Information Systems;
   Computer Science, Theory & Methods
SC Computer Science
GA BG8OY
UT WOS:000392561900043
DA 2020-12-08
ER

PT J
AU Amaku, M
   Burattini, MN
   Coutinho, FAB
   Massad, E
AF Amaku, Marcos
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
   Massad, Eduardo
TI Modeling the Competition Between Viruses in a Complex Plant-Pathogen
   System
SO PHYTOPATHOLOGY
LA English
DT Article
DE virus competition
ID YELLOW DWARF VIRUS; APHID TRANSMISSION; ACCESS PERIODS; EVOLUTION;
   VIRULENCE
AB In this article, we propose a mathematical model that describes the competition between two plant virus strains (MAV and PAV) for both the host plant (oat) and their aphid vectors. We found that although PAV is transmitted by two aphids and MAV by only one, this fact, by itself, does not explain the complete replacement of MAV by PAV in New York State during the period from 1961 through 1976; an interpretation that is in agreement with the theories of A. G. Power. Also, although MAV wins the competition within aphids, we assumed that, in 1961, PAV mutated into a new variant such that this new variant was able to overcome MAV within the plants during a latent period. As shown below, this is sufficient to explain the swap of strains; that is, the dominant MAV was replaced by PAV, also in agreement with Power's expectations.
C1 [Amaku, Marcos] Univ Sao Paulo, Sch Vet Med, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Massad, Eduardo] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Massad, Eduardo] LIM 01 HCFMUSP, Sao Paulo, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London, England.
RP Amaku, M (corresponding author), Univ Sao Paulo, Sch Vet Med, Sao Paulo, Brazil.
EM amaku@usp.br
RI Burattini, Marcelo N/J-9272-2014; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011; Coutinho, Francisco A
   B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Amaku,
   Marcos/0000-0003-4752-6774; Massad, Eduardo/0000-0002-7200-2916;
   Coutinho, Francisco A B/0000-0003-3127-3071
FU LIM 01 HCFMUSP; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); CNPqNational Council for Scientific and Technological
   Development (CNPq)
FX We thank J. R. Parra and J. R. S. Lopes of ESALQ-USP for their
   illuminating advice concerning the biology of the complex
   aphids-viruses-plants, and the editor and one anonymous reviewer for
   their very useful suggestion to improve this manuscript. This work was
   partially supported by LIM 01 HCFMUSP, FAPESP, and CNPq.
CR Amaku M, 2010, B MATH BIOL, V72, P1294, DOI 10.1007/s11538-009-9495-6
   Day T, 2001, EVOLUTION, V55, P2389, DOI 10.1111/j.0014-3820.2001.tb00754.x
   Dib L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040007
   GILDOW FE, 1980, PHYTOPATHOLOGY, V70, P122, DOI 10.1094/Phyto-70-122
   GRAY SM, 1991, PHYTOPATHOLOGY, V81, P539, DOI 10.1094/Phyto-81-539
   Lipsitch M, 1996, EVOLUTION, V50, P1729, DOI 10.1111/j.1558-5646.1996.tb03560.x
   LIPSITCH M, 1995, J THEOR BIOL, V174, P427, DOI 10.1006/jtbi.1995.0109
   Manrubia SC, 2006, PHYS LIFE REV, V3, P65, DOI 10.1016/j.plrev.2005.11.002
   MASSAD E, 1997, EVOLUTION, V50, P916
   Massad E, 2008, APPL MATH COMPUT, V201, P161, DOI 10.1016/j.amc.2007.12.007
   Perelson AS, 1999, SIAM REV, V41, P3, DOI 10.1137/S0036144598335107
   Power AG, 1996, ECOLOGY, V77, P1004, DOI 10.2307/2265571
   POWER AG, 1991, PHYTOPATHOLOGY, V81, P545, DOI 10.1094/Phyto-81-545
   ROCHOW WF, 1979, PHYTOPATHOLOGY, V69, P655, DOI 10.1094/Phyto-69-655
   WEN F, 1991, J GEN VIROL, V72, P729
   Zhang XS, 2001, PHYTOPATHOLOGY, V91, P924, DOI 10.1094/PHYTO.2001.91.10.924
NR 16
TC 6
Z9 6
U1 0
U2 13
PU AMER PHYTOPATHOLOGICAL SOC
PI ST PAUL
PA 3340 PILOT KNOB ROAD, ST PAUL, MN 55121 USA
SN 0031-949X
J9 PHYTOPATHOLOGY
JI Phytopathology
PD OCT
PY 2010
VL 100
IS 10
BP 1042
EP 1047
DI 10.1094/PHYTO-10-09-0289
PG 6
WC Plant Sciences
SC Plant Sciences
GA 651XY
UT WOS:000281962100008
PM 20839939
OA Bronze
DA 2020-12-08
ER

PT J
AU da Rocha, AF
   Rocha, FT
   Burattini, MN
   Massad, E
AF da Rocha, Armando Freitas
   Rocha, Fabio Theoto
   Burattini, Marcelo Nascimento
   Massad, Eduardo
TI Neurodynamics of an election
SO BRAIN RESEARCH
LA English
DT Article
DE EEG; Decision-making; Voting; Brain networks; ERP; Distributed
   processing; Benefits; Risks
ID GRAPH-THEORETICAL ANALYSIS; DEFAULT MODE; DECISION-MAKING; HUMAN BRAIN;
   FUNCTIONAL CONNECTIVITY; MORAL JUDGMENT; SMALL-WORLD; NETWORKS; EEG;
   HYPOTHESIS
AB Variables influencing decision-making in real settings, as in the case of voting decisions, are uncontrollable and in many times even unknown to the experimenter. In this case, the experimenter has to study the intention to decide (vote) as close as possible in time to the moment of the real decision (election day). Here, we investigated the brain activity associated with the voting intention declared 1 week before the election day of the Brazilian Firearms Control Referendum about prohibiting the commerce of firearms. Two alliances arose in the Congress to run the campaigns for YES (for the prohibition of firearm commerce) and NO (against the prohibition of firearm commerce) voting. Time constraints imposed by the necessity of studying a reasonable number (here, 32) of voters during a very short time (5 days) made the EEG the tool of choice for recording the brain activity associated with voting decision. Recent fMRI and EEG studies have shown decision-making as a process due to the enrollment of defined neuronal networks. In this work, a special EEG technique is applied to study the topology of the voting decision-making networks and is compared to the results of standard ERP procedures. The results show that voting decision-making enrolled networks in charge of calculating the benefits and risks of the decision of prohibiting or allowing firearm commerce and that the topology of such networks was vote-(i.e., YES/NO-) sensitive. (C) 2010 Elsevier B.V. All rights reserved.
C1 [da Rocha, Armando Freitas; Rocha, Fabio Theoto] RANI Res Nat & Artificial Intelligence, BR-13207110 Jundiai, Brazil.
   [da Rocha, Armando Freitas; Rocha, Fabio Theoto; Burattini, Marcelo Nascimento; Massad, Eduardo] Univ Sao Paulo, Sch Med, BR-5405000 Sao Paulo, Brazil.
   [da Rocha, Armando Freitas; Rocha, Fabio Theoto; Burattini, Marcelo Nascimento; Massad, Eduardo] LIM01 HCFMUSP, BR-5405000 Sao Paulo, Brazil.
RP da Rocha, AF (corresponding author), Rua Tenente Ary Aps 172, BR-13207110 Jundiai, Brazil.
EM armando@enscer.com.br; fabio@enscer.com.br; mnburatti@usp.br;
   edmassad@usp.br
RI Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916
CR Alegre M, 2006, CLIN NEUROPHYSIOL, V117, P16, DOI 10.1016/j.clinph.2005.08.030
   Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509
   Chen ACN, 2008, NEUROIMAGE, V41, P561, DOI 10.1016/j.neuroimage.2007.12.064
   Chen PF, 2009, BIOL PSYCHOL, V82, P111, DOI 10.1016/j.biopsycho.2009.06.007
   Cohen MX, 2007, NEUROIMAGE, V35, P968, DOI 10.1016/j.neuroimage.2006.11.056
   Dosenbach NUF, 2008, TRENDS COGN SCI, V12, P99, DOI 10.1016/j.tics.2008.01.001
   Dosenbach NUF, 2006, NEURON, V50, P799, DOI 10.1016/j.neuron.2006.04.031
   DOSENBACH NUF, 2007, PNNAS, V104, P11703
   Esposito F, 2009, NEUROIMAGE, V47, P112, DOI 10.1016/j.neuroimage.2009.03.074
   Fair DA, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000381
   Ferri R, 2008, CLIN NEUROPHYSIOL, V119, P2026, DOI 10.1016/j.clinph.2008.04.294
   Foz FB, 2002, PEDIATR NEUROL, V26, P106, DOI 10.1016/S0887-8994(01)00368-X
   Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113
   Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017
   Goldman RI, 2009, NEUROIMAGE, V47, P136, DOI 10.1016/j.neuroimage.2009.03.062
   Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027
   Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100
   Hauk O, 2006, NEUROIMAGE, V30, P1383, DOI 10.1016/j.neuroimage.2005.11.048
   Heldmann M, 2005, J PSYCHOPHYSIOL, V19, P270, DOI 10.1027/0269-8803.19.4.270
   Huettel SA, 2006, NEURON, V49, P765, DOI 10.1016/j.neuron.2006.01.024
   Iacoboni M, 2004, NEUROIMAGE, V21, P1167, DOI 10.1016/j.neuroimage.2003.11.013
   Ino T, 2010, CORTEX, V46, P2, DOI 10.1016/j.cortex.2009.02.022
   Iturria-Medina Y, 2008, NEUROIMAGE, V40, P1064, DOI 10.1016/j.neuroimage.2007.10.060
   Jacobs J, 2006, NEUROIMAGE, V32, P978, DOI 10.1016/j.neuroimage.2006.02.018
   Keenan JP, 2000, TRENDS COGN SCI, V4, P338, DOI 10.1016/S1364-6613(00)01521-7
   Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008
   Kliemann D, 2008, NEUROPSYCHOLOGIA, V46, P2949, DOI 10.1016/j.neuropsychologia.2008.06.010
   Knutson B, 2007, NEURON, V53, P147, DOI 10.1016/j.neuron.2006.11.010
   Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104
   Marchiori M, 2000, PHYSICA A, V285, P539, DOI 10.1016/S0378-4371(00)00311-3
   McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907
   Micheloyannis S, 2006, NEUROSCI LETT, V402, P273, DOI 10.1016/j.neulet.2006.04.006
   Moll J, 2007, TRENDS COGN SCI, V11, P319, DOI 10.1016/j.tics.2007.06.001
   Olofsson JK, 2008, BIOL PSYCHOL, V77, P247, DOI 10.1016/j.biopsycho.2007.11.006
   Platek SM, 2009, NEUROPSYCHOLOGIA, V47, P849, DOI 10.1016/j.neuropsychologia.2008.12.027
   Poiezzi D, 2008, BEHAV BRAIN RES, V187, P116, DOI 10.1016/j.bbr.2007.09.001
   Polezzi D, 2008, BEHAV BRAIN RES, V190, P218, DOI 10.1016/j.bbr.2008.03.003
   Polezzi D, 2010, NEUROIMAGE, V49, P1886, DOI 10.1016/j.neuroimage.2009.08.068
   Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676
   Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010
   Robertson D, 2007, NEUROPSYCHOLOGIA, V45, P755, DOI 10.1016/j.neuropsychologia.2006.08.014
   ROCHA AF, 2009, J BIOL SYST, V17, P10
   Rocha AF, 2004, BRAIN FUZZY ARITHMET
   Rocha FT, 2005, COGNITIVE BRAIN RES, V22, P359, DOI 10.1016/j.cogbrainres.2004.09.008
   Schilbach L, 2008, CONSCIOUS COGN, V17, P457, DOI 10.1016/j.concog.2008.03.013
   Uddin LQ, 2005, NEUROIMAGE, V25, P926, DOI 10.1016/j.neuroimage.2004.12.018
   Utku H, 2002, J NEUROSCI METH, V114, P25, DOI 10.1016/S0165-0270(01)00519-2
   van den Heuvel MP, 2008, NEUROIMAGE, V43, P528, DOI 10.1016/j.neuroimage.2008.08.010
   Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918
   Younga L, 2008, NEUROIMAGE, V40, P1912, DOI 10.1016/j.neuroimage.2008.01.057
NR 50
TC 6
Z9 6
U1 2
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
EI 1872-6240
J9 BRAIN RES
JI Brain Res.
PD SEP 10
PY 2010
VL 1351
BP 198
EP 211
DI 10.1016/j.brainres.2010.06.046
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 653UD
UT WOS:000282121500019
PM 20599820
DA 2020-12-08
ER

PT J
AU Motta, AL
   de Almeida, GMD
   de Almeida, JN
   Burattini, MN
   Rossi, F
AF Motta, Adriana Lopes
   Duboc de Almeida, Gisele Madeira
   de Almeida Junior, Joao Nobrega
   Burattini, Marcelo Nascimento
   Rossi, Flavia
TI Candidemia epidemiology and susceptibility profile in the largest
   Brazilian teaching hospital complex
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE candidemia; Candida spp; susceptibility testing; Candida epidemiology;
   Candida Etest; antifungal susceptibility profile; Candida antifungal
   agents; azoles
ID ANTIMICROBIAL SURVEILLANCE PROGRAM; GLOBAL ANTIFUNGAL-SURVEILLANCE;
   BROTH MICRODILUTION METHOD; BLOOD-STREAM INFECTIONS; IN-VITRO
   SUSCEPTIBILITY; UNITED-STATES; AMPHOTERICIN-B; FLUCONAZOLE;
   PARAPSILOSIS; CASPOFUNGIN
AB Introduction: Although the spectrum of fungi causing bloodstream fungal infections continues to expand, Candida spp. remains responsible for the majority of these cases. Objective: The purpose of this study was to characterize the candidemia epidemiology, species distribution and antifungal susceptibility patterns at a Brazilian tertiary teaching public hospital with 2,500 beds. Methods: Records from the microbiology laboratory were used to identify patients with positive blood cultures during 2006. The in vitro activity of amphotericin B, caspofungin, itraconazole, fluconazole, voricanozole, and posaconazole were determined using the Etest method. Results: One hundred and thirty-six cases of candidemia were identified and 100 strains were available for antifungal susceptibility testing. The overall incidence of candidemia was 1.87 cases/1.000 admissions and 0.27 cases/1.000 patient-days. Among the patients, 58.1% were male, and the median age was 40 years old. C. albicans was the most common species (52.2%), followed by C. parapsilosis (22.1%), C. tropicalis (14.8%), and C. glabrata (6.6%). All strains were susceptible to amphotericin B with a MIC90 of 0.5 mu g/mL. Overall susceptibility for voriconozole, fluconazole, and caspofungin was >= 97% with a MIC90 of 0.064, 4.0 and 1.0 mu g/mL, respectively. For itraconazole the susceptibility rate was 81% with a MIC90 of 0.5 mu g/mL. Posaconazole also demonstrated good in vitro activity with a MIC90 of 0.25 mu g/mL. Conclusion: This is the first antifungal susceptibility report in our institution.
C1 [Motta, Adriana Lopes; Duboc de Almeida, Gisele Madeira; de Almeida Junior, Joao Nobrega; Burattini, Marcelo Nascimento; Rossi, Flavia] Univ Sao Paulo, Dept Pathol, Microbiol Lab, Div Cent Lab,LIM 03, Sao Paulo, Brazil.
RP Motta, AL (corresponding author), Rua Capote Valente 668,Complement Apt 32, BR-05409002 Sao Paulo, Brazil.
EM drilomotta@hotmail.com
RI Burattini, Marcelo N/J-9272-2014; Motta, Adriana/B-7272-2013
OI Burattini, Marcelo N/0000-0002-5407-6890; Nobrega de Almeida Junior,
   Joao/0000-0002-3766-026X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX Financial Support: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP).
CR Alexander BD, 2007, J CLIN MICROBIOL, V45, P698, DOI 10.1128/JCM.01840-06
   Almirante B, 2005, J CLIN MICROBIOL, V43, P1829, DOI 10.1128/JCM.43.4.1829-1835.2005
   Aquino Valério Rodrigues, 2005, Braz J Infect Dis, V9, P411, DOI 10.1590/S1413-86702005000500009
   Arendrup MC, 2005, J CLIN MICROBIOL, V50, P3496
   Barry AL, 2002, ANTIMICROB AGENTS CH, V46, P1781, DOI 10.1128/AAC.46.6.1781-1784.2002
   Bassetti M, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-21
   BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
   Borst A, 2005, ANTIMICROB AGENTS CH, V49, P783, DOI 10.1128/AAC.49.2.783-787.2005
   Brito LR, 2006, MED MYCOL, V44, P261, DOI 10.1080/13693780500421476
   Caton E, 2006, REV ESP QUIM, V19, P267
   Chang HC, 2001, J CLIN MICROBIOL, V39, P1328, DOI 10.1128/JCM.39.4.1328-1333.2001
   Chryssanthou E, 2001, J CLIN MICROBIOL, V39, P4181, DOI 10.1128/JCM.39.11.4181-4183.2001
   CLSI, 2008, M27A3 NCCLS CLSI
   Colombo AL, 2007, INFECT CONT HOSP EP, V28, P570, DOI 10.1086/513615
   Colombo AL, 2006, J CLIN MICROBIOL, V44, P2816, DOI 10.1128/JCM.00773-06
   Cornelius JC, 2006, ANTIMICROB AGENTS CH, V49, P767
   Diekema DJ, 2007, J CLIN MICROBIOL, V45, P1974, DOI 10.1128/JCM.02087-06
   Eggimann P, 2003, LANCET INFECT DIS, V3, P685, DOI 10.1016/S1473-3099(03)00801-6
   Epinel-Ingroff A, 2008, J CLIN MICROBIOL, V43, P4535
   Garcia-Effron G, 2008, ANTIMICROB AGENTS CH, V52, P2305, DOI 10.1128/AAC.00262-08
   Girao E, 2008, MED MYCOL, V46, P581, DOI 10.1080/13693780802004996
   Godoy P, 2003, MEM I OSWALDO CRUZ, V98, P401, DOI 10.1590/S0074-02762003000300020
   Krcmery V, 2002, J HOSP INFECT, V50, P243, DOI 10.1053/jhin.2001.1151
   Krogh-Madsen M, 2006, CLIN INFECT DIS, V42, P938, DOI 10.1086/500939
   Levin AS, 1998, DIAGN MICR INFEC DIS, V30, P243, DOI 10.1016/S0732-8893(98)00006-6
   Macphail GLP, 2002, MYCOSES, V45, P141, DOI 10.1046/j.1439-0507.2002.00741.x
   Magill SS, 2006, J CLIN MICROBIOL, V44, P529, DOI 10.1128/JCM.44.2.529-535.2006
   Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139
   Morace G, 2002, J CLIN MICROBIOL, V40, P2953, DOI 10.1128/JCM.40.8.2953-2958.2002
   Moudgal V, 2005, ANTIMICROB AGENTS CH, V49, P767, DOI 10.1128/AAC.49.2.767-769.2005
   Nguyen MH, 1998, J INFECT DIS, V177, P425, DOI 10.1086/514193
   Ostrosky-Zeichner L, 2003, ANTIMICROB AGENTS CH, V47, P3149, DOI 10.1128/AAC.47.10.3149-3154.2003
   Pasqualotto AC, 2008, INFECT CONT HOSP EP, V29, P898, DOI 10.1086/590191
   Peman J, 2005, EUR J CLIN MICROBIOL, V24, P23, DOI 10.1007/s10096-004-1267-5
   Pfaller MA, 2008, J CLIN MICROBIOL, V46, P2620, DOI 10.1128/JCM.00566-08
   Pfaller MA, 2008, J CLIN MICROBIOL, V46, P842, DOI 10.1128/JCM.02122-07
   Pfaller MA, 2008, J CLIN MICROBIOL, V46, P551, DOI 10.1128/JCM.01952-07
   Pfaller MA, 2008, J CLIN MICROBIOL, V46, P150, DOI 10.1128/JCM.01901-07
   Pfaller MA, 2007, CLIN MICROBIOL REV, V20, P133, DOI 10.1128/CMR.00029-06
   Pfaller MA, 2000, ANTIMICROB AGENTS CH, V44, P747, DOI 10.1128/AAC.44.3.747-751.2000
   Pfaller MA, 2005, J CLIN MICROBIOL, V43, P5848, DOI 10.1128/JCM.43.12.5848-5859.2005
   Pfaller MA, 2001, J CLIN MICROBIOL, V39, P3254, DOI 10.1128/JCM.39.9.3254-3259.2001
   Richet H, 2002, CLIN MICROBIOL INFEC, V8, P405, DOI 10.1046/j.1469-0691.2002.00446.x
   Tortorano AM, 2004, EUR J CLIN MICROBIOL, V23, P317, DOI 10.1007/s10096-004-1103-y
   Trick WE, 2002, CLIN INFECT DIS, V35, P627, DOI 10.1086/342300
NR 45
TC 42
Z9 44
U1 0
U2 7
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2010
VL 14
IS 5
BP 441
EP 448
DI 10.1590/S1413-86702010000500004
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA 705CU
UT WOS:000286107300004
PM 21221471
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Franco, MRG
   Caiaffa, HH
   Burattini, MN
   Rossi, F
AF Gomes Franco, Maria Renata
   Caiaffa-Filho, Helio Hehl
   Burattini, Marcelo Nascimento
   Rossi, Flavia
TI Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa
   in a brazilian university hospital
SO CLINICS
LA English
DT Article
DE Pseudomonas aeruginosa; imipenem resistance; metallo-beta-lactamases
   (MBL); MBL detection; SPM-1
ID ANTIMICROBIAL-SURVEILLANCE-PROGRAM; DOUBLE-DISK SYNERGY; MOLECULAR
   CHARACTERIZATION; LATIN-AMERICA; DISSEMINATION; MICROBIOLOGY; DIVERSITY;
   TESTS; ETEST; HODGE
AB INTRODUCTION: Imipenem-resistant Pseudomonas aeruginosa resulting from metallo-beta-lactamases has been reported to be an important cause of nosocomial infection and is a critical therapeutic problem worldwide, especially in the case of bacteremia.
   OBJECTIVES: To determine the frequency of metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa isolates and to compare methods of phenotypic and molecular detection.
   METHODS: During 2006, 69 imipenem-resistant Pseudomonas aeruginosa samples were isolated from blood and tested for metallo-beta-lactamase production using phenotypic methods. Minimal Inhibitory Concentratrions (MIC) (mu g/mL) was determined with commercial microdilution panels. Pulsed Field Gel Electrophoresis (PFGE) was performed among metallo-beta-lactamase producers.
   RESULTS: Of all the blood isolates, 34.5% were found to be imipenem-resistant Pseudomonas aeruginosa. Positive phenotypic tests for metallo-beta-lactamases ranged from 28%-77%, and Polymerase Chain Reaction (PCR) were positive in 30% (of note, 81% of those samples were bla(SPM-1) and 19% were bla(VIM-2)). Ethylenediamine tetracetic acid (EDTA) combinations for the detected enzymes had low kappa values; thus, care should be taken when use it as a phenotypic indicator of MBL. Despite a very resistant antibiogram, four isolates demonstrated the worrisome finding of a colistin MIC in the resistant range. PFGE showed a clonal pattern.
   CONCLUSION: Metallo-beta-lactamases among imipenem-resistant Pseudomonas aeruginosa were detected in 30.4% of imipenem-resistant Pseudomonas aeruginosa isolates. This number might have been higher if other genes were included. SPM-1 was the predominant enzyme found. Phenotypic tests with low kappa values could be misleading when testing for metallo-beta-lactamases. Polymerase Chain Reaction detection remains the gold standard.
C1 [Gomes Franco, Maria Renata; Caiaffa-Filho, Helio Hehl; Rossi, Flavia] Univ Sao Paulo, Fac Med, Hosp Clin, Div Lab Cent, Sao Paulo, Brazil.
RP Franco, MRG (corresponding author), Univ Sao Paulo, Fac Med, Hosp Clin, Div Lab Cent, Sao Paulo, Brazil.
EM mrenatagf@ig.com.br
RI Caiaffa-Filho, Helio H/H-6982-2012; Burattini, Marcelo N/J-9272-2014
OI Caiaffa-Filho, Helio H/0000-0001-6048-4527; Burattini, Marcelo
   N/0000-0002-5407-6890
CR Arakawa Y, 2000, J CLIN MICROBIOL, V38, P40
   BUSH K, 1995, ANTIMICROB AGENTS CH, V39, P1211, DOI 10.1128/AAC.39.6.1211
   Castanheira M, 2004, ANTIMICROB AGENTS CH, V48, P4654, DOI 10.1128/AAC.48.12.4654-4661.2004
   Chu YW, 2005, INT J ANTIMICROB AG, V26, P340, DOI 10.1016/j.ijantimicag.2005.07.004
   *CLIN LAB STAND I, M2A8 CLSI
   Clinical and Laboratory Standards Institute, 2005, M100S15 CLSI
   Clinical and Laboratory Standards Institute, 2007, M100S17 CLSI
   Clinical and Laboratory Standards Institute/ NCCLS, 2006, M100S16 CLSI
   Danel F, 2001, BIOCHEMISTRY-US, V40, P9412, DOI 10.1021/bi0025969
   Denny Brian, 2003, Journal of Microbiology Immunology and Infection, V36, P72
   Gales AC, 2003, J ANTIMICROB CHEMOTH, V52, P699, DOI 10.1093/jac/dkg416
   ILSTRUP DM, 1990, CLIN MICROBIOL REV, V3, P219, DOI 10.1128/CMR.3.3.219-226.1990
   KAUFMANN ME, 1998, CAP, V15, P33
   Lee K, 2003, J CLIN MICROBIOL, V41, P4623, DOI 10.1128/JCM.41.10.4623-4629.2003
   Lee K, 2001, CLIN MICROBIOL INFEC, V7, P88, DOI 10.1046/j.1469-0691.2001.00204.x
   LIVERMORE DM, 1992, ANTIMICROB AGENTS CH, V36, P2046, DOI 10.1128/AAC.36.9.2046
   Livermore DM, 2002, CLIN INFECT DIS, V34, P634, DOI 10.1086/338782
   Livermore DM, 2001, J ANTIMICROB CHEMOTH, V47, P247, DOI 10.1093/jac/47.3.247
   Marra A, 2006, BMC INFECT DIS, V14, P6
   Marra AR, 2006, ANTIMICROB AGENTS CH, V50, P388, DOI 10.1128/AAC.50.1.388-390.2006
   Martins AF, 2007, INFECTION, V35, P457, DOI 10.1007/s15010-007-6289-3
   Mendes Rodrigo Elisandro, 2006, J. Bras. Patol. Med. Lab., V42, P103, DOI 10.1590/S1676-24442006000200007
   Picao RC, 2008, J CLIN MICROBIOL, V46, P2028, DOI 10.1128/JCM.00818-07
   Queenan AM, 2007, CLIN MICROBIOL REV, V20, P440, DOI 10.1128/CMR.00001-07
   Sader HS, 2005, INT J ANTIMICROB AG, V25, P57, DOI 10.1016/j.ijantimicag.2004.08.013
   Sader HS, 2005, CLIN MICROBIOL INFEC, V11, P73, DOI 10.1111/j.1469-0691.2004.01031.x
   TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995
   Toleman MA, 2005, J ANTIMICROB CHEMOTH, V55, P61, DOI 10.1093/jac/dkh512
   Toleman MA, 2002, J ANTIMICROB CHEMOTH, V50, P673, DOI 10.1093/jac/dkf210
   VIEIRA VV, 2005, CLIN MICROBIOL INFEC
   Viera AJ, 2005, FAM MED, V37, P360
   Walsh TR, 2002, J CLIN MICROBIOL, V40, P2755, DOI 10.1128/JCM.40.8.2755-2759.2002
   Walsh TR, 2005, CLIN MICROBIOL REV, V18, P306, DOI 10.1128/CMR.18.2.306-325.2005
   Yan JJ, 2001, ANTIMICROB AGENTS CH, V45, P2224, DOI 10.1128/AAC.45.8.2224-2228.2001
NR 34
TC 57
Z9 60
U1 0
U2 9
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
J9 CLINICS
JI Clinics
PD SEP
PY 2010
VL 65
IS 9
BP 825
EP 829
DI 10.1590/S1807-59322010000900002
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 675TK
UT WOS:000283858300002
PM 21049207
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Amaku, M
   Burattini, MN
   Coutinho, FAB
   Massad, E
AF Amaku, Marcos
   Burattini, Marcelo Nascimento
   Coutinho, Francisco Antonio Bezerra
   Massad, Eduardo
TI Modeling the Dynamics of Viral Evolution Considering Competition Within
   Individual Hosts and at Population Level: The Effects of Treatment
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Viral competition; Evolution; Anti-viral treatment; Mutation
ID WITHIN-HOST; PATHOGEN VIRULENCE; IN-VIVO; HIV; VIRUS; SUPERINFECTION;
   EPIDEMIOLOGY; TRANSMISSION; COINFECTION; SELECTION
AB We consider two viral strains competing against each other within individual hosts (at cellular level) and at population level (for infecting hosts) by studying two cases. In the first case, the strains do not mutate into each other. In this case, we found that each individual in the population can be infected by only one strain and that co-existence in the population is possible only when the strain that has the greater basic intracellular reproduction number, R (0c) , has the smaller population number R (0p) . Treatment against the one strain shifts the population equilibrium toward the other strain in a complicated way (see Appendix B). In the second case, we assume that the strain that has the greater intracellular number R (0c) can mutate into the other strain. In this case, individual hosts can be simultaneously infected by both strains (co-existence within the host). Treatment shifts the prevalence of the two strains within the hosts, depending on the mortality induced by the treatment, which is, in turn, dependent upon the doses given to each individual. The relative proportions of the strains at the population level, under treatment, depend both on the relative proportions within the hosts (which is determined by the dosage of treatment) and on the number of individuals treated per unit time, that is, the rate of treatment. Implications for cases of real diseases are briefly discussed.
C1 [Burattini, Marcelo Nascimento; Coutinho, Francisco Antonio Bezerra; Massad, Eduardo] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento; Coutinho, Francisco Antonio Bezerra; Massad, Eduardo] LIM01 HCFMUSP, BR-05405000 Sao Paulo, Brazil.
   [Amaku, Marcos] Univ Sao Paulo, Sch Vet Med, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/H-6143-2011; Amaku, Marcos/D-5252-2012; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho, Francisco
   A B/H-5644-2011
OI Amaku, Marcos/0000-0003-4752-6774; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); LIM01-HCFMUSP
FX This work was partially supported by FAPESP, CNPq, and LIM01-HCFMUSP.
CR Ball CL, 2007, B MATH BIOL, V69, P2361, DOI 10.1007/s11538-007-9223-z
   BONHOEFFER S, 1994, P ROY SOC B-BIOL SCI, V258, P133, DOI 10.1098/rspb.1994.0153
   BREMERMANN HJ, 1989, J MATH BIOL, V27, P179, DOI 10.1007/BF00276102
   Burattini M. N., 2008, BIOSCI HYPOTHESES, V1, P168, DOI DOI 10.1016/J.BIHY.2008.05.003
   Coombs D, 2007, THEOR POPUL BIOL, V72, P576, DOI 10.1016/j.tpb.2007.08.005
   Day T, 2001, EVOLUTION, V55, P2389, DOI 10.1111/j.0014-3820.2001.tb00754.x
   Dixit NM, 2005, P NATL ACAD SCI USA, V102, P8198, DOI 10.1073/pnas.0407498102
   Gandon S, 2001, NATURE, V414, P751, DOI 10.1038/414751a
   HOCHBERG ME, 1990, AM NAT, V136, P517, DOI 10.1086/285111
   Leontiev VV, 2008, INFECT GENET EVOL, V8, P40, DOI 10.1016/j.meegid.2007.09.008
   LEVIN S, 1981, AM NAT, V117, P308, DOI 10.1086/283708
   Lipsitch M, 1996, EVOLUTION, V50, P1729, DOI 10.1111/j.1558-5646.1996.tb03560.x
   LIPSITCH M, 1995, J THEOR BIOL, V174, P427, DOI 10.1006/jtbi.1995.0109
   Manrubia SC, 2006, PHYS LIFE REV, V3, P65, DOI 10.1016/j.plrev.2005.11.002
   MASSAD E, 1997, EVOLUTION, V50, P916
   MAY RM, 1995, P ROY SOC B-BIOL SCI, V261, P209, DOI 10.1098/rspb.1995.0138
   Mideo N, 2008, TRENDS ECOL EVOL, V23, P511, DOI 10.1016/j.tree.2008.05.009
   Mosquera J, 1998, J THEOR BIOL, V195, P293, DOI 10.1006/jtbi.1998.0793
   Nowak MA, 2004, VIRUS DYNAMICS MATH
   Perelson AS, 1999, SIAM REV, V41, P3, DOI 10.1137/S0036144598335107
   Perelson AS, 2002, NAT REV IMMUNOL, V2, P28, DOI 10.1038/nri700
   Power AG, 1996, ECOLOGY, V77, P1004, DOI 10.2307/2265571
   ROCHOW WF, 1979, PHYTOPATHOLOGY, V69, P655, DOI 10.1094/Phyto-69-655
   Sguanci L, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S2-S5
   van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004
   Wodarz D., 2007, KILLER CELL DYNAMICS
   Wodarz D, 2007, P ROY SOC B-BIOL SCI, V274, P2481, DOI 10.1098/rspb.2007.0413
   Zhang XS, 2001, PHYTOPATHOLOGY, V91, P924, DOI 10.1094/PHYTO.2001.91.10.924
NR 28
TC 9
Z9 9
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0092-8240
J9 B MATH BIOL
JI Bull. Math. Biol.
PD JUL
PY 2010
VL 72
IS 5
BP 1294
EP 1314
DI 10.1007/s11538-009-9495-6
PG 21
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 627TL
UT WOS:000280065700011
PM 20091353
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Ma, S
   Burattini, MN
AF Massad, E.
   Coutinho, F. A. B.
   Ma, S.
   Burattini, M. N.
TI FOR DEBATE A hypothesis for the 2007 dengue outbreak in Singapore
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Aedes; dengue; haze; models; mosquito mortality
ID ANTHROPIC ENVIRONMENT; POPULATION-DYNAMICS; MOSQUITOS DIPTERA; BRAZIL;
   MALARIA; FEVER; CULICIDAE; DISEASE; SYSTEM
AB A previous mathematical model explaining dengue in Singapore predicted a reasonable outbreak of about 6500 cases for 2006 and a very mild outbreak with about 2000 cases for 2007. However, only 3051 cases were reported in 2006 while more than 7800 were reported in the first 44 weeks of 2007. We hypothesized that the combination of haze with other local sources of particulate matter had a significant impact on mosquito life expectancy, significantly increasing their mortality rate. To test the hypothesis a mathematical model based on the reproduction number of dengue fever and aimed at comparing the impact of several possible alternative control strategies was proposed. This model also aimed at contributing to the understanding of the causes of dengue resurgence in Singapore in the last decade. The model's simulation demonstrated that an increase in mosquito mortality in 2006 and either a reduction in mortality or an increase in the carrying capacity of mosquitoes in 2007 explained the patterned observed in Singapore. Based on the model's simulation we concluded that the fewer than expected number of dengue cases in Singapore in 2006 was caused by an increase in mosquito mortality due to the disproportionate haze affecting the country that year and that particularly favourable environmental conditions in 2007 propitiated mosquitoes with a lower mortality rate, which explains the greater than expected number of dengue cases in 2007. Whether our hypothesis is plausible or not should be debated further.
C1 [Massad, E.; Coutinho, F. A. B.; Burattini, M. N.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
   [Massad, E.] Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
   [Ma, S.] Minist Hlth, Singapore, Singapore.
RP Massad, E (corresponding author), Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014;
   Massad, Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; 
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); Courage Fund for Infectious Diseases;  [LIM01-HCFMUSP]
FX This work was supported by LIM01-HCFMUSP, CNPq, FAPESP and the Courage
   Fund for Infectious Diseases.
CR Biran A, 2007, T ROY SOC TROP MED H, V101, P1065, DOI 10.1016/j.trstmh.2007.07.010
   Brownstin JS, 2003, J INVERTEBR PATHOL, V84, P24, DOI 10.1016/S0022-2011(03)00082-X
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   Chowell G, 2008, EPIDEMIOL INFECT, V136, P1667, DOI 10.1017/S0950268808000290
   Chowell G, 2007, MATH BIOSCI, V208, P571, DOI 10.1016/j.mbs.2006.11.011
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho FAB, 2005, MATH COMPUT SIMULAT, V70, P149, DOI 10.1016/j.matcom.2005.06.003
   DAVIS EE, 1994, J AM MOSQUITO CONTR, V10, P316
   Dulhunty JM, 2000, ACTA TROP, V75, P185, DOI 10.1016/S0001-706X(00)00057-7
   Forattini O. P., 1996, MED CULICIDOLOGY
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   FORATTINI OP, 1995, REV SAUDE PUBL, V29, P199, DOI 10.1590/S0034-89101995000300007
   GUBLER DJ, 2001, DENGUE DENGUE HEMORR, P45
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   HARTLEY MK, 2006, AM MIDL NAT, V157, P92
   Luz PM, 2003, MEM I OSWALDO CRUZ, V98, P871, DOI 10.1590/S0074-02762003000700002
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   *MIN HLTH SING, 2005, WEEKL INF DIS B, V1
   MOORE SJ, 2004, TRADITIONAL MED PLAN, P343
   Ocampo CB, 2004, AM J TROP MED HYG, V71, P506, DOI 10.4269/ajtmh.2004.71.506
   Palsson K, 1999, ACTA TROP, V72, P39, DOI 10.1016/S0001-706X(98)00083-7
   Rodhain F., 2001, DENGUE DENGUE HEMORR, P45
   Tabuti JRS, 2008, J ETHNOPHARMACOL, V116, P33, DOI 10.1016/j.jep.2007.10.036
   Wilder-Smith A, 2005, EPIDEMIOL INFECT, V133, P667, DOI 10.1017/S0950268805003821
   2007, KEY ENV STAT
NR 26
TC 14
Z9 14
U1 0
U2 6
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2010
VL 138
IS 7
BP 951
EP 957
DI 10.1017/S0950268809990501
PG 7
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 614RX
UT WOS:000279078500003
PM 19653928
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Ma, S
   Burattini, MN
AF Massad, E.
   Coutinho, F. A. B.
   Ma, S.
   Burattini, M. N.
TI The 2007 dengue outbreak in Singapore Reply
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Letter
C1 [Massad, E.] Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
   [Ma, S.] Minist Hlth, Singapore, Singapore.
   [Massad, E.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil.
RP Massad, E (corresponding author), Natl Univ Singapore, Singapore, Singapore.
EM edmassad@dim.fm.usp.br
RI Burattini, Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011;
   Massad, Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; Massad, Eduardo/0000-0002-7200-2916; 
CR Massad E, 2010, EPIDEMIOL INFECT, V138, P951, DOI 10.1017/S0950268809990501
NR 1
TC 0
Z9 0
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUL
PY 2010
VL 138
IS 7
BP 959
EP 961
PG 3
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 614RX
UT WOS:000279078500005
DA 2020-12-08
ER

PT J
AU Ribeiro, RB
   Martins, HS
   dos Santos, VA
   El Khouri, M
   Duarte, LS
   Burattini, MN
   Cordeiro, Q
   Camargo, LMA
   Corbett, CEP
AF Ribeiro, Rafael Bernardon
   Martins, Herlon Saraiva
   dos Santos, Vera Aparecida
   El Khouri, Marcelo
   Duarte, Leandro Savoy
   Burattini, Marcelo Nascimento
   Cordeiro, Quirino
   Aranha Camargo, Luiz Marcelo
   Pereira Corbett, Carlos Eduardo
TI EVALUATION OF Helicobacter pylory COLONIZATION BY SEROLOGIC TEST (IgG)
   AND DYSPEPSIA IN VOLUNTEERS FROM THE COUNTRYSIDE OF MONTE NEGRO, IN THE
   BRAZILIAN WESTERN AMAZON REGION
SO REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO
LA English
DT Article
DE Seroprevalence; Helicobacter pylori; Dyspepsia; Western Amazon
ID NONULCER DYSPEPSIA; CHILD TRANSMISSION; RISK-FACTORS; INFECTION;
   PREVALENCE
AB The present study intended to analyze the seroprevalence of Helicobacter IgG, and its relation to dyspepsia in a population from the western Amazon region. During the "Projeto Bandeira Cientifica", a University of Sao Paulo Medical School program, in Monte Negro's rural areas, state of Rondonia, 266 blood samples were collected from volunteers. The material was tested for IgG antibodies anti-Helicobacter pylori by ELISA method and the participants were also interviewed on dyspepsia, hygiene and social aspects. Participants aged between five and 81 years old (34 years on average), 149 (56%) were female and 117 (44%) male. We found 210 (78.9%) positive, 50 (18.8%) negative and six (2.3%) undetermined samples. Dyspeptic complaints were found in 226 cases (85.2%). There was no statistical association between dyspepsia and positive serology for H. pylori. We concluded that the seroprevalence in all age categories is similar to results found in other studies conducted in developing countries, including those from Brazil. On the other hand, the seroprevalence found in Monte Negro was higher than that reported in developed countries. As expected, there was a progressive increase in the positivity for H. pylori in older age groups.
C1 [Ribeiro, Rafael Bernardon] Univ Sao Paulo, Fac Med, Lab Patol Molestias Infecciosas, BR-01246903 Sao Paulo, Brazil.
   [dos Santos, Vera Aparecida; Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Hosp Clin, Secao Immol,Div Lab Cent, BR-01246903 Sao Paulo, Brazil.
   [Martins, Herlon Saraiva] Univ Sao Paulo, Univ Hosp, Hosp Clin FMUSP, BR-01246903 Sao Paulo, Brazil.
   [Aranha Camargo, Luiz Marcelo] Univ Sao Paulo, Inst Ciencias Biomed, BR-01246903 Sao Paulo, Brazil.
RP Ribeiro, RB (corresponding author), Univ Sao Paulo, Fac Med, Lab Patol Molestias Infecciosas, Av Dr Arnaldo 455,Sala 1215, BR-01246903 Sao Paulo, Brazil.
EM rafael@usp.br
RI Martins, Herlon S/H-2181-2014; Burattini, Marcelo N/J-9272-2014;
   CAMARGO, LMA/B-4156-2009; Ribeiro, Rafael B/D-5712-2014; Inagemp,
   Inct/J-9451-2013; Ribeiro, Rafael Bernardon/V-9052-2019; Corbett, Carlos
   E P/R-7090-2018
OI Martins, Herlon S/0000-0003-1056-155X; Burattini, Marcelo
   N/0000-0002-5407-6890; CAMARGO, LMA/0000-0001-9486-6195; Ribeiro, Rafael
   B/0000-0002-2942-4793; Ribeiro, Rafael Bernardon/0000-0002-2942-4793; 
CR Brown LM, 2000, EPIDEMIOL REV, V22, P283, DOI 10.1093/oxfordjournals.epirev.a018040
   Camargo LMA, 2002, MEM I OSWALDO CRUZ, V97, P193, DOI 10.1590/S0074-02762002000200008
   Cartagenes VD, 2009, REV SOC BRAS MED TRO, V42, P298, DOI 10.1590/S0037-86822009000300011
   Chehter EZ, 2007, SAO PAULO MED J, V125, P300, DOI 10.1590/S1516-31802007000500012
   Cunha RPA, 2003, T ROY SOC TROP MED H, V97, P382, DOI 10.1016/S0035-9203(03)90063-0
   Gisbert JP, 1998, REV ESP ENFERM DIG, V90, P441
   GOLDBAUM M, 1999, REV MED FMUSP, V78, P498
   Graham DY, 2010, J CLIN GASTROENTEROL, V44, P167, DOI 10.1097/MCG.0b013e3181c64c69
   Herbarth O, 2001, ENVIRON HEALTH PERSP, V109, P573, DOI 10.2307/3455030
   Lewis J D, 2000, Gastroenterology, V119, P1795, DOI 10.1016/S0016-5085(00)70030-8
   Moayyedi P, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002096.pub4, 10.1002/14651858.CD002096.pub2]
   Nelson DB, 2000, AM J GASTROENTEROL, V95, P3412, DOI 10.1111/j.1572-0241.2000.03354.x
   Quigley EMM, 2008, CURR OPIN GASTROEN, V24, P692, DOI 10.1097/MOG.0b013e328313b983
   RAMIREZRAMOS A, 1992, GUT, V33, P604
   Rehnberg-Laiho L, 2001, EPIDEMIOL INFECT, V126, P37, DOI 10.1017/S0950268801005027
   Selgrad M, 2008, DIGEST DIS, V26, P210, DOI 10.1159/000121348
   Tindberg Y, 2001, GASTROENTEROLOGY, V121, P310, DOI 10.1053/gast.2001.26282
   Vakil N, 2010, AM J GASTROENTEROL, V105, P572, DOI 10.1038/ajg.2009.709
   van Zanten SJOV, 2000, BRIT MED J, V321, P648, DOI 10.1136/bmj.321.7262.648
NR 19
TC 3
Z9 3
U1 0
U2 3
PU INST MEDICINA TROPICAL SAO PAULO
PI SAO PAULO
PA AV DR ENEAS CARVALHO DE AGUIAR, 470, C CESAR, SAO PAULO, 05403-000,
   BRAZIL
SN 0036-4665
J9 REV INST MED TROP SP
JI Rev. Inst. Med. Trop. Sao Paulo
PD JUL-AUG
PY 2010
VL 52
IS 4
BP 203
EP 206
DI 10.1590/S0036-46652010000400007
PG 4
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 647FS
UT WOS:000281603800007
PM 21748228
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Almeida, J
   Caiaffa, H
   Cury, AP
   Almeida, GD
   Garcia, DO
   Burattini, MN
   Rossi, F
AF Almeida, J.
   Caiaffa, H.
   Cury, A. P.
   Almeida, G. D.
   Garcia, D. O.
   Burattini, M. N.
   Rossi, F.
TI Decreased susceptibility to polymyxins emerging during treatment for
   carbapenem-resistant Enterobacter aerogenes infection
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Almeida, J.; Caiaffa, H.; Cury, A. P.; Almeida, G. D.; Burattini, M. N.; Rossi, F.] Univ Sao Paulo, Sao Paulo, Brazil.
   [Garcia, D. O.] Adolfo Lutz Inst, Sao Paulo, Brazil.
RI Caiaffa-Filho, Helio H/H-6982-2012; Burattini, Marcelo N/J-9272-2014
OI Caiaffa-Filho, Helio H/0000-0001-6048-4527; Burattini, Marcelo
   N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E42
EP E42
DI 10.1016/j.ijid.2010.02.1581
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298200102
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Motta, A
   Almeida, GD
   Almeida, JN
   Pinto, MI
   Burattini, MN
   Rossi, F
AF Motta, A.
   Almeida, G. D.
   Almeida, J. N., Jr.
   Pinto, M. I.
   Burattini, M. N.
   Rossi, F.
TI Analysis of candidemia epidemiological data and antifungigram by
   distinct methodologies in a large Brazilian teaching hospital
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Meeting Abstract
C1 [Motta, A.; Almeida, G. D.; Almeida, J. N., Jr.; Pinto, M. I.; Burattini, M. N.; Rossi, F.] Univ Sao Paulo, Hosp Clin, Fac Med, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD MAR
PY 2010
VL 14
SU 1
BP E125
EP E125
DI 10.1016/j.ijid.2010.02.1761
PG 1
WC Infectious Diseases
SC Infectious Diseases
GA 578MQ
UT WOS:000276298200282
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FA
   Struchiner, CJ
AF Massad, Eduardo
   Burattini, Marcelo Nascimento
   Coutinho, Francisco Antonio
   Struchiner, Claudio Jose
TI The risk of acquiring the new influenza A(H1N1) for Brazilian travelers
   to Chile, Argentina and the USA
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE influenza A (H1N1); travelers; risk estimation; mathematical models
ID DENGUE
AB We estimate the risk of acquiring the new influenza A( H1N1) for Brazilian travelers to Chile, Argentina and the USA. This is done by a mathematical model that quantifies the intensity of transmission of the new virus in those countries and the probability that one individual has of acquiring the influenza depending on the date of arrival and time spent in the area. The maximum estimated risk reached 7.5 cases per 10,000 visitors to Chile, 17 cases per 10,000 travelers to Argentina and 23 cases per 10,000 travelers to the USA. The estimated number of imported cases until 27 July is 57 +/- 9 from Chile, 136 +/- 27 from the USA and 301 +/- 21 from Argentina, which are in accord with the official figures. Estimating the number of imported cases was particularly important for the moment of the disease introduction into this country, but it will certainly be important again as a tool to calculate the number of future imported cases from northern countries in our next inter-epidemic season, were imported cases can constitute again the majority of the new influenza burden to the Brazilian health services.
C1 [Massad, Eduardo; Burattini, Marcelo Nascimento; Coutinho, Francisco Antonio] Univ Sao Paulo, Fac Med, Rua Teodoro Sampaio 115,2 Andar, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London, England.
   [Struchiner, Claudio Jose] Fiocruz MS, Programa Comp Cient, BR-21045900 Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Rua Teodoro Sampaio 115,2 Andar, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/H-6143-2011; Struchiner, Claudio J/M-9360-2013; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Coutinho,
   Francisco A B/H-5644-2011
OI Struchiner, Claudio J/0000-0003-2114-847X; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890;
   Coutinho, Francisco A B/0000-0003-3127-3071
FU LIM01-HCFMUSP; CNPqNational Council for Scientific and Technological
   Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ)
FX LIM01-HCFMUSP, CNPq, FAPESP, FAPERJ
CR ANDERSON R M, 1991
   Choisy M., 2007, ENCY INFECT DIS MODE, P379, DOI [10.1002/9780470114209.ch22, DOI 10.1002/9780470114209.CH22]
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Massad E, 2008, J TRAVEL MED, V15, P147, DOI 10.1111/j.1708-8305.2008.00186.x
   Massad E, 2007, MED HYPOTHESES, V68, P442, DOI 10.1016/j.mehy.2006.07.041
   Massad E, 2009, J TRAVEL MED, V16, P191, DOI 10.1111/j.1708-8305.2009.00310.x
   Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157
NR 7
TC 6
Z9 6
U1 0
U2 6
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD MAR
PY 2010
VL 105
IS 2
BP 179
EP 183
DI 10.1590/S0074-02762010000200012
PG 5
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 589MQ
UT WOS:000277152900012
PM 20428678
OA DOAJ Gold, Green Accepted
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Amaku, M
AF Massad, E.
   Coutinho, F. A. B.
   Burattini, M. N.
   Amaku, M.
TI Estimation of R-0 from the initial phase of an outbreak of a
   vector-borne infection
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE basic reproduction number; epidemiology; mathematical models;
   vector-borne infections; dengue fever
ID THRESHOLD CONDITIONS; DENGUE; DYNAMICS; NUMBER; FEVER
AB The magnitude of the basic reproduction ratio R-0 of an epidemic can be estimated in several ways, namely, from the final size of the epidemic, from the average age at first infection, or from the initial growth phase of the outbreak. In this paper, we discuss this last method for estimating R-0 for vector-borne infections. Implicit in these models is the assumption that there is an exponential phase of the outbreaks, which implies that in all cases R-0 > 1. We demonstrate that an outbreak is possible, even in cases where R-0 is less than one, provided that the vector-to-human component of R-0 is greater than one and that a certain number of infected vectors are introduced into the affected population. This theory is applied to two real epidemiological dengue situations in the southeastern part of Brazil, one where R-0 is less than one, and other one where R-0 is greater than one. In both cases, the model mirrors the real situations with reasonable accuracy.
C1 [Massad, E.; Coutinho, F. A. B.; Burattini, M. N.] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Massad, E.; Coutinho, F. A. B.; Burattini, M. N.] LIM 01 HCFMUSP, Sao Paulo, Brazil.
   [Massad, E.] London Sch Hyg & Trop Med, London WC1, England.
   [Amaku, M.] Univ Sao Paulo, Sch Vet Med, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014;
   Massad, Eduardo/B-1169-2012; Amaku, Marcos/D-5252-2012; Massad,
   Eduardo/H-6143-2011
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Amaku,
   Marcos/0000-0003-4752-6774; 
CR ANDERSON R M, 1991
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   Choisy M., 2007, ENCY INFECT DIS MODE, P379, DOI [10.1002/9780470114209.ch22, DOI 10.1002/9780470114209.CH22]
   Coelho GE, 2008, MEM I OSWALDO CRUZ, V103, P535, DOI 10.1590/S0074-02762008000600004
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Diekmann O, 2000, MATH EPIDEMIOLOGY IN
   Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103
   Favier C, 2006, TROP MED INT HEALTH, V11, P332, DOI 10.1111/j.1365-3156.2006.01560.x
   Hale JK, 1993, INTRO FUNCTIONAL DIF
   Heesterbeek JAP, 2002, ACTA BIOTHEOR, V50, P189, DOI 10.1023/A:1016599411804
   Heffernan JM, 2005, J R SOC INTERFACE, V2, P281, DOI 10.1098/rsif.2005.0042
   Lopez LF, 2000, J MATH BIOL, V40, P199, DOI 10.1007/s002850050178
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Wallinga J, 2007, P ROY SOC B-BIOL SCI, V274, P599, DOI 10.1098/rspb.2006.3754
   Wearing HJ, 2005, PLOS MED, V2, P621, DOI 10.1371/journal.pmed.0020174
NR 19
TC 34
Z9 34
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD JAN
PY 2010
VL 15
IS 1
BP 120
EP 126
DI 10.1111/j.1365-3156.2009.02413.x
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 531JU
UT WOS:000272662600017
PM 19891761
OA Bronze
DA 2020-12-08
ER

PT J
AU Massad, E
   Behrens, RH
   Burattini, MN
   Coutinho, FAB
AF Massad, Eduardo
   Behrens, Ronald H.
   Burattini, Marcelo N.
   Coutinho, Francisco A. B.
TI Modeling the risk of malaria for travelers to areas with stable malaria
   transmission
SO MALARIA JOURNAL
LA English
DT Article
ID YELLOW-FEVER; DENGUE
AB Background: Malaria is an important threat to travelers visiting endemic regions. The risk of acquiring malaria is complex and a number of factors including transmission intensity, duration of exposure, season of the year and use of chemoprophylaxis have to be taken into account estimating risk.
   Materials and methods: A mathematical model was developed to estimate the risk of non-immune individual acquiring falciparum malaria when traveling to the Amazon region of Brazil. The risk of malaria infection to travelers was calculated as a function of duration of exposure and season of arrival.
   Results: The results suggest significant variation of risk for non-immune travelers depending on arrival season, duration of the visit and transmission intensity. The calculated risk for visitors staying longer than 4 months during peak transmission was 0.5% per visit.
   Conclusions: Risk estimates based on mathematical modeling based on accurate data can be a valuable tool in assessing risk/benefits and cost/benefits when deciding on the value of interventions for travelers to malaria endemic regions.
C1 [Massad, Eduardo; Burattini, Marcelo N.; Coutinho, Francisco A. B.] Univ Sao Paulo, Sch Med, Dept Pathol, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo; Burattini, Marcelo N.; Coutinho, Francisco A. B.] LIM 01 HCFMUSP, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo; Behrens, Ronald H.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Dept Pathol, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@dim.fm.usp.br; Ron.Behrens@lshtm.ac.uk; mnburatt@usp.br;
   coutinho@dim.fm.usp.br
RI Massad, Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071; 
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); LIM01-HCF-MUSP; Department of Health's NIHR Biomedical Research
   CentresNational Institute for Health Research (NIHR)
FX This work was partially supported by FAPESP, CNPq and LIM01-HCF-MUSP.;
   It was in part undertaken at UCLH/UCL who receive a proportion of
   funding from the Department of Health's NIHR Biomedical Research Centres
   funding scheme.
CR Askling HH, 2005, EMERG INFECT DIS, V11, P436, DOI 10.3201/eid1103.040677
   Behrens RH, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-7
   Behrens RH, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-114
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   BURATTINI MN, 1993, EPIDEMIOL INFECT, V111, P503, DOI 10.1017/S0950268800057241
   Chen LH, 2006, JAMA-J AM MED ASSOC, V296, P2234, DOI 10.1001/jama.296.18.2234
   Dos Santos RL, 2004, J MED ENTOMOL, V41, P997
   Dos Santos RL, 2002, J MED ENTOMOL, V39, P926
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   House HR, 2008, EMERG MED CLIN N AM, V26, P499, DOI 10.1016/j.emc.2008.01.008
   LADISLAW JLB, 2006, SITUACAO MALARIA AMA
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 2003, REV SAUDE PUBL, V37, P477, DOI [10.1590/S0034-89102003000400013, 10.1590/s0034-89102003000400013]
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Massad E, 2008, J TRAVEL MED, V15, P147, DOI 10.1111/j.1708-8305.2008.00186.x
   Molineaux L., 1988, P913
   Molineaux L, 1980, GARKI PROJECT RES EP
   Noronha E, 2000, Rev Soc Bras Med Trop, V33, P185, DOI 10.1590/S0037-86822000000200005
   Okell LC, 2008, PLOS MED, V5, P1617, DOI 10.1371/journal.pmed.0050226
   Tada Yuki, 2008, Travel Med Infect Dis, V6, P368, DOI 10.1016/j.tmaid.2008.08.002
   TADEI W, 1997, ENTOMOLOGIA MALARIA, P157
   TAYLOR JR, 2001, INTRO ERROR ANAL STU, P126
   WYSE APP, 2007, THESIS LAB NACL COMP
NR 24
TC 19
Z9 19
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2875
J9 MALARIA J
JI Malar. J.
PD DEC 16
PY 2009
VL 8
AR 296
DI 10.1186/1475-2875-8-296
PG 7
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 545UK
UT WOS:000273762200001
PM 20015392
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Da Rocha, AF
   Burattini, MN
   Rocha, FT
   Massad, E
AF Da Rocha, Armando Freitas
   Burattini, Marcelo Nascimento
   Rocha, Fabio Theoto
   Massad, Eduardo
TI A NEUROECONOMIC MODELING OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
   (ADHD)
SO JOURNAL OF BIOLOGICAL SYSTEMS
LA English
DT Article
DE AD/HD; Neuroeconomics; Modeling; Decision-Making; Risk; Reward Cost
   Benefit Evaluation
ID DEFICIT HYPERACTIVITY DISORDER; DECISION-MAKING; ANTERIOR CINGULATE;
   WORKING-MEMORY; PREFRONTAL CORTEX; BRAIN; REWARD; PREFERENCES;
   IMPULSIVITY; PERSPECTIVE
AB In this paper we present a new neuroeconomics model for decision-making applied to the Attention-Deficit/Hyperactivity Disorder (ADHD). The model is based on the hypothesis that decision-making is dependent on the evaluation of expected rewards and risks assessed simultaneously in two decision spaces: the personal (PDS) and the interpersonal emotional spaces (IDS). Motivation to act is triggered by necessities identified in PDS or IDS. The adequacy of an action in fulfilling a given necessity is assumed to be dependent on the expected reward and risk evaluated in the decision spaces. Conflict generated by expected reward and risk influences the easiness (cognitive effort) and the future perspective of the decision-making. Finally, the willingness (not) to act is proposed to be a function of the expected reward (or risk), adequacy, easiness and future perspective. The two most frequent clinical forms are ADHD hyperactive (AD/HDhyp) and ADHD inattentive (AD/HDdin). AD/HDhyp behavior is hypothesized to be a consequence of experiencing high rewarding expectancies for short periods of time, low risk evaluation, and short future perspective for decision-making. AD/HDin is hypothesized to be a consequence of experiencing high rewarding expectancies for long periods of time, low risk evaluation, and long future perspective for decision-making.
C1 [Da Rocha, Armando Freitas; Burattini, Marcelo Nascimento; Rocha, Fabio Theoto; Massad, Eduardo] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
RP Da Rocha, AF (corresponding author), Rua Tenente Ary Aps 172, BR-13207110 Jundiai, Brazil.
EM armando@enscer.com.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Rocha, Armando Freitas
   da/0000-0002-1301-8491
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [04/00743-4]
FX We would like to thank two anonymous referees because their interesting
   comments helped to improve this manuscript. We also acknowledge the
   partial financial support by CNPq to E. Massad and FAPESP - grant
   04/00743-4 to A. F. Rocha.
CR Alcaro A, 2007, BRAIN RES REV, V56, P283, DOI 10.1016/j.brainresrev.2007.07.014
   American Psychiatric Association, 1994, DIAGN STAT MENT DIS, V4
   Ariely D, 2008, TRENDS COGN SCI, V12, P13, DOI 10.1016/j.tics.2007.10.008
   Baddeley A, 2003, J COMMUN DISORD, V36, P189, DOI 10.1016/S0021-9924(03)00019-4
   BECHARA A, 2005, GAMES EC BEHAV
   Berns GS, 2007, TRENDS COGN SCI, V11, P482, DOI 10.1016/j.tics.2007.08.011
   Berridge KC, 2003, BRAIN COGNITION, V52, P106, DOI 10.1016/S0278-2626(03)00014-9
   Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2
   BOTVINICK MM, 2004, TRENDS COGN SCI, V2044, P529
   Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034
   Carver CS, 2006, PSYCHIAT RES, V144, P1, DOI 10.1016/j.psychres.2006.03.013
   de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735
   Ernst M, 2004, NEUROPSYCHOLOGIA, V42, P1585, DOI 10.1016/j.neuropsychologia.2004.05.011
   Fehr E, 2004, CURR OPIN NEUROBIOL, V14, P784, DOI 10.1016/j.conb.2004.10.007
   Fehr E, 2007, TRENDS COGN SCI, V11, P419, DOI 10.1016/j.tics.2007.09.002
   Fellows LK, 2005, NEUROPSYCHOLOGIA, V43, P1214, DOI 10.1016/j.neuropsychologia.2004.07.018
   Graeff FG, 2004, NEUROSCI BIOBEHAV R, V28, P239, DOI 10.1016/j.neubiorev.2003.12.004
   Graff-Guerrero A, 2005, NEUROIMAGE, V25, P1197, DOI 10.1016/j.neuroimage.2004.12.020
   Gray J., 2000, NEUROPSYCHOLOGY ANXI
   Hariri AR, 2006, TRENDS COGN SCI, V10, P182, DOI 10.1016/j.tics.2006.02.011
   Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046
   Krain AL, 2006, NEUROIMAGE, V32, P477, DOI 10.1016/j.neuroimage.2006.02.047
   Laibson D, 1998, EUR ECON REV, V42, P861, DOI 10.1016/S0014-2921(97)00132-3
   LeDoux J., 1996, EMOTIONAL BRAIN MYST
   McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907
   MICHELE F, 2005, INT J PSYCHOPHYSIOL, V58, P81
   O'Doherty J, 2001, NAT NEUROSCI, V4, P95
   Panksepp J, 1998, AFFECTIVE NEUROSCIEN
   Passamonti L, 2006, BIOL PSYCHIAT, V59, P334, DOI 10.1016/j.biopsych.2005.07.027
   Paulus MP, 2006, NEUROIMAGE, V30, P668, DOI 10.1016/j.neuroimage.2005.09.061
   Paulus MP, 2002, NEUROIMAGE, V15, P836, DOI 10.1006/nimg.2001.1031
   Rocha AF, 1997, PROG NEUROBIOL, V53, P121, DOI 10.1016/S0301-0082(97)00015-4
   Rocha AF, 2004, BRAIN FUZZY ARITHMET
   Rocha FT, 2005, COGNITIVE BRAIN RES, V22, P359, DOI 10.1016/j.cogbrainres.2004.09.008
   Rogers RD, 2004, BIOL PSYCHIAT, V55, P594, DOI 10.1016/j.biopsych.2003.11.012
   Ruchkin DS, 2003, BEHAV BRAIN SCI, V26, P709, DOI 10.1017/S0140525X03000165
   Sagvolden T, 2005, BEHAV BRAIN SCI, V28, P397, DOI 10.1017/S0140525X05000075
   Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976
   Seidman LJ, 2006, CLIN PSYCHOL REV, V26, P466, DOI 10.1016/j.cpr.2006.01.004
   Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019
   Sergeant JA, 2003, NEUROSCI BIOBEHAV R, V27, P583, DOI 10.1016/j.neubiorev.2003.08.004
   Seymour B, 2008, CURR OPIN NEUROBIOL, V18, P173, DOI 10.1016/j.conb.2008.07.010
   Sonuga-Barke EJS, 2003, NEUROSCI BIOBEHAV R, V27, P593, DOI 10.1016/j.neubiorev.2003.08.005
   Tobler PN, 2007, NEURON, V54, P167, DOI 10.1016/j.neuron.2007.03.004
   Valkalopoulos C, 2007, MED HYPOTHESES, V68, P210, DOI 10.1016/j.mehy.2006.07.018
   van Gaalen MM, 2006, BIOL PSYCHIAT, V60, P66, DOI 10.1016/j.biopsych.2005.06.005
   VANDENBERGH FS, 2007, PHARM BIOCH BEHAV, V85, P736
   Waldman ID, 2006, CLIN PSYCHOL REV, V26, P396, DOI 10.1016/j.cpr.2006.01.007
   Walton ME, 2004, NAT NEUROSCI, V7, P1259, DOI 10.1038/nn1339
   Weber B, 2007, NEUROIMAGE, V35, P441, DOI 10.1016/j.neuroimage.2006.11.034
   Winstanley CA, 2006, CLIN PSYCHOL REV, V26, P379, DOI 10.1016/j.cpr.2006.01.001
NR 51
TC 3
Z9 3
U1 0
U2 10
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0218-3390
EI 1793-6470
J9 J BIOL SYST
JI J. Biol. Syst.
PD DEC
PY 2009
VL 17
IS 4
BP 597
EP 622
DI 10.1142/S021833900900306X
PG 26
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 541OT
UT WOS:000273426400004
DA 2020-12-08
ER

PT J
AU Alves, ANL
   Sumita, NM
   Burattini, MN
   Della Rosa, HV
AF Alves, A. N. L.
   Sumita, N. M.
   Burattini, M. N.
   Della Rosa, H. V.
TI Spot urine porphyrins/creatinine ratio profile of healthy Brazilian
   individuals adjusted for personal habits
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Spot urine; Urinary porphyrins; Healthy population; Reference values
ID PORPHYRIA-CUTANEA-TARDA; REFERENCE VALUES; HEPATITIS-C; EXPOSURE;
   CREATININE; EXCRETION; ALCOHOL; MERCURY; WORKERS; LEAD
AB Changes in urinary porphyrin excretion may be the result of hereditary causes and/or from environmental or occupational exposure. The objective of this study was to measure the amount of some porphyrins in spot urine samples obtained from volunteers randomly selected from a healthy adult population of Sao Paulo with a sensitive HPLC method and to estimate normal ranges for a non-exposed population. Spot urine samples were collected from 126 subjects (both genders, 18 to 65 years old) not occupationally exposed to porphyrinogenic agents. Porphyrin fractions were separated on RP-18 HPLC column eluted with a methanol/ammonium acetate buffer gradient, pH 4.0, and measured fluorometrically (excitation 405 nm/emission 620 nm). The amount of porphyrins was corrected for urinary creatinine excretion. Only 8-carboxyl (uro) and 4-carboxyl (copro) porphyrins were quantified as mu g/g creatinine. Data regarding age, gender, occupational activities, smoking and drinking habits were analyzed by Mann-Whitney and Kruskal-Wallis tests. Uroporphyrin results did not differ significantly between the subgroups studied. Copro and uro + copro porphyrins were significantly different for smokers (P = 0.008) and occupational activities (P = 0.004). With respect to alcohol consumption, only men drinking >20 g/week showed significant differences in the levels of copro (P = 0.022) and uro + copro porphyrins (P = 0.012). The 2.5-97.5th percentile limit values, excluding those for subjects with an alcohol drinking habit >20 g/week, were 0-20.8, 11.7-93.1, and 15.9-102.9 mu g/g creatinine for uro, copro and uro + copro porphyrins, respectively. These percentile limit values can be proposed as a first attempt to provide urinary porphyrin reference values for our population, serving for an early diagnosis of porphyrinopathies or as biomarkers of exposure to porphyrinogenic agents.
C1 [Alves, A. N. L.; Sumita, N. M.; Burattini, M. N.] Hosp Clin Sao Paulo, Div Lab Cent, Fac Med, BR-05403000 Sao Paulo, Brazil.
   [Alves, A. N. L.; Sumita, N. M.; Burattini, M. N.] Hosp Clin Sao Paulo, Fac Med, LIM 03, BR-05403000 Sao Paulo, Brazil.
   [Alves, A. N. L.; Della Rosa, H. V.] Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Hosp Clin Sao Paulo, Div Lab Cent, Fac Med, Av Dr Eneas de Carvalho Aguiar,155 Predio Ambulat, BR-05403000 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
FU Fundacao Faculdade de Medicina; Faculdade de Ciencias Farmaceuticas,
   Universidade de Sao Paulo;  [LIM 03-HCFMUSP]
FX Research supported by LIM 03-HCFMUSP, Fundacao Faculdade de Medicina and
   Faculdade de Ciencias Farmaceuticas, Universidade de Sao Paulo.
CR Melito VA, 2006, ACTA BIOQUIM CLIN L, V40, P29
   Almehmi Ammar, 2005, W V Med J, V101, P19
   Apostoli P, 2002, AM J IND MED, V42, P180, DOI 10.1002/ajim.10123
   Apostoli P, 1999, INT ARCH OCC ENV HEA, V72, P191, DOI 10.1007/s004200050361
   BURATTI M, 1987, BIOL MONITORING EXPO, P309
   Bussab W.O., 1987, ESTATISTICA BASICA
   *CETESB, 2003, NOT REL QUAL AR EST
   Cho JH, 2003, VET HUM TOXICOL, V45, P193
   Clinical and Laboratory Standards Institute (CLSI), 2008, DEF EST VER REF INT, V28
   *CLSI, 2009, UR APPR GUID, V29
   Conover W. J., 1980, PRACTICAL NONPARAMET
   Costa CA, 1997, CLIN CHEM, V43, P1196
   Cribier B, 2009, DERMATOLOGY, V218, P15, DOI 10.1159/000173696
   Daniell William E., 1997, Environmental Health Perspectives, V105, P37, DOI 10.2307/3433396
   Doss MO, 2000, ALCOHOL ALCOHOLISM, V35, P109, DOI 10.1093/alcalc/35.2.109
   ELDER GH, 1987, OCCUPATIONAL ENV CHE, P232
   HEINEGAR.D, 1973, CLIN CHIM ACTA, V43, P305, DOI 10.1016/0009-8981(73)90466-X
   Hindmarsh JT, 2003, CLIN CHIM ACTA, V333, P203, DOI 10.1016/S0009-8981(03)00187-6
   Hryhorczuk DO, 1998, ENVIRON HEALTH PERSP, V106, P401, DOI 10.2307/3434067
   JOHNSON PM, 1988, CLIN CHEM, V34, P103
   Klaassen C.D., 2001, CASARETT DOULLS TOXI
   Alves Atecla Nunciata Lopes, 2007, Rev. Bras. Cienc. Farm., V43, P581, DOI 10.1590/S1516-93322007000400011
   Mor Z, 1997, CLIN DERMATOL, V15, P147, DOI 10.1016/S0738-081X(96)00117-4
   NAVAS S, 1995, HEPATOLOGY, V21, P279, DOI 10.1016/0270-9139(95)90081-0
   Nordmann Y, 2002, CLIN CHIM ACTA, V325, P17, DOI 10.1016/S0009-8981(02)00276-0
   Pingree SD, 2001, TOXICOL SCI, V61, P234, DOI 10.1093/toxsci/61.2.234
   Poblete-Gutierrez P, 2006, EUR J DERMATOL, V16, P230
   Poulsen OM, 1997, PURE APPL CHEM, V69, P1601, DOI 10.1351/pac199769071601
   Santos JL, 1996, MED CLIN-BARCELONA, V107, P614
   SCHREIBER WE, 1983, CLIN CHEM, V29, P527
   Sterling Richard K, 2006, Curr Gastroenterol Rep, V8, P53, DOI 10.1007/s11894-006-0064-y
   Sunyer Jordi, 2002, Environ Health, V1, P1, DOI 10.1186/1476-069X-1-1
   Tutor-Crespo MJ, 2005, J PHARMACOL SCI, V99, P323, DOI 10.1254/jphs.FPE05003X
   VERDON CP, TESTING TOXIC METALS
   Woods JS, 1998, J OCCUP ENVIRON MED, V40, P1090
   World Health Organization, 1996, BIOL MON CHEM EXP WO, V1
   Wu HJ, 2004, TOXICOL LETT, V154, P149, DOI 10.1016/j.toxlet.2004.08.005
NR 37
TC 2
Z9 3
U1 0
U2 7
PU ASSOC BRAS DIVULG CIENTIFICA
PI RIBEIRAO PRETO
PA FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL
SN 0100-879X
EI 1414-431X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD AUG
PY 2009
VL 42
IS 8
BP 700
EP 706
DI 10.1590/S0100-879X2009005000002
PG 7
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 485LI
UT WOS:000269123000002
PM 19448892
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Coutinho, FAB
   Massad, E
AF Burattini, M. N.
   Coutinho, F. A. B.
   Massad, E.
TI A hypothesis for explaining single outbreaks (like the Black Death in
   European cities) of vector-borne infections
SO MEDICAL HYPOTHESES
LA English
DT Article
ID CHIKUNGUNYA
AB We propose a mechanism by which single outbreaks of vector-borne infections can happen even when the value of the basic reproduction number, R-o, of the infection is below one. With this hypothesis we have shown that dynamical models simulations demonstrate that the arrival of a relatively small (with respect to the host population) number of infected vectors can trigger a short-lived epidemic but with a huge number of cases. These episodes are characterized by a sudden outbreak in a previously virgin area that last from weeks to a few months, and then disappear without leaving vestiges.
   The hypothesis proposed in this paper to explain those single outbreaks of vector-borne infections, even when total basic reproduction number, Ro, is less than one (which explain the fact that those infections fail to establish themselves at endemic levels), is that the vector-to-host component of Ro is greater than one and that a sufficient amount of infected vectors are imported to the vulnerable area, triggering the outbreak.
   We tested the hypothesis by performing numerical simulations that reproduce the observed outbreaks of chikungunya in Italy in 2007 and the plague in Florence in 1348.
   The theory proposed provides an explanation for isolated outbreaks of vector-borne infections, ways to calculate the size of those outbreaks from the number of infected vectors arriving in the affected areas. Given the ever-increasing worldwide transportation network, providing a high degree of mobility from endemic to virgin areas, the proposed mechanism may have important implications for public health planning. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Burattini, M. N.; Coutinho, F. A. B.; Massad, E.] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, SP, Brazil.
   [Burattini, M. N.; Coutinho, F. A. B.; Massad, E.] Univ Sao Paulo, HCFMUSP, LIM01, BR-05405000 Sao Paulo, SP, Brazil.
   [Massad, E.] Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014;
   Massad, Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916
CR CIMERMAN S, 1997, BRAZ J INFECT DIS, V1, P135
   Coutinho FAB, 2006, BIOMAT 2005, P213, DOI 10.1142/9789812773685_0013
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   Hochedez P, 2006, EMERG INFECT DIS, V12, P1565, DOI 10.3201/eid1210.060495
   Kamath Sandhya, 2006, J Assoc Physicians India, V54, P725
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   LUMSDEN W. H. R., 1955, TANGANYIKA TERRITORY IN 1952 53 II TRANS ROY SOC TROP MED AND HYG, V49, P33, DOI 10.1016/0035-9203(55)90081-X
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2008, J TRAVEL MED, V15, P147, DOI 10.1111/j.1708-8305.2008.00186.x
   Rezza G, 2007, LANCET, V370, P1840, DOI 10.1016/S0140-6736(07)61779-6
   ZIEGLER P, 1984, BLACK DEATH
NR 11
TC 1
Z9 1
U1 1
U2 16
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2009
VL 73
IS 1
BP 110
EP 114
DI 10.1016/j.mehy.2009.01.036
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 452ZG
UT WOS:000266579100034
PM 19264416
DA 2020-12-08
ER

PT J
AU Mendes, ME
   Romano, P
   Batista, VRM
   Ebner, PAR
   Burattini, MN
   Sumita, NM
AF Mendes, M. E.
   Romano, P.
   Batista, V. R. Morsoleto
   Ebner, P. A. Rezende
   Burattini, M. N.
   Sumita, N. M.
TI The transferrin soluble receptor (sTfR): an application protocol for the
   Roche/Hitachi Modular P800 Chemistry System
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 19-23, 2009
CL Chicago, IL
SP Amer Assoc Clin Chem
C1 Univ Sao Paulo, Fac Med, Hosp Clin, Cent Lab Div, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Labs Med Invest LIM 03, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2009
VL 55
IS 6
BP A196
EP A197
PG 2
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 456ZZ
UT WOS:000266895401196
DA 2020-12-08
ER

PT J
AU Mendes, ME
   Sumita, NM
   Novais, RCD
   Lavorato, LMO
   Rotondaro, RG
   Burattini, MN
AF Mendes, M. E.
   Sumita, N. M.
   Dionisio Novais, R. C.
   Oliveira Lavorato, L. M.
   Rotondaro, R. G.
   Burattini, M. N.
TI Six Sigma implementation in a public clinical laboratory : application
   to reduce corrective maintenance in the equipments
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 19-23, 2009
CL Chicago, IL
SP Amer Assoc Clin Chem
C1 [Mendes, M. E.; Sumita, N. M.; Dionisio Novais, R. C.; Oliveira Lavorato, L. M.; Burattini, M. N.] Univ Sao Paulo, Cent Lab Div, Sao Paulo, Brazil.
   [Mendes, M. E.; Sumita, N. M.; Dionisio Novais, R. C.; Oliveira Lavorato, L. M.; Burattini, M. N.] Univ Sao Paulo, Lab Med Invest LIM 03, Hosp Clin, Fac Med, Sao Paulo, Brazil.
   [Rotondaro, R. G.] Univ Sao Paulo, Escola Politecn, Dept Engn Producao, Sao Paulo, Brazil.
RI Mendes, Maria E/B-4207-2015; Burattini, Marcelo N/J-9272-2014
OI Mendes, Maria E/0000-0001-9835-8761; Burattini, Marcelo
   N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2009
VL 55
IS 6
BP A30
EP A30
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 456ZZ
UT WOS:000266895400090
DA 2020-12-08
ER

PT J
AU Caldeira, LD
   Burattini, MN
AF Caldeira, Luciane de Fatima
   Burattini, Marcelo Nascimento
TI Analysis of antimicrobials' consumption profile in a University Hospital
   of Western Parana, Brazil
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Medicines/Defined Daily Doses; Medicines/utilization;
   Antimicrobials/consumption Pharmacoepidemiology
ID IMPACT
AB The objective of this study was to analyze the variation in antimicrobials' consumption and the costs related to their use at a University Hospital between 1999 and 2004. The annual consumption of nine antimicrobials, expressed in DDD/100 patients-day, and the direct costs with their acquisition were evaluated. Analysis of variance and regression techniques were used to compare data, considering a significance level of 5%. The most consumed antimicrobials were amikacin and ceftriaxone. In general, antimicrobials consumption, expressed in DDD/100 patients-day, increased from 9.21 in 1999 to 25.08 in 2004 (p <= 0.0001). When analyzing antimicrobial consumption as related to specific hospital units, the ICU showed the highest consumption followed by Chemotherapy and Medical Clinical units, respectively. In addition, the number of patients-day increased from 2671/month in 1999 to 3502/rnonth in 2004, p <= 0.0001. As a consequence, total expenditure with antimicrobials increased from R$ 98.89 per 100 patients-day in 1999 to R$ 731.26 in 2004, p <= 0.0001. Between 1999 and 2004 significant increases in both consumption and financial expenditure with antimicrobials were observed.
C1 [Caldeira, Luciane de Fatima] State Univ Western Parana, Dept Hosp Pharm, Fac Pharm, Curitiba, Parana, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Dept Med, Sao Paulo, Brazil.
RP Caldeira, LD (corresponding author), Univ Estadual Oeste Parana, Rua Univ 1-619,Jardim Univ,Caixa Postal 701, BR-85819110 Cascavel, PR, Brazil.
EM luciane-caldeira@hotmail.com
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR BORGES GM, 2005, BRAZ J INFECT DIS, V9, P88
   CAPELLA D, 1994, EPIDEMIOLOGIA MED PR, P95
   Carling P, 2003, INFECT CONT HOSP EP, V24, P699, DOI 10.1086/502278
   CASTRO M, 1999, INFECCAO HOSP EPIDEM, P383
   CAVALCANTE AJW, 2005, BRAZ J INFECT DIS, V9, P161
   Cook PP, 2004, J ANTIMICROB CHEMOTH, V53, P853, DOI 10.1093/jac/dkh163
   de Castro MS, 2002, REV SAUDE PUBL, V36, P553, DOI 10.1590/S0034-89102002000600003
   Fernandes AT, 2000, INFECCAO HOSP SUAS I
   FOLLADOR W, 2005, FARMACIA HOSP SUAS I, P175
   Gould IM, 2002, CURR OPIN INFECT DIS, V15, P395, DOI 10.1097/00001432-200208000-00007
   HIDALGO SR, 2003, THESIS U FEDERAL SAO
   LAPORTE JR, 1993, PRINCIPIOS EPIDEMILO
   LAPORTE JR, 1989, EPIDEMIOLOGIA MED PR
   LEE D, 1994, PHARMACOEPIDEM DR S, P279
   Loeffler JM, 2003, SCAND J INFECT DIS, V35, P843, DOI 10.1080/00365540310016646
   Lopez-Medrano F, 2005, ENFERM INFEC MICR CL, V23, P186, DOI 10.1157/13073141
   Murthy R, 2001, CHEST, V119, p405S, DOI 10.1378/chest.119.2_suppl.405S
   Najera LH, 2003, PHARMACOEPIDEM DR S, V12, P243, DOI 10.1002/pds.768
   Shankar PR, 2003, AM J INFECT CONTROL, V31, P410, DOI 10.1067/mic.2003.57
   WENZEL RP, 1997, PREVENTION CONTROL N, P323
NR 20
TC 2
Z9 3
U1 0
U2 0
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984-8250
EI 2175-9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PD APR-JUN
PY 2009
VL 45
IS 2
BP 295
EP 302
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 492KH
UT WOS:000269653900015
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Chaib, E
   Burattini, MN
AF Massad, E.
   Coutinho, F. A. B.
   Chaib, E.
   Burattini, M. N.
TI Cost-effectiveness analysis of a hypothetical hepatitis C vaccine
   compared to antiviral therapy
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
DE Basic reproduction number; cost-effectiveness analysis; hepatitis C;
   modelling; vaccination
ID SAO-PAULO; INFECTION; VIRUS; HCV; PERSISTENCE; BEHAVIOR; HIV
AB We propose a mathematical model to simulate the dynamics of hepatitis C virus (HCV) infection in the state of Sao Paulo, Brazil. We assumed that a hypothetical vaccine, which cost was taken to be the initial cost of the vaccine against hepatitis B exists and it is introduced in the model. We computed its cost-effectiveness compared with the anti-HCV therapy. The calculated basic reproduction number was 1.20. The model predicts that without intervention a steady state exists with an HCV prevalence of 3%, in agreement with the Current epidemiological data. Starting from this steady state three interventions were simulated: indiscriminate vaccination, selective vaccination and anti-HCV therapy. Selective vaccination proved to be the strategy with the best cost-effectiveness ratio, followed by indiscriminate vaccination and anti-HCV therapy.
C1 [Massad, E.; Coutinho, F. A. B.; Burattini, M. N.] Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   [Massad, E.; Coutinho, F. A. B.; Chaib, E.; Burattini, M. N.] HCFMUSP, LIM01, Sao Paulo, Brazil.
   [Massad, E.] London Sch Hyg & Trop Med, London WC1, England.
   [Chaib, E.] Univ Oxford, Oxford, England.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455,7382, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Massad, Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012; Burattini,
   Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071
CR Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505
   Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371
   Brown RS, 2005, NATURE, V436, P973, DOI 10.1038/nature04083
   Burattini MN, 2000, REV SAUDE PUBL, V34, P431, DOI 10.1590/S0034-89102000000500001
   Chaib E, 2005, TRANSPLANT P, V37, P4329, DOI 10.1016/j.transproceed.2005.11.014
   CHAIB E, 2004, HEPATOCELLULAR CARCI
   Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076
   CROFTS N, 1999, TECHNICAL REPORT SER, V3
   GAYOTTO LCC, 2001, DOENCAS FIGADO VIAS
   HOOFNAGLE JH, 2002, HEPATOLOGY, V36, P521
   Houghton M, 2005, NATURE, V436, P961, DOI 10.1038/nature04081
   Lloyd AL, 2001, P ROY SOC B-BIOL SCI, V268, P847, DOI 10.1098/rspb.2000.1572
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Luz PM, 2003, MEM I OSWALDO CRUZ, V98, P871, DOI 10.1590/S0074-02762003000700002
   MCKAY MD, 1979, TECHNOMETRICS, V21, P239, DOI 10.2307/1268522
   Merion RM, 2005, AM J TRANSPLANT, V5, P307, DOI 10.1111/j.1600-6143.2004.00703.x
   *NIH, 2000, NIH CONS STAT REC, V75, P18
   Poynard T, 2000, BEST PRACT RES CL GA, V14, P211, DOI 10.1053/bega.1999.0071
   Pybus OG, 2001, SCIENCE, V292, P2323, DOI 10.1126/science.1058321
   Saltelli A., 2000, SENSITIVITY ANAL GAU
   Schinaia G, 2005, ADV COMPLEX SYST, V8, P33, DOI 10.1142/S021952590500035X
   SILVA LC, 2001, LIVER BILIARY TRACT, P470
   Strazza L, 2007, CAD SAUDE PUBLICA, V23, P197, DOI 10.1590/S0102-311X2007000100021
   WHO, 2000, WKLY EPIDEMIOL REC, V75, P18
   WONG JB, 1999 ANN M
NR 25
TC 19
Z9 19
U1 0
U2 11
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD FEB
PY 2009
VL 137
IS 2
BP 241
EP 249
DI 10.1017/S0950268808000873
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 399BG
UT WOS:000262774800015
PM 18631422
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FAB
AF Massad, E.
   Burattini, M. N.
   Coutinho, F. A. B.
BE Mondaini, RP
TI MODELING THE RISK OF FALCIPARUM MALARIA FOR TRAVELERS TO HOLOENDEMIC
   REGIONS
SO BIOMAT 2008
LA English
DT Proceedings Paper
CT International Symposium on Mathematical and Computational Biology
CY NOV 22-27, 2008
CL Campos do Jordao, BRAZIL
SP CAPES, Natl Res Council, PETROBRAS Oil Co, PETROBRAS - CENPES Res Ctr
ID DENGUE
AB Malaria has emerged as a frequent problem in international travelers. The risk depends on destination, duration and season of travel. However, data to quantify the true risk for travelers to acquire malaria are lacking. Methods: We used mathematical models to estimate the risk of non-immune persons to acquire malaria when traveling to the Amazon region. From the force of infection we calculated the risk of dengue dependent on duration of stay and season of arrival. Our data highlight that the risk for non-immune travelers to acquire malaria in the Amazon region is substantial but varies greatly with seasons and epidemic cycles. For instance, for a traveler who stays in the Amazon for 120 days during the high season, the risk of acquiring malaria was 0.16%. Risk estimates based on mathematical modelling will help the travel medicine provider give better evidence based advice for travelers to malarial countries.
C1 [Massad, E.; Burattini, M. N.; Coutinho, F. A. B.] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; 
CR Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   *FUNASA, 2001, MAN TER MAL
   Garnham P. C. C., 1988, Malaria: principles and practice of malariology. Volume 1., P61
   House HR, 2008, EMERG MED CLIN N AM, V26, P499, DOI 10.1016/j.emc.2008.01.008
   KROGSTAD DJ, 1999, TROPICAL INFECT DIS, P736
   LADISLAW JLB, 2006, SITUACAO MALARIA AMA
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2008, J TRAVEL MED, V15, P147, DOI 10.1111/j.1708-8305.2008.00186.x
   Tada Yuki, 2008, Travel Med Infect Dis, V6, P368, DOI 10.1016/j.tmaid.2008.08.002
   White N. J., 1996, Manson's tropical diseases., P1087
   *WHO, 2004, BAS FACTS MAL
   WYSE APP, 2007, THESIS LAB NACL COMP
NR 14
TC 0
Z9 0
U1 0
U2 3
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE
PY 2009
BP 211
EP 222
DI 10.1142/9789814271820_0013
PG 12
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA BMO60
UT WOS:000273131300013
DA 2020-12-08
ER

PT J
AU de Souza, PML
   Jacob, W
   Santarem, JM
   da Silva, AR
   Li, HY
   Burattini, MN
AF Loiola de Souza, Paula Maria
   Jacob-Filho, Wilson
   Santarem, Jose Maria
   da Silva, Alexandre Rodrigues
   Li, Ho Yeh
   Burattini, Marcelo Nascimento
TI PROGRESSIVE RESISTANCE TRAINING IN ELDERLY HIV- POSITIVE PATIENTS: DOES
   IT WORK?
SO CLINICS
LA English
DT Article
DE Weight lifting; HIV/AIDS; Elderly; Body composition; Physical fitness
ID BODY-COMPOSITION; EXERCISE; INDIVIDUALS; STRENGTH; FITNESS
AB BACKGROUND: Elderly people present alterations in body composition and physical fitness, compromising their quality of life. Chronic diseases, including HIV/AIDS, worsen this situation. Resistance exercises are prescribed to improve fitness and promote healthier and independent aging. Recovery of strength and physical fitness is the goal of exercise in AIDS wasting syndrome.
   OBJECTIVE: This study describes a case series of HIV-positive elderly patients who participated in a progressive resistance training program and evaluates their body composition, muscular strength, physical fitness and the evolution of CD4(+) and CD8(+) cell counts.
   METHODS: Subjects were prospectively recruited for nine months. The training program consisted of three sets of 8-12 repetitions of leg press, seated row, lumbar extension and chest press, performed with free weight machines hts, twice/week for one year. Infectious disease physicians followed patients and reported all relevant clinical data. Body composition was assessed by anthropometric measures and dual-energy x-ray absorptiometry before and after the training program.
   RESULTS: Fourteen patients, aged 62-71 years old, of both genders, without regular physical activity who had an average of nine years of HIV/AIDS history were enrolled. The strengths of major muscle groups increased (74%-122%, p=0.003-0.021) with a corresponding improvement in sit-standing and walking 2.4 m tests (p=0.003). There were no changes in clinical conditions and body composition measures, but triceps and thigh skinfolds were significantly reduced (p=0.037). In addition, there were significant increases in the CD4(+) counts (N=151 cells; p=0.008) and the CD4(+)/CD8(+) ratio (0.63 to 0.81, p=0.009).
   CONCLUSION: Resistance training increased strength, improved physical fitness, reduced upper and lower limb skinfolds, and were associated with an improvement in the CD4(+) and CD4(+)/CD8(+) counts in HIV positive elderly patients without significant side effects.
C1 [Loiola de Souza, Paula Maria; Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo, Brazil.
   [Jacob-Filho, Wilson; Santarem, Jose Maria] Univ Sao Paulo, Fac Med, Dept Clin Med, Sao Paulo, Brazil.
   [da Silva, Alexandre Rodrigues; Li, Ho Yeh] Univ Sao Paulo, Fac Med, Dept Infect Dis, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Discipline Med Informat & LIM 01 03, Hosp Clin, Sao Paulo, Brazil.
   [Jacob-Filho, Wilson; Santarem, Jose Maria] Univ Sao Paulo, Ctr Estudos Ciencias Atividade Fis CECAFI, Fac Med, Sao Paulo, Brazil.
   [Burattini, Marcelo Nascimento] Univ Fed Sao Paulo, Infect Dis Clin, Sao Paulo, Brazil.
RP de Souza, PML (corresponding author), Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Burattini, Marcelo N/J-9272-2014; Ho, Yeh Li/A-7197-2013
OI Burattini, Marcelo N/0000-0002-5407-6890; Ho, Yeh Li/0000-0001-8719-2508
CR Bruunsgaard H, 2000, IMMUNOL CELL BIOL, V78, P523, DOI 10.1046/j.1440-1711.2000.00965.x
   Calloway C., 1988, ANTHROPOMETRIC STAND, P39
   Centers for Disease Control (CDC), 1993, MMWR, V41
   ELLIS K, 2000, PHYSIOL REV, V80, P662
   FIATARONE MA, 1994, NEW ENGL J MED, V330, P1769, DOI 10.1056/NEJM199406233302501
   Grimes DA, 2002, LANCET, V359, P145, DOI 10.1016/S0140-6736(02)07373-7
   GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902
   HARRISON GG, 1988, ANTHROPOMETRIC STAND, P55
   Hunter GR, 2004, SPORTS MED, V34, P329, DOI 10.2165/00007256-200434050-00005
   *IBGE, SINT IND SOC 2005
   Jones SP, 2001, AIDS, V15, P2049, DOI 10.1097/00002030-200110190-00021
   Katz P, 2001, J AM GERIATR SOC, V49, P808
   Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027
   Lox CL, 1996, INT J BEHAV MED, V3, P55, DOI 10.1207/s15327558ijbm0301_5
   Malita FM, 2005, CAN J APPL PHYSIOL, V30, P233, DOI 10.1139/h05-117
   Paw MJMCA, 2000, MED SCI SPORT EXER, V32, P2005, DOI 10.1097/00005768-200012000-00006
   Roubenoff R, 2000, AM J MANAG CARE, V6, P1003
   Roubenoff R, 1999, AIDS, V13, P231, DOI 10.1097/00002030-199902040-00011
   Sullo A, 2003, MED SPORT, V56, P57
   Utter AC, 1998, INT J SPORT NUTR, V8, P213, DOI 10.1123/ijsn.8.3.213
   Williams MA, 2007, CIRCULATION, V116, P572, DOI 10.1161/CIRCULATIONAHA.107.185214
   Winett RA, 2001, PREV MED, V33, P503, DOI 10.1006/pmed.2001.0909
NR 22
TC 28
Z9 28
U1 0
U2 4
PU HOSPITAL CLINICAS, UNIV SAO PAULO
PI SAO PAULO
PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL
SN 1807-5932
EI 1980-5322
J9 CLINICS
JI Clinics
PD OCT
PY 2008
VL 63
IS 5
BP 619
EP 624
DI 10.1590/S1807-59322008000500009
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 361ZQ
UT WOS:000260168400008
PM 18925321
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Rozman, MA
   Alves, IS
   Porto, MA
   Gomes, PO
   Ribeiro, NM
   Nogueira, LAA
   Caseiro, MM
   da Silva, VA
   Massad, E
   Burattini, MN
AF Rozman, Mauro Abrahao
   Alves, Igor Santino
   Porto, Marcela Alves
   Gomes, Patricia Oliveira
   Ribeiro, Nilva Maria
   Andrade Nogueira, Lucyene Aparecida
   Caseiro, Marcos Monteiro
   da Silva, Vera Aparecida
   Massad, Eduardo
   Burattini, Marcelo Nascimento
TI HIV infection and related risk behaviors in a community of recyclable
   waste collectors of Santos, Brazil
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE solid waste segregators; HIV; hepatitis B virus; hepacivirus; syphilis;
   risk factors; seroepidemiologic studies
ID SAO-PAULO; PARENTERAL TRANSMISSION; PRISON; HCV; INMATES; WOMEN; WARTS
AB OBJECTIVE: To estimate the seroprevalence of HIV, hepatitis B and C and syphilis and to describe risk behaviors associated to their transmission among recyclable waste collectors.
   METHODS: A seroepidemiological survey was carried out in the city of Santos, Southeastern Brazil, in 2005. A total of 315 individuals were enrolled in the survey, of which 253 subjects underwent serological testing HIV, hepatitis B and C and syphilis. Statistical analysis consisted of univariate and bivariate analyses (cross-tabulation and odds ratio) and multivariate analysis (by logistic regression), relating HIV infection with established risk behaviors and seropositivity.
   RESULTS: Overall seroprevalences were: HIV, 8.9%; hepatitis B, 34.4%; hepatitis C, 12.4%; and syphilis, 18.4%. Subjects were characterized by a predominance of males with low educational and economic levels, subjected to parenteral and sexual exposures to HIV and other sexually transmitted infections. Multivariate analysis results indicated that risk factors for both sexually and parenterally related exposure were significantly associated with HIV in this community.
   CONCLUSIONS: Seroprevalences found in the study were approximately 10 to 12 times higher than the national average. These communities are socially marginalized and generally not recognized by national programs as potentially endangered populations.
C1 [Rozman, Mauro Abrahao; Alves, Igor Santino; Porto, Marcela Alves; Gomes, Patricia Oliveira; Ribeiro, Nilva Maria; Andrade Nogueira, Lucyene Aparecida; Caseiro, Marcos Monteiro] Univ Catolica Santos, Ctr Ciencias Saude, Santos, SP, Brazil.
   [da Silva, Vera Aparecida; Massad, Eduardo; Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London, England.
RP Burattini, MN (corresponding author), R Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916
CR Berthier HC, 2003, RESOUR CONSERV RECY, V39, P193, DOI 10.1016/S0921-3449(03)00027-2
   Burattini MN, 2000, REV SAUDE PUBL, V34, P431, DOI 10.1590/S0034-89102000000500001
   Burattini MN, 2005, INT J STD AIDS, V16, P836, DOI 10.1258/095646205774988136
   Carvalho Heraclito Barbosa De, 1996, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V12, P84
   Fonseca Maria Goretti P., 2003, Cad. Saúde Pública, V19, P1351, DOI 10.1590/S0102-311X2003000500013
   Fonseca MGP, 2002, REV SAUDE PUBL, V36, P678, DOI 10.1590/S0034-89102002000700004
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   Goncalves MAG, 2003, INT J STD AIDS, V14, P309, DOI 10.1258/095646203321605503
   Goncalves MAG, 2003, TUMORI, V89, P9
   Hsu E, 2005, WASTE MANAGE, V25, P53, DOI 10.1016/j.wasman.2004.07.003
   Lwanga SK, 1991, SAMPLE SIZE DETERMIN
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   Masui T, 2000, EUR J OPER RES, V122, P405, DOI 10.1016/S0377-2217(99)00242-8
   *MIN SAUD, 2005, B EP AIDS DST, V1
   Rozman M, 1998, INT J STD AIDS, V9, P183, DOI 10.1258/0956462981921855
   Rozman MA, 2007, INT J STD AIDS, V18, P653, DOI 10.1258/095646207781568574
   SEGURADO AAC, 1995, J ACQ IMMUN DEF SYND, V10, P200
   Strazza L, 2004, BRAZ J MED BIOL RES, V37, P771, DOI 10.1590/S0100-879X2004000500020
   Strazza L, 2007, CAD SAUDE PUBLICA, V23, P197, DOI 10.1590/S0102-311X2007000100021
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P135
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P7
   Zanetta DMT, 1999, INT J STD AIDS, V10, P98, DOI 10.1258/0956462991913718
NR 23
TC 2
Z9 2
U1 0
U2 4
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD OCT
PY 2008
VL 42
IS 5
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 356AN
UT WOS:000259751200008
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Coelho, GE
   Burattini, MN
   Teixeira, MD
   Coutinho, FAB
   Massad, E
AF Coelho, Giovanini E.
   Burattini, Marcelo Nascimento
   Teixeira, Maria da Gloria
   Bezerra Coutinho, Francisco Antonio
   Massad, Eduardo
TI Dynamics of the 2006/2007 dengue outbreak in Brazil
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE dengue; larval index; basic reproduction number; force of infection
ID ANTHROPIC ENVIRONMENT; MOSQUITOS DIPTERA; YELLOW-FEVER; SOUTH-EASTERN;
   CULICIDAE
AB We analyzed dengue incidence in the period between October 2006-July 2007 of 146 cities around the country were Larval Index Rapid Assay (LIRA) surveillance was carried out in October 2006. Of these, we chosen 61 cities that had 500 or more cases reported during this period. We calculated the incidence coefficient, the force of infection (lambda) and the basic reproduction number (R-0) of dengue in those 61 cities and correlated those variables with the LIRA. We concluded that lambda and R-0 are more associated with the number of cases than LIRA. In addition, the average R-0 for the 2006/2007 dengue season was almost as high as that calculated for the 2001/2002 season, the worst in Brazilian history.
C1 [Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio; Massad, Eduardo] Univ Sao Paulo, Fac Med, BR-05405000 Sao Paulo, Brazil.
   [Coelho, Giovanini E.] Minist Saude, Programa Nacl Controle Dengue, Brasilia, DF, Brazil.
   [Teixeira, Maria da Gloria] Univ Fed Bahia, Inst Saude Coletiva, Salvador, BA, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, London WC1, England.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Fac Med, R Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Teixeira, Maria Gloria/G-4808-2012;
   Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011; Massad,
   Eduardo/B-1169-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Teixeira, Maria
   Gloria/0000-0003-3318-3408; Burattini, Marcelo N/0000-0002-5407-6890;
   Massad, Eduardo/0000-0002-7200-2916
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); LIM01 HC-FMUSP
FX Financial support: CNPq, FAPESP, LIM01 HC-FMUSP
CR BANG YH, 1981, B WORLD HEALTH ORGAN, V59, P107
   Burattini MN, 2008, EPIDEMIOL INFECT, V136, P309, DOI 10.1017/S0950268807008667
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho FAB, 1999, MATH COMPUT MODEL, V30, P97, DOI 10.1016/S0895-7177(99)00119-3
   da Cunha R V, 1997, Rev Soc Bras Med Trop, V30, P379, DOI 10.1590/S0037-86821997000500005
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P227, DOI 10.1590/S0034-89101993000400001
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   FORATTINI OP, 1995, REV SAUDE PUBL, V29, P199, DOI 10.1590/S0034-89101995000300007
   GERMAIN M, 1980, AM J TROP MED HYG, V29, P929, DOI 10.4269/ajtmh.1980.29.929
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Luz PM, 2003, MEM I OSWALDO CRUZ, V98, P871, DOI 10.1590/S0074-02762003000700002
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   *MS MIN SAUD, 2005, DIAGN RAP NOS MUN VI
   *MS MIN SAUD, 2007, GRAPH SHOW HIST SER
   *MS MIN SAUD, 2007, EP B REP 2007 DENG O
NR 16
TC 40
Z9 41
U1 1
U2 11
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD SEP
PY 2008
VL 103
IS 6
BP 535
EP U7
DI 10.1590/S0074-02762008000600004
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 365DL
UT WOS:000260386000004
PM 18949321
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FAB
AF Massad, Eduardo
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
TI An optimization model for antibiotic use
SO APPLIED MATHEMATICS AND COMPUTATION
LA English
DT Article
DE antibiotics; evolution of resistance; mathematical model; optimization
ID ANTIMICROBIAL RESISTANCE; UNITED-STATES; TETRACYCLINE RESISTANCE;
   POPULATION-DYNAMICS; EVOLUTION; SUSCEPTIBILITY; DISSEMINATION;
   DETERMINANT; PROGRAM
AB There is a positive correlation between the intensity of use of a given antibiotic and the prevalence of resistant strains. The more you treat, more patients infected with resistant strains appears and, as a consequence, the higher the mortality due to the infection and the longer the hospitalization time. In contrast, the less you treat, the higher the mortality rates and the longer the hospitalization time of patients infected with sensitive strains that could be successfully treated. The hypothesis proposed in this paper is an attempt to solve such a conflict: there must be an optimum treatment intensity that minimizes both the additional mortality and hospitalization time due to the infection by both sensitive and resistant bacteria strains. In order to test this hypothesis we applied a simple mathematical model that allowed us to estimate the optimum proportion of patients to be treated in order to minimize the total number of deaths and hospitalization time due to the infection in a hospital setting. (C) 2007 Elsevier Inc. All rights reserved.
C1 [Massad, Eduardo; Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio] Univ Sao Paulo, Sch Med, LIM HCFMUSP 01, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London WC1E 7HT, England.
   [Burattini, Marcelo Nascimento] LIM 03 HCFMUSP, BR-05405000 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, LIM HCFMUSP 01, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; Massad, Eduardo/0000-0002-7200-2916
CR AMYES SGB, 2001, MAGIC BULLETS LOST H
   Archibald L, 1997, CLIN INFECT DIS, V24, P211, DOI 10.1093/clinids/24.2.211
   AUSTIN DJ, 1999, STUDIES ANTIBIOTIC R
   Chang S, 2003, NEW ENGL J MED, V348, P1342, DOI 10.1056/NEJMoa025025
   Flamm RK, 2004, ANTIMICROB AGENTS CH, V48, P2431, DOI 10.1128/AAC.48.7.2431-2436.2004
   Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004
   Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0
   Hsueh PR, 2005, INT J ANTIMICROB AG, V26, P463, DOI 10.1016/j.ijantimicag.2005.08.016
   Jumbe N, 2003, J CLIN INVEST, V112, P275, DOI 10.1172/JCI200316814
   KOPECKO DJ, 1980, PROG MOL SUBCELL BIO, V7, P135
   Laxminarayan R, 2001, J ENVIRON ECON MANAG, V42, P183, DOI 10.1006/jeem.2000.1156
   Levin BR, 2001, CLIN INFECT DIS, V33, pS161, DOI 10.1086/321843
   Levy SB, 1998, SCI AM, V278, P46, DOI 10.1038/scientificamerican0398-46
   Lipsitch M, 1997, ANTIMICROB AGENTS CH, V41, P363, DOI 10.1128/AAC.41.2.363
   Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312
   LUPSKI JR, 1987, REV INFECT DIS, V9, P357
   MALHOTRAKUMAR S, 2007, EFFECT AZITHROMYCIN
   MASSAD E, 1993, INT J BIOMED COMPUT, V33, P65, DOI 10.1016/0020-7101(93)90060-J
   MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033
   Medeiros AA, 1997, CLIN INFECT DIS, V24, pS19, DOI 10.1093/clinids/24.Supplement_1.S19
   MORSE SA, 1986, ANTIMICROB AGENTS CH, V30, P664, DOI 10.1128/AAC.30.5.664
   Opal SM, 2005, PRINCIPLES PRACTICE, P253
   Palumbi SR, 2001, SCIENCE, V293, P1786, DOI 10.1126/science.293.5536.1786
   PAPADOPOULOU B, 1988, ANTIMICROB AGENTS CH, V32, P945, DOI 10.1128/AAC.32.6.945
   Rhomberg PR, 2004, INT J ANTIMICROB AG, V23, P52, DOI 10.1016/j.ijantimicag.2003.05.010
   ROBERTS MC, 1986, ANTIMICROB AGENTS CH, V29, P350, DOI 10.1128/AAC.29.2.350
   Sader HS, 2003, DIAGN MICR INFEC DIS, V47, P361, DOI 10.1016/S0732-8893(03)00052-X
   Tran JH, 2002, P NATL ACAD SCI USA, V99, P5638, DOI 10.1073/pnas.082092899
   Walsh C., 2003, ANTIBIOTICS ACTIONS
   Woodford N, 2007, CLIN MICROBIOL INFEC, V13, P5, DOI 10.1111/j.1469-0691.2006.01492.x
NR 30
TC 14
Z9 16
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0096-3003
EI 1873-5649
J9 APPL MATH COMPUT
JI Appl. Math. Comput.
PD JUL 15
PY 2008
VL 201
IS 1-2
BP 161
EP 167
DI 10.1016/j.amc.2007.12.007
PG 7
WC Mathematics, Applied
SC Mathematics
GA 312HQ
UT WOS:000256660400015
DA 2020-12-08
ER

PT J
AU Massad, E
   Struchiner, CJ
   Burattini, MN
   Coutinho, FAB
AF Massad, Eduardo
   Struchiner, Claudio Jose
   Burattini, Marcelo Nascimento
   Bezerra Coutinho, Francisco Antonio
TI An optimal vaccination strategy against rotavirus
SO VACCINE
LA English
DT Letter
ID SAO-PAULO STATE; RUBELLA; BRAZIL
C1 [Massad, Eduardo; Burattini, Marcelo Nascimento; Bezerra Coutinho, Francisco Antonio] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   [Struchiner, Claudio Jose] Fiocruz MS, BR-21045900 Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/H-6143-2011; Coutinho, Francisco A B/H-5644-2011; Struchiner,
   Claudio J/M-9360-2013
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Struchiner, Claudio J/0000-0003-2114-847X
CR Bauch CT, 2003, P NATL ACAD SCI USA, V100, P10564, DOI 10.1073/pnas.1731324100
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   NETO RSD, 1994, EPIDEMIOL INFECT, V113, P161, DOI 10.1017/S095026880005158X
   Parashar UD, 2003, EMERG INFECT DIS, V9, P565, DOI 10.3201/eid0905.020562
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   1999, MMWR, V48, P1
NR 8
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD JUN 2
PY 2008
VL 26
IS 23
BP 2807
EP 2807
DI 10.1016/j.vaccine.2008.03.053
PG 1
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 312CA
UT WOS:000256645500001
PM 18448212
DA 2020-12-08
ER

PT J
AU Sumita, NM
   Mendes, ME
   Romano, P
   Batista, VRM
   Yamasaki, LMM
   Fragoso, GVC
   Saihg, RRC
   Burattini, MN
   Rotondaro, RG
   Boarin, S
AF Sumita, N. M.
   Mendes, M. E.
   Romano, P.
   Batista, V. R. Morsoleto
   Yamasaki, L. M. Midori
   Fragoso, G. V. Castro
   Saihg, R. R. C.
   Burattini, M. N.
   Rotondaro, R. G.
   Boarin, S.
TI The benefits of the implementation of the Six Sigma methodology in a
   clinical chemistry laboratory process of a public medical school
   hospital
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 60th Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 27-31, 2008
CL Washington, DC
SP Amer Assoc Clin Chem
C1 [Sumita, N. M.; Mendes, M. E.; Romano, P.; Batista, V. R. Morsoleto; Yamasaki, L. M. Midori; Fragoso, G. V. Castro; Saihg, R. R. C.; Burattini, M. N.] HC FMUSP, LIM 03, Sao Paulo, Brazil.
   [Rotondaro, R. G.; Boarin, S.] POLI USP, Escola Engn Prod, Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Mendes, Maria E/B-4207-2015
OI Burattini, Marcelo N/0000-0002-5407-6890; Mendes, Maria
   E/0000-0001-9835-8761
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2008
VL 54
IS 6
SU S
MA B9
BP A51
EP A51
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 307NN
UT WOS:000256325700156
DA 2020-12-08
ER

PT J
AU Nunes, CM
   de Lima, VMF
   de Paula, HB
   Perri, SHV
   de Andrade, AM
   Dias, FEF
   Burattini, MN
AF Nunes, Caris Maroni
   Felix de Lima, Valeria Marcal
   de Paula, Henrique Borges
   Venturoli Perri, Silvia Helena
   de Andrade, Andrea Maria
   Ferreira Dias, Francisca Elda
   Burattini, Marcelo Nascimento
TI Dog culling and replacement in an area endemic for visceral
   leishmaniasis in Brazil
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE canine visceral leishmaniasis; dog culling; dog replacement
ID EPIDEMIOLOGY; CANINE; TRANSMISSION; IMPACT
AB Measures employed to control visceral leishmaniasis in Brazil have focused on vector control by residual insecticide spraying and diagnosis of infection with elimination of positive dogs. We describe dog culling and replacement in a Brazilian endemic area (the Alvorada District, Aracatuba, SP) in order to better understand dog population dynamics when elimination of the dog reservoir is adopted as the main control measure. From August 2002 to July 2004, 60.9% of the estimated dog population for the area was culled with a mean age of 34 months old. The presence of anti-Leishmania sp. antibodies was recorded for only 26.7% of the euthanized canines. Replacement was observed in 38.8% of the cases, some of them by 2 or more dogs and in a mean time of 4 months. Dogs were replaced mostly by puppies of both sexes with a mean age of 6.8 months. From August 2002 to April 2005 we were able to follow-up 116 of these dogs, during a mean time of 8.7 months. Canine visceral leishmaniasis seropositivity by ELISA was observed in 42.2% of the followed dogs, 30.6% of which were already positive at the first evaluation. By the end of the follow-up period 37% of the dogs were submitted to euthanasia, with a mean age of 18.3 months. In the studied CVL endemic area of Brazil, euthanasia and the subsequent replacement ratio were high, increasing the dog population turnover and leading to a younger population that might be more susceptible to a variety of other infectious diseases in addition to CVL. Dog culling as a control strategy for VL should be reassessed. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Nunes, Caris Maroni; Felix de Lima, Valeria Marcal; de Paula, Henrique Borges; Venturoli Perri, Silvia Helena] Univ Sao Paulo, UNESP, BR-16050680 Aracatuba, SP, Brazil.
   [de Andrade, Andrea Maria] Ctr Zoonosis Control, BR-16050470 Aracatuba, SP, Brazil.
   [Ferreira Dias, Francisca Elda] Fed Univ Tocantins, UFT, BR-77904970 Palmas, Tocantis, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, USP, BR-01246903 Sao Paulo, Brazil.
RP Nunes, CM (corresponding author), Univ Sao Paulo, UNESP, Rua Clovis Pestana,793 Jd D Amelia, BR-16050680 Aracatuba, SP, Brazil.
EM caris@fmva.unesp.br
RI Burattini, Marcelo N/J-9272-2014; Nunes, Caris M/R-9337-2016; Perri,
   Silvia H V/D-5494-2013; de Lima, Valeria M.F./B-7867-2013
OI Burattini, Marcelo N/0000-0002-5407-6890; Nunes, Caris
   M/0000-0002-5463-3845; Perri, Silvia H V/0000-0001-5083-5557; de Lima,
   Valeria M.F./0000-0002-0954-5045
CR Alvar J, 2006, TRENDS PARASITOL, V22, P552, DOI 10.1016/j.pt.2006.09.004
   ANDRADE A. M., 2006, THESIS U ESTADUAL PA
   Andrade AM, 2007, REV SOC BRAS MED TRO, V40, P594, DOI 10.1590/S0037-86822007000500021
   Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53
   Braga M D, 1998, Rev Soc Bras Med Trop, V31, P419, DOI 10.1590/S0037-86821998000500001
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   CAMARGONEVES VLF, 2004, B EPI PAULISTA, V1, P1
   Costa Antonio I. P. Da, 1997, Revista de Saude Publica, V31, P632
   Costa C H, 2001, Rev Soc Bras Med Trop, V34, P223
   Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312
   Dantas-Torres Filipe, 2006, Rev. Inst. Med. trop. S. Paulo, V48, P151, DOI 10.1590/S0036-46652006000300007
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   DIETZE R, 1997, CLIN INFECT DIS, V25, P240
   Dye C, 1996, AM J TROP MED HYG, V55, P125, DOI 10.4269/ajtmh.1996.55.125
   *IBGE, 2007, I BRAS GEOGR EST MIN
   Kitala P, 2001, ACTA TROP, V78, P217, DOI 10.1016/S0001-706X(01)00082-1
   Lainson R, 2005, MEM I OSWALDO CRUZ, V100, P811, DOI 10.1590/S0074-02762005000800001
   LIMA VMF, 2003, PESQUI VET BRAZ, V25, P215
   Moreira ED, 2004, VET PARASITOL, V122, P245, DOI 10.1016/j.vetpar.2004.05.019
   Palatnik-de-Sousa CB, 2001, AM J TROP MED HYG, V65, P510, DOI 10.4269/ajtmh.2001.65.510
   PAULO S, 2007, SECR SAUD CTR VIG EP
   SAS Institute Inc, 1999, SAS ONLINEDOC VERS 8
NR 22
TC 67
Z9 69
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY 6
PY 2008
VL 153
IS 1-2
BP 19
EP 23
DI 10.1016/j.vetpar.2008.01.005
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 298DM
UT WOS:000255666600005
PM 18314275
DA 2020-12-08
ER

PT J
AU Massad, E
   Ma, S
   Burattini, MN
   Tun, Y
   Coutinho, FAB
   Ang, LW
AF Massad, Eduardo
   Ma, Stefan
   Burattini, Marcelo Nascimento
   Tun, Ye
   Coutinho, Francisco Antonio Bezerra
   Ang, Li Wei
TI The risk of chikungunya fever in a dengue-endemic area
SO JOURNAL OF TRAVEL MEDICINE
LA English
DT Article
ID THRESHOLD CONDITIONS; AEDES-AEGYPTI; YELLOW-FEVER; POPULATION-DYNAMICS;
   MOSQUITOS DIPTERA; SAO-PAULO; INFECTION; CULICIDAE; TRANSMISSION;
   VACCINATION
AB Background. Chikungunya, an alphavirus of the Togaviridae family, causes a febrile disease transmitted to humans by the bite of infected Aedes mosquitoes. This infection is reaching endemic levels in many Southeast Asian countries. Symptoms include sudden onset of fever, chills, headache, nausea, vomiting, joint pain with or without swelling, low back pain, and rash. According to the World Health Organization, there are 2 billion people living in Aedes-infested areas. In addition, traveling to these areas is popular, making the potential risk of infections transmitted by the bite of infected Aedes mosquitoes very high.
   Methods. We proposed a mathematical model to estimate the risk of acquiring chikungunya fever in an Aedes-infested area by taking the prevalence of dengue fever into account. The basic reproduction number for chikungunya fever R-0chik can be written as a function of the basic reproduction number of dengue R-0dengue by calculating the ratio R-0chik/R-0dengue. From R-0chik, we estimated the force of infection and the risk of acquiring the disease both for local residents of a dengue-endemic area and for travelers to this area.
   Results. We calculated that R-0chik is 64.4% that of R-0dengue. The model was applied to a hypothetical situation, namely, estimating the individual risk of acquiring chikungunya fever in a dengue-endemic area, both for local inhabitants (22% in steady state) and for visiting travelers (from 0.31% to 1.23% depending on the time spent in the area).
   Conclusions. The method proposed based on the output of a dynamical model is innovative and provided an estimation of the risk of infection, both for local inhabitants and for visiting travelers.
C1 [Massad, Eduardo; Burattini, Marcelo Nascimento; Coutinho, Francisco Antonio Bezerra] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   [Massad, Eduardo] Univ London, London Sch Hyg & Trop Med, London, England.
   [Ma, Stefan; Tun, Ye; Ang, Li Wei] Minist Hlth, Singapore, Singapore.
   [Massad, Eduardo] Natl Univ Singapore, Courage Fund Singapore, Singapore, Singapore.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, LIM 01-HCFMUSP,Rua Teodoro Sampaio,115,2nd Floor, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Massad, Eduardo/B-1169-2012;
   Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014
OI Coutinho, Francisco A B/0000-0003-3127-3071; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890;
   Ang, Li Wei/0000-0002-0036-255X
CR Abramowitz M., 1970, HDB MATH FUNCTIONS
   ANDERSON R M, 1991
   Bodenmann P, 2006, LANCET, V368, P258, DOI 10.1016/S0140-6736(06)69046-6
   Brownstin JS, 2003, J INVERTEBR PATHOL, V84, P24, DOI 10.1016/S0022-2011(03)00082-X
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   Canyon DV, 1999, B ENTOMOL RES, V89, P35, DOI 10.1017/S000748539900005X
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho FAB, 2005, MATH COMPUT SIMULAT, V70, P149, DOI 10.1016/j.matcom.2005.06.003
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   Dos Santos RL, 2004, J MED ENTOMOL, V41, P997
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P398, DOI 10.1590/S0034-89101993000600002
   GARRETJONES C, 1964, B WORLD HEALTH ORGAN, V30, P242
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   Hochedez P, 2006, EMERG INFECT DIS, V12, P1565, DOI 10.3201/eid1210.060495
   Hufnagel L, 2004, P NATL ACAD SCI USA, V101, P15124, DOI 10.1073/pnas.0308344101
   Kamath Sandhya, 2006, J Assoc Physicians India, V54, P725
   KAY BH, 1979, J MED ENTOMOL, V16, P59, DOI 10.1093/jmedent/16.1.59
   KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   LUMSDEN W. H. R., 1955, TANGANYIKA TERRITORY IN 1952 53 II TRANS ROY SOC TROP MED AND HYG, V49, P33, DOI 10.1016/0035-9203(55)90081-X
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES C, 1994, T R SOC TROP MED HYG, V88, P88
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 2005, VACCINE, V23, P3908, DOI 10.1016/j.vaccine.2005.03.002
   Massad E, 2003, REV SAUDE PUBL, V37, P477, DOI [10.1590/S0034-89102003000400013, 10.1590/s0034-89102003000400013]
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   *MIN HLTH SING, 2005, FIN REP EXP PAN DENG
   Mishra B, 2006, LANCET, V368, P918, DOI 10.1016/S0140-6736(06)69370-7
   Molineaux L, 1980, THE GARKI PROJECT
   Mourya DT, 2006, LANCET, V368, P186, DOI 10.1016/S0140-6736(06)69017-X
   MurraySmith S, 1996, AUST NZ J PUBL HEAL, V20, P545, DOI 10.1111/j.1467-842X.1996.tb01637.x
   Ocampo CB, 2004, AM J TROP MED HYG, V71, P506, DOI 10.4269/ajtmh.2004.71.506
   Parola P, 2006, EMERG INFECT DIS, V12, P1493, DOI 10.3201/eid1210.060610
   *WHO, CHIK DENG S W IND OC
   Wilder-Smith A, 2004, TROP MED INT HEALTH, V9, P305, DOI 10.1046/j.1365-3156.2003.01177.x
NR 35
TC 48
Z9 50
U1 0
U2 15
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1195-1982
EI 1708-8305
J9 J TRAVEL MED
JI J. Travel Med.
PD MAY-JUN
PY 2008
VL 15
IS 3
BP 147
EP 155
DI 10.1111/j.1708-8305.2008.00186.x
PG 9
WC Public, Environmental & Occupational Health; Infectious Diseases;
   Medicine, General & Internal
SC Public, Environmental & Occupational Health; Infectious Diseases;
   General & Internal Medicine
GA 304HZ
UT WOS:000256101900002
PM 18494691
OA Bronze
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Chen, M
   Chow, A
   Coutinho, FAB
   Goh, KT
   Lopez, LF
   Ma, S
   Massad, E
AF Burattini, M. N.
   Chen, M.
   Chow, A.
   Coutinho, F. A. B.
   Goh, K. T.
   Lopez, L. F.
   Ma, S.
   Massad, E.
TI Modelling the control strategies against dengue in Singapore
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID SAO-PAULO STATE; THRESHOLD CONDITIONS; POPULATION-DYNAMICS;
   YELLOW-FEVER; TRANSMISSION; INFECTION; EPIDEMIC; SYSTEM; BRAZIL; RISK
AB Notified cases of dengue infections in Singapore reached historical highs in 2004 (9459 cases) and 2005 (13 817 cases) and the reason for such all increase is still to be established. We apply a mathematical model for dengue infection that takes into account the seasonal variation in incidence, characteristic of dengue fever, and which mimics the 2004-2005 epidemics in Singapore. We simulated a set of possible control strategies and confirmed the intuitive belief that killing adult mosquitoes is the most effective strategy to control an ongoing epidemic. On the other hand, the control of immature forms was very efficient ill preventing the resurgence of dengue epidemics. Since the control of immature forms allows the reduction of adulticide, it seems that the best strategy is to combine both adulticide and larvicide control measures during an outbreak, followed by the maintenance of larvicide methods after the epidemic has subsided. In addition, the model showed that the mixed strategy of adulticide and larvicide methods introduced by the government seems to be very effective in reducing the number of cases in the first weeks after the start of control.
C1 [Burattini, M. N.; Coutinho, F. A. B.; Lopez, L. F.; Massad, E.] Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   [Chen, M.] Tan Tock Seng Hosp, Communicable Dis Ctr, Singapore, Singapore.
   [Chow, A.; Goh, K. T.; Ma, S.] Minist Hlth, Singapore, Singapore.
   [Massad, E.] Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, LIM 01-HCFMUSP,Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Chen, Mark/Q-5605-2019; Coutinho, Francisco A B/H-5644-2011; Lopez, Luis
   F/C-4721-2012; Massad, Eduardo/H-6143-2011; Burattini, Marcelo
   N/J-9272-2014; Massad, Eduardo/B-1169-2012
OI Chen, Mark/0000-0001-9369-5830; Coutinho, Francisco A
   B/0000-0003-3127-3071; Lopez, Luis F/0000-0003-4097-6887; Burattini,
   Marcelo N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916
FU LIM01/HCFMUSP; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); CNPqNational Council for Scientific and Technological
   Development (CNPq); Courage Fund
FX This work was supported by LIM01/HCFMUSP, FAPESP, CNPq and the Courage
   Fund.
CR Brownstin JS, 2003, J INVERTEBR PATHOL, V84, P24, DOI 10.1016/S0022-2011(03)00082-X
   Coutinho FAB, 2006, B MATH BIOL, V68, P2263, DOI 10.1007/s11538-006-9108-6
   Coutinho FAB, 2005, MATH COMPUT SIMULAT, V70, P149, DOI 10.1016/j.matcom.2005.06.003
   Forattini O. P., 1996, MED CULICIDOLOGY
   GOH KT, 1995, LANCET, V346, P1098, DOI 10.1016/S0140-6736(95)91771-3
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2003, REV SAUDE PUBL, V37, P477, DOI [10.1590/S0034-89102003000400013, 10.1590/s0034-89102003000400013]
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   *MIN HLTH SING, 2005, FIN REP EXP PAN DENG
   *MOH, 2005, MOH WEEKL INF DIS B, V1
   *NAT ENV AG, 2005, MIN ENV WAT RES SING
   NEWTON EAC, 1992, AM J TROP MED HYG, V47, P709, DOI 10.4269/ajtmh.1992.47.709
   Ocampo CB, 2004, AM J TROP MED HYG, V71, P506, DOI 10.4269/ajtmh.2004.71.506
   Ooi EE, 2006, EMERG INFECT DIS, V12, P887, DOI 10.3201/10.3201/eid1206.051210
   WHO. World Health Organization, 2002, DENG DENG HAEM FEV
   Wilder-Smith A, 2004, TROP MED INT HEALTH, V9, P305, DOI 10.1046/j.1365-3156.2003.01177.x
NR 20
TC 97
Z9 99
U1 3
U2 26
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD MAR
PY 2008
VL 136
IS 3
BP 309
EP 319
DI 10.1017/S0950268807008667
PG 11
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 348GF
UT WOS:000259198300003
PM 17540051
OA Green Accepted, Green Published
DA 2020-12-08
ER

PT S
AU Weiderpass, HA
   Yamamoto, JF
   Salomao, SR
   Berezovsky, A
   Pereira, JM
   Sacai, PY
   de Oliveira, JP
   Costa, MA
   Burattini, MN
AF Weiderpass, Heinar A.
   Yamamoto, Jorge F.
   Salomao, Solange R.
   Berezovsky, Adriana
   Pereira, Josenilson M.
   Sacai, Paula Y.
   de Oliveira, Jose Pedro
   Costa, Marcio A.
   Burattini, Marcelo N.
BE Sahiner, B
   Manning, DJ
TI Steady-state sweep visual evoked potential processing denoised by
   wavelet transform
SO MEDICAL IMAGING 2008: IMAGE PERCEPTION, OBSERVER PERFORMANCE, AND
   TECHNOLOGY ASSESSMENT
SE Proceedings of SPIE
LA English
DT Proceedings Paper
CT Medical Imaging 2008 Conference
CY FEB 17-19, 2008
CL San Diego, CA
SP SPIE, Amer Assoc Phys Med, Amer Physiol Soc, Comp Assisted Radiol & Surg, Soc Imaging Sci & Technol, Med Image Percept Soc, Radiol Soc N Amer, Soc Imaging Informat Med, Soc Mol Imaging, DICOM Standards Comm
DE visual acuity; visual evoked potential; wavelet filtering
ID INFANTS; ACUITY
AB Visually evoked potential (VEP) is a very small electrical signal originated in the visual cortex in response to periodic visual stimulation. Sweep-VEP is a modified VEP procedure used to measure grating visual acuity in non-verbal and preverbal patients. This biopotential is buried in a large amount of electroencephalographic (EEG) noise and movement related artifact. The signal-to-noise ratio (SNR) plays a dominant role in determining both systematic and statistic errors. The purpose of this study is to present a method based on wavelet transform technique for filtering and extracting steady-tate sweep-VEP. Counter-phase sine-wave luminance gratings modulated at 6 Hz were used as stimuli to determine sweep-VEP grating acuity thresholds. The amplitude and phase of the second-harmonic (12 Hz) pattern reversal response were analyzed using the fast Fourier transform after the wavelet filtering. The wavelet transform method was used to decompose the VEP signal into wavelet coefficients by a discrete wavelet analysis to determine which coefficients yield significant activity at the corresponding frequency. In a subsequent step only significant coefficients were considered and the remaining was set to zero allowing a reconstruction of the VEP signal. This procedure resulted in filtering out other frequencies that were considered noise. Numerical simulations and analyses of human VEP data showed that this method has provided higher SNR when compared with the classical recursive least squares (RLS) method. An additional advantage was a more appropriate phase analysis showing more realistic second-harmonic amplitude value during phase brake.
C1 [Weiderpass, Heinar A.] Univ Sao Paulo, Fac Med, BR-01246903 Sao Paulo, Brazil.
RP Weiderpass, HA (corresponding author), Univ Sao Paulo, Fac Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM heinar_weiderpass@terra.com.br
RI Berezovsky, Adriana/F-2341-2013; Salomao, Solange R/G-9500-2012;
   Burattini, Marcelo N/J-9272-2014; Sacai, Paula Y/B-6525-2014
OI Berezovsky, Adriana/0000-0001-6350-8221; Salomao, Solange
   R/0000-0002-3436-5599; Burattini, Marcelo N/0000-0002-5407-6890; 
CR Bach M, 1999, DOC OPHTHALMOL, V99, P69, DOI 10.1023/A:1002648202420
   Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011
   CIBIS GW, 1995, GRAEF ARCH CLIN EXP, V233, P605, DOI 10.1007/BF00185279
   da Costa MF, 2004, BEHAV BRAIN RES, V149, P145, DOI 10.1016/S0166-4328(03)00223-7
   Gottlob I, 1990, J Pediatr Ophthalmol Strabismus, V27, P40
   HERRMAN CS, 2005, TODD HANDY, P229
   Hoffman DR, 2003, J PEDIATR-US, V142, P669, DOI 10.1067/mpd.2003.213
   JAMPOLSKY A, 1994, J PEDIATR OPHTHALMOL, V31, P6
   Kochs E, 2001, ANESTHESIOLOGY, V95, P1141, DOI 10.1097/00000542-200111000-00018
   MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463
   Meigen T, 1999, DOC OPHTHALMOL, V98, P207, DOI 10.1023/A:1002097208337
   NORCIA AM, 1985, ELECTROEN CLIN NEURO, V61, P359, DOI 10.1016/0013-4694(85)91026-0
   NORCIA AM, 1991, INVEST OPHTH VIS SCI, V32, P436
   NORCIA AM, 1988, INVEST OPHTH VIS SCI, V29, P44
   PELI E, 1988, APPL OPTICS, V27, P1094, DOI 10.1364/AO.27.001094
   Quiroga RQ, 2001, BRAIN RES PROTOC, V8, P16, DOI 10.1016/S1385-299X(01)00077-0
   TANG Y, 1993, ELECTROEN CLIN NEURO, V88, P323, DOI 10.1016/0168-5597(93)90056-U
   TANG Y, 1995, EVOKED POTENTIAL, V96, P268, DOI 10.1016/0168-5597(94)00309-3
   TANG Y, 1995, MED BIOL ENG COMPUT, V33, P391, DOI 10.1007/BF02510521
   Till C, 2003, NEUROTOXICOLOGY, V24, P725, DOI 10.1016/S0161-813X(02)00212-7
   VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P
   Wang CT, 2003, IEEE T INSTRUM MEAS, V52, P1296, DOI 10.1109/TIM.2003.816807
NR 22
TC 0
Z9 0
U1 0
U2 4
PU SPIE-INT SOC OPTICAL ENGINEERING
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA
SN 0277-786X
EI 1996-756X
BN 978-0-8194-7101-7
J9 PROC SPIE
PY 2008
VL 6917
AR 69171A
DI 10.1117/12.770371
PG 11
WC Optics; Radiology, Nuclear Medicine & Medical Imaging
SC Optics; Radiology, Nuclear Medicine & Medical Imaging
GA BHT13
UT WOS:000256058800043
DA 2020-12-08
ER

PT J
AU De Almeida, GMD
   Costa, SF
   Melhem, M
   Motta, AL
   Szeszs, MW
   Miyashita, F
   Pierrotti, LC
   Rossi, F
   Burattini, MN
AF Duboc De Almeida, Gisele M.
   Costa, Silvia Figueiredo
   Melhem, Marcia
   Motta, Adriana L.
   Szeszs, Maria Walderez
   Miyashita, Fumiko
   Pierrotti, Ligia C.
   Rossi, Flavia
   Burattini, Marcelo N.
TI Rhodotorula spp. isolated from blood cultures: clinical and
   microbiological aspects
SO MEDICAL MYCOLOGY
LA English
DT Article; Proceedings Paper
CT 12th International Congress of Infectious Diseases
CY JUN 15-18, 2006
CL Lisbon, PORTUGAL
DE Rhodotorula; bloodstream infections; clinical characteristics;
   antifungal susceptibility testing
ID BONE-MARROW TRANSPLANTATION; CENTRAL VENOUS CATHETERS; BASIDIOMYCETOUS
   YEASTS; FUNGAL-INFECTIONS; RISK-FACTORS; FUNGEMIA; RUBRA; EPIDEMIOLOGY;
   SURVEILLANCE; PATHOGENS
AB The emergence of less common fungal pathogens has been increasingly reported in the last decade. We describe 25 cases of Rhodotorula spp. isolated from blood cultures at a large Brazilian tertiary teaching hospital from 1996-2004. We also investigated the in vitro activity of four antifungal drugs, using a standardized method. The median age of patients was 43 years. The majority of patients (88%) had a central venous catheter (CVC) and 10 (40%) were recipients of a bone marrow transplant. The episode was classified as a bloodstream infection (BSI) in 80% of the patients. Amphotericin B deoxycholate was the most common antifungal used and CVC was removed in 89.5% of the patients. Death occurred in four patients (17.4%), all classified as BSI. All strains were identified as R. mucilaginosa by conventional methods. Misidentification of the species was observed in 20% and 5% of the strains with the Vitek Yeast Biochemical Card and API 20C AUX systems, respectively. Amphotericin B demonstrated good in vitro activity (MIC50/90, 0.5 mu g/ml) and the MICs for fluconazole were high for all strains (MIC50/90, 64 mu g/ml).
C1 [Duboc De Almeida, Gisele M.; Motta, Adriana L.; Rossi, Flavia; Burattini, Marcelo N.] Univ Sao Paulo, Microbiol Lab, Div Cent Lab, LIM Dept Pathol 03, Sao Paulo, Brazil.
   [Costa, Silvia Figueiredo] Univ Sao Paulo, LIM Dept Infect Dis 54, Sao Paulo, Brazil.
   [Melhem, Marcia; Szeszs, Maria Walderez; Miyashita, Fumiko] Adolfo Lutz Inst, Sao Paulo, Brazil.
   [Pierrotti, Ligia C.] Univ Sao Paulo, Dept Infect Dis, Sao Paulo, Brazil.
RP De Almeida, GMD (corresponding author), Rua Inhambu 864, BR-04520013 Sao Paulo, Brazil.
EM gmduboc@hcnet.usp.br
RI MELHEM, MARCIA/D-4477-2012; Pierrotti, Ligia Camera/U-9225-2017;
   Pierrotti, Ligia/C-5804-2015; Burattini, Marcelo N/J-9272-2014; Costa,
   Silvia F/K-4768-2012; Motta, Adriana/B-7272-2013
OI MELHEM, MARCIA/0000-0002-1335-8808; Pierrotti, Ligia
   Camera/0000-0002-0216-3028; Burattini, Marcelo N/0000-0002-5407-6890;
   Costa, Silvia F/0000-0003-1087-752X; 
CR Ahmed A, 1998, Med Health R I, V81, P22
   Alliot C, 2000, CLIN ONCOL-UK, V12, P115
   Anatoliotaki Maria, 2003, Clin Lab, V49, P49
   Arvanitidou M, 1999, LETT APPL MICROBIOL, V29, P81, DOI 10.1046/j.1365-2672.1999.00583.x
   Bawazeer AM, 2003, CAN J OPHTHALMOL, V38, P225, DOI 10.1016/S0008-4182(03)80065-0
   Biswas SK, 2001, INT J SYST EVOL MICR, V51, P1191, DOI 10.1099/00207713-51-3-1191
   BRAUN DK, 1992, MYCOSES, V35, P305, DOI 10.1111/j.1439-0507.1992.tb00882.x
   Butinar L, 2005, FEMS MICROBIOL LETT, V244, P229, DOI 10.1016/j.femsle.2005.01.043
   *CBS, CBS YEAST DAT DAT IN
   CHAO TY, 1994, BONE MARROW TRANSPL, V14, P647
   Chung Jin-Won, 2002, Journal of Infection and Chemotherapy, V8, P109
   Colombo AL, 1997, BRAZ J INFECT DIS, V1, P204
   Colombo AL, 2006, J CLIN MICROBIOL, V44, P2816, DOI 10.1128/JCM.00773-06
   Cutrona Anthony F, 2002, Am J Orthop (Belle Mead NJ), V31, P137
   Diekema DJ, 2005, J CLIN MICROBIOL, V43, P476, DOI 10.1128/JCM.43.1.476-478.2005
   EISENBERG ES, 1983, AM J MED, V75, P349, DOI 10.1016/0002-9343(83)91216-0
   Erer B, 2000, BONE MARROW TRANSPL, V25, P745, DOI 10.1038/sj.bmt.1702231
   FELL JW, 2000, YEASTS TAXONOMIC STU, P800
   Fleming RV, 2002, INFECT DIS CLIN N AM, V16, P915, DOI 10.1016/S0891-5520(02)00041-7
   GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3
   GOLDANI LZ, 1995, J MED VET MYCOL, V33, P267
   HAZEN KC, 1995, CLIN MICROBIOL REV, V8, P462, DOI 10.1128/CMR.8.4.462
   Hsueh PR, 2003, J CLIN MICROBIOL, V41, P857, DOI 10.1128/JCM.41.2.857-859.2003
   KIEHN TE, 1992, CLIN INFECT DIS, V14, P841, DOI 10.1093/clinids/14.4.841
   KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009
   Kontoyiannis DP, 2004, SCAND J INFECT DIS, V36, P564, DOI 10.1080/00365540410017563
   Kovacicova G, 2001, SCAND J INFECT DIS, V33, P367, DOI 10.1080/003655401750174020
   Krcmery V, 1999, J HOSP INFECT, V41, P181, DOI [10.1016/S0195-6701(99)90042-7, 10.1016/S0195-6701(99)90015-4]
   Kwon-Chung K.J., 1992, MED MYCOL, P768
   Lanzafame H, 2001, J CLIN MICROBIOL, V39, P410, DOI 10.1128/JCM.39.1.410.2001
   Lo Re V, 2003, CLIN MICROBIOL INFEC, V9, P897, DOI 10.1046/j.1469-0691.2003.00641.x
   Lunardi LW, 2006, CLIN INFECT DIS, V43, pE60, DOI 10.1086/507036
   MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301
   Merkur AB, 2002, BRIT J OPHTHALMOL, V86, P1444, DOI 10.1136/bjo.86.12.1444
   MORRISON VA, 1993, MEDICINE, V72, P78, DOI 10.1097/00005792-199303000-00002
   *NAT COMM CLIN LAB, 2002, M27A2 NCCLS
   NAVEH Y, 1975, BRIT HEART J, V37, P101, DOI 10.1136/hrt.37.1.101
   Nowakowska D, 2004, J INFECTION, V48, P339, DOI 10.1016/j.jinf.2004.01.017
   Pasqualotto GC, 2005, J PEDIAT HEMATOL ONC, V27, P232, DOI 10.1097/01.mph.0000158970.27196.c5
   Perfect JR, 1996, CLIN INFECT DIS, V22, pS112, DOI 10.1093/clinids/22.Supplement_2.S112
   Perniola R, 2006, EUR J CLIN MICROBIOL, V25, P193, DOI 10.1007/s10096-006-0114-2
   Petrocheilou-Paschou V, 2001, CLIN MICROBIOL INFEC, V7, P100, DOI 10.1046/j.1469-0691.2001.00203.x
   Pfaller MA, 2004, J CLIN MICROBIOL, V42, P4419, DOI 10.1128/JCM.42.10.4419-4431.2004
   Safdar N, 2005, ANN INTERN MED, V142, P451, DOI 10.7326/0003-4819-142-6-200503150-00011
   Samonis G, 2001, INFECTION, V29, P173, DOI 10.1007/s15010-001-1066-1
   Serena C, 2004, ANTIMICROB AGENTS CH, V48, P2724, DOI 10.1128/AAC.48.7.2724-2726.2004
   Sheu Ming-Jia, 1994, Journal of the Formosan Medical Association, V93, P645
   Tortorano AM, 2004, EUR J CLIN MICROBIOL, V23, P317, DOI 10.1007/s10096-004-1103-y
   Trindade RC, 2002, SYST APPL MICROBIOL, V25, P294, DOI 10.1078/072320202320386488
   WARREN NG, 1999, MANUAL CLIN MICROBIO, P1184
   Wisplinghoff H, 2004, CLIN INFECT DIS, V39, P309, DOI 10.1086/421946
   Zaas AK, 2003, J CLIN MICROBIOL, V41, P5233, DOI 10.1128/JCM.41.11.5233-5235.2003
NR 52
TC 32
Z9 32
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1369-3786
EI 1460-2709
J9 MED MYCOL
JI Med. Mycol.
PY 2008
VL 46
IS 6
BP 547
EP 556
DI 10.1080/13693780801972490
PG 10
WC Infectious Diseases; Mycology; Veterinary Sciences
SC Infectious Diseases; Mycology; Veterinary Sciences
GA 345EP
UT WOS:000258979200004
PM 19180725
DA 2020-12-08
ER

PT J
AU Nunes, CM
   Burattini, MN
AF Nunes, Caris Maroni
   Burattini, Marcelo Nascimento
TI Elimination and replacement of canine reservoir in an area endemic for
   visceral leishmaniasis
SO REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL
LA Portuguese
DT Article; Proceedings Paper
CT 24th Annual Conference on Applied Research on Chagas Disease/12th Annual
   Conference on Applied Research in Leishmaniasis
CY OCT 23-25, 2008
CL Uberaba, BRAZIL
DE Visceral leishmaniasis; Culling; Canine replacement
ID BRAZIL; TRANSMISSION; IMPACT
AB This work reviews studies about dog culling in Brazilian endemic areas for visceral leishmaniasis, as well as studies on dog replacement after euthanasia in areas where it is indicated as a control measure for this zoonosis.
C1 [Nunes, Caris Maroni] Univ Estadual Paulista, Dept Apoio Prod & Saude Anim, Curso Med Vet, Aracatuba, SP, Brazil.
   [Burattini, Marcelo Nascimento] Univ Sao Paulo, Fac Med, Dept Patol, Sao Paulo, Brazil.
RP Nunes, CM (corresponding author), Rua Clovis Pestana, 793 Jd D Amelia, BR-16050680 Aracatuba, SP, Brazil.
EM caris@fmva.unesp.br
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR Andrade AM, 2007, REV SOC BRAS MED TRO, V40, P594, DOI 10.1590/S0037-86822007000500021
   Ashford DA, 1998, AM J TROP MED HYG, V59, P53, DOI 10.4269/ajtmh.1998.59.53
   CAMARGONEVES VLF, 2004, B EPIDEMIOLOGICO PAU, V1, P12
   Costa C H, 2001, Rev Soc Bras Med Trop, V34, P223
   COSTA CHN, 1990, REV SAUDE PUBL, V24, P361, DOI 10.1590/S0034-89101990000500003
   Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312
   Dietze R, 1997, CLIN INFECT DIS, V25, P1240, DOI 10.1086/516096
   Gontijo Célia Maria Ferreira, 2004, Rev. bras. epidemiol., V7, P338
   LAINSON R, 2005, MEMORIAS I OSWALDO C, V100, P117
   de Souza VMM, 2008, EPIDEMIOL SERV SAUDE, V17, P97
   Moreira ED, 2004, VET PARASITOL, V122, P245, DOI 10.1016/j.vetpar.2004.05.019
   Costa CHN, 2007, REV SOC BRAS MED TRO, V40, P415, DOI 10.1590/S0037-86822007000400009
   Nunes CM, 2008, VET PARASITOL, V153, P19, DOI 10.1016/j.vetpar.2008.01.005
   Palatnik-de-Sousa CB, 2001, AM J TROP MED HYG, V65, P510, DOI 10.4269/ajtmh.2001.65.510
NR 14
TC 0
Z9 0
U1 0
U2 2
PU SOC BRASILEIRA MEDICINA TROPICAL
PI BRASILIA
PA UNIV BRASILIA, NUCLEO MEDICINA TROPICAL E NUTRICAO, CAIXA POSTAL 4356,
   BRASILIA, DF 70919-970, BRAZIL
SN 0037-8682
J9 REV SOC BRAS MED TRO
JI Rev. Soc. Bras. Med. Trop.
PY 2008
VL 41
SU 3
BP 90
EP 91
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 521TD
UT WOS:000271946100021
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Rozman, MA
   Alves, IS
   Porto, MA
   Gomes, PO
   Ribeiro, NM
   Nogueira, LAA
   Caseiro, MM
   da Silva, VA
   Massad, E
   Burattini, MN
AF Rozman, Mauro Abrahao
   Alves, Igor Santino
   Porto, Marcela Alves
   Gomes, Patricia Oliveira
   Ribeiro, Nilva Maria
   Andrade Nogueira, Lucyene Aparecida
   Caseiro, Marcos Monteiro
   da Silva, Vera Aparecida
   Massad, Eduardo
   Burattini, Marcelo Nascimento
TI HIV and related infections in a sample of recyclable waste collectors of
   Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Letter
ID PARENTERAL TRANSMISSION; PRISONERS; HCV
C1 Univ Sao Paulo, Fac Med, Cent Lab, Hosp & Clin Dept Clin Pathol, BR-05403 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, BR-05405 Sao Paulo, Brazil.
   Univ London, London Sch Hyg & Trop Med, Dept Infect & Trop Med, London, England.
EM mnburaft@usp.br
RI Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916
CR Burattini MN, 2000, REV SAUDE PUBL, V34, P431, DOI 10.1590/S0034-89102000000500001
   Burattini MN, 2005, INT J STD AIDS, V16, P836, DOI 10.1258/095646205774988136
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   *MIN SAUD, 2005, B EP AIDST
   Strazza L, 2004, BRAZ J MED BIOL RES, V37, P771, DOI 10.1590/S0100-879X2004000500020
   Strazza L, 2007, CAD SAUDE PUBLICA, V23, P197, DOI 10.1590/S0102-311X2007000100021
   Zanetta DMT, 1999, INT J STD AIDS, V10, P98, DOI 10.1258/0956462991913718
   ZANIN M, METODOLOGIA INCUBACA
NR 8
TC 4
Z9 5
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD SEP
PY 2007
VL 18
IS 9
BP 653
EP 654
DI 10.1258/095646207781568574
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 209GA
UT WOS:000249375800024
PM 17785020
DA 2020-12-08
ER

PT J
AU Jukeniura, EM
   Burattini, MN
   Pereira, CAP
   Braga, ALF
   Medeiros, EAS
AF Jukeniura, Elisa M.
   Burattini, Marcelo N.
   Pereira, Carlos A. P.
   Braga, Alfesio L. F.
   Medeiros, Eduardo A. S.
TI Control of multi-resistant bacteria and ventilator-associated pneumonia:
   Is it possible with changes in antibiotics?
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE ventilator associated pneumonia; multi-resistant bacteria; infection
   control
ID ANTIMICROBIAL RESISTANCE; UNIT
AB Potent antimicrobial agents have been developed as a response to the development of antibiotic-resistant bacteria, which especially affect patients with prolonged hospitalization in Intensive Care Units (ICU) and who had been previously treated with antimicrobials, especially third-generation cephalosporins. This study was to determine how changes in the empirical treatment of infections in ICU patients affect the incidence of Gram-negative bacteria species and their susceptibility to antimicrobials, and examine the impact of these changes on nosocomial infections. A prospective interventional study was performed in a university hospital during two periods: 1) First period (September 1999 to February 2000); and 2) Second period (August 2000 to December 2000); empirical treatment was changed from ceftriaxone and/or ceftazidime in the first period to piperacillin/tazobactam in the second. ICU epidemiological and infection control rates, as well as bacterial isolates from upper airways were analyzed. Ceftazidime consumption dropped from 34.83 to 0.85 DDD/1000 patients per day (p=0.004). Piperacillin/tazobactam was originally not available; its consumption reached 157.07 DDD/1000 patients per day in the second period (p=0.0002). Eighty-seven patients and 66 patients were evaluated for upper airway colonization in the first and second periods, respectively. There was a significant decrease in the incidence of K. pneumoniae (p=0.004) and P mirabilis (p=0.036), restoration of K. pneumoniae susceptibility to cephalosporins (p<0.0001) and reduction of ventilator-associated pneumonia rates (p<0.0001). However, there was an increase in R aeruginosa incidence (p=0.005) and increases in ceftazidime (p=0.003) and meropenem (p<0.0001) susceptibilities. Changing antimicrobial selective pressure on multi-resistant Gram-negative bacteria helps control ventilator-associated pneumonia and decreases antimicrobial resistance.
C1 [Jukeniura, Elisa M.; Burattini, Marcelo N.; Pereira, Carlos A. P.; Medeiros, Eduardo A. S.] Univ Fed Sao Paulo, Sch Med, Dept Internal Med, Div Infect Dis, Sao Paulo, Brazil.
   [Braga, Alfesio L. F.] Univ Catolica Santos, Collect Hlth Posgrad Program, Sao Paulo, Brazil.
RP Jukeniura, EM (corresponding author), Rua Napoleao De Barros 690,2o Andar, BR-04024002 Sao Paulo, Brazil.
EM elisricardo@hotmail.com
RI Medeiros, Eduardo A/B-9825-2012; Burattini, Marcelo N/J-9272-2014;
   Braga, Alfesio/G-6920-2012
OI Medeiros, Eduardo A/0000-0002-6205-259X; Burattini, Marcelo
   N/0000-0002-5407-6890; Braga, Alfesio/0000-0003-3254-3029
CR Baquero F, 1998, CLIN INFECT DIS, V27, pS5, DOI 10.1086/514916
   Bernstein JM, 1999, CHEST, V115, p1S, DOI 10.1378/chest.115.suppl_1.1S
   EMORI TG, 1991, AM J INFECT CONTROL, V19, P19, DOI 10.1016/0196-6553(91)90157-8
   Flaherty JP, 1996, INFECT CONT HOSP EP, V17, P236
   Fridkin SK, 1999, CLIN INFECT DIS, V29, P245, DOI 10.1086/520193
   GALES AC, 1997, BRAZ J INFECT DIS, P196
   Gruson D, 2000, AM J RESP CRIT CARE, V162, P837, DOI 10.1164/ajrccm.162.3.9905050
   Jukemura EM, 2000, INFECT CONT HOSP EP, V21, P95
   Kollef MH, 1997, AM J RESP CRIT CARE, V156, P1040, DOI 10.1164/ajrccm.156.4.9701046
   Martins ST, 2004, MEM I OSWALDO CRUZ, V99, P331, DOI 10.1590/S0074-02762004000300017
   MEYER KS, 1993, ANN INTERN MED, V119, P353, DOI 10.7326/0003-4819-119-5-199309010-00001
   National Committee for Clinical Laboratory Standards (NCCLS), 2001, M100S11 NCCLS
   Patterson JE, 2000, INFECT CONT HOSP EP, V21, P455, DOI 10.1086/501787
   Pitout JDD, 1997, AM J MED, V103, P51, DOI 10.1016/S0002-9343(97)00044-2
   Rahal JJ, 1998, JAMA-J AM MED ASSOC, V280, P1233, DOI 10.1001/jama.280.14.1233
   Smith DW, 1999, PHARMACOTHERAPY, V19, p129S, DOI 10.1592/phco.19.12.129S.31584
   Troillet N, 1997, CLIN INFECT DIS, V25, P1094, DOI 10.1086/516092
   WHO Collaborating Centre for Drug Statistics Methodology, 2000, AN THER CHEM ATC CLA
NR 18
TC 3
Z9 4
U1 0
U2 2
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD AUG
PY 2007
VL 11
IS 4
BP 418
EP 422
DI 10.1590/S1413-86702007000400010
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 279XL
UT WOS:000254388600010
PM 17873997
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Mendes, ME
   Sumita, NM
   Novais, RC
   Lavorato, LM
   Domingos, PC
   Romano, P
   Burattini, MN
AF Mendes, M. E.
   Sumita, N. M.
   Novais, R. C.
   Lavorato, L. M.
   Domingos, P. C.
   Romano, P.
   Burattini, M. N.
TI Critical analysis of an automated chemistry analyzer system performance
   in the clinical laboratory of a public university hospital
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 59th Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 15-19, 2007
CL San Diego, CA
SP Amer Assoc Clin Chem
C1 Univ Sao Paulo, Hosp & Clin, Fac Med, Cent Lab Div,Labs Med Invest, Sao Paulo, Brazil.
RI Mendes, Maria E/B-4207-2015; Burattini, Marcelo N/J-9272-2014
OI Mendes, Maria E/0000-0001-9835-8761; Burattini, Marcelo
   N/0000-0002-5407-6890
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2007
VL 53
IS 6
SU S
MA D145
BP A206
EP A206
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 172ZJ
UT WOS:000246843000643
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
AF Lopez, L. F.
   Coutinho, Francisco A. B.
   Burattini, Marcelo N.
   Massad, Eduardo
TI A schematic age-structured compartment model of the impact of
   antiretroviral on HIV incidence and prevalence (vol 71, pg 131, 2006)
SO MATHEMATICS AND COMPUTERS IN SIMULATION
LA English
DT Correction
C1 Univ Sao Paulo, BR-05405000 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Rua Teodoro Sampaio 155, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Lopez, Luis F/C-4721-2012; Massad,
   Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; Lopez, Luis F/0000-0003-4097-6887; 
CR Lopez LF, 2006, MATH COMPUT SIMULAT, V71, P131, DOI 10.1016/j.matcom.2006.01.004
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4754
J9 MATH COMPUT SIMULAT
JI Math. Comput. Simul.
PD FEB 6
PY 2007
VL 73
IS 6
BP 408
EP 408
DI 10.1016/j.matcom.2006.09.001
PG 1
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 132HG
UT WOS:000243933300006
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
AF Lopez, L. F.
   Coutinho, F. A. B.
   Burattini, M. N.
   Massad, E.
TI A schematic age-structured compartment model of the impact of
   antiretroviral therapy on HIV incidence and prevalence (vol 71, pg 131,
   2006)
SO MATHEMATICS AND COMPUTERS IN SIMULATION
LA English
DT Correction
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, HCFMUSP, LIM01, BR-01246903 Sao Paulo, Brazil.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Massad,
   Eduardo/H-6143-2011; Coutinho, Francisco A B/H-5644-2011; Massad,
   Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Lopez, Luis
   F/0000-0003-4097-6887; Coutinho, Francisco A B/0000-0003-3127-3071;
   Massad, Eduardo/0000-0002-7200-2916
CR Lopez LF, 2006, MATH COMPUT SIMULAT, V71, P131, DOI 10.1016/j.matcom.2006.01.004
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4754
J9 MATH COMPUT SIMULAT
JI Math. Comput. Simul.
PD JAN 10
PY 2007
VL 73
IS 5
BP 341
EP 341
DI 10.1016/j.matcom.2006.05.001
PG 1
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 127NA
UT WOS:000243591800007
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
AF Massad, Eduardo
   Burattini, Marcelo Nascimento
   Coutinho, Francisco Antonio Bezerra
   Lopez, Luiz Fernandes
TI The 1918 influenza A epidemic in the city of Sao Paulo, Brazil
SO MEDICAL HYPOTHESES
LA English
DT Article
AB The 1918 pandernic H1N1 outbreak in the city of Sao Paulo is revisited. The outbreak lasted for 10 weeks and reached 116,771 officially recorded cases amongst 523,194 inhabitants. The total number of deaths summed up to 5331, with a letality rate of 4.5% and an overall mortality rate of around 1%. We propose a mathematical model that tallies available data with good accuracy and allows the estimation of the basic reproductive number, R-0. The model showed a remarkably good accuracy in retrieving the real data from Sao Paulo city outbreak considering the total number of recorded cases and deaths and the timing of the outbreak. The basic reproduction number calculated of 2.68 can be compared to estimates carried out for other flu strains, like the estimates for H3N2, whose values ranged from 1.5 to 2.5.
   We hypothesize that the Southern parts of the world in which there was relatively little impact of the Great War, like South America, suffered a much tower H1N1 influenza mortality as compared with that reported for the Northern hemisphere heavily affected by the I World War. (c) 2006 Elsevier Ltd. All. rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-05405000 Sao Paulo, Brazil.
   HCFMUSP, LIM01, BR-05405000 Sao Paulo, Brazil.
   London Sch Hyg & Trop Med, London WC1, England.
   HCFMUSP, LIM47, BR-05405000 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Rua Teodoro Sampaio 115, BR-05405000 Sao Paulo, Brazil.
EM edmassad@usp.brb
RI Massad, Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012; Coutinho,
   Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/H-6143-2011
OI Massad, Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; 
CR ANDERSON R M, 1991
   CROSBY AW, 1993, INFLUENZA CAMBRIDGE
   FILHO CB, 2003, GRIPE ESPANHOLA SAO, P393
   Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254
   LONGINI IM, 1978, MATH BIOSCI, V38, P141, DOI 10.1016/0025-5564(78)90023-8
   Longini IM, 2005, AM J EPIDEMIOL, V161, P303, DOI 10.1093/aje/kwi053
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   NICHOLSON KG, 1998, TXB INFLUENZA
   O'Neill PD, 2001, J R STAT SOC C-APPL, V50, P283
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   TEIXEIRA AL, 2003, HIST CIENC SAUDE-MAN, V10, P757
NR 12
TC 40
Z9 40
U1 0
U2 4
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2007
VL 68
IS 2
BP 442
EP 445
DI 10.1016/j.mehy.2006.07.041
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 126WI
UT WOS:000243545800040
PM 17011139
DA 2020-12-08
ER

PT J
AU Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Massad, E
AF Coutinho, F. A. B.
   Burattini, M. N.
   Lopez, L. F.
   Massad, E.
TI Threshold conditions for a non-autonomous epidemic system describing the
   population dynamics of dengue
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE dengue; vector-borne; Aedes aegypti; Aedes albopictus; overwinter;
   vertical transmission; modeling; non-autonomous systems
ID MOSQUITOS; PERSISTENCE; GENERATIONS; BRAZIL; VIRUS
AB A non-autonomous dynamical system, in which the seasonal variation of a mosquito vector population is modeled, is proposed to investigate dengue overwintering. A time-dependent threshold, R(t), is deduced such that when its yearly average, denoted by (R) over bar, is less than 1, the disease does not invade the populations and when (R) over bar is greater than 1 it does. By not invading the population we mean that the number of infected individuals always decrease in subsequent seasons of transmission. Using the same threshold, all the qualitative features of the resulting epidemic can be understood. Our model suggests that trans-ovarial infection in the mosquitoes facilitates dengue overwintering. We also explain the delay between the peak in the mosquitoes population and the peak in dengue cases.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIM01, BR-01246903 Sao Paulo, Brazil.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011; Burattini,
   Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Coutinho, Francisco A
   B/H-5644-2011
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Lopez, Luis F/0000-0003-4097-6887; Coutinho,
   Francisco A B/0000-0003-3127-3071
CR BANCROFT TL, 1906, AUSTRALAS MED GAZ, V25, P17
   Beaty B.J., 1996, BIOL DIS VECTORS
   Crochu S, 2004, J GEN VIROL, V85, P1971, DOI 10.1099/vir.0.79850-0
   ELSGOLTS EL, 1966, INTRO THEORY DIFFERE
   FORATTINI OP, 1995, REV SAUDE PUBL, V29, P199, DOI 10.1590/S0034-89101995000300007
   FORATTINI OP, 2002, MED CULICIDOLOGY EDU
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Joshi V, 2002, AM J TROP MED HYG, V67, P158, DOI 10.4269/ajtmh.2002.67.158
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Luz PM, 2003, MEM I OSWALDO CRUZ, V98, P871, DOI 10.1590/S0074-02762003000700002
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   MONATH TP, 1996, VIROLOGY, P961
   RODAHIN F, 1997, DENGUE DENGUE HEMORR
   SHROYER DA, 1990, J AM MOSQUITO CONTR, V6, P312
NR 15
TC 87
Z9 89
U1 1
U2 35
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD NOV
PY 2006
VL 68
IS 8
BP 2263
EP 2282
DI 10.1007/s11538-006-9108-6
PG 20
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 102FQ
UT WOS:000241796800018
PM 16952019
DA 2020-12-08
ER

PT J
AU Mendics, ME
   Sumita, NM
   Novaes, RC
   Lavorato, LM
   Guimaraes, LA
   Burattini, MN
AF Mendics, M. E.
   Sumita, N. M.
   Novaes, R. C.
   Lavorato, L. M.
   Guimaraes, L. A.
   Burattini, M. N.
TI Performance of blood gas analyzers in An University Hospital Medical
   Laboratory through a set of maintenance indicators
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 58th Annual Meeting of the American-Association-of-Clinical-Chemistry
CY JUL 23-27, 2006
CL Chicago, IL
SP Amer Assoc Clin Chem
C1 Univ Sao Paulo, Hosp Clin, Fac Med, Cent Lab Div, BR-05508 Sao Paulo, Brazil.
   Univ Sao Paulo, Hosp Clin, Fac Med, Labs Med Invest,LIM 03, BR-05508 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2006
VL 52
IS 6
SU S
MA C11
BP A82
EP A82
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 048CT
UT WOS:000237925900253
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
AF Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
TI A schematic age-structured compartment model of the impact of
   antiretroviral therapy on HIV incidence and prevalence
SO MATHEMATICS AND COMPUTERS IN SIMULATION
LA English
DT Article
DE HAART; deterministic model; Brazil
ID IMMUNODEFICIENCY-VIRUS TYPE-1; NATURAL-HISTORY; TRANSMISSION; INFECTION;
   PROBABILITY; PROGRAMS; PLASMA; RISK
AB A simple deterministic model is proposed to represent the basic aspects concerning the effects of different antiretroviral treatment schedules on HIV incidence and prevalence of affected populations. The model mimics current treatment guidelines applied in Brazil. However, the model does not intend to fit the data with any acceptable degree of accuracy since uncertainties on the values of the parameters and on the precise effect of the treatment put some limits on the practical implications of our model from which only orders of magnitude and some qualitative effects can be deduced. So, this paper intends to provide a conceptual and mechanistic understanding of the possible long-term effects of treatment on the dynamics of HIV transmission.
   According to the model, the effect of the treatment depends on the level of sexual activity of the subpopulations considered, being more pronounced on the subpopulations with the highest sexual activity levels. Also, inefficient treatment can be prejudicial depending on the level of sexual activity and on the capacity to provide adequate treatment coverages to the population affected. (c) 2006 IMACS. Published by Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, BR-01246903 Sao Paulo, Brazil.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/H-6143-2011; Coutinho, Francisco A B/H-5644-2011;
   Massad, Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012; Burattini,
   Marcelo N/J-9272-2014
OI Coutinho, Francisco A B/0000-0003-3127-3071; Massad,
   Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Burattini, Marcelo N/0000-0002-5407-6890
CR Amaku M, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051907
   ANDERSON RM, 1991, NATURE, V350, P356, DOI 10.1038/350356a0
   ANDERSON RM, 1988, TROP GEOG MED S, V3, pS30
   Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650
   CARLINI EA, 2002, LEVANTAMENTO DOMICIL, P299
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   Coutinho FAB, 1999, REV SAUDE PUBL, V33, P329, DOI 10.1590/S0034-89101999000400002
   Coutinho FAB, 2001, B MATH BIOL, V63, P1041, DOI 10.1006/bulm.2001.0257
   Coutinho FAB, 1999, MATH COMPUT MODEL, V30, P97, DOI 10.1016/S0895-7177(99)00119-3
   Craib KJP, 2000, AIDS, V14, P303, DOI 10.1097/00002030-200002180-00013
   deCarvalho HB, 1996, J ACQ IMMUN DEF SYND, V12, P84, DOI 10.1097/00042560-199605010-00012
   ERB P, 1994, J ACQ IMMUN DEF SYND, V7, P261
   Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2
   HANNA GJ, 2000, PRINCIPLES PRACTICE, P1479
   Levin BR, 1996, MATH BIOSCI, V132, P69, DOI 10.1016/0025-5564(95)00053-4
   Lopez LF, 2000, J MATH BIOL, V40, P199, DOI 10.1007/s002850050178
   Massad E, 2002, INT J STD AIDS, V13, P430, DOI 10.1258/095646202760029895
   MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Oxman GL, 1996, SEX TRANSM DIS, V23, P30, DOI 10.1097/00007435-199601000-00008
   Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   SZTERENFELD C, 1995, AIDS STD HLTH PROMOT, V4, P8
   Szwarcwald C L, 2000, Cad Saude Publica, V16, P113
   VELLA S, 2000, HIV 1 COPY NUMBER IN
NR 27
TC 4
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4754
EI 1872-7166
J9 MATH COMPUT SIMULAT
JI Math. Comput. Simul.
PD APR 11
PY 2006
VL 71
IS 2
BP 131
EP 148
DI 10.1016/j.matcom.2006.01.004
PG 18
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 030YN
UT WOS:000236671400005
DA 2020-12-08
ER

PT B
AU Coutinho, FAB
   Massad, E
   Lopez, LF
   Burattini, MN
AF Coutinho, Francisco A. B.
   Massad, Eduardo
   Lopez, Luiz F.
   Burattini, Marcelo N.
BE Mondaini, R
   Dilao, R
TI Modeling plague dynamics Endemic states, outbreaks and epidemic waves
SO BIOMAT 2005
LA English
DT Proceedings Paper
CT International Symposium on Mathematical and Computational Biology
   (BIOMAT 2005)
CY DEC 03-08, 2005
CL Petropolis, BRAZIL
SP CAPES, FINEP, Natl Lab Sci Comp
AB This paper is intended to contribute to the understanding of plague dynamics through a mathematical modelling of its natural history. Plague is a very complex system, comprising up to three type of hosts and two vectors. This implies in a multicompartment system with several (73 in our model) parameters, few of each have been measured. Therefore, we used reasonable values for those less known parameters and studied the behaviour of the system. The model was applied to describe two distinct epidemiological scenarios; one epidemic outbreak of short duration (Florence, 1348), and one endemic state (Viet Nam, present day).
C1 [Coutinho, Francisco A. B.; Massad, Eduardo; Lopez, Luiz F.; Burattini, Marcelo N.] Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
   [Massad, Eduardo] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London, England.
RP Coutinho, FAB (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Lopez, Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Mondaini, Rubem/G-7767-2014; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011
OI Lopez, Luis F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916;
   Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890; 
CR BARNETT SA, 2001, STORY RATS
   Beesley WN, 1998, ZOONOSES, P873
   Butler T, 1983, PLAGUE OTHER YERSINI
   Butler T, 2000, PRINCIPLES PRACTICE, P2406
   CAMPBELL GL, 1997, HARRISONS PRINCIPLES, P975
   DEFOE D, 1969, J PLAGUE YEAR
   DENNIS DT, 1999, TROPICAL INFECT DIS, P506
   Frean JA, 1996, ANTIMICROB AGENTS CH, V40, P2646, DOI 10.1128/AAC.40.11.2646
   Gratz N., 1994, RODENT PESTS THEIR C
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Lopez LF, 1999, MATH COMPUT MODEL, V29, P55, DOI 10.1016/S0895-7177(99)00062-X
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2001, THEOR POPUL BIOL, V60, P265, DOI 10.1006/tpbi.2000.1494
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Moore J., 2002, PARASITES BEHAV ANIM
   Murray J. D., 1993, MATH BIOL
   Politzer R., 1954, WHO MONOGRAPH SERIES, V22
   SERVICE NW, 1986, LECT NOTES MED ENTOM
   SLACK P, 1989, T ROY SOC TROP MED H, V83, P461, DOI 10.1016/0035-9203(89)90247-2
   SMITH MD, 1996, MANSONS TROPICAL DIS, P918
   ZIEGLER P, 1984, BLACK DEATH
NR 21
TC 1
Z9 1
U1 0
U2 3
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE
BN 978-981-256-797-0
PY 2006
BP 213
EP 230
DI 10.1142/9789812773685_0013
PG 18
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA BGE68
UT WOS:000246340600013
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
TI The impact of imperfect vaccines on the evolution of HIV virulence
SO MEDICAL HYPOTHESES
LA English
DT Article
ID INFECTION
AB A theoretical framework is proposed on which some hypotheses related to the impact of imperfect vaccines on the evolution of HIV virulence can be tested. For this, a linear increase of risk behaviour with vaccine efficacy is assumed. This is based on the hypothesis that people are prone to relax preventive measures by knowing that they and their partners are vaccinated and that this effect is more intense the more effective the vaccine is known to be. An additional, and perhaps more important hypothesis is related to the theoretical possibility that increased risk behaviour of some vaccinated individuals in partially protected populations could act as a selective pressure toward more virulent HIV strains. Those hypotheses were tested by a mathematical model that considers three different HIV strains competing against each other in a population partially protected by imperfect vaccines of distinct efficacies. Simulations of the model demonstrated that, under the above hypotheses, there is a shift in HIV virulence towards more aggressive strains with increase in vaccine efficacy, associated with a marked reduction in the total amount of transmission and, consequently, in the prevalence of HIV. Potential ways for further testing the theory/model and the implications of the results are discussed. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, LIM 01, HCFMUSP, BR-01246903 Sao Paulo, Brazil.
   Univ London, London Sch Hyg & Trop Med, London, England.
   Fiocruz MS, Fundacao Oswaldo Cruz, Program Sci Computat, BR-21045900 Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/H-6143-2011; Lopez, Luis F/C-4721-2012; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho, Francisco
   A B/H-5644-2011; Struchiner, Claudio J/M-9360-2013
OI Lopez, Luis F/0000-0003-4097-6887; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071; Struchiner, Claudio
   J/0000-0003-2114-847X
CR Blower S, 2002, QUANTIATIVE EVALUATION OF HIV PREVENTION PROGRAMS, P260
   BREMERMANN HJ, 1989, J MATH BIOL, V27, P179, DOI 10.1007/BF00276102
   Buchbinder S., 1999, IAVI REPORT, V4, P9
   Chesney MA, 1997, J ACQ IMMUN DEF SYND, V16, P266, DOI 10.1097/00042560-199712010-00007
   Coutinho FAB, 1999, REV SAUDE PUBL, V33, P329, DOI 10.1590/S0034-89101999000400002
   Gumel A.B., 2004, COMMUN NONLINEAR SCI, V9, P649, DOI DOI 10.1016/S1007-5704(03)00024-8
   Massad E, 1996, EVOLUTION, V50, P916, DOI [10.2307/2410863, 10.1111/j.1558-5646.1996.tb03900.x]
   Massad E, 2001, MATH COMPUT MODEL, V34, P345, DOI 10.1016/S0895-7177(01)00066-8
   *UNAIDS, 2004, UN JOINT PROGR HIV A
NR 9
TC 4
Z9 4
U1 0
U2 5
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2006
VL 66
IS 5
BP 907
EP 911
DI 10.1016/j.mehy.2005.11.042
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 028BA
UT WOS:000236459100006
PM 16442745
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Strazza, L
   Paoliello, AA
   de Carvalho, HB
   de Azevedo, RS
   Coutinho, FAB
   Massad, E
AF Burattini, MN
   Strazza, L
   Paoliello, AA
   de Carvalho, HB
   de Azevedo, RS
   Coutinho, FAB
   Massad, E
TI The change from intravenous to crack cocaine and its impact on reducing
   HIV incidence in Brazilian prisons
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Letter
ID PARENTERAL TRANSMISSION; HIV/AIDS; HCV
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIM 01, BR-01246903 Sao Paulo, Brazil.
   Univ London, London Sch Hyg & Trop Med, London WC1E 7HU, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Azevedo, Raymundo S/B-7593-2008; Massad, Eduardo/H-6143-2011; Carvalho,
   Heraclito/C-1334-2012; Coutinho, Francisco A B/H-5644-2011; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014
OI Azevedo, Raymundo S/0000-0003-0660-2371; Carvalho,
   Heraclito/0000-0002-7037-5655; Coutinho, Francisco A
   B/0000-0003-3127-3071; Massad, Eduardo/0000-0002-7200-2916; Burattini,
   Marcelo N/0000-0002-5407-6890
CR Burattini MN, 2000, REV SAUDE PUBL, V34, P431, DOI 10.1590/S0034-89102000000500001
   Burattini MN, 1998, MATH COMPUT MODEL, V28, P21, DOI 10.1016/S0895-7177(98)00095-8
   Lopes F, 2001, Cad Saude Publica, V17, P1473, DOI 10.1590/S0102-311X2001000600031
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   Rozman M, 1998, INT J STD AIDS, V9, P183, DOI 10.1258/0956462981921855
   Strazza L, 2004, BRAZ J MED BIOL RES, V37, P771, DOI 10.1590/S0100-879X2004000500020
NR 6
TC 7
Z9 9
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD DEC
PY 2005
VL 16
IS 12
BP 836
EP 837
DI 10.1258/095646205774988136
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 994NK
UT WOS:000234038300019
PM 16336774
DA 2020-12-08
ER

PT J
AU Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Massad, E
AF Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Massad, E
TI An approximate threshold condition for non-autonomous system: An
   application to a vector-borne infection
SO MATHEMATICS AND COMPUTERS IN SIMULATION
LA English
DT Article
DE non-autonomous systems; stability analysis; thresholds; dengue;
   epidemics
AB A non-autonomous system is proposed to model the seasonal pattern of dengue fever. We found that an approximate threshold condition for infection persistence describes all possible behaviors of the system.
   As far as we know, the kind of analysis here proposed is entirely new. No precise mathematical theorems are demonstrated but we give enough numerical evidence to support the conclusions. (c) 2005 IMACS. Published by Elsevier B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIM 01, BR-01246903 Sao Paulo, Brazil.
   Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Lopez, Luis F/C-4721-2012; Massad, Eduardo/H-6143-2011; Coutinho,
   Francisco A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Lopez, Luis F/0000-0003-4097-6887; Coutinho, Francisco A
   B/0000-0003-3127-3071; Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916
CR COUTINHO FAB, 2004, UNPUB B MATH BIOL
   ELSGOLTS EL, 1966, INTRO THEORY DIFFERE
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
NR 4
TC 27
Z9 29
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-4754
EI 1872-7166
J9 MATH COMPUT SIMULAT
JI Math. Comput. Simul.
PD NOV 8
PY 2005
VL 70
IS 3
BP 149
EP 158
DI 10.1016/j.matcom.2005.06.003
PG 10
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 982YV
UT WOS:000233199200002
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
TI Yellow fever vaccination: How much is enough?
SO VACCINE
LA English
DT Article
DE yellow fever; vaccination; adverse events
ID ADVANCED AGE; RISK-FACTOR; DENGUE; PERSISTENCE
AB In recent years, a growing number of serious adverse events (including deaths) associated with the yellow fever (YF) vaccine has been reported. If YF vaccination were incorporated in routine programs, administered to children, the risk of deaths from this vaccine would be minimized provided that mortality of children vaccinated below I year were negligible. However, in affected areas the vaccine is administered to all age groups. This poses a dilemma to public health authorities - what proportion of a population subject to low risk of YF outbreaks should be vaccinated in order to minimize the total number of serious adverse events (including deaths) due both to natural infection and vaccination? In other words, how much vaccination is safe?
   Our results suggest that, depending on the age-specific rates of developing vaccine-induced serious adverse events and the risk of yellow fever outbreaks, the optimum proportion to vaccinate may be lower than the proportion that would prevent an epidemics or even be zero. We also show that the vaccine should not be applied to individuals older than 60 years of age because the risk of serious adverse events (including deaths) is higher for that age class. Our work is instrumental to the discussion on the optimum strategy to vaccinate affected populations against yellow fever.
   Therefore, the aim of this work is to estimate the optimum proportion to vaccinate against YF taking into account the risks of serious adverse events associated with both the vaccine and natural infection. (c) 2005 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, BR-01246903 Sao Paulo, Brazil.
   Univ London, London Sch Hyg & Trop Med, London, England.
   Fiocruz MS, Fdn Oswaldo Cruz, Program Sci Computat, BR-21045900 Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo,455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Lopez, Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012; Struchiner,
   Claudio J/M-9360-2013; Massad, Eduardo/H-6143-2011; Coutinho, Francisco
   A B/H-5644-2011; Burattini, Marcelo N/J-9272-2014
OI Lopez, Luis F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916;
   Struchiner, Claudio J/0000-0003-2114-847X; Coutinho, Francisco A
   B/0000-0003-3127-3071; Burattini, Marcelo N/0000-0002-5407-6890
CR ANDERSON R M, 1991
   Bauch CT, 2003, P NATL ACAD SCI USA, V100, P10564, DOI 10.1073/pnas.1731324100
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P989
   Chan RC, 2001, LANCET, V358, P121, DOI 10.1016/S0140-6736(01)05341-7
   Codeco CT, 2004, T ROY SOC TROP MED H, V98, P702, DOI 10.1016/j.trstmh.2003.12.019
   Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103
   Gubler D, 1997, DENGUE DENGUE HEMORR
   Gubler DJ, 2004, COMP IMMUNOL MICROB, V27, P319, DOI 10.1016/j.cimid.2004.03.013
   Khromava AY, 2005, VACCINE, V23, P3256, DOI 10.1016/j.vaccine.2005.01.089
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Martin M, 2001, EMERG INFECT DIS, V7, P945, DOI 10.3201/eid0706.010605
   Martin M, 2001, LANCET, V358, P98, DOI 10.1016/S0140-6736(01)05327-2
   Massad E, 2003, REV SAUDE PUBL, V37, P477, DOI [10.1590/S0034-89102003000400013, 10.1590/s0034-89102003000400013]
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Monath T. P., 1990, Tropical and geographical medicine., P661
   Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   STRUCHINER CJ, 2004, EPIDEMIOL INFECT
   Vasconcelos PFC, 2001, LANCET, V358, P91, DOI 10.1016/S0140-6736(01)05326-0
NR 20
TC 36
Z9 36
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD JUN 10
PY 2005
VL 23
IS 30
BP 3908
EP 3914
DI 10.1016/j.vaccine.2005.03.002
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 936GR
UT WOS:000229844000006
PM 15917112
DA 2020-12-08
ER

PT J
AU Cunha, RMD
   Kallas, EG
   Rodrigues, DS
   Burattini, MN
   Salomao, R
AF Cunha, RMD
   Kallas, EG
   Rodrigues, DS
   Burattini, MN
   Salomao, R
TI Interferon-gamma and tumour necrosis factor-alpha production by CD4(+)T
   and CD8(+)T lymphocytes in AIDS patients with tuberculosis
SO CLINICAL AND EXPERIMENTAL IMMUNOLOGY
LA English
DT Article
DE AIDS; cytokines; tuberculosis
ID IMMUNODEFICIENCY-VIRUS-INFECTION; BACILLUS-CALMETTE-GUERIN;
   MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; T-CELLS; CYTOKINE
   RESPONSES; IMMUNE ACTIVATION; HIV REPLICATION; IN-VITRO; PROTECTION
AB Tuberculosis (TB) is usually more severe in HIV-infected patients, and the immune derangement found in co-infected patients may differ from that in each isolated disease. Following mitogen stimulation of peripheral blood mononuclear cells (PBMC), interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha production was evaluated in T cells by flow cytometry, and in culture supernatants by enzyme-linked immunosorbent assay (ELISA) in 33 individuals: 11 AIDS patients with tuberculosis, six asymptomatic HIV-1-infected patients, eight patients with tuberculosis and eight healthy controls. The proportion of CD4(+) T lymphocytes expressing IFN-gamma did not differ between the groups, whereas a trend towards increased proportions of TNF-alpha-expression in CD4(+) T cells was observed in the TB compared to the HIV group, while intermediate values were observed in co-infected patients. Detection of IFN-gamma and TNF-alpha in CD8(+) T lymphocytes was higher in TB than in HIV individuals. Co-infected patients presented intermediate values for IFN-gamma, while TNF-alpha detection was similar to that in HIV mono-infection. In conclusion, the proportion of T cells expressing IFN-gamma was relatively preserved in co-infected patients compared to TB patients, while the percentage of T cells expressing TNF-alpha was decreased, mainly in CD8(+) T lymphocytes. However, the marked reduction in T lymphocyte numbers in co-infected patients led to a striking reduction of both cytokines in PBMC supernatants, a finding that is consistent with the impaired response to Mycobacterium tuberculosis.
C1 Univ Fed Sao Paulo, UNIFESP, Div Infect Dis, Immunol Lab, BR-04039032 Sao Paulo, Brazil.
RP Salomao, R (corresponding author), Univ Fed Sao Paulo, UNIFESP, Div Infect Dis, Immunol Lab, Rua Pedro de Toledo 781,15 Andar, BR-04039032 Sao Paulo, Brazil.
EM rsalomao-dipa@pesquisa.epm.br
RI Kallas, Esper G/C-9539-2012; Burattini, Marcelo N/J-9272-2014; Salomao,
   Reinaldo/C-6419-2013
OI Burattini, Marcelo N/0000-0002-5407-6890; Salomao,
   Reinaldo/0000-0003-1149-4598; Kallas, Esper/0000-0003-2026-6925
CR BECK JS, 1985, CLIN EXP IMMUNOL, V60, P49
   Cohen O., 1999, FUNDAMENTAL IMMUNOLO, P1455
   COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243
   ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185
   FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249
   Garrait V, 1997, J IMMUNOL, V159, P2824
   Goletti D, 1998, J INFECT DIS, V177, P1332, DOI 10.1086/515276
   Goletti D, 1996, J IMMUNOL, V157, P1271
   Jones BE, 1997, CLIN INFECT DIS, V24, P988, DOI 10.1093/clinids/24.5.988
   KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435
   KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4
   Markowitz N, 1997, ANN INTERN MED, V126, P123, DOI 10.7326/0003-4819-126-2-199701150-00005
   McDyer JF, 1997, J IMMUNOL, V158, P492
   MUTIS T, 1993, EUR J IMMUNOL, V23, P2189, DOI 10.1002/eji.1830230921
   ONWUBALILI JK, 1987, TUBERCLE, V68, P195, DOI 10.1016/0041-3879(87)90055-9
   ORME IM, 1983, J EXP MED, V158, P74, DOI 10.1084/jem.158.1.74
   POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151
   Rodrigues DSS, 2002, CLIN EXP IMMUNOL, V128, P149, DOI 10.1046/j.1365-2249.2002.01809.x
   Rodrigues Denise do Socorro S., 2003, Braz J Infect Dis, V7, P161, DOI 10.1590/S1413-86702003000200010
   SINGHAL M, 1989, TUBERCLE, V70, P171, DOI 10.1016/0041-3879(89)90047-0
   Sousa AO, 1998, J INFECT DIS, V177, P1554, DOI 10.1086/515326
   TAKASHIMA T, 1990, INFECT IMMUN, V58, P3286, DOI 10.1128/IAI.58.10.3286-3292.1990
   Tascon RE, 1998, INFECT IMMUN, V66, P830, DOI 10.1128/IAI.66.2.830-834.1998
   Toossi Z, 1997, J ACQ IMMUN DEF SYND, V15, P325, DOI 10.1097/00042560-199708150-00001
   Toossi Z, 2001, CLIN EXP IMMUNOL, V123, P233, DOI 10.1046/j.1365-2249.2001.01401.x
   TURETT GS, 1994, CHEST, V105, P1335, DOI 10.1378/chest.105.5.1335
   Vanham G, 1996, CLIN EXP IMMUNOL, V103, P30, DOI 10.1046/j.1365-2249.1996.907600.x
   WHALEN C, 1995, AM J RESP CRIT CARE, V151, P129, DOI 10.1164/ajrccm.151.1.7812542
   Whalen C, 1997, AIDS, V11, P455, DOI 10.1097/00002030-199704000-00008
   Whalen CC, 2000, AIDS, V14, P1219, DOI 10.1097/00002030-200006160-00020
   Xing Z, 1998, INFECT IMMUN, V66, P5537, DOI 10.1128/IAI.66.11.5537-5542.1998
   ZHANG M, 1994, J CLIN INVEST, V94, P2435, DOI 10.1172/JCI117611
NR 32
TC 13
Z9 13
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9104
EI 1365-2249
J9 CLIN EXP IMMUNOL
JI Clin. Exp. Immunol.
PD JUN
PY 2005
VL 140
IS 3
BP 491
EP 497
DI 10.1111/j.1365-2249.2005.02796.x
PG 7
WC Immunology
SC Immunology
GA 927UW
UT WOS:000229227000011
PM 15932510
OA Green Published
DA 2020-12-08
ER

PT J
AU Romano, P
   Sumita, NM
   Mendes, ME
   Batista, VRM
   Ebner, PAR
   Burattini, MN
   Araujo, LMP
   Castro, MCR
   Neto, ED
AF Romano, P
   Sumita, NM
   Mendes, ME
   Batista, VRM
   Ebner, PAR
   Burattini, MN
   Araujo, LMP
   Castro, MCR
   Neto, ED
TI The EMITO (R) 2000 Dade Behring mycophenolic acid assay: An application
   protocol for the Cobas Mira Plus Chemistry system
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 24-28, 2005
CL Orlando, FL
SP Amer Assoc Clin Chem
C1 Univ Sao Paulo, Fac Med, Hosp Clin, Cent Lab Div, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Labs Med Invest LIM03, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Renal Transplantat Unit, Sao Paulo, Brazil.
RI Neto, Elias David/O-3866-2018; Mendes, Maria E/B-4207-2015; Burattini,
   Marcelo N/J-9272-2014; de castro, maria cristina ribeiro/B-6648-2009
OI Mendes, Maria E/0000-0001-9835-8761; Burattini, Marcelo
   N/0000-0002-5407-6890; de castro, maria cristina
   ribeiro/0000-0002-6731-8369
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PY 2005
VL 51
SU 6
BP A147
EP A147
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 930YH
UT WOS:000229452500476
DA 2020-12-08
ER

PT J
AU Sumita, NM
   Mendes, ME
   Novais, RCD
   Lavorato, LM
   Burattini, MN
AF Sumita, NM
   Mendes, ME
   Novais, RCD
   Lavorato, LM
   Burattini, MN
TI The performance of the equipment management indicators after
   introduction a new technology in the public laboratory
SO CLINICAL CHEMISTRY
LA English
DT Meeting Abstract
CT 57th Annual Meeting of the American-Association-for-Clinical-Chemistry
CY JUL 24-28, 2005
CL Orlando, FL
SP Amer Assoc Clin Chem
C1 Univ Sao Paulo, Fac Med, Hosp Clin, Cent Lab Div, Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, Hosp Clin, Labs Med Invest LIM 03, Sao Paulo, Brazil.
RI Mendes, Maria E/B-4207-2015; Burattini, Marcelo N/J-9272-2014
OI Mendes, Maria E/0000-0001-9835-8761; Burattini, Marcelo
   N/0000-0002-5407-6890
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
J9 CLIN CHEM
JI Clin. Chem.
PY 2005
VL 51
SU 6
BP A82
EP A82
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA 930YH
UT WOS:000229452500263
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Lopez, LF
   Coutinho, FAB
AF Massad, E
   Burattini, MN
   Lopez, LF
   Coutinho, FAB
TI Forecasting versus projection models in epidemiology: The case of the
   SARS epidemics
SO MEDICAL HYPOTHESES
LA English
DT Article
ID SAO-PAULO STATE; YELLOW-FEVER; DENGUE; VACCINATION; OUTBREAK; RISK
AB In this work we propose a simple mathematical model for the analysis of the impact of control measures against an emerging infection, namely, the severe acute respiratory syndrome (SARS). The model provides a testable hypothesis by considering a dynamical equation for the contact parameter, which drops exponentially with time, simulating control measures. We discuss the role of modelling in public health and we analyse the distinction between forecasting and projection models as assessing toots for the estimation of the impact of intervention strategies. The model is applied to the communities of Hong Kong and Toronto (Canada) and it mimics those epidemics with fairly good accuracy. The estimated values for the basic reproduction number, R-0, were 1.2 for Hong Kong and 1.32 for Toronto (Canada). The model projects that, in the absence of control, the final number of cases would be 320,000 in Hong Kong and 36,900 in Toronto (Canada). In contrast, with control measures, which reduce the contact rate to about 25 % of its initial value, the expected final number of cases is reduced to 1778 in Hong Kong and 226 in Toronto (Canada). Although SARS can be a devastating infection, early recognition, prompt isolation, and appropriate precaution measures, can be very effective to Limit its spread. (c) 2005 Elsevier Ltd. ALL rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, SP, Brazil.
   London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Lopez, Luis F/C-4721-2012; Burattini,
   Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011; Massad,
   Eduardo/H-6143-2011
OI Massad, Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; 
CR Amaku M, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051907
   ANDERSON R M, 1991
   ANDERSON RM, 1988, TROP GEOGR MED, V40, pS30
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   BURATTINI MN, 1993, EPIDEMIOL INFECT, V111, P503, DOI 10.1017/S0950268800057241
   Caswell H. A. L., 1989, MATRIX POPULATION MO
   *CDC, 2003, SEV AC RESP SYNDR WH
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chow PKH, 2004, EMERG INFECT DIS, V10, P249, DOI 10.3201/eid1002.030397
   Hsieh YH, 2004, EMERG INFECT DIS, V10, P201, DOI 10.3201/eid1002.030515
   KEYFITZ N, 1972, J AM STAT ASSOC, V67, P347, DOI 10.2307/2284381
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2003, REV SAUDE PUBL, V37, P477, DOI [10.1590/S0034-89102003000400013, 10.1590/s0034-89102003000400013]
   MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Meltzer MI, 2004, EMERG INFECT DIS, V10, P207, DOI 10.3201/eid1002.030426
   Shen Z, 2004, EMERG INFECT DIS, V10, P256, DOI 10.3201/eid1002.030732
   *WER, 2003, WKLY EPIDEMIOL REC, V78, P1
   *WHO, 2004, EB11333 WHO
   WHO, 2003, SEV AC RESP SYNDR SA
   World Health Organization, 2003, CUM NUMB REP PROB CA
NR 23
TC 24
Z9 25
U1 2
U2 17
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2005
VL 65
IS 1
BP 17
EP 22
DI 10.1016/j.mehy.2004.09.029
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 932DW
UT WOS:000229535400003
PM 15893110
OA Green Published
DA 2020-12-08
ER

PT J
AU Dos Santos, RL
   Forattini, OP
   Burattini, MN
AF Dos Santos, RL
   Forattini, OP
   Burattini, MN
TI Anopheles albitarsis s.l. (Diptera : Culicidae) survivorship and density
   in a rice irrigation area of the state of Sao Paulo, Brazil
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Anopheles albitarsis; survival; malaria; rice irrigation; density
ID SOUTH-EASTERN BRAZIL; ANTHROPIC ENVIRONMENT; MOSQUITOS DIPTERA; MALARIA;
   SYSTEM
AB Collections of Anopheles albitarsis Arribalzaga s.l. were conducted from May 1996 to June 2000 to estimate the human biting rate, and mark-release-recapture experiments were carried out to estimate the daily survival probability. The density of An. albitarsis females showed a marked seasonal variation, with peaks as high as 629 individuals per human per night in the wet season. The low daily survival probability of 0.61 is an important factor limiting the vectorial capacity of An. albitarsis s.l. in southeastern Brazil.
C1 Univ Sao Paulo, Fac Saude Publ, BR-01246940 Sao Paulo, Brazil.
RP Dos Santos, RL (corresponding author), Minist Hlth, SAS Quadra 4 Bloco N, BR-70756010 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR BURKOT TR, 1995, ANN TROP MED PARASIT, V89, P125, DOI 10.1080/00034983.1995.11812943
   DEANE L M, 1986, Memorias do Instituto Oswaldo Cruz, V81, P5, DOI 10.1590/S0074-02761986000600002
   DEANE LM, 1988, AM J TROP MED HYG, V38, P223, DOI 10.4269/ajtmh.1988.38.223
   Forattini OP, 1996, REV SAUDE PUBL, V30, P299, DOI 10.1590/S0034-89101996000400002
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P227, DOI 10.1590/S0034-89101993000400001
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P313, DOI 10.1590/S0034-89101993000500001
   ROUDIL G, 1945, Rev Orthop Chir Appar Mot, V31, P69
   Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241
   Kakitani I, 2000, REV SAUDE PUBL, V34, P33, DOI 10.1590/S0034-89102000000100007
   KLEIN TA, 1991, AM J TROP MED HYG, V45, P463, DOI 10.4269/ajtmh.1991.45.463
   LASANTOS R, 2002, J MED ENTOMOL, V39, P926
   MILBY M M, 1989, Bulletin of the Society for Vector Ecology, V14, P47
   Molineaux L., 1988, P913
   RUBIOPALIS Y, 1994, AM J TROP MED HYG, V50, P420, DOI 10.4269/ajtmh.1994.50.420
   Santos-Machado TM, 1999, INT J PEDIAT HEM ONC, V6, P33
   Smith D. P., 1977, MATH DEMOGRAPHY SELE
   WILKERSON RC, 1995, J MED ENTOMOL, V32, P697, DOI 10.1093/jmedent/32.5.697
   World Health Organization, 1962, WHO MONOGRAPH SERIES
NR 18
TC 4
Z9 4
U1 0
U2 5
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD SEP
PY 2004
VL 41
IS 5
BP 997
EP 1000
PG 4
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 860FP
UT WOS:000224328200030
PM 15535635
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
TI The Eyam plague revisited: did the village isolation change transmission
   from fleas to pulmonary?
SO MEDICAL HYPOTHESES
LA English
DT Article
AB Back in the 17th century the Derbyshire village of Eyam fell victim to the Black Death, which is thought to have arrived from London in some old clothes brought by a travelling tailor. The village population was 350 at the commencement of plague, of which only 83 survived. Led by the church leaders, the village community realized that the whole surrounding region was at risk from the epidemic, and therefore decided to seat themselves off from the other surrounding villages. In the first 275 days of the outbreak, transmission was predominantly from infected fleas to susceptible humans. From then onward, mortality sharply increased, which indicates a changing in transmission pattern. We hypothesize that the confinement facilitated the spread of the infection by increasing the contact rate through direct transmission among humans. This would be more consistent with pulmonary plague, a deadlier form of the disease. In order to test the above hypothesis we designed a mathematical model for plague dynamics, incorporating both the indirect (fleas-rats-humans) and direct (human-to-human) transmissions of the infection. Our results show remarkable agreement between data and the model, [ending support to our hypotheses. The Eyam plague episode is celebrated as a remarkable act of collective self-sacrifice. However, to the best of our knowledge, there were no evidence before that the confinement actually increased the burden payed by the commoners.
   In the light of our results, it can be said that the hypothesis that confinement facilitated the spread of the infection by increasing the contact rate through direct transmission is plausible. (C) 2004 Elsevier Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo,455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Lopez, Luis F/C-4721-2012; Coutinho, Francisco A
   B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Coutinho, Francisco A B/0000-0003-3127-3071
CR BARNET SA, 2001, STORY RATS
   Butler T, 1983, PLAGUE OTHER YERSINI
   DENNIS DT, 1999, TROPICAL INFECT DIS, P506
   Gratz N., 1994, RODENT PESTS THEIR C
   Lopez LF, 2002, CR BIOL, V325, P1073, DOI 10.1016/S1631-0691(02)01534-2
   Moore J., 2002, PARASITES BEHAV ANIM
   SERVICE NW, 1986, LECT NOTES MED ENTOM
   SLACK P, 1989, T ROY SOC TROP MED H, V83, P461, DOI 10.1016/0035-9203(89)90247-2
   SMITH MD, 1996, MANSONS TROPICAL DIS, P918
   ZIEGLER P, 1984, BLACK DEATH
NR 10
TC 18
Z9 18
U1 0
U2 2
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
J9 MED HYPOTHESES
JI Med. Hypotheses
PY 2004
VL 63
IS 5
BP 911
EP 915
DI 10.1016/j.mehy.2004.03.028
PG 5
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 867OU
UT WOS:000224852700025
PM 15488668
DA 2020-12-08
ER

PT J
AU Massad, E
   Ortega, NRS
   Struchiner, CJ
   Burattini, MN
AF Massad, E
   Ortega, NRS
   Struchiner, CJ
   Burattini, MN
TI Fuzzy epidemics
SO ARTIFICIAL INTELLIGENCE IN MEDICINE
LA English
DT Article
DE epidemiology; risk analysis; infectious diseases; fuzzy logic; fuzzy
   clustering
ID MEASLES OUTBREAK; REPRESENTATION; VACCINATION; COMMUNITY; SYSTEMS; VIRUS
AB The purpose of this paper is to provide a review of the current state of fuzzy logic theory in epidemioloy, which is a recent area of research. We present four applications of fuzzy logic theory in epidemic problems, using linguistic fuzzy models, possibility measure, probability of fuzzy events and fuzzy decision making techniques. The results demonstrate that the applications of fuzzy sets in epidemiology is a very promising area of research. The final discussion sets the future stage of fuzzy sets application in epidemiology. (C) 2002 Elsevier Science B.V. All rights reserved.
C1 Univ Sao Paulo, Sch Publ Hlth, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Phys, Rio De Janeiro, Brazil.
   Fiocruz MS, Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Publ Hlth, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Ortega, Neli/C-6494-2013; Struchiner, Claudio J/M-9360-2013; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011; Massad,
   Eduardo/B-1169-2012
OI Struchiner, Claudio J/0000-0003-2114-847X; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916
CR ADLASSNIG KP, 2000, FUZZY DIAGNOSTIC THE
   ANDERSON R M, 1991
   BELLMAN RE, 1970, MANAGE SCI B-APPL, V17, pB141
   BRAVO R, 1995, MED CLIN-BARCELONA, V104, P530
   Ferson S, 1996, RELIAB ENG SYST SAFE, V54, P133, DOI 10.1016/S0951-8320(96)00071-3
   GREENLAND S, 1987, AM J EPIDEMIOL, V125, P761, DOI 10.1093/oxfordjournals.aje.a114593
   Helgason CM, 1998, NEURAL NETWORKS, V11, P549, DOI 10.1016/S0893-6080(97)00149-4
   HUGHES C, 1989, MED INFORM, V14, P269, DOI 10.3109/14639238908999281
   HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157, DOI 10.1093/oxfordjournals.aje.a115627
   Klir G.J., 1995, FUZZY SETS FUZZY LOG
   MARKOWITZ LE, 1994, VACCINES, P229
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Ortega NRS, 2000, KYBERNETES, V29, P201, DOI 10.1108/03684920010312768
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY
   Sadegh-Zadeh K, 1999, ARTIF INTELL MED, V17, P87, DOI 10.1016/S0933-3657(99)00015-9
   Shafer G., 1987, ANAL FUZZY INFORMATI, V1, P51
   WEEKS RM, 1992, B WORLD HEALTH ORGAN, V70, P317
   Yager RR, 1994, ESSENTIALS FUZZY MOD
   Yen J, 1999, FUZZY LOGIC INTELLIG
   Zadeh L. A., 1978, Fuzzy Sets and Systems, V1, P3, DOI 10.1016/0165-0114(78)90029-5
   ZADEH LA, 1968, J MATH ANAL APPL, V23, P421, DOI 10.1016/0022-247X(68)90078-4
   ZADEH LA, 1973, IEEE T SYST MAN CYB, VSMC3, P28, DOI 10.1109/TSMC.1973.5408575
   ZIMMERMAN HJ, 1996, FUZZY INFORMATION EN, P471
NR 25
TC 26
Z9 26
U1 1
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0933-3657
EI 1873-2860
J9 ARTIF INTELL MED
JI Artif. Intell. Med.
PD NOV
PY 2003
VL 29
IS 3
BP 241
EP 259
AR PII S0933-3657(02)00070-2
DI 10.1016/S0933-3657(02)00070-2
PG 19
WC Computer Science, Artificial Intelligence; Engineering, Biomedical;
   Medical Informatics
SC Computer Science; Engineering; Medical Informatics
GA 755LT
UT WOS:000187404900004
PM 14656489
DA 2020-12-08
ER

PT J
AU Zanetta, DMT
   Cabrera, EMS
   Azevedo, RS
   Burattini, MN
   Massad, E
AF Zanetta, DMT
   Cabrera, EMS
   Azevedo, RS
   Burattini, MN
   Massad, E
TI Seroprevalence of rubella antibodies in the State of Sao Paulo, Brazil,
   8 years after the introduction of vaccine
SO VACCINE
LA English
DT Article
DE rubella; seroepidemiology; vaccination
ID MEASLES; STRATEGY; MUMPS; FINLAND
AB Rubella vaccine was introduced in the official immunization calendar of the State of Sao Paulo, in 1992, at 15 months of age, following a mass vaccination targeting all children between 1 and 10 years of age. This mixed strategy was designed taking into account serological data and mathematical models to estimate the optimal ages for vaccination. To evaluate the efficacy of routine vaccination on rubella infection in Sao Jose do Rio Preto, State of Sao Paulo, 8 years after the introduction of vaccine, a seroprevalence survey was carried out in December 2000, comprising 1536 subjects aging from 6 months to 25 years. Rubella specific IgG was detected in blood samples by enzyme-linked immunosorbent assay (ELISA). From 18 months to 5 years of age (covered by a mass vaccination campaign 6 months before the Study) the seroprevalence was above 90%. From 6 to 8 years of age (vaccinated by routine schedule at 15 months), the seroprevalence was 76%. Front 9 to 18 years of age (vaccinated at the mass campaign that introduced the vaccine 8 years before) the seroprevalence was about 85%. After 20 years of age, protection was acquired by previous infection, as they were not covered by any vaccine program. From 20 to 25 years of age, the seroprevalence was 70%. As the seroprevalence remains low at ages not vaccinated, it should be expected low infection rates at this age window. Despite this, the present situation deserves care, as routine vaccination is given a protection below the minimum level necessary (80%). The efficacy of the proposed strategy depends on better routine vaccination coverage. A second dose of vaccine should also be considered. (C) 2003 Elsevier Science Ltd. All rights reserved.
C1 Med Sch Sao Jose Rio Preto, Dept Epidemiol & Publ Hlth, FAMERP, Sao Jose Do Rio Preto, SP, Brazil.
   Univ Sao Paulo, Sch Med, Dept Pathol, Sao Paulo, Brazil.
   HCFMUSP, LIM 01, Sao Paulo, Brazil.
RP Zanetta, DMT (corresponding author), Med Sch Sao Jose Rio Preto, Dept Epidemiol & Publ Hlth, FAMERP, Sao Jose Do Rio Preto, SP, Brazil.
RI Zanetta, Dirce M T/G-4950-2013; Azevedo, Raymundo S/B-7593-2008;
   Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Cabrera, Eliana/B-3190-2016
OI Azevedo, Raymundo S/0000-0003-0660-2371; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Cabrera,
   Eliana/0000-0002-6967-5773
CR ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   AZEVEDONETO RS, 1994, EPIDEMIOL INFECT, V113, P161
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   Davidkin I, 2000, VACCINE, V18, P3106, DOI 10.1016/S0264-410X(00)00139-0
   HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511
   Johnson CE, 1996, PEDIATR INFECT DIS J, V15, P687, DOI 10.1097/00006454-199608000-00010
   KNOX EG, 1980, INT J EPIDEMIOL, V9, P13, DOI 10.1093/ije/9.1.13
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
   Peltola H, 2000, JAMA-J AM MED ASSOC, V284, P2643, DOI 10.1001/jama.284.20.2643
   Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69
   van Druten J A, 1986, Dev Biol Stand, V65, P53
NR 12
TC 7
Z9 8
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD SEP 8
PY 2003
VL 21
IS 25-26
BP 3795
EP 3800
DI 10.1016/S0264-410X(03)00315-3
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 719YY
UT WOS:000185233700039
PM 12922113
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
AF Massad, E
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
TI Dengue and the risk of urban yellow fever reintroduction in Sao Paulo
   State, Brazil
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE yellow fever, epidemiology; dengue, epidemiology; mathematical models;
   disease outbreaks; Aedes; yellow fever vaccine
AB Objective To propose a mathematical method for the estimation of the Basic Reproduction Number, R-0, of urban yellow fever in a dengue-infested area.
   Methods The method is based on the assumption that, as the same vector (Aedes aegypti) causes both infections, all the quantities related to the mosquito, estimated from the initial phase of dengue epidemic, could be applied to yellow fever dynamics. It is demonstrated that R-0 for yellow fever is, on average, 43% lower than that for dengue. This difference is due to the longer dengue viremia and its shorter extrinsic incubation period.
   Results In this study the analysis was expanded to the epidemiological situation of dengue in Sao Paulo in the year 2001. The total number of dengue cases increased from 3,582 in 2000 to 51,348 in 2001. It was then calculated R-0 for yellow fever for every city which have shown R-0 of dengue greater than 1. It was also estimated the total number of unprotected people living in highly risky areas for urban yellow fever.
   Conclusions Currently there is a great number of non-vaccinated people living in Aedes aegypti infested area in the state of Sao Paulo.
C1 Univ Sao Paulo, Fac Med, BR-01246903 Sao Paulo, SP, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Fac Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.
EM edmassad@usp.br
RI Coutinho, Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011; Lopez,
   Luis F/C-4721-2012; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/B-1169-2012
OI Coutinho, Francisco A B/0000-0003-3127-3071; Lopez, Luis
   F/0000-0003-4097-6887; Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916
CR ANDERSON R M, 1991
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   Degallier N, 1996, B SOC PATHOL EXOT, V89, P128
   FORATTINI OP, 1986, REV SAUDE PUBL, V20, P244, DOI 10.1590/S0034-89101986000300009
   FORATTINI OP, 2002, CULICIDOLOGIA MED ID, V2, P498
   FRAIHA H, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P289
   Franco O, 1969, Rev Bras Malariol Doencas Trop, V21, P729
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Molineaux L, 1980, THE GARKI PROJECT
   Monath T. P., 1990, Tropical and geographical medicine., P661
   Monath TP, 1999, LANCET, V353, P1541, DOI 10.1016/S0140-6736(99)00155-5
   Monath TP, 1999, VACCINES, P815
NR 15
TC 46
Z9 47
U1 0
U2 15
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD AUG
PY 2003
VL 37
IS 4
BP 477
EP 484
DI 10.1590/S0034-89102003000400013
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 723EW
UT WOS:000185420300012
PM 12937709
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Goncalves, MAG
   Burattini, MN
   Donadi, EA
   Massad, E
AF Goncalves, MAG
   Burattini, MN
   Donadi, EA
   Massad, E
TI Anogenital warts contributing to the risk of squamous intraepithelial
   lesions among HIV-positive women of Sao Paulo, Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE human papillomavirus; human immunodeficiency virus; squamous
   intraepithelial lesions; cervical intraepithelial neoplasia; acquired
   immunodeficiency syndrome
ID HUMAN-PAPILLOMAVIRUS INFECTION; HUMAN-IMMUNODEFICIENCY-VIRUS;
   CERVICAL-CANCER; NEOPLASIA; HPV; IMMUNOSUPPRESSION
AB Unsafe sexual practices may expose HIV-positive women to high-grade squamous intraepithelial lesions (SIL) and to infection with oncogenic human papillomavirus (HPV) types. A cross sectional study of 141 HIV-positive women was designed to evaluate risk factors for the development of cervico-vaginal SIL and HPV-DNA detection/typing. Uni- and multivariate forward stepwise analysis was used to determine the relationship between risk variables and HPV infection and between risk behaviour, HPV and HIV infection with development of SIL. Univariate analysis showed that HPV-DNA infection was related to previous and recurrent anogenital warts, male genital warts and cytological alteration. For final multivariate analysis, both HPV type (undetermined- and high-risk, OR=29.3 and 112.0, respectively) were statistically associated (P=0.019) with high-grade cervico-vaginal SIL. The presence of anogenital warts as well as high- and undetermined-risk HPV infection may alert to cyto/histopathological alterations. These results point out the importance of the use of barrier methods and routine early genitoscopy/treatment for HIV-infected partners.
C1 Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Med, Div Clin Immunol, BR-14049900 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Med Informat, BR-14049900 Sao Paulo, Brazil.
   Univ Sao Paulo, Sch Med, HCFMUSP, LIM01, BR-14049900 Sao Paulo, Brazil.
RP Goncalves, MAG (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Med, Div Clin Immunol, Av Bandeirantes 3900, BR-14049900 Sao Paulo, Brazil.
RI donadi, eduardo A/H-7080-2013; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014
OI donadi, eduardo A/0000-0002-9457-9601; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890
CR BRAUN L, 1994, AM J PATHOL, V144, P209
   Cappiello G, 1997, INT J CANCER, V72, P982
   CAVALCANTI SMB, 1997, P BRAS PATHOL, V33, P62
   CONTI M, 1993, GYNECOL ONCOL, V49, P344, DOI 10.1006/gyno.1993.1137
   DEAN AG, 1994, EPIINFO VERRSION 6 W
   DEPALO G, 1993, MANUALE COLPOSCOPIA
   DIXON WJ, 1992, BMDP STAT SOFTWARE M, V1
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   FRANCO EL, 1994, JNCI-J NATL CANCER I, V86, P1558, DOI 10.1093/jnci/86.20.1558
   FRANCO EL, 1995, J INFECT DIS, V172, P856
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   GROSS EG, 1997, HUMAN PAPILLOMAVIRUS
   Heard I, 2000, OBSTET GYNECOL, V96, P403, DOI 10.1016/S0029-7844(00)00948-0
   HO GYF, 1994, INT J CANCER, V56, P788, DOI 10.1002/ijc.2910560605
   *INT AG RES CANC, 1995, IARC MON HUM PAP, V64
   KURMAN RJ, 1994, BETHESDA SYSTEM REPO
   LEY C, 1991, J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997
   MEISELS A, 1976, ACTA CYTOL, V20, P505
   Palefsky J M, 1998, J Natl Cancer Inst Monogr, P15
   PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205
   PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612
   PUROLA E, 1977, ACTA CYTOL, V21, P26
   REID R, 1985, AM J OBSTET GYNECOL, V153, P611, DOI 10.1016/S0002-9378(85)80244-1
   SCHIFFMAN MH, 1993, J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958
   SECK AC, 1994, INT J STD AIDS, V5, P189
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M
   TWEDDEL G, 1994, GYNECOL ONCOL, V52, P161, DOI 10.1006/gyno.1994.1024
   VERNON SD, 1994, J INFECT DIS, V169, P1108, DOI 10.1093/infdis/169.5.1108
   Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5
   WILLIAMS AB, 1994, OBSTET GYNECOL, V83, P205
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
   WRIGHT TC, 1996, HUMAN PAPILLOMAVIRUS
NR 33
TC 4
Z9 6
U1 0
U2 0
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD MAY
PY 2003
VL 14
IS 5
BP 309
EP 313
DI 10.1258/095646203321605503
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 677MG
UT WOS:000182811700004
PM 12803937
DA 2020-12-08
ER

PT J
AU Amaku, M
   Coutinho, FAB
   Azevedo, RS
   Burattini, MN
   Lopez, LF
   Massad, E
AF Amaku, M
   Coutinho, FAB
   Azevedo, RS
   Burattini, MN
   Lopez, LF
   Massad, E
TI Vaccination against rubella: Analysis of the temporal evolution of the
   age-dependent force of infection and the effects of different contact
   patterns
SO PHYSICAL REVIEW E
LA English
DT Article
ID SAO-PAULO STATE; MEASLES; STABILITY; THRESHOLD; PROGRAMS; STRATEGY;
   MUMPS
AB In this paper, we analyze the temporal evolution of the age-dependent force of infection and incidence of rubella, after the introduction of a very specific vaccination program in a previously nonvaccinated population where rubella was in endemic steady state. We deduce an integral equation for the age-dependent force of infection, which depends on a number of parameters that can be estimated from the force of infection in a steady state prior to the vaccination program. We present the results of our simulations, which are compared with observed data. We also examine the influence of contact patterns among members of a community on the age-dependent intensity of transmission of rubella and on the results of vaccination strategies. As an example of the theory proposed, we calculate the effects of vaccination strategies for four communities from Caieiras (Brazil), Huixquilucan (Mexico), Finland, and the United Kingdom. The results for each community differ considerably according to the distinct intensity and pattern of transmission in the absence of vaccination. We conclude that this simple vaccination program is not very efficient (very slow) in the goal of eradicating the disease. This gives support to a mixed strategy, proposed by Massad , accepted and implemented by the government of the State of Sao Paulo, Brazil.
C1 Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Med Vet Prevent & Saude Anim, BR-05508000 Sao Paulo, Brazil.
   Univ Sao Paulo, Fac Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIM01, BR-01246903 Sao Paulo, Brazil.
RP Amaku, M (corresponding author), Univ Sao Paulo, Fac Med Vet & Zootecnia, Dept Med Vet Prevent & Saude Anim, Ave Prof Dr Orlando Marques de Paiva 87, BR-05508000 Sao Paulo, Brazil.
EM amaku@vps.fmvz.usp.br
RI Massad, Eduardo/H-6143-2011; Amaku, Marcos/D-5252-2012; Burattini,
   Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Azevedo, Raymundo
   S/B-7593-2008; Coutinho, Francisco A B/H-5644-2011; Massad,
   Eduardo/B-1169-2012
OI Amaku, Marcos/0000-0003-4752-6774; Burattini, Marcelo
   N/0000-0002-5407-6890; Lopez, Luis F/0000-0003-4097-6887; Azevedo,
   Raymundo S/0000-0003-0660-2371; Coutinho, Francisco A
   B/0000-0003-3127-3071; Massad, Eduardo/0000-0002-7200-2916
CR ANDERSON R M, 1991
   Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P1048
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   Edmunds WJ, 2000, EPIDEMIOL INFECT, V125, P635, DOI 10.1017/S0950268800004672
   FARRINGTON CP, 1990, STAT MED, V9, P953, DOI 10.1002/sim.4780090811
   Farrington CP, 2001, J R STAT SOC C-APPL, V50, P251, DOI 10.1111/1467-9876.00233
   GOLUBJATNIKOV R, 1971, AM J TROP MED HYG, V20, P958, DOI 10.4269/ajtmh.1971.20.958
   GREENHALGH D, 1987, IMA J MATH APPL MED, V4, P109
   GRIFFITHS D. A., 1974, Applied Statistics, V23, P330, DOI 10.2307/2347126
   INABA H, 1990, J MATH BIOL, V28, P411
   Kot M., 2000, ELEMENTS MATH ECOLOG
   Lopez LF, 2000, J MATH BIOL, V40, P199, DOI 10.1007/s002850050178
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
   MASSAD E, UNPUB, P44301
   Massad Eduardo, 1995, Journal of Biological Systems, V3, P803, DOI 10.1142/S0218339095000733
   NETO RSD, 1994, EPIDEMIOL INFECT, V113, P161, DOI 10.1017/S095026880005158X
   PLOTKI SA, 1999, VACCINES, P44301
   Plotkin SA, 2001, VACCINE, V19, P3311, DOI 10.1016/S0264-410X(01)00073-1
   TRUCCO E, 1965, B MATH BIOPHYS, V27, P285, DOI 10.1007/BF02478406
   Ukkonen P, 1996, SCAND J INFECT DIS, V28, P31, DOI 10.3109/00365549609027146
   van der Heijden OG, 1998, EPIDEMIOL INFECT, V121, P653, DOI 10.1017/S0950268898001472
NR 22
TC 26
Z9 26
U1 0
U2 4
PU AMER PHYSICAL SOC
PI COLLEGE PK
PA ONE PHYSICS ELLIPSE, COLLEGE PK, MD 20740-3844 USA
SN 1539-3755
EI 1550-2376
J9 PHYS REV E
JI Phys. Rev. E
PD MAY
PY 2003
VL 67
IS 5
AR 051907
DI 10.1103/PhysRevE.67.051907
PN 1
PG 11
WC Physics, Fluids & Plasmas; Physics, Mathematical
SC Physics
GA 689GA
UT WOS:000183482200060
PM 12786178
DA 2020-12-08
ER

PT J
AU Goncalves, MAG
   Burattini, MN
   Donadi, EA
   Massad, E
AF Goncalves, MAG
   Burattini, MN
   Donadi, EA
   Massad, E
TI Risk factors associated with genital warts in HIV-positive Brazilian
   women
SO TUMORI
LA English
DT Article
DE antiretroviral therapy; cervical intraepithelial neoplasia; human
   immunodeficiency virus; human papillomavirus
ID HUMAN-IMMUNODEFICIENCY-VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA;
   HUMAN-PAPILLOMAVIRUS; INFECTED WOMEN; SEROPOSITIVE WOMEN; VIRAL LOAD;
   LESIONS; HPV; ABNORMALITIES; DYSPLASIA
AB Aims and background: In Brazil, the female population has been, increasingly infected with human immunodeficiency virus (HIV), and uterine cervix carcinoma now represents the second highest cause of mortality. Although HIV infection among women is associated with an increased prevalence of cervical cancer precursors, the co-infection with human papillomavirus (HPV) is considered to be a necessary but not sufficient factor to induce genital lesions. This study was conducted to identify risk factors associated with the history of genital warts among HIV-positive women.
   Methods: A comparative cross-sectional evaluation was applied to 141 HIV-positive women. All patients were submitted to colposcopy, smear cytology, directed biopsy, and HPV-DNA detection. The chi-square, Fisher's exact test, and the odds ratio (OR, 95%; confidence interval, CI) were used to evaluate associations between history of genital warts and risk factors.
   Results: A history of genital warts presented associations with: a) age at first sexual intercourse :517 years (OR, 0.42; Cl, 0.16-1.11); b) history of genital warts in sex partners (OR, 11.39; Cl, 4.21-30.76), especially with recurrent episodes (OR, 6.60; Cl, 2.69-16.12); c) drug addiction (OR, 2.38; Cl, 1.09-5.19), especially in crack users (OR, 5.34; Cl, 1.64-17.41); d) cervical HPV infection (OR, 2.75; Cl 1.09-6.90); e) cervical infection caused by only one HPV type (OR, 2.77; Cl 1.06-7.20); f) perianal HPV infection (OR, 2.30; Cl, 0.70-7.56), associated with negative results for undetermined risk HPV (OR, 8.41; P = 0.04); and g) no antiretroviral therapy (OR, 3.41; P = 0.07).
   Conclusions: Evaluation of behavioral risk factors associated with a genital wart history is an important tool to prevent and reduce persistent HPV infection, and consequently genital cancer precursors in HIV infected women.
C1 Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Med, Div Clin Immunol, BR-14049900 Ribeirao Preto, Brazil.
   Univ Sao Paulo, Sch Med, Discipline Med Informat, LMO1 HCFMUSP, Sao Paulo, Brazil.
RP Goncalves, MAG (corresponding author), Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Med, Div Clin Immunol, Ave Bandeirantes 3900, BR-14049900 Ribeirao Preto, Brazil.
RI Massad, Eduardo/H-6143-2011; donadi, eduardo A/H-7080-2013; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014
OI donadi, eduardo A/0000-0002-9457-9601; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890
CR Ahdieh L, 2000, AM J EPIDEMIOL, V151, P1148, DOI 10.1093/oxfordjournals.aje.a010165
   Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1
   [Anonymous], 1990, Wkly Epidemiol Rec, V65, P221
   Cardillo M, 2001, CANCER CYTOPATHOL, V93, P111, DOI 10.1002/cncr.9016
   CONTI M, 1993, GYNECOL ONCOL, V49, P344, DOI 10.1006/gyno.1993.1137
   CREAGH T, 1995, J CLIN PATHOL, V48, P59, DOI 10.1136/jcp.48.1.59
   Cubie HA, 2000, SEX TRANSM INFECT, V76, P257, DOI 10.1136/sti.76.4.257
   Davis AT, 2001, GYNECOL ONCOL, V80, P350, DOI 10.1006/gyno.2000.6104
   Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031
   ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
   Fruchter RG, 1996, OBSTET GYNECOL, V87, P338, DOI 10.1016/0029-7844(95)00408-4
   Goncalves MAG, 1999, INT J STD AIDS, V10, P803, DOI 10.1258/0956462991913583
   GONCALVES MAG, 2002, INT J STD AIDS, V13, P1
   Grimm JW, 1997, PHYSIOL BEHAV, V61, P755, DOI 10.1016/S0031-9384(96)00532-X
   Heard I, 2000, OBSTET GYNECOL, V96, P403, DOI 10.1016/S0029-7844(00)00948-0
   Heard I, 1998, AIDS, V12, P1459, DOI 10.1097/00002030-199812000-00007
   Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703
   *INT AG RES CANC, 1995, IARC MON HUM PAP, V64
   KING TS, 1993, J PHARMACOL EXP THER, V264, P29
   KREISS JK, 1992, SEX TRANSM DIS, V19, P54, DOI 10.1097/00007435-199201000-00011
   Londesborough P, 1996, INT J CANCER, V69, P364
   MAIMAN M, 1991, OBSTET GYNECOL, V78, P84
   MANDELBLATT JS, 1999, CANCER EPIDEM BIOMAR, V8, P729
   Mayrand MH, 2000, J CLIN MICROBIOL, V38, P3388, DOI 10.1128/JCM.38.9.3388-3393.2000
   Palefsky Joel, 2002, AIDS Clin Care, V14, P44
   PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612
   SPURRETT B, 1988, LANCET, V1, P237
   WRIGHT TC, 1994, OBSTET GYNECOL, V84, P591
   WRIGHT TC, 1996, PAPILOMAVIRUS HUMANO, V2, P837
NR 29
TC 13
Z9 19
U1 0
U2 2
PU PENSIERO SCIENTIFICO EDITOR
PI ROME
PA VIA BRADANO 3/C, 00199 ROME, ITALY
SN 0300-8916
J9 TUMORI
JI Tumori
PD JAN-FEB
PY 2003
VL 89
IS 1
BP 9
EP 15
PG 7
WC Oncology
SC Oncology
GA 672RE
UT WOS:000182534600003
PM 12729354
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
AF Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
TI Threshold conditions for infection persistence in complex host-vectors
   interactions
SO COMPTES RENDUS BIOLOGIES
LA English
DT Article
DE basic reproductive number; vector-borne infections; yellow fever
ID FIRST RECORDED OUTBREAK; YELLOW-FEVER; DISEASE; KENYA
AB As classically defined by Macdonald in the early 1950s, for the case of diseases with one vector and one host, the Basic Reproduction Number, R-0. is defined as the number of secondary infections caused by a single infective of the same type (vector or host) during, its infectiousness period in an entirely susceptible population. In the case of a disease which has one vector and one host, it is easy to show that R-0 coincides with the threshold for the establishment of an endemic state: if R-0 > 1 (< 1), the disease can invade (cannot invade) the host population. In this paper we examine various epidemic situations in which there are more than one vector and/or host. We show that in those more complex systems it is not possible to deduce a single R-0 but rather a threshold for infection persistence which is a composite of several quantities closely related to the classical expression of R-0 Another definition of R-0 given by Diekmann, Heesterbeek and Metz, and denoted in this paper R-0(NGO) is discussed and applied as an alternative to calculate the thresholds for infection establishment.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIMO1, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Lopez, Luis F/C-4721-2012; Massad, Eduardo/H-6143-2011; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Coutinho,
   Francisco A B/H-5644-2011
OI Lopez, Luis F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916;
   Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071
CR Beaty B.J., 1996, BIOL DIS VECTORS
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   DIEKMANN O, 2000, MATH EPIDEMIOLOGY IN
   Dietz K, 1993, Stat Methods Med Res, V2, P23, DOI 10.1177/096228029300200103
   Digoutte JP, 1999, B SOC PATHOL EXOT, V92, P343
   GODDARD J, 2000, INFECT DIS ARTHROPOD
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Massad E, 2001, T ROY SOC TROP MED H, V95, P370, DOI 10.1016/S0035-9203(01)90184-1
   Monath T. P., 1990, Tropical and geographical medicine., P661
   Monath TP, 1999, LANCET, V353, P1541, DOI 10.1016/S0140-6736(99)00155-5
   Monath TP, 1999, VACCINES, P815
   Murray J. D., 1993, MATH BIOL
   NOLD A, 1980, MATH BIOSCI, V52, P227, DOI 10.1016/0025-5564(80)90069-3
   Palmer S.R., 1998, ZOONOSES BIOL CLIN P, P3
   Reiter P, 1998, AM J TROP MED HYG, V59, P650, DOI 10.4269/ajtmh.1998.59.650
   Sanders EJ, 1998, AM J TROP MED HYG, V59, P644, DOI 10.4269/ajtmh.1998.59.644
NR 17
TC 39
Z9 40
U1 0
U2 11
PU EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS CEDEX 15
PA 23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE
SN 1631-0691
J9 CR BIOL
JI C. R. Biol.
PD NOV
PY 2002
VL 325
IS 11
BP 1073
EP 1084
DI 10.1016/S1631-0691(02)01534-2
PG 12
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA 628UU
UT WOS:000180015600001
PM 12506721
DA 2020-12-08
ER

PT J
AU Dos Santos, RL
   Forattini, OP
   Burattini, MN
AF Dos Santos, RL
   Forattini, OP
   Burattini, MN
TI Laboratory and field observations on duration of gonotrophic cycle of
   Anopheles albitarsis s.l. (Diptera : Culicidae) in southeastern Brazil
SO JOURNAL OF MEDICAL ENTOMOLOGY
LA English
DT Article
DE Anopheles albitarsis; gonotrophic cycle duration;
   mark-release-recapture; vectorial capacity
ID MOSQUITOS
AB Mark-release-recapture experiments were conducted to determine the duration of the gonotrophic cycle of Anopheles albitarsis s.l. in Ribeira Valley, State of Sao Paulo, Brazil. Separate experiments with females collected from the field were followed under laboratory conditions. A mean of 2.4 d was characteristic for the gonotrophic cycle for wild-caught females, whereas 4.4 d was characteristic for females in the laboratory conditions.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Fed Univ Sao Paulo R Napoleao Barros, Infect Dis Discipline, BR-0424062 Sao Paulo, Brazil.
RP Dos Santos, RL (corresponding author), Univ Sao Paulo, Fac Saude Publ, Av Dr Arnaldo 715, BR-01246940 Sao Paulo, SP, Brazil.
EM rlacorte@usp.br
RI Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890
CR CHARLWOOD JD, 1989, ANN TROP MED PARASIT, V83, P569, DOI 10.1080/00034983.1989.11812389
   DAVIDSON G, 1954, NATURE, V174, P792, DOI 10.1038/174792a0
   DEANE L M, 1986, Memorias do Instituto Oswaldo Cruz, V81, P5, DOI 10.1590/S0074-02761986000600002
   Detinova TS, 1962, WHO MONOGR SER, V47, P1
   FERNANDEZSALAS I, 1994, J MED ENTOMOL, V31, P340, DOI 10.1093/jmedent/31.3.340
   FORATTINI OP, 1993, REV SAUDE PUBL, V27, P227, DOI 10.1590/S0034-89101993000400001
   FORATTINI OP, 1995, REV SAUDE PUBL, V28, P329
   Kakitani I, 2000, REV SAUDE PUBL, V34, P33, DOI 10.1590/S0034-89102000000100007
   Lounibos LP, 1998, J VECTOR ECOL, V23, P195
   OLIVEIRAFERREIR.J, 1990, AM J TROP MED HYG, V43, P6
   PANDAY RS, 1977, MOSQ NEWS, V37, P728
   Povoa MM, 2000, T ROY SOC TROP MED H, V94, P106, DOI 10.1016/S0035-9203(00)90457-7
   RUBIOPALIS Y, 1994, MED VET ENTOMOL, V8, P275, DOI 10.1111/j.1365-2915.1994.tb00509.x
   SEGURA MNO, 1998, THESIS U FEDERAL PAR
   *STATS, 1994, STAT COMP PROGR VERS
   WILKERSON RC, 1995, J MED ENTOMOL, V32, P697, DOI 10.1093/jmedent/32.5.697
NR 16
TC 7
Z9 7
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-2585
EI 1938-2928
J9 J MED ENTOMOL
JI J. Med. Entomol.
PD NOV
PY 2002
VL 39
IS 6
BP 926
EP 930
PG 5
WC Entomology; Veterinary Sciences
SC Entomology; Veterinary Sciences
GA 622WE
UT WOS:000179669900019
PM 12495194
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
AF Massad, E
   Burattini, MN
   Coutinho, FAB
   Lopez, LF
TI Which phase of the natural history of HIV infection is more
   transmissible?
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Letter
ID IMMUNODEFICIENCY-VIRUS TYPE-1; PLASMA
C1 Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Lopez, Luis F/C-4721-2012; Massad,
   Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011; Coutinho, Francisco A
   B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Lopez, Luis
   F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071
CR Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650
   Coutinho FAB, 2001, B MATH BIOL, V63, P1041, DOI 10.1006/bulm.2001.0257
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
NR 6
TC 2
Z9 2
U1 0
U2 5
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD JUN
PY 2002
VL 13
IS 6
BP 430
EP 431
DI 10.1258/095646202760029895
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 557JF
UT WOS:000175904900016
PM 12015021
DA 2020-12-08
ER

PT J
AU de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
AF de Jesus, AR
   Silva, A
   Santana, LB
   Magalhaes, A
   de Jesus, AA
   de Almeida, RP
   Rego, MAV
   Burattini, MN
   Pearce, EJ
   Carvalho, EM
TI Clinical and immunologic evaluation of 31 patients with acute
   schistosomiasis mansoni
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article; Proceedings Paper
CT 49th Annual Meeting of the
   American-Society-of-Tropical-Medicine-and-Hygiene
CY OCT 29-NOV 02, 2000
CL HOUSTON, TEXAS
SP Amer Soc Trop Med & Hyg
ID CIRCULATING IMMUNE-COMPLEXES; MURINE SCHISTOSOMIASIS; CYTOKINE
   PRODUCTION; RESPONSES; ANTIGENS; INFECTION; DISEASE; GAMMA; TYPE-1;
   IL-10
AB Thirty-one patients with acute schistosomiasis were evaluated clinically and immunologically. Cytokine levels were determined in peripheral blood mononuclear cell (PBMC) supernatants. Levels of total and antigen-specific IgE, tumor necrosis factor (TNF)-alpha, and immune complexes were measured in serum samples. Clinical findings included general symptoms, liver damage, pulmonary involvement, and pericarditis. All patients had eosinophilia. Immune complexes were detected in 55% of the patients (mean +/- SD, 7.8 +/- 7.6 mug Eq/mL) and were associated with cough, dyspnea, and abnormal chest radiographic findings. Levels (mean +/- SD) of TNF-alpha (1349.3 +/- 767.6 pg/mL), interleukin (IL)-1 (2683 +/- 1270 mug/mL), and IL-6 (382 +/- 52.3 pg/mL) were elevated in PBMC. Serum TNF-alpha levels were elevated in 87% of the patients and were associated with abdominal pain. Higher interferon-gamma levels were detected in PBMC of patients with acute disease than in those of patients with chronic schistosomiasis; IL-5 levels were higher in those with chronic disease. Low IL-5 levels were associated with weight loss. Proinflammatory cytokines and immune complexes with low Th2 responses might explain the immunopathogenesis of acute schistosomiasis.
C1 Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
   Univ Fed Sergipe, Dept Doencas Infecciosas, Sergipe, Brazil.
   Univ Fed Sao Paulo, Serv Doencas Infecciosas, Sao Paulo, Brazil.
   Cornell Univ, Coll Vet Med, Dept Microbiol Immunol & Parasitol, Ithaca, NY 14853 USA.
RP Carvalho, EM (corresponding author), Univ Fed Bahia, Hosp Univ Prof Edgard Santos, Serv Imunol, BR-40110160 Salvador, Brazil.
RI almeida, roque/F-5609-2012; Burattini, Marcelo Nascimento/J-9272-2014
OI Burattini, Marcelo Nascimento/0000-0002-5407-6890
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639,
   P50AI030639, P50AI030639, P50AI030639, P50AI030639, P50AI030639] Funding
   Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [AI-30639] Funding
   Source: Medline
CR ABDELWAHAB MF, 1992, AM J TROP MED HYG, V46, P403, DOI 10.4269/ajtmh.1992.46.403
   Angstwurm K, 1998, NEUROSCIENCE, V86, P627, DOI 10.1016/S0306-4522(98)00032-3
   Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633
   ARAUJO MI, 1994, BRAZ J MED BIOL RES, V27, P1619
   BACH JF, 1997, LANCET, V350, P11
   BahiaOliveira LMG, 1996, PARASITE IMMUNOL, V18, P53, DOI 10.1046/j.1365-3024.1996.d01-49.x
   BARRALNETTO M, 1991, J INFECT DIS, V163, P853, DOI 10.1093/infdis/163.4.853
   Bina J. C., 1981, Revista de Patologia Tropical, V10, P221
   BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488
   Brunet LR, 1997, J IMMUNOL, V159, P777
   de Jesus AR, 2000, INFECT IMMUN, V68, P2797, DOI 10.1128/IAI.68.5.2797-2803.2000
   DEJESUS AMR, 1993, EUR J IMMUNOL, V23, P152, DOI 10.1002/eji.1830230125
   Dinarello CA, 2000, NEW ENGL J MED, V343, P732, DOI 10.1056/NEJM200009073431011
   Doumenge JP, 1987, ATLAS GLOBAL DISTRIB
   Fallon PG, 2000, EUR J IMMUNOL, V30, P470, DOI 10.1002/1521-4141(200002)30:2&lt;470::AID-IMMU470&gt;3.0.CO;2-T
   FARID Z, 1989, TROP GEOGR MED, V41, P172
   GAZZINELLI G, 1985, J IMMUNOL, V135, P2121
   GAZZINELLI RT, 1988, AM J TROP MED HYG, V39, P288, DOI 10.4269/ajtmh.1988.39.288
   GELFAND V, 1981, CENT AFR J MED, V27, P219
   Gryzch JM, 1991, J IMMUNOL, V146, P1322
   HIATT RA, 1979, J INFECT DIS, V139, P659, DOI 10.1093/infdis/139.6.659
   HIATT RA, 1980, J INFECT DIS, V142, P665, DOI 10.1093/infdis/142.5.665
   Hoffmann KF, 2000, J IMMUNOL, V164, P6406, DOI 10.4049/jimmunol.164.12.6406
   KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295
   KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532
   KATZ N, 1966, J PARASITOL, V52, P917, DOI 10.2307/3276534
   KEMENY DM, 1991, PRACTICAL GUIDE ELIS
   Kox WJ, 2000, INTENS CARE MED, V26, pS124, DOI 10.1007/s001340051129
   Kubler-Kielb J, 2000, Postepy Hig Med Dosw, V54, P119
   LAMBERTUCCI J, 1989, T R SOC MED HYG, V83, P76
   Lambertucci J. R., 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P399, DOI 10.1590/S0036-46651993000500003
   Lambertucci JR, 1997, MEM I OSWALDO CRUZ, V92, P631, DOI 10.1590/S0074-02761997000500013
   LAWLEY TJ, 1979, CLIN EXP IMMUNOL, V37, P221
   Montenegro SML, 1999, J INFECT DIS, V179, P1502, DOI 10.1086/314748
   MOSMANN TR, 1986, J IMMUNOL, V136, P2348
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045
   Mwatha JK, 1998, J IMMUNOL, V160, P1992
   Pearce EJ, 1996, EXP PARASITOL, V84, P295, DOI 10.1006/expr.1996.0116
   PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159
   PESSOA SB, 1977, PARASITOLOGIA MED, P399
   RABELLO A, 1995, MEM I OSWALDO CRUZ, V90, P277, DOI 10.1590/S0074-02761995000200026
   Rabello ALT, 1997, CLIN INFECT DIS, V24, P304, DOI 10.1093/clinids/24.3.304
   Sabin EA, 1996, J INFECT DIS, V173, P269, DOI 10.1093/infdis/173.1.269
   VANDEUREN M, 1995, J INFECT DIS, V172, P433, DOI 10.1093/infdis/172.2.433
   *WHO, 1985, REP WHO EXP COMM CON
   *WHO, 1995, WHO UNICEF JOINT PRO
   World Health Organization, 1993, WHO TECHN REP SER, V830
   Wynn TA, 1998, J IMMUNOL, V160, P4473
NR 48
TC 112
Z9 115
U1 0
U2 9
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JAN 1
PY 2002
VL 185
IS 1
BP 98
EP 105
DI 10.1086/324668
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 502AZ
UT WOS:000172722600013
PM 11756987
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Yu, ALF
   Amaku, M
   Burattini, MN
   Massad, E
   Azevedo, RS
AF Yu, ALF
   Amaku, M
   Burattini, MN
   Massad, E
   Azevedo, RS
TI Varicella transmission in two samples of children with different social
   behaviour in the State of Sao Paulo, Brazil
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID ZOSTER-VIRUS; AGE; INFECTION; MEASLES; MUMPS
AB In order to establish the differences in transmission pattern of varicella-zoster virus (VZV), a comparative seroepidemiological study was carried out in two different children samples. Children aged 1-11 years, were randomly selected from state schools of Sao Paulo city, Brazil. Individuals aged 1-15 years were sampled by cluster from Caieiras city. Children aged 3 years or under from Caieiras were not attending school, while those from Sao Paulo were attending all-day nurseries or kindergarten. The presence of antibodies to VZV was analysed by ELISA technique. The force of infection and contact rate were determined by mathematical techniques. The average age of first infection was 2.87 +/- 0.14 years and 4.07 +/- 0.47 years for Sao Paulo and Caieiras, respectively. The average force of infection estimated was 0.29 year(-1) for Sao Paulo and was 0.26 year(-1) for Caieiras. The proportion of seropositivity and the force of infection were higher in Sao Paulo school children up to 3 years of age compared with Caieiras children, where the social contact starts later. In conclusion, social changes affecting contact among children may influence varicella epidemiology.
C1 Univ Sao Paulo, Sch Med, Disciplina Informat Med, HCFMUSP,LIM 01, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Phys, BR-01246903 Sao Paulo, Brazil.
RP Yu, ALF (corresponding author), Univ Sao Paulo, Sch Med, Disciplina Informat Med, HCFMUSP,LIM 01, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Massad, Eduardo/B-1169-2012; Frugis Yu, Ana Lucia/K-9092-2016;
   Burattini, Marcelo N/J-9272-2014; Azevedo, Raymundo S/B-7593-2008;
   Amaku, Marcos/D-5252-2012; Massad, Eduardo/H-6143-2011
OI Massad, Eduardo/0000-0002-7200-2916; Frugis Yu, Ana
   Lucia/0000-0003-2207-3940; Burattini, Marcelo N/0000-0002-5407-6890;
   Azevedo, Raymundo S/0000-0003-0660-2371; Amaku,
   Marcos/0000-0003-4752-6774; 
CR ANDERSON R M, 1991
   ARVIN AM, 1996, FIELDS VIROLOGY, P2547
   CRISTOFANI LM, 1991, VACCINE, V9, P873, DOI 10.1016/0264-410X(91)90006-R
   FARRINGTON CP, 1990, STAT MED, V9, P953, DOI 10.1002/sim.4780090811
   GARNETT GP, 1993, EPIDEMIOL INFECT, V110, P361, DOI 10.1017/S0950268800068308
   GARNETT GP, 1992, EPIDEMIOL INFECT, V108, P495, DOI 10.1017/S0950268800050007
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859
   HOPESIMPSON RE, 1952, LANCET, V2, P549, DOI DOI 10.1016/S0140-6736(52)91357-3
   KANGRO HO, 1994, J MED VIROL, V43, P91, DOI 10.1002/jmv.1890430117
   LONDON WP, 1973, AM J EPIDEMIOL, V98, P453, DOI 10.1093/oxfordjournals.aje.a121575
   MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
   MASSAD E, 1990, MATH COMPUT MODEL, V13, P101, DOI 10.1016/0895-7177(90)90057-T
   Massad Eduardo, 1995, Journal of Biological Systems, V3, P803, DOI 10.1142/S0218339095000733
   NETO RSD, 1994, EPIDEMIOL INFECT, V113, P161, DOI 10.1017/S095026880005158X
   PREBLUD SR, 1981, PEDIATRICS, V68, P14
   ROSS AH, 1962, NEW ENGL J MED, V267, P369, DOI 10.1056/NEJM196208232670801
   TAKAHASHI M, 1994, VACCINES, P387
   Yu Ana Lucia Frugis, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P125, DOI 10.1590/S0036-46652000000300002
NR 18
TC 9
Z9 9
U1 0
U2 4
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 2001
VL 127
IS 3
BP 493
EP 500
DI 10.1017/S0950268801006124
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 518LV
UT WOS:000173670600015
PM 11811883
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
TI A model-independent analysis of the demographic impact of HIV/AIDS in
   the state of Sao Paulo, Brazil
SO JOURNAL OF BIOLOGICAL SYSTEMS
LA English
DT Article
DE demography; HIV; AIDS; mortality; life expectancy
ID HIV-INFECTION; DRUG-USERS; AIDS; MORTALITY; AFRICA
AB The devastating figures that recently emerged from a demographic study of the impact of HIV/AIDS in some African countries mark the return to the conditions of the XIXth century, when high birth rates were neutralized by equally high death rates. In the State of Sao Paulo, Brazil, AIDS is the second cause of death among men aged twenty to forty nine years and the first cause of death of women in the same age class. In this work we propose a mathematical treatment to evaluate the impact of AIDS mortality on the age structure of an affected population, namely, that of the state of Sao Paulo, Brazil. We propose four indicators for the estimation of the impact of AIDS mortality. The first is the age-dependent differences in ten years survival probabilities attributable to AIDS. The second is the difference in the average age of survivors after 10 years of AIDS. The next is the conventional life expectancy at birth for children born in 1996 and with AIDS prevalence assumed at its maximum value and remaining in steady-state afterwards, Finally, we calculate the differences in the life expectancy of individuals considering the effect of AIDS for only ten years. We found that, in the period between 1987 and 1996 the effects were small but very interesting. However, projecting to the future the conditions of 1996, we calculate that the population of the state of Sao Paulo would lose 3 years in the average life expectancy at birth.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Lopez, Luis F/C-4721-2012; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011; Burattini,
   Marcelo N/J-9272-2014
OI Lopez, Luis F/0000-0003-4097-6887; Massad, Eduardo/0000-0002-7200-2916;
   Coutinho, Francisco A B/0000-0003-3127-3071; Burattini, Marcelo
   N/0000-0002-5407-6890
CR ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0
   Burattini MN, 1998, MATH COMPUT MODEL, V28, P21, DOI 10.1016/S0895-7177(98)00095-8
   Carvalho Heraclito Barbosa De, 1996, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V12, P84
   GARNETT GP, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90522-R
   Heath KV, 1998, INT J EPIDEMIOL, V27, P685, DOI 10.1093/ije/27.4.685
   Hogg RS, 1997, INT J EPIDEMIOL, V26, P657, DOI 10.1093/ije/26.3.657
   LOWBEER D, INT C AIDS 1996
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   PEARCE F, 1998, NEW SCI         1017, P12
   Ragni MV, 1996, J ACQ IMMUN DEF SYND, V13, P160, DOI 10.1097/00042560-199610010-00007
   SCOTT S, 1998, HUMAN DEMOGRAPHY DIS
   *SECR HLTH STAT SA, 1998, B EP, P11
   TRUCCO E, 1965, B MATH BIOPHYS, V27, P285, DOI 10.1007/BF02478406
   *UN, 1994, AIDS DEM AFR
   WAY PO, INT C AIDS 1994
   Zanetta DMT, 1999, INT J STD AIDS, V10, P98, DOI 10.1258/0956462991913718
NR 17
TC 0
Z9 0
U1 0
U2 1
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA JOURNAL DEPT PO BOX 128 FARRER ROAD, SINGAPORE 912805, SINGAPORE
SN 0218-3390
J9 J BIOL SYST
JI J. Biol. Syst.
PD DEC
PY 2001
VL 9
IS 4
BP 255
EP 267
DI 10.1142/S0218339001000402
PG 13
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 515DJ
UT WOS:000173479900003
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Sallum, PC
   Lopez, LF
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Sallum, PC
   Lopez, LF
TI A mixed ectoparasite-microparasite model for bat-transmitted rabies
SO THEORETICAL POPULATION BIOLOGY
LA English
DT Article
DE vampire bats; rabies; control; modeling
ID TRANSMISSION; INFECTIONS; DYNAMICS
AB This paper considers the transmission of rabies to domestic livestock by vampire bats. Vampire bats act as ectoparasites on cattle both by ingesting a small amount of blood every night and by prolonging bleeding by the action of anticoagulant substances in their saliva. In addition to this parasitic action bats may also transmit rabies, inflicting important losses on affected herds by the inevitable mortality due to the infection. We modeled this complex interaction and we also demonstrate that bat control measures are more effective in reducing rabies prevalence and mortality by rabies than cattle vaccination. (C) 2001 Elsevier Science.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Lopez, Luis F/C-4721-2012; Coutinho, Francisco A
   B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Coutinho, Francisco A B/0000-0003-3127-3071
CR ANDERSON R M, 1991
   ARELLANOSOTA C, 1988, REV INFECT DIS, V10, pS707
   BERAN GW, 1981, CRC HDB SERIES ZOONO, V2
   Brass D. A., 1994, RABIES BATS NATURAL
   BURATTINI MN, 1999, J BIOL SYST, V6, P337
   Constantine D.G., 1988, P167
   DARLING K, 1997, KOMODO DRAGON
   DELPIETRO HA, 1992, PREV VET MED, V14, P13, DOI 10.1016/0167-5877(92)90080-Y
   ELSGOLTS EL, 1966, INTRO THEORY DIFFERE
   FENTON MB, 1992, BATS
   GOODWIN GEORGE G., 1961, BULL AMER MUS NAT HIST, V122, P187
   GREENHALL AM, 1970, P 4 VERT PEST C CAL
   HARINASUTA T, 1990, TROPICAL GEOGRAPHICA, pCH55
   JOHNSON RT, 1982, VIRAL INFECT NERVOUS
   Lomnicki A, 1988, POPULATION ECOLOGY I
   Lopez LF, 1999, MATH COMPUT MODEL, V29, P55, DOI 10.1016/S0895-7177(99)00062-X
   MACDONAL.G, 1965, T ROY SOC TROP MED H, V59, P489, DOI 10.1016/0035-9203(65)90152-5
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MASSAD E, 1987, EVOLUTION, V41, P1127, DOI [10.2307/2409198, 10.1111/j.1558-5646.1987.tb05883.x]
   May R.M., 1973, STABILITY COMPLEXITY
   MAY RM, 1977, MATH BIOSCI, V35, P301, DOI 10.1016/0025-5564(77)90030-X
   Mayr Ernst, 1970, POPULATIONS SPECIES
   Mead DG, 2000, SCIENCE, V287, P485, DOI 10.1126/science.287.5452.485
   Pianka E.R., 1983, EVOLUTIONARY ECOLOGY
   Pulliam H.R., 1989, P25
   Roughgarden J, 1979, THEORY POPULATION GE
   STEELE JH, 1973, SCAND J INFECT DIS, V5, P299, DOI 10.3109/inf.1973.5.issue-4.12
   THOMPSON RD, 1977, J WILDLIFE MANAGE, V41, P736, DOI 10.2307/3799998
   *WHO, 1957, 121 WHO EXP COMM RAB
   *WHO, 1966, 321 WHO EXP COMM RAB
   *WHO, 1984, 709 WHO EXP COMM RAB
   *WHO, 1973, 523 WHO EXP COMM RAB
   Yang HM, 1997, J THEOR BIOL, V188, P495, DOI 10.1006/jtbi.1997.0479
NR 34
TC 12
Z9 14
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0040-5809
EI 1096-0325
J9 THEOR POPUL BIOL
JI Theor. Popul. Biol.
PD DEC
PY 2001
VL 60
IS 4
BP 265
EP 279
DI 10.1006/tpbi.2000.1494
PG 15
WC Ecology; Evolutionary Biology; Genetics & Heredity; Mathematical &
   Computational Biology
SC Environmental Sciences & Ecology; Evolutionary Biology; Genetics &
   Heredity; Mathematical & Computational Biology
GA 533CA
UT WOS:000174510800001
PM 11878829
DA 2020-12-08
ER

PT J
AU Coutinho, FAB
   Lopez, LF
   Burattini, MN
   Massad, E
AF Coutinho, FAB
   Lopez, LF
   Burattini, MN
   Massad, E
TI Modelling the natural history of HIV infection in individuals and its
   epidemiological implications
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-FACTORS; VIRAL LOAD; PLASMA;
   TRANSMISSION; TYPE-1; RNA; PROGRESSION; AIDS; VIREMIA
AB The variation of viraemia in the natural course of HIV infection is expected to have major influence on the probability of transmission and, consequently, on the epidemiology of HIV/AIDS.
   In this paper we propose a model which takes into account the time evolution of HIV viraemia (measured as HIV-RNA copies per ml of blood) in an infected individual and its impact on the threshold for the establishment of an endemic level, and mainly on the relative contribution of each of the clinical phases of the infection to the total transmission of HIV per infected individual. We consider that an infected individual passes through three phases of viraemia. The first phase, which lasts for 6-7 weeks. is characterized by very high viraemia. In the second phase, which lasts about 10 years., the viraemia is much lower., increasing again in the last phase, which lasts up to two years. and ends in full-blown AIDS.
   We show that the relative contribution of each phase to the total transmission of HIV is very sensitive to the model we assume for the dependence of the transmissibility of HIV on the viral load. For instance, if we assume that transmissibility is proportional to the decimal logarithm of viraemia, then the second phase predominates always, Due to the epidemiological importance of this fact, it is clear that further improvement on virological research to better understand the dependence of HIV transmissibility on the viral concentration in biological fluids is necessary. (C) 2001 Society for Mathematical Biology.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   LIM01 HCFMUSP, BR-01246903 Sao Paulo, Brazil.
RP Coutinho, FAB (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Lopez, Luis F/C-4721-2012; Coutinho, Francisco A
   B/H-5644-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Lopez, Luis F/0000-0003-4097-6887;
   Coutinho, Francisco A B/0000-0003-3127-3071
CR AHLGREN DJ, 1990, J ACQ IMMUN DEF SYND, V3, P631
   ANDERSON R M, 1991
   AOKISEI S, 1992, AIDS RES HUM RETROV, V8, P1263, DOI 10.1089/aid.1992.8.1263
   Arfken G, 1970, MATH METHODS PHYSICI
   BAGASRA O, 1992, NEW ENGL J MED, V326, P1385, DOI 10.1056/NEJM199205213262103
   BAGNARELLI P, 1991, J MED VIROL, V34, P89, DOI 10.1002/jmv.1890340204
   Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650
   BRAVO R, 1995, MED CLIN-BARCELONA, V104, P530
   Brookmeyer R, 1994, AIDS EPIDEMIOLOGY QU
   CAMERON DW, 1989, LANCET, V2, P403
   CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993
   COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   Coutinho FAB, 1999, REV SAUDE PUBL, V33, P329, DOI 10.1590/S0034-89101999000400002
   Coutinho FAB, 1999, MATH COMPUT MODEL, V30, P97, DOI 10.1016/S0895-7177(99)00119-3
   Dickover RE, 1996, JAMA-J AM MED ASSOC, V275, P599, DOI 10.1001/jama.275.8.599
   EASTERBROOK PJ, 1994, AIDS, V8, P1179, DOI 10.1097/00002030-199408000-00023
   ERB P, 1994, J ACQ IMMUN DEF SYND, V7, P261
   Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602
   GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405
   Griffel D.H., 1981, APPL FUNCTIONAL ANAL
   HENRARD DR, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92660-8
   HETHCOTE HW, 1992, MODELLING HIV TRANSM
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   HOLODNIY M, 1991, J INFECT DIS, V163, P862, DOI 10.1093/infdis/163.4.862
   HOUN HY, 1987, ANN CLIN LAB SCI, V17, P279
   HYMAN JM, 1988, MATH BIOSCI, V90, P415, DOI 10.1016/0025-5564(88)90078-8
   JACKSON J B, 1988, Clinical Microbiology Reviews, V1, P124
   JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169
   JURRIAANS S, 1995, THESIS U AMSTERDAM
   KEET IPM, 1993, AIDS, V7, P51, DOI 10.1097/00002030-199301000-00008
   KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C
   Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   Levin BR, 1996, MATH BIOSCI, V132, P69, DOI 10.1016/0025-5564(95)00053-4
   LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959
   Lopez LF, 2000, J MATH BIOL, V40, P199, DOI 10.1007/s002850050178
   MASSAD E, 1989, MATH COMPUT MODEL, V12, P89, DOI 10.1016/0895-7177(89)90448-2
   MAY RM, 1990, PARASITOLOGY, V100, pS89, DOI 10.1017/S0031182000073042
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   OSMOND D, 1988, AM J PUBLIC HEALTH, V78, P944, DOI 10.2105/AJPH.78.8.944
   PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089
   PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233
   Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303
   SANO K, 1987, J CLIN MICROBIOL, V25, P2415, DOI 10.1128/JCM.25.12.2415-2417.1987
   SIMMONDS P, 1990, AIDS (London), V4, pS77
   SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504
   VANGRIENSVEN GJP, 1990, AM J EPIDEMIOL, V132, P203
   Vella S, 2000, ANTIVIR RES, V47, P189, DOI 10.1016/S0166-3542(00)00107-8
NR 49
TC 18
Z9 18
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD NOV
PY 2001
VL 63
IS 6
BP 1041
EP 1062
DI 10.1006/bulm.2001.0257
PG 22
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA 492WP
UT WOS:000172190800003
PM 11732175
DA 2020-12-08
ER

PT J
AU Zanetta, RAC
   Amaku, M
   Azevedo, RS
   Zanetta, DMT
   Burattini, MN
   Massad, E
AF Zanetta, RAC
   Amaku, M
   Azevedo, RS
   Zanetta, DMT
   Burattini, MN
   Massad, E
TI Optimal age for vaccination against measles in the State of Sao Paulo,
   Brazil, taking into account the mother's serostatus
SO VACCINE
LA English
DT Article
DE measles; vaccine; mathematical modeling; seroprevalence; seroconversion;
   optimal ages for vaccination
ID INFANTS; IMMUNITY; ANTIBODY; 6-MONTH-OLD; WOMEN; MODEL
AB In order to investigate if the changing levels of measles antibody in women resulting from extensive vaccination programs influence the susceptibility of children, we measured the seroprevalence of measles virus antibody of children in the first year of life and of their mothers. We compared maternal antibody decay of two groups of children: those whose mothers were 25 years old or more (mothers born in the pre-vaccination era), and less than 25 years old (mothers born in the vaccination era). Therefore, the 25-year-age cut-off was chosen to distinguish between vaccinated and non-vaccinated mothers. We also compared the immunogenicity of measles vaccine in children from 6 to 12 months of age, in these two groups and also according to their mother's serostatus. The optimal age of vaccination for a routine program was estimated by means of mathematical models.
   This study was carried out in a sample of 1216 mothers and their respective children, Our results indicate that the optimal age for vaccination of the whole sample was 15 months, 17 months for children born from older mothers, 14 months for children born from younger mothers, 17 months for children born from seropositive mothers and 12 months for children born from seronegative mothers. Therefore, a change to an earlier age of routine vaccination is not justified by our results. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Discipline Med Informat, Fac Med, BR-01246903 Sao Paulo, Brazil.
   LIM01 HCFMUSP, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Fis, BR-01246903 Sao Paulo, Brazil.
   Fac Med Sao Jose Rio Preto, Sao Jose Do Rio Preto, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Discipline Med Informat, Fac Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Amaku,
   Marcos/D-5252-2012; Azevedo, Raymundo S/B-7593-2008; Zanetta, Dirce M
   T/G-4950-2013; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Amaku, Marcos/0000-0003-4752-6774; Azevedo,
   Raymundo S/0000-0003-0660-2371; 
CR ANDERSON R M, 1991
   *CDC, 1998, P 1997 INT M COSP WH, V47, P1
   DAGAN R, 1995, PEDIATR INFECT DIS J, V14, P965, DOI 10.1097/00006454-199511000-00008
   FARRINGTON CP, 1990, STAT MED, V9, P953, DOI 10.1002/sim.4780090811
   HETHCOTE HW, 1988, MATH BIOSCI, V89, P29, DOI 10.1016/0025-5564(88)90111-3
   JOHNSON CE, 1994, PEDIATRICS, V93, P939
   KACICA MA, 1995, J MED VIROL, V45, P227, DOI 10.1002/jmv.1890450220
   KRUGMAN S, 1965, J PEDIATR-US, V66, P471, DOI 10.1016/S0022-3476(65)80112-3
   Kumar ML, 1998, VACCINE, V16, P2047, DOI 10.1016/S0264-410X(98)00083-8
   LENNON JL, 1986, J PEDIATR-US, V108, P671, DOI 10.1016/S0022-3476(86)81039-3
   MALDONADO YA, 1995, PEDIATRICS, V96, P447
   Markowitz LE, 1996, PEDIATRICS, V97, P53
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MASSAD E, 1990, MATH COMPUT MODEL, V13, P101, DOI 10.1016/0895-7177(90)90057-T
   Massad E, 1999, INT J EPIDEMIOL, V28, P550, DOI 10.1093/ije/28.3.550
   Massad Eduardo, 1995, Journal of Biological Systems, V3, P803, DOI 10.1142/S0218339095000733
   Nates SV, 1998, PEDIATR INFECT DIS J, V17, P313, DOI 10.1097/00006454-199804000-00009
   Orenstein W A, 1986, Dev Biol Stand, V65, P13
   PABST HF, 1992, PEDIATR INFECT DIS J, V11, P525, DOI 10.1097/00006454-199207000-00004
   REDD SC, 1999, VACCINES, P227
NR 20
TC 20
Z9 21
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD OCT 12
PY 2001
VL 20
IS 1-2
BP 226
EP 234
DI 10.1016/S0264-410X(01)00267-5
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 481GR
UT WOS:000171512000033
PM 11567768
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
   Struchiner, CJ
TI Modeling the impact of imperfect HIV vaccines on the incidence of the
   infection
SO MATHEMATICAL AND COMPUTER MODELLING
LA English
DT Article
DE HIV; vaccines; transmission dynamics; mathematical modeling; control
   strategies
ID SEROPREVALENCE; EFFICACY; TRIALS
AB One concern about HIV vaccine trials is that participants might develop a false sense of security and increase their risk behavior. This fear has (at least partially) impaired the development of extensive clinical trials on HIV vaccines and are, in principle, justified. In this paper, we develop a dynamical model which allows experiments on the effects of an imperfect vaccine on a population prone to change its risk behavior. Our results show that even the poorest of the candidate vaccines to be seriously considered, may have beneficial effects on reducing transmission, even when risk behaviors increases. (C) 2001 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Procc Fiocruz, Rio De Janeiro, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Massad, Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Coutinho,
   Francisco A B/H-5644-2011; Struchiner, Claudio J/M-9360-2013; Lopez,
   Luis F/C-4721-2012; Massad, Eduardo/H-6143-2011
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; Coutinho, Francisco A B/0000-0003-3127-3071;
   Struchiner, Claudio J/0000-0003-2114-847X; Lopez, Luis
   F/0000-0003-4097-6887; 
CR ANDERSON R M, 1991
   Anderson R. M., 1982, POPULATION DYNAMICS
   Buchbinder S., 1999, IAVI REPORT, V4, P9
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   CHAISSON RE, 2000, PRINCIPLES PRACTICES, P1398
   Chesney MA, 1997, J ACQ IMMUN DEF SYND, V16, P266, DOI 10.1097/00042560-199712010-00007
   Coutinho FAB, 1999, MATH COMPUT MODEL, V30, P97, DOI 10.1016/S0895-7177(99)00119-3
   Desai KN, 1999, EPIDEMIOL INFECT, V123, P65, DOI 10.1017/S0950268899002642
   Frey SE, 1999, INFECT DIS CLIN N AM, V13, P95, DOI 10.1016/S0891-5520(05)70045-3
   Halloran ME, 1999, EPIDEMIOL REV, V21, P73, DOI 10.1093/oxfordjournals.epirev.a017990
   HALLORAN ME, 1994, STAT MED, V13, P357, DOI 10.1002/sim.4780130404
   Jackson DJ, 1999, AIDS, V13, P583, DOI 10.1097/00002030-199904010-00007
   Kahne T, 1999, INT J MOL MED, V4, P3
   Limpakarnjanarat K, 1999, SEX TRANSM INFECT, V75, P30, DOI 10.1136/sti.75.1.30
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075
   Ohshige K, 1999, Nihon Koshu Eisei Zasshi, V46, P61
   Pal BB, 1999, INDIAN J MED RES, V109, P199
   Perez Gonzalez K, 1999, Gac Sanit, V13, P7
   van Gorkom J, 1999, E AFR MED J, V76, P452
   VOELKER R, JAMA, V281, P889
   1998, LANCET, V352, P24
NR 22
TC 15
Z9 15
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-7177
EI 1872-9479
J9 MATH COMPUT MODEL
JI Math. Comput. Model.
PD AUG
PY 2001
VL 34
IS 3-4
BP 345
EP 351
DI 10.1016/S0895-7177(01)00066-8
PG 7
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 443CF
UT WOS:000169321300010
DA 2020-12-08
ER

PT J
AU Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
AF Massad, E
   Coutinho, FAB
   Burattini, MN
   Lopez, LF
TI The risk of yellow fever in a dengue-infested area
SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
DE vector-borne infections; dengue; yellow fever; basic reproduction
   number; modelling; trends; vaccination coverage; Brazil
ID 1ST RECORDED OUTBREAK; KENYA
AB Yellow fever and dengue are viral infections that in urban centres are transmitted by the same arthropod vector, a mosquito of the genus Aedes. In order to estimate the risk of an epidemic of urban yellow fever in a dengue-infested area we calculated the threshold in the basic reproduction number, R-0, of dengue, above which any single sylvatic yellow fever-infected individual will trigger an urban yellow fever epidemic. Specifically, we analysed the relationship between the extrinsic incubation period and the duration of viraemia, from which it is possible to define the R-0 for dengue that would also suggest an outbreak potential for yellow fever. We also calculated the critical proportion of people to vaccinate against yellow fever in order to prevent an epidemic in a dengue-endemic area. The theory proposed is illustrated by the case of Sao Paulo State in southern Brazil, where dengue is endemic and the risk of urban yellow fever is already imminent.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Lopez, Luis F/C-4721-2012; Burattini, Marcelo N/J-9272-2014; Massad,
   Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012; Coutinho, Francisco A
   B/H-5644-2011
OI Lopez, Luis F/0000-0003-4097-6887; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071
CR ANDERSON R M, 1991
   Buratti M, 1998, J COMB DES, V6, P337, DOI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
   Digoutte JP, 1999, B SOC PATHOL EXOT, V92, P343
   Halstead S. B., 1990, Tropical and geographical medicine., P675
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   MARQUES CA, 1994, T ROY SOC TROP MED H, V88, P58, DOI 10.1016/0035-9203(94)90498-7
   Molineaux L, 1980, THE GARKI PROJECT
   Monath T. P., 1990, Tropical and geographical medicine., P661
   Monath TP, 1999, LANCET, V353, P1541, DOI 10.1016/S0140-6736(99)00155-5
   Monath TP, 1999, VACCINES, P815
   Monath TP, 1996, FIELDS VIROLOGY, P961
   Reiter P, 1998, AM J TROP MED HYG, V59, P650, DOI 10.4269/ajtmh.1998.59.650
   RICE CM, 1996, VIROLOGY, P931
   Sanders EJ, 1998, AM J TROP MED HYG, V59, P644, DOI 10.4269/ajtmh.1998.59.644
   *SEADE, 2000, FUND SIST EST AN DAD
   Van der Stuyft P, 1999, LANCET, V353, P1558, DOI 10.1016/S0140-6736(99)03291-2
   Woodring Jennifer L., 1996, P51
   1999, LANCET, V353, P1546
NR 18
TC 87
Z9 90
U1 1
U2 31
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0035-9203
EI 1878-3503
J9 T ROY SOC TROP MED H
JI Trans. Roy. Soc. Trop. Med. Hyg.
PD JUL-AUG
PY 2001
VL 95
IS 4
BP 370
EP 374
DI 10.1016/S0035-9203(01)90184-1
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 478GJ
UT WOS:000171336900006
PM 11579875
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Massad, E
   Rozman, M
   Azevedo, RS
   Carvalho, HB
AF Burattini, MN
   Massad, E
   Rozman, M
   Azevedo, RS
   Carvalho, HB
TI Correlation between HIV and HCV in Brazilian prisoners: evidence for
   parenteral transmission inside prison
SO REVISTA DE SAUDE PUBLICA
LA English
DT Article
DE acquired immunodeficiency syndrome, epidemiology; hepatitis
   epidemiology; HIV seroprevalence; prisoners; substance-related
   disorders; risk factors; seroepidemiologic studies; drug usage; male
   prisioners
ID HEPATITIS-C VIRUS; RISK; INFECTION; INMATES
AB Objective It is an accepted fact that confinement conditions increase the risk of some infections related to sexual and/or injecting drugs practices. Mathematical techniques were applied to estimate time-dependent incidence densities of HIV infection among inmates.
   Methods A total of 631 prisoners from a Brazilian prison with 4,900 inmates at that time were interviewed and their blood drawn. Risky behavior for HIV infection was analyzed, and serological tests for HIV, hepatitis C and syphilis were performed, intended as surrogates for parenteral and sexual HIV transmission, respectively. Mathematical techniques were used to estimate the incidence density ratio, as related to the time of imprisonment.
   Results Prevalence were: HIV - 16%; HCV - 34%; and syphilis - 18%. The main risk behaviors related to HIV infection were HCV prevalence (OR=10.49) and the acknowledged use of injecting drugs (OR=3.36). Incidence density ratio derivation showed that the risk of acquiring HIV infection increases with the time of imprisonment, peaking around three years after incarceration.
   Conclusions The correlation between HIV and HCV seroprevalence and the results of the mathematical analysis suggest that HIV transmission in this population is predominantly due to parenteral exposure by injecting drug, and that it increases with time of imprisonment.
C1 Univ Sao Paulo, Fac Med, Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Ave Doutor Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Carvalho, Heraclito/C-1334-2012; Massad, Eduardo/H-6143-2011; Burattini,
   Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Azevedo, Raymundo
   S/B-7593-2008
OI Carvalho, Heraclito/0000-0002-7037-5655; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Azevedo,
   Raymundo S/0000-0003-0660-2371
CR *AISN SOFTW, 1992, JAND SCI TABL VERS 3
   BURATTINI MN, 1993, EPIDEMIOL INFECT, V111, P503, DOI 10.1017/S0950268800057241
   deCarvalho HB, 1996, J ACQ IMMUN DEF SYND, V12, P84, DOI 10.1097/00042560-199605010-00012
   DESENCLOS JC, 1995, PRESSE MED, V24, P7
   Diaz RS, 1999, AIDS, V13, P1417, DOI 10.1097/00002030-199907300-00024
   GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293
   LORENCO R, 1992, THESIS SAO PAULO ESC
   LWANGA SK, 1991, SAMPLE SIZES DETERMI
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   Massad E, 1999, EUR J EPIDEMIOL, V15, P439, DOI 10.1023/A:1007523027876
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MCKEE KJ, 1995, AIDS CARE, V7, P159, DOI 10.1080/09540129550126687
   Muench H, 1959, CATALYTIC MODELS EPI
   MUTTER RC, 1994, ARCH INTERN MED, V154, P793, DOI 10.1001/archinte.154.7.793
   PEIXINHO ZF, 1990, NAT IMMUN CELL GROW, V9, P133
   PONT J, 1994, EUR J EPIDEMIOL, V10, P285, DOI 10.1007/BF01719351
   POWER KG, 1992, BRIT J ADDICT, V87, P35
   ROTILY M, 1994, AIDS, V8, P1341, DOI 10.1097/00002030-199409000-00020
   Rozman M, 1998, INT J STD AIDS, V9, P183, DOI 10.1258/0956462981921855
   WATTS DM, 1994, T ROY SOC TROP MED H, V88, P55, DOI 10.1016/0035-9203(94)90495-2
   *WHO COLL STUD GRO, 1994, FIN REP WHO PSA PROG
   Zanetta DMT, 1999, INT J STD AIDS, V10, P98, DOI 10.1258/0956462991913718
NR 22
TC 42
Z9 49
U1 0
U2 9
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01246-904SP SAO PAULO,
   BRAZIL
SN 0034-8910
EI 1518-8787
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD OCT
PY 2000
VL 34
IS 5
BP 431
EP 436
DI 10.1590/S0034-89102000000500001
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 377CV
UT WOS:000165495100001
PM 11105105
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Goncalves, MAG
   Massad, E
   Burattini, MN
   Villa, LL
AF Goncalves, MAG
   Massad, E
   Burattini, MN
   Villa, LL
TI Relationship between human papillomavirus (HPV) genotyping and genital
   neoplasia in HIV-positive patients of Santos City, Sao Paulo, Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE human papillomavirus (HPV); human immunodeficiency virus (HIV); acquired
   immunodeficiency syndrome (AIDS); cervical intraepithelial neoplasia
   (CIN); squamous intraepithelial lesion (SIL); colposcopy
ID HUMAN-IMMUNODEFICIENCY-VIRUS; WOMEN; INFECTION; RISK; AMPLIFICATION;
   POLYMERASE; LESIONS; CERVIX; DNA
AB Among HIV-positive women, infection with multiple human papillomavirus (HPV) types is known to be more frequent and persistent, as well as a greater prevalence of high-grade genital lesions. This study aims to characterize, for the first time in Brazil, HPV presence and types among HIV-positive women of a high-risk population for genital intraepithelial neoplasia (GIN) development. A non-anonymous, voluntary, cross-sectional epidemiological survey was conducted, from June 1996 to April 1997, among 141 HIV-positive women followed at the Center of Reference in AIDS (CRAIDS). They were submitted to gynaecological examination, cytological screening and biopsies whenever necessary, for GIN and HPV DNA detection through polymerase chain reaction (PCR) technique. Positive HPV DNA were found in 80.8% patients. Two or more HPV types were detected in 45% of the samples. The most frequent HPV types detected were 16, 18 (30.5%); 61, 53 (24.4%), and non-identified types (18.7%). According to the oncogenic potential, 34.8% were considered of high-risk types. Among these HIV-positive patients, a great variety of HPV types, including high-risk types, was found in anogenital environment, as well as among young women, a gr eat prevalence of high-grade genital lesions. Thus, it should strengthen the need for a periodical careful gynaecological examination among those women.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; VILLA,
   LUISA/AAH-4761-2019; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; VILLA, LUISA/0000-0003-4074-2335; 
CR BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077
   DEAN AG, 1994, EPILNFO VERSION 6 WO
   DIXON WJ, 1992, BMDP STAT SOFTWARE M, V1
   GROSS EG, 1997, HUMAN PAPILLOMA VIRU
   HO GYF, 1994, INT J CANCER, V56, P788, DOI 10.1002/ijc.2910560605
   JOHNSON JC, 1992, OBSTET GYNECOL, V79, P321, DOI 10.1097/00006250-199203000-00001
   KURMAN RJ, 1994, BETHESDA SYSTEM REPO
   LORINCZ AT, 1992, OBSTET GYNECOL, V79, P328, DOI 10.1097/00006250-199203000-00002
   MANOS MM, 1989, CANCER CEL, V7, P209
   MEISELS A, 1976, ACTA CYTOL, V20, P505
   MEMAR OM, 1995, J INVEST DERMATOL, V105, pS99, DOI 10.1111/1523-1747.ep12316241
   Miotti PG, 1996, J INFECT DIS, V173, P714, DOI 10.1093/infdis/173.3.714
   PETRY KU, 1994, INT J CANCER, V57, P836, DOI 10.1002/ijc.2910570612
   PUROLA E, 1977, ACTA CYTOL, V21, P26
   RICHART RM, 1990, OBSTET GYNECOL, V75, P131
   SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875
   SPITZER M, 1993, GYNECOL ONCOL, V49, P243, DOI 10.1006/gyno.1993.1115
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   SUN XW, 1995, OBSTET GYNECOL, V85, P680, DOI 10.1016/0029-7844(95)00025-M
   TWEDDEL G, 1994, GYNECOL ONCOL, V52, P161, DOI 10.1006/gyno.1994.1024
   VERNON SD, 1994, J INFECT DIS, V169, P1108, DOI 10.1093/infdis/169.5.1108
   Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5
NR 22
TC 32
Z9 39
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD DEC
PY 1999
VL 10
IS 12
BP 803
EP 807
DI 10.1258/0956462991913583
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 260FR
UT WOS:000083939300007
PM 10639061
DA 2020-12-08
ER

PT J
AU Coutinho, FAB
   Massad, E
   Menezes, RX
   Burattini, MN
AF Coutinho, FAB
   Massad, E
   Menezes, RX
   Burattini, MN
TI A theoretical model of the evolution of virulence in sexually
   transmitted HIV/AIDS
SO REVISTA DE SAUDE PUBLICA
LA English
DT Editorial Material
DE acquired inmunodeficiency syndrome; virulence; models statistical
ID IMMUNODEFICIENCY-VIRUS TYPE-1; RISK-FACTORS; MALE TRANSMISSION;
   HIV-INFECTION; FEMALE; SEROCONVERSION; MEN
AB Introduction The evolution of virulence in host-parasite relationships has been the subject of several publications. In the case of HIV virulence, some authors suggest that the evolution of HIV Virulence correlates with the rate of acquisition of new sexual partners. In contrast some other authors argue that the level of HIV virulence is independent of the sexual activity of the host population.
   Methods Provide a mathematical model for the study of the potential influence of human sexual behaviour on the evolution of virulence of HIV is provided.
   Results The results indicated that, when the probability of acquisition of infection is a function both of the sexual activity and of the virulence level of HIV strains, the evolution of HIV virulence correlates positively with the rate of acquisition of new sexual partners.
   Conclusion It is concluded that in the case of a host population with a low (high) rate of exchange of sexual partners the evolution of HIV virulence is such that the less (more) virulent strain prevails.
C1 Univ Sao Paulo, Fac Med, Dept Patol, Lab Invest Med 01, Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; 
CR BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22
   BREMERMANN HJ, 1989, J MATH BIOL, V27, P179, DOI 10.1007/BF00276102
   BURCHAM JL, 1989, MED J AUSTRALIA, V150, P634, DOI 10.5694/j.1326-5377.1989.tb136727.x
   CAMERON DW, 1989, LANCET, V2, P403
   Ewald P. W., 1994, EVOLUTION INFECT DIS
   FENNER F., 1957, JOUR HYG, V55, P149
   Fenner F., 1965, MYXOMATOSIS
   LATIF AS, 1989, AIDS, V3, P519, DOI 10.1097/00002030-198908000-00006
   Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203
   LIPSITCH M, 1995, J THEOR BIOL, V174, P427, DOI 10.1006/jtbi.1995.0109
   MASSAD E, 1987, EVOLUTION, V41, P1127, DOI [10.2307/2409198, 10.1111/j.1558-5646.1987.tb05883.x]
   MASSAD E, 1995, MATH MODEL SCI COMPU, V26, P810
   MASTRO TD, 1994, LANCET, V343, P204, DOI 10.1016/S0140-6736(94)90990-3
   May R.M., 1983, P186
   Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167
   PAPE JW, 1990, J ACQ IMMUN DEF SYND, V3, P995
   PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233
   SIMMONDS P, 1990, AIDS S1, V4, pS77
   WEISER B, 1994, P NATL ACAD SCI USA, V91, P8037, DOI 10.1073/pnas.91.17.8037
NR 19
TC 5
Z9 5
U1 0
U2 5
PU REVISTA DE SAUDE PUBLICA
PI SAO PAULO
PA FACULDADE SAUDE PUBL DA USP, AV DR ARNALDO 715, 01255 SAO PAULO, BRAZIL
SN 0034-8910
J9 REV SAUDE PUBL
JI Rev. Saude Publica
PD AUG
PY 1999
VL 33
IS 4
BP 329
EP 333
DI 10.1590/S0034-89101999000400002
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 250VR
UT WOS:000083410200002
PM 10542465
OA DOAJ Gold
DA 2020-12-08
ER

PT J
AU Coutinho, FAB
   Massad, E
   Lopez, LF
   Burattini, MN
   Struchiner, CJ
   Azevedo-Neto, RS
AF Coutinho, FAB
   Massad, E
   Lopez, LF
   Burattini, MN
   Struchiner, CJ
   Azevedo-Neto, RS
TI Modelling heterogeneities in individual frailties in epidemic models
SO MATHEMATICAL AND COMPUTER MODELLING
LA English
DT Article
DE infectious diseases; heterogeneities; force of infection; functional
   analysis; basic reproduction number
ID POPULATIONS; THRESHOLD
AB A central question in epidemiology is how heterogeneity, in its different manifestations, influences the dynamics and intensity of infections. The individual differences have been named frailty in the demography literature in the context of susceptibility to death. In epidemic theory, heterogeneity in the host population has not be treated systematically before, except for variations in the ability to transmit the disease. In this paper, we propose an epidemic model, taking into account the phenomenon of frailty in the various transition rates, and analyse its effect on the observable rates. We develop expressions for the steady state distribution of the force of infection, number of infected and various observed epidemic parameters. In particular, we show how apparently age-dependent parameters may arise fi om heterogeneity in situations where no explicit age-dependence is built into the model. Using standard linearization methods, the basic reproduction number is determined. Finally, we show how the force of infection can be determined from an integral equation and apply the methods of functional analysis to prove existence and uniqueness of the endemic equilibrium. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
   Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil.
RP Coutinho, FAB (corresponding author), Univ Sao Paulo, Sch Med, BR-05508 Sao Paulo, Brazil.
RI Massad, Eduardo/B-1169-2012; Azevedo, Raymundo S/B-7593-2008; Massad,
   Eduardo/H-6143-2011; Struchiner, Claudio J/M-9360-2013; Burattini,
   Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011; Lopez, Luis
   F/C-4721-2012
OI Massad, Eduardo/0000-0002-7200-2916; Azevedo, Raymundo
   S/0000-0003-0660-2371; Struchiner, Claudio J/0000-0003-2114-847X;
   Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; Lopez, Luis F/0000-0003-4097-6887
CR AALEN OO, 1988, STAT MED, V7, P1121, DOI 10.1002/sim.4780071105
   Abramowitz M., 1965, HDB MATH FUNCTIONS
   ANDERSON R M, 1991
   ANDREASEN V, 1996, P 3 EUR C MATH APPL, P329
   Athreya K. B., 1972, BRANCHING PROCESSES
   BECKER NG, 1990, LECT NOTES BIOMATH, V86, P90, DOI DOI 10.1007/978-3-662-10067-7-9
   CASTILLOCHAVES CC, 1989, LECT NOTES BIOMATHEM, V83
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Griffel D.H., 1981, APPL FUNCTIONAL ANAL
   Halloran ME, 1996, AM J EPIDEMIOL, V144, P83, DOI 10.1093/oxfordjournals.aje.a008858
   HASIBEDER G, 1996, MODELS INFECT HUMAN
   Hethcote H, 1996, MODELS INFECT HUMAN
   Hethcote H. W., 1992, LECT NOTES BIOMATHEM, V95
   HOUGAARD P, 1984, BIOMETRIKA, V71, P75, DOI 10.2307/2336399
   HOUGAARD P, 1986, BIOMETRIKA, V73, P387, DOI 10.1093/biomet/73.2.387
   INABA H, 1990, J MATH BIOL, V28, P411
   JOHNSON AM, 1996, MODELS INFECT HUMAN
   Jordan D.W, 1977, NONLINEAR ORDINARY D
   Krasnosel'skii MA, 1964, POSITIVE SOLUTIONS O
   LIN XD, 1993, MATH BIOSCI, V118, P181, DOI 10.1016/0025-5564(93)90051-B
   Longini IM, 2006, APPL STAT, V45, P165, DOI 10.2307/2986152
   Lopez LF, 1999, MATH COMPUT MODEL, V29, P55, DOI 10.1016/S0895-7177(99)00062-X
   LOPEZ LF, UNPUB J MATH BIOL
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   Massad Eduardo, 1995, Journal of Biological Systems, V3, P803, DOI 10.1142/S0218339095000733
   Morris M, 1996, MODELS INFECT HUMAN
   Muench H, 1959, CATALYTIC MODELS EPI
   Segel LA, 1980, MATH MODELS MOL CELL
   VAUPEL JW, 1979, DEMOGRAPHY, V16, P439, DOI 10.2307/2061224
NR 31
TC 32
Z9 32
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-7177
EI 1872-9479
J9 MATH COMPUT MODEL
JI Math. Comput. Model.
PD JUL
PY 1999
VL 30
IS 1-2
BP 97
EP 115
DI 10.1016/S0895-7177(99)00119-3
PG 19
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 222DZ
UT WOS:000081769300008
DA 2020-12-08
ER

PT J
AU Massad, E
   Burattini, MN
   Ortega, NRS
AF Massad, E
   Burattini, MN
   Ortega, NRS
TI Fuzzy Logic and measles vaccination: designing a control strategy
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE measles; vaccination; fuzzy decision making; control strategies
ID CONTROL-SYSTEMS; COMMUNITY; OUTBREAK
AB Background The State of Sao Paulo, the most populous in Brazil, was virtually free of measles from 1987 until the end of 1996 when the number of cases started to rise. It reached alarming numbers in the middle of 1997 and local health authorities decided to implement a mass vaccination campaign.
   Methods Fuzzy Decision Making techniques are applied to the design of the vaccination campaign.
   Results The mass vaccination strategy chosen changed the natural course of the epidemic. It had a significant impact on the epidemic in the metropolitan area of Sao Paulo city, but a second epidemic in the State's interior forced the public health authorities to implement a second mass vaccination campaign 2 months after the first.
   Conclusions Fuzzy Logic techniques are a powerful tool for the design of control strategies against epidemics of infectious diseases.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   HCFMUSP, LIM01, BR-01246903 Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Massad, Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012; Burattini,
   Marcelo N/J-9272-2014; Ortega, Neli/C-6494-2013
OI Massad, Eduardo/0000-0002-7200-2916; Burattini, Marcelo
   N/0000-0002-5407-6890; 
CR ANDERSON R M, 1991
   BELLMAN RE, 1970, MANAGE SCI B-APPL, V17, pB141
   HUTCHINS SS, 1990, AM J EPIDEMIOL, V132, P157, DOI 10.1093/oxfordjournals.aje.a115627
   Klir G.J., 1995, FUZZY SETS FUZZY LOG
   LEE CC, 1990, IEEE T SYST MAN CYB, V20, P404, DOI 10.1109/21.52551
   LEE CC, 1990, IEEE T SYST MAN CYB, V20, P419, DOI 10.1109/21.52552
   MARKOWITZ LE, 1994, VACCINES, P229
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MASSAD E, 1997, SOFT COMPUTING SOCO, P58
   MURRAY CJL, 1996, GLOBAL HLTH STAT GLO, V2
   Nokes DJ, 1997, TRENDS MICROBIOL, V5, P14, DOI 10.1016/S0966-842X(97)81769-6
   STRUCHINER CJ, 1997, SOFT COMPUTING SOCO, P64
   WEEKS RM, 1992, B WORLD HEALTH ORGAN, V70, P317
   Yager RR, 1994, ESSENTIALS FUZZY MOD
   Zadeh L. A., 1978, Fuzzy Sets and Systems, V1, P3, DOI 10.1016/0165-0114(78)90029-5
   ZADEH LA, 1973, IEEE T SYST MAN CYB, VSMC3, P28, DOI 10.1109/TSMC.1973.5408575
   ZIMMERMAN HJ, 1996, FUZZY INFORMATION EN, P471
NR 17
TC 40
Z9 40
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD JUN
PY 1999
VL 28
IS 3
BP 550
EP 557
DI 10.1093/ije/28.3.550
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 213XP
UT WOS:000081298800029
PM 10405863
OA Bronze
DA 2020-12-08
ER

PT J
AU Massad, E
   Rozman, M
   Azevedo, RS
   Silveira, ASB
   Takey, K
   Yamamoto, YI
   Strazza, L
   Ferreira, MMC
   Carvalho, HB
   Burattini, MN
AF Massad, E
   Rozman, M
   Azevedo, RS
   Silveira, ASB
   Takey, K
   Yamamoto, YI
   Strazza, L
   Ferreira, MMC
   Carvalho, HB
   Burattini, MN
TI Seroprevalence of HIV, HCV and syphilis in Brazilian prisoners:
   Preponderance of parenteral transmission
SO EUROPEAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE AIDS; hepatitis C; injecting drug abusers; prisoners; seroprevalence
ID HEPATITIS-C VIRUS; DRUG-USERS; RISK-FACTORS; INFECTION; INMATES; AIDS;
   SURVEILLANCE; PREVALENCE; SPREAD; MISUSE
AB Between November 1993 and April 1994, our physicians' team interviewed and took blood samples of 631 prisoners randomly drawn from the largest prison of South America, which counted about 4700 inmates at that time. The interview consisted of questions related to risk behaviour for HIV infection, and the subjects were asked to provide blood for serological tests for HIV, hepatitis C and syphilis. Our main purpose was to investigate the relationship between HCV and injecting drug use as related to HIV seropositivity. Participation in the study was voluntary and confidentiality was guaranteed. Overall prevalences found were as follows: HIV: 16% (95% confidence interval (CI): 13-19%); HCV: 34% (95% CI: 30-38%), and syphilis: 18% (95% CI: 15-21%). Acknowledged use of ever injecting drug was 22% and no other parenteral risk was reported. Our results, as compared with other studies in the same prison, suggest that HIV prevalence has been stable in recent years, and that the major risk factor for HIV infection in this population is parenteral exposure by injecting drug use.
C1 Univ Sao Paulo, NUPAIDS, Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Av Doutor Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Massad, Eduardo/H-6143-2011; Azevedo, Raymundo S/B-7593-2008; Massad,
   Eduardo/B-1169-2012; Burattini, Marcelo N/J-9272-2014; Carvalho,
   Heraclito/C-1334-2012
OI Azevedo, Raymundo S/0000-0003-0660-2371; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890;
   Carvalho, Heraclito/0000-0002-7037-5655
CR Abeni D, 1998, SOC AS AIDS, P168
   Bastos F, 1998, SOC AS AIDS, P149
   BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017
   BIRD AG, 1994, AIDS, V8, P1345, DOI 10.1097/00002030-199409000-00021
   BREWER TF, 1988, AIDS, V2, P363, DOI 10.1097/00002030-198810000-00005
   CARVALHO HB, 1996, PUB C, V1099, P454
   CARVELL ALM, 1990, BRIT MED J, V300, P1383, DOI 10.1136/bmj.300.6736.1383
   CDC, 1986, MMWR-MORBID MORTAL W, V35, P195
   *CDCP, 1993, MMWR RECOMM REP, V7, P1
   *CDCP, 1989, MMWR-MORBID MORTAL W, V38, P313
   DEAN AD, 1990, EPI INFO VERSION 5 W
   deCarvalho HB, 1996, J ACQ IMMUN DEF SYND, V12, P84, DOI 10.1097/00042560-199605010-00012
   DESENCLOS JC, 1995, PRESSE MED, V24, P7
   DOLAN K, 1995, AIDS, V9, P825, DOI 10.1097/00002030-199508000-00001
   DYE S, 1991, BRIT MED J, V302, P1506, DOI 10.1136/bmj.302.6791.1506
   FERREIRA OC, 1994, J ACQ IMMUN DEF SYND, V7, P1124
   GAUGHWIN MD, 1991, HIV AIDS PRIS C P CA
   GORE SM, 1995, BRIT MED J, V311, P1135, DOI 10.1136/bmj.311.7013.1135
   GORE SM, 1995, BRIT MED J, V310, P293, DOI 10.1136/bmj.310.6975.293
   HARDING TW, 1987, LANCET, V2, P1260
   HORSBURGH CR, 1990, AM J PUBLIC HEALTH, V80, P209, DOI 10.2105/AJPH.80.2.209
   IWARSON S, 1995, CLIN INFECT DIS, V20, P1361, DOI 10.1093/clinids/20.5.1361
   KENNEDY DH, 1991, BRIT MED J, V302, P1507, DOI 10.1136/bmj.302.6791.1507
   LORENCO R, 1992, THESIS ESCOLA PAULIS
   LWANGA SK, 1994, SAMPLE SIZES DETERMI
   MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MASSAD E, 1996, PUB C, V1146, P461
   MCKEE KJ, 1992, SCOT MED J, V37, P132, DOI 10.1177/003693309203700502
   Mesquita F, 1998, SOC AS AIDS, P243
   MULLER T, 1995, SOZ PRAVENTIV MED, V40, P285, DOI 10.1007/BF01299196
   *NUPAIDS, 1996, HIV AIDS EM POP CONF
   OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66
   PEIXINHO ZF, 1990, NAT IMMUN CELL GROW, V9, P133
   ROTILY M, 1994, AIDS, V8, P1341, DOI 10.1097/00002030-199409000-00020
   ROZMAN MA, 1996, 7 INT C INF DIS, P12
   ROZMAN MA, 1995, THESIS U SAO PAULO S
   *STAT EP RES CORP, 1990, EGR REF MAN
   STRANG J, 1993, CRIM BEHAV MENT HEAL, V3, P393
   Strathdee S A, 1998, AIDS, V12 Suppl A, pS71
   *US NAT COMM AIDS, 1990, REP HIV DIS CORR FAC
   VLAHOV D, 1991, JAMA-J AM MED ASSOC, V265, P1129, DOI 10.1001/jama.265.9.1129
   WATTS DM, 1994, T ROY SOC TROP MED H, V88, P55, DOI 10.1016/0035-9203(94)90495-2
   *WHO, 1987, LANCET, V2, P1263
   *WHO INT COLL GROU, 1994, MULT STUD DRUG INJ R
   WORMSER GP, 1983, ANN INTERN MED, V98, P297, DOI 10.7326/0003-4819-98-3-297
NR 46
TC 33
Z9 39
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0393-2990
EI 1573-7284
J9 EUR J EPIDEMIOL
JI Eur. J. Epidemiol.
PD MAY
PY 1999
VL 15
IS 5
BP 439
EP 445
DI 10.1023/A:1007523027876
PG 7
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 209ME
UT WOS:000081051200004
PM 10442469
DA 2020-12-08
ER

PT J
AU Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
AF Lopez, LF
   Coutinho, FAB
   Burattini, MN
   Massad, E
TI Modelling the spread of infections when the contact rate among
   individuals is short ranged: Propagation of epidemic waves
SO MATHEMATICAL AND COMPUTER MODELLING
LA English
DT Article
DE epidemic models; force of infection; epidemic waves; geographical spread
AB Integral equations for the force of infection were derived taking into account spatial variables. Those equations were studied both numerically and with functional analysis techniques. Threshold conditions for the establishment of the infection were also derived. The existence of travelling waves of the infection was investigated. An integral equation for the shape of the wave front was deduced. Conditions for the existence of those waves were derived independently of the velocity of propagation. The model differs from previous studies in that we allow recovery from the infectious status and/or demographic structure in the host population, that is, deaths and births of individuals. (C) 1999 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, Discipline Med Informat, BR-01246903 Sao Paulo, Brazil.
RP Lopez, LF (corresponding author), Univ Sao Paulo, Sch Med, Discipline Med Informat, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM lopez@dns2.fm.usp.br
RI Massad, Eduardo/B-1169-2012; Coutinho, Francisco A B/H-5644-2011;
   Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014; Lopez,
   Luis F/C-4721-2012
OI Massad, Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; Burattini, Marcelo N/0000-0002-5407-6890; Lopez,
   Luis F/0000-0003-4097-6887
CR ANDERSON R M, 1991
   ATKINSON C, 1976, MATH PROC CAMBRIDGE, V80, P315, DOI 10.1017/S0305004100052944
   Cliff AD, 1995, EPIDEMIC MODELS THEI, P119
   CLIFF AD, 1980, STATISTICAL APPLICAT, P5
   DIEKMANN O, 1978, J MATH BIOL, V6, P109, DOI 10.1007/BF02450783
   Griffel D.H., 1981, APPL FUNCTIONAL ANAL
   Krasnosel'skii MA, 1964, POSITIVE SOLUTIONS O
   LOPEZ LF, UNPUB J MATH BIOL
   METZ JAJ, 1995, EPIDEMIC MODELS THEI, P150
   MOLLISON D, 1977, J ROY STAT SOC B MET, V39, P283
   SAATY TL, 1967, MODERN NONLINEAR EQU
   THIEME HR, 1977, J MATH BIOL, V4, P337, DOI 10.1007/BF00275082
NR 12
TC 6
Z9 6
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-7177
EI 1872-9479
J9 MATH COMPUT MODEL
JI Math. Comput. Model.
PD APR
PY 1999
VL 29
IS 7
BP 55
EP 69
DI 10.1016/S0895-7177(99)00062-X
PG 15
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 194EX
UT WOS:000080180100005
DA 2020-12-08
ER

PT J
AU Zanetta, DMT
   Strazza, L
   Azevedo, RS
   Carvalho, HB
   Massad, E
   Menezes, RX
   Ferreira, DP
   Burattini, MN
AF Zanetta, DMT
   Strazza, L
   Azevedo, RS
   Carvalho, HB
   Massad, E
   Menezes, RX
   Ferreira, DP
   Burattini, MN
TI HIV infection and related risk behaviours in a disadvantaged youth
   institution of Sao Paulo, Brazil
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Article
DE HIV; disadvantaged youth; seroepidemiology; risk behaviour; illicit drug
   use and sex behaviours
ID STREET YOUTH; SUBSTANCE USE; DRUG-USE; VIRUS-INFECTION; SEXUAL-BEHAVIOR;
   BELO-HORIZONTE; AIDS KNOWLEDGE; ADOLESCENTS; PREVENTION; PROFILE
AB Ln order to study the prevalence of HIV and related risky behaviours among disadvantaged youth, we interviewed and bled, between December 1994 and April 1995, 1122 young males and 93 young; females who were serving time in FEBEM, a state institution that cares for homeless and offender youth of Sao Paulo, Brazil. Our questionnaire covered the following areas: sexual practices and use of illicit drugs; knowledge of HIV and STDs and their prevention; and myths and beliefs about AIDS. Seroprevalence of HN was assessed and related with risk-taking behaviours by means of uni-, bi- and multivariate analysis. We found 2.6% of the males and 10.3% of the females to be positive to HIV. The prevalence of hepatitis C virus (HCV) antibodies resulted in 5.9% for males and 4.6% for females, respectively. The risk for parenterally transmitted HIV among the males was higher than that for sexually related transmission. The inverse relationship was found among the females.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Zanetta, Dirce M T/G-4950-2013; Massad, Eduardo/H-6143-2011; Carvalho,
   Heraclito/C-1334-2012; Massad, Eduardo/B-1169-2012; Burattini, Marcelo
   N/J-9272-2014; Azevedo, Raymundo S/B-7593-2008
OI Carvalho, Heraclito/0000-0002-7037-5655; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890;
   Azevedo, Raymundo S/0000-0003-0660-2371
CR ANTHONY JC, 1995, DRUG ALCOHOL DEPEN, V40, P9, DOI 10.1016/0376-8716(95)01194-3
   Bodsworth NJ, 1996, GENITOURIN MED, V72, P118
   CAMPOS R, 1994, CHILD DEV, V65, P319
   Clements K, 1997, J ADOLESCENT HEALTH, V20, P343, DOI 10.1016/S1054-139X(97)00033-5
   deCarvalho HB, 1996, J ACQ IMMUN DEF SYND, V12, P84, DOI 10.1097/00042560-199605010-00012
   Dukarm CP, 1996, ARCH PEDIAT ADOL MED, V150, P797, DOI 10.1001/archpedi.1996.02170330023004
   Earl Daniel Thad, 1995, Journal of the American Osteopathic Association, V95, P725
   EISENSTEIN E, 1993, J PAEDIATR CHILD H, V29, pS46, DOI 10.1111/j.1440-1754.1993.tb02261.x
   FENDRICH M, 1995, INT J ADDICT, V30, P1363, DOI 10.3109/10826089509055838
   FORD K, 1995, J ACQ IMMUN DEF SYND, V10, P569, DOI 10.1097/00042560-199510050-00011
   HEIN K, 1980, PEDIATRICS, V66, P239
   HENDEE WR, 1990, JAMA-J AM MED ASSOC, V263, P987
   Kandel DB, 1996, ARCH GEN PSYCHIAT, V53, P71
   Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1
   KIPKE MD, 1995, ARCH PEDIAT ADOL MED, V149, P513, DOI 10.1001/archpedi.1995.02170180043006
   KoniakGriffin D, 1995, NURS RES, V44, P340
   Kral AH, 1997, INT J STD AIDS, V8, P109, DOI 10.1258/0956462971919651
   LURIE P, 1995, AIDS, V9, pS31
   LYNSKEY MT, 1993, NEW ZEAL MED J, V106, P511
   MACDONALD NE, 1994, PEDIATR INFECT DIS J, V13, P690, DOI 10.1097/00006454-199408000-00003
   Metsch LR, 1995, J PSYCHOACTIVE DRUGS, V27, P435, DOI 10.1080/02791072.1995.10471707
   MILLSTEIN SG, 1995, J ADOLESCENT HEALTH, V17, P83, DOI 10.1016/1054-139X(95)00065-Z
   OH MK, 1994, SEX TRANSM DIS, V21, P127, DOI 10.1097/00007435-199405000-00001
   RAFFAELLI M, 1995, AIDS EDUC PREV, V7, P287
   ROTHERAMBORUS MJ, 1995, AIDS EDUC PREV, V7, P320
   Rozman M, 1998, INT J STD AIDS, V9, P183, DOI 10.1258/0956462981921855
   Sullivan TR, 1996, HEALTH SOC WORK, V21, P58, DOI 10.1093/hsw/21.1.58
   Suwanagool S, 1995, J Med Assoc Thai, V78, P355
   Tubman JG, 1996, J ADOLESCENT HEALTH, V18, P182, DOI 10.1016/1054-139X(95)00128-F
   *UNAIDS WHO WORK G, 1997, REP GLOB HIV AIDS EP
   WALSH A, 1995, SOC BIOL, V42, P95
   Yee BWK, 1995, HEALTH PSYCHOL, V14, P622, DOI 10.1037/0278-6133.14.7.622
NR 32
TC 21
Z9 25
U1 0
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0956-4624
EI 1758-1052
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD FEB
PY 1999
VL 10
IS 2
BP 98
EP 104
DI 10.1258/0956462991913718
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 164TQ
UT WOS:000078480000005
PM 10215114
DA 2020-12-08
ER

PT J
AU Soni, LMF
   Burattini, MN
   Pignatari, ACC
   Gompertz, OF
   Colombo, AL
AF Soni, LMF
   Burattini, MN
   Pignatari, ACC
   Gompertz, OF
   Colombo, AL
TI Comparative study of agar diffusion test and the NCCLS macrobroth method
   for in vitro susceptibility testing of Candida spp.
SO MYCOPATHOLOGIA
LA English
DT Article
DE Candida; resistance; susceptibility testing
ID NATIONAL-COMMITTEE; FLUCONAZOLE; STANDARDS; ITRACONAZOLE; INFECTIONS;
   SYSTEM
AB We performed a prospective double-blind study to evaluate the correlation between inhibition zones obtained by a disk-diffusion test, using Neo-sensitabs of fluconazole (Rosco Diagnostica), and the MICs generated by the NCCLS macrobroth dilution assay. Eighty clinical isolates, representing 5 of the clinically relevant species of Candida, were tested simultaneously by both methods. A clear inverse correlation was found between the results obtained by both tests (r = -0.69). In addition, there was high degree of agreement between methods in the identification of susceptible isolates. However, the resistance definition by disk-diffusion test had a positive predictive value of only 17%. Our data support the hypothesis that Rosco Fluconazole Neo-sensitabs have potential as a screening test for the identification of Candida isolates susceptible to fluconazole. Resistant isolates should be further investigated by standardized broth procedures.
C1 UNIFESP, Escola Paulista Med, Div Infect Dis, BR-04023062 Sao Paulo, Brazil.
   UNIFESP, Escola Paulista Med, Div Cellular Biol, Sao Paulo, Brazil.
RP Colombo, AL (corresponding author), UNIFESP, Escola Paulista Med, Div Infect Dis, Rua Botucatu 740, BR-04023062 Sao Paulo, Brazil.
RI Colombo, Arnaldo Lopes/V-4417-2019; Burattini, Marcelo N/J-9272-2014;
   Colombo, Arnaldo Lopes/H-4397-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Colombo, Arnaldo
   Lopes/0000-0003-0793-8491; Pignatari, Antonio/0000-0002-2146-8476
CR Barry AL, 1996, J CLIN MICROBIOL, V34, P2154, DOI 10.1128/JCM.34.9.2154-2157.1996
   BECKSAGUE CM, 1993, J INFECT DIS, V167, P1247, DOI 10.1093/infdis/167.5.1247
   CASALS JB, 1991, ANTIBACTERIAL ANTIFU, P55
   COLOMBO AL, 1995, J ANTIMICROB CHEMOTH, V36, P93, DOI 10.1093/jac/36.1.93
   COLOMBO AL, 1995, J CLIN MICROBIOL, V33, P535, DOI 10.1128/JCM.33.3.535-540.1995
   ESPINELINGROFF A, 1994, DIAGN MICR INFEC DIS, V20, P81, DOI 10.1016/0732-8893(94)90096-5
   *NAT COMM CLIN LAB, 1997, M27A NAT COMM CLIN L, V17, P1
   *NAT COMM CLIN LAB, A5 NAT COMM CLIN LAB
   PFALLER MA, 1994, J CLIN MICROBIOL, V32, P1992, DOI 10.1128/JCM.32.8.1992-1996.1994
   PFALLER MA, 1995, J CLIN MICROBIOL, V33, P1104, DOI 10.1128/JCM.33.5.1104-1107.1995
   REX JH, 1993, CLIN MICROBIOL REV, V6, P367, DOI 10.1128/CMR.6.4.367-381.1993
   Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235
   SANDVEN P, 1993, ANTIMICROB AGENTS CH, V37, P2443, DOI 10.1128/AAC.37.11.2443
   TIBALLI RN, 1995, J CLIN MICROBIOL, V33, P915, DOI 10.1128/JCM.33.4.915-917.1995
NR 14
TC 6
Z9 6
U1 0
U2 1
PU KLUWER ACADEMIC PUBL
PI DORDRECHT
PA SPUIBOULEVARD 50, PO BOX 17, 3300 AA DORDRECHT, NETHERLANDS
SN 0301-486X
J9 MYCOPATHOLOGIA
JI Mycopathologia
PY 1999
VL 145
IS 3
BP 131
EP 135
DI 10.1023/A:1007068826861
PG 5
WC Mycology
SC Mycology
GA 269PR
UT WOS:000084487200005
PM 10685448
DA 2020-12-08
ER

PT J
AU Saldiva, SR
   Silveira, AS
   Philippi, ST
   Torres, DM
   Mangini, AC
   Dias, RMD
   da Silva, RM
   Buratini, MN
   Massad, E
AF Saldiva, SR
   Silveira, AS
   Philippi, ST
   Torres, DM
   Mangini, AC
   Dias, RMD
   da Silva, RM
   Buratini, MN
   Massad, E
TI Ascaris-Trichuris association and malnutrition in Brazilian children
SO PAEDIATRIC AND PERINATAL EPIDEMIOLOGY
LA English
DT Article
ID PROTEIN-ENERGY MALNUTRITION; INFECTION; LUMBRICOIDES; TRICHIURA; GROWTH;
   ALBENDAZOLE; HOOKWORM; PREDISPOSITION; GUATEMALA; HISTORY
AB This work was designed to evaluate the role of intestinal parasites on nutritional status in three rural areas of Brazil. A total of 520 children aged 1-12 years were studied through a questionnaire concerning housing, socio-economic conditions and a 24-h food intake recall. Measurements of weight and height were also performed, and three stool samples were collected on consecutive days for parasitological analysis. Scores of the standard deviation (z-scores) for the weight-for-height and height-for-age were used to characterise the growth profile. A high prevalence of intestinal parasites was detected, with Giardia lamblia (44%), Endolimax nana (43%), Ascaris lumbricoides (41%) and Trichuris trichiura (40%) being the most prevalent. Eleven per cent of the children were classified as showing stunting. Inadequate daily caloric intake was observed in 78% of the population and the proportion of those with inadequate protein intake was 34%. Logistic regression analysis was employed for the multivariate study. Stunting was significantly associated with estimators of low economic income, inadequate protein intake and polyparasitism, especially the association between Ascaris lumbricoides and Trichuris trichiura.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, HCFMUSP, LIM01, BR-01246903 Sao Paulo, Brazil.
   Univ Sao Paulo, Inst Publ Hlth, Sao Paulo, Brazil.
   Adolfo Lutz Inst, Sao Paulo, Brazil.
RP Massad, E (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM edmassad@usp.br
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; DIAS, ROGERIO/G-4022-2012; Philippi,
   Sonia/C-4895-2013; Saldiva, Silvia RDM/G-5859-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; 
CR ANDERSON MA, 1995, B WORLD HEALTH ORGAN, V73, P165
   ANDERSON TJC, 1993, MEM I OSWALDO CRUZ, V88, P53, DOI 10.1590/S0074-02761993000100010
   [Anonymous], 1985, World Health Organ Tech Rep Ser, V724, P1
   [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929
   ARMITAGE P, 1994, STAT METHODS MED RES, pCH4
   BLOEMBERG BPM, 1989, AM J EPIDEMIOL, V130, P1047, DOI 10.1093/oxfordjournals.aje.a115405
   BLUMENTHAL DS, 1976, AM J TROP MED HYG, V25, P682, DOI 10.4269/ajtmh.1976.25.682
   BUNDY DAP, 1992, PARASITOLOGY, V104, pS105, DOI 10.1017/S0031182000075284
   BUZZARD IM, 1994, AM J CLIN NUTR, V59, p275S, DOI 10.1093/ajcn/59.1.275S
   CHAN L, 1994, PARASITOLOGY, V108, P77, DOI 10.1017/S0031182000078549
   CHAN L, 1994, T ROY SOC TROP MED H, V88, P46, DOI 10.1016/0035-9203(94)90492-8
   COOPER ES, 1990, EUR J CLIN NUTR, V44, P285
   COOPER ES, 1992, PARASITOLOGY, V104, pS91, DOI 10.1017/S0031182000075272
   CROMPTON DWT, 1992, T ROY SOC TROP MED H, V86, P577, DOI 10.1016/0035-9203(92)90133-W
   DIXON WJ, 1990, BMDP STAT SOFTWARE I
   FARTHING MJG, 1986, AM J CLIN NUTR, V43, P395
   FOO LC, 1990, TROP GEOGR MED, V42, P8
   GELTZ R, 1984, FOOD PROCESSOR NUTR
   GILMAN RH, 1983, T ROY SOC TROP MED H, V77, P432, DOI 10.1016/0035-9203(83)90103-7
   GUPTA MC, 1990, J TROP PEDIATRICS, V36, P189, DOI 10.1093/tropej/36.4.189
   GUPTA MC, 1977, LANCET, V2, P108
   HALL A, 1993, T ROY SOC TROP MED H, V87, P241, DOI 10.1016/0035-9203(93)90108-3
   HALL A, 1994, T ROY SOC TROP MED H, V88, P110, DOI 10.1016/0035-9203(94)90525-8
   HLAING T, 1993, PARASITOLOGY, V107, pS125, DOI 10.1017/S0031182000075557
   Hoffman W, 1934, PUERTO RICO J PUBLIC, V9, P281, DOI DOI 10.1590/S0037-86822012000300024
   Hosmer DW, 1989, APPL LOGISTIC REGRES
   Jellife DB, 1968, EVALUACION ESTADO NU
   Latham M C, 1984, Food Nutr (Roma), V10, P5
   LATHAM MC, 1982, T ROY SOC TROP MED H, V76, P734, DOI 10.1016/0035-9203(82)90093-1
   LUNN PG, 1993, P NUTR SOC, V52, P101, DOI 10.1079/PNS19930042
   LYTLE LA, 1993, J AM DIET ASSOC, V93, P1431, DOI 10.1016/0002-8223(93)92247-U
   *NATL CTR HLTH STA, 1976, MONTHL VIT STAT RE S, V25
   PRENTICE AM, 1988, LANCET, V2, P1066
   SALEM G, 1994, REV EPIDEMIOL SANTE, V42, P322
   *SCI COORD CTR PAR, 1992, PARTN CHILD DEV INT
   STEPHENSON LS, 1993, J NUTR, V123, P656
   STEPHENSON LS, 1993, J NUTR, V123, P1036
   THEINHLAING, 1991, T ROY SOC TROP MED H, V85, P523, DOI 10.1016/0035-9203(91)90242-Q
   WAKELIN D, 1986, T ROY SOC TROP MED H, V80, P742, DOI 10.1016/0035-9203(86)90373-1
   WALKERSMITH JA, 1986, DIARRHEA MALNUTRITIO
NR 40
TC 42
Z9 51
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-5022
EI 1365-3016
J9 PAEDIATR PERINAT EP
JI Paediatr. Perinat. Epidemiol.
PD JAN
PY 1999
VL 13
IS 1
BP 89
EP 98
PG 10
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology;
   Pediatrics
GA 159RV
UT WOS:000078188800013
PM 9987788
DA 2020-12-08
ER

PT J
AU Milan, EP
   Burattini, MN
   Kallas, EG
   Fischmann, O
   Costa, PRD
   Colombo, AL
AF Milan, EP
   Burattini, MN
   Kallas, EG
   Fischmann, O
   Costa, PRD
   Colombo, AL
TI Azole resistance among oral Candida species isolates from AIDS patients
   under ketoconazole exposure
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
ID HIV-INFECTED PATIENTS; FLUCONAZOLE-RESISTANT; ALBICANS STRAINS;
   DRUG-RESISTANCE; SUSCEPTIBILITY; ITRACONAZOLE; EMERGENCE; GLABRATA;
   THERAPY; YEASTS
AB This is a prospective study designed to investigate species distribution and azole susceptibility profile among Candida spp. isolated from the oral cavities of AIDS patients. One hundred thirty-two AIDS patients sequentially admitted at a teaching tertiary care hospital were enrolled in this study. Samples were obtained by swabbing the oral cavities of the patients. Yeast isolates were identified by classical methods and the antifungal susceptibility profile was further determined according to the NCCLS microbroth assay. Among all patients with prescriptions of systemic antifungal drugs, ketoconazole had been elected to treat 56% of patients. We found 82% of oral yeast carriage, 22% of them harboring non-albicans species. Overall rates of susceptibility dose dependent/resistance to azoles was 16% for itraconazole, 13% for ketoconazole, and 10% for fluconazole with a high agreement rate among the susceptibility profiles of all isolates tested against the triazoles. (C) 1998 Elsevier, Science Inc.
C1 Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Cellular Biol, Escola Paulista Med, BR-04023062 Sao Paulo, Brazil.
   Hosp Servidor Publ Estadual Francisco Moratto de, Sao Paulo, Brazil.
   Univ Fed Rio Grande do Norte, Dept Microbiol & Parasitol, BR-59072970 Natal, RN, Brazil.
RP Colombo, AL (corresponding author), Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, Rua Botucatu 740,Vila Clementino, BR-04023062 Sao Paulo, Brazil.
RI Kallas, Esper G/C-9539-2012; Burattini, Marcelo N/J-9272-2014; Colombo,
   Arnaldo Lopes/V-4417-2019; Colombo, Arnaldo Lopes/H-4397-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Colombo, Arnaldo
   Lopes/0000-0003-0793-8491; Kallas, Esper/0000-0003-2026-6925
CR Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1
   Barchiesi F, 1996, ANTIMICROB AGENTS CH, V40, P1317, DOI 10.1128/AAC.40.5.1317
   BARCHIESI F, 1994, J CLIN MICROBIOL, V32, P2494, DOI 10.1128/JCM.32.10.2494-2500.1994
   BODEY GP, 1992, CLIN INFECT DIS, V14, pS161, DOI 10.1093/clinids/14.Supplement_1.S161
   COLOMBO AL, 1995, J ANTIMICROB CHEMOTH, V36, P93, DOI 10.1093/jac/36.1.93
   Dronda F, 1996, EUR J CLIN MICROBIOL, V15, P446, DOI 10.1007/BF01691310
   DUPONT B, 1994, J MED VET MYCOL, V32, P65
   DUPONT B, 1992, J MED VET MYCOL, V30, P19
   EspinelIngroff A, 1997, INFECT DIS CLIN N AM, V11, P929, DOI 10.1016/S0891-5520(05)70398-6
   HITCHCOCK CA, 1993, ANTIMICROB AGENTS CH, V37, P1962, DOI 10.1128/AAC.37.9.1962
   IMAM N, 1990, AM J MED, V89, P142, DOI 10.1016/0002-9343(90)90291-K
   JOHNSON EM, 1995, J ANTIMICROB CHEMOTH, V35, P103, DOI 10.1093/jac/35.1.103
   Kreger-van Rij NJW, 1984, YEASTS TAXONOMIC STU
   LEGUENNEC R, 1995, J CLIN MICROBIOL, V33, P2732, DOI 10.1128/JCM.33.10.2732-2737.1995
   LYNCH DP, 1994, ORAL SURG ORAL MED O, V78, P189, DOI 10.1016/0030-4220(94)90146-5
   Maenza JR, 1996, J INFECT DIS, V173, P219, DOI 10.1093/infdis/173.1.219
   MENESES EA, 1993, C BRAS MICR 17 SANT, P150
   MILLON L, 1994, J CLIN MICROBIOL, V32, P1115, DOI 10.1128/JCM.32.4.1115-1118.1994
   NCCLS, 1997, NCCLS, V17, P1
   PERSONS DA, 1991, NEW ENGL J MED, V325, P1315
   Rex JH, 1997, CLIN INFECT DIS, V24, P235, DOI 10.1093/clinids/24.2.235
   RODRIGUEZTUDELA JL, 1995, J ANTIMICROB CHEMOTH, V35, P793, DOI 10.1093/jac/35.6.793
   SANGEORZAN JA, 1994, AM J MED, V97, P339, DOI 10.1016/0002-9343(94)90300-X
   STGERMAIN G, 1995, J ANTIMICROB CHEMOTH, V36, P109, DOI 10.1093/jac/36.1.109
   TAVITIAN A, 1986, GASTROENTEROLOGY, V90, P443, DOI 10.1016/0016-5085(86)90946-7
   Torres-Rodriguez Josep M., 1996, Revista Iberoamericana de Micologia, V13, pS30
   Vanden Bossche H, 1994, Trends Microbiol, V2, P393, DOI 10.1016/0966-842X(94)90618-1
   VANDEN BOSSCHE H, 1994, J MED VET MYCOL, V32, P189
   VANDERWALT JP, 1971, YEASTS TAXONOMIC STU, P35
   WARNOCK DW, 1988, LANCET, V2, P1310
NR 30
TC 19
Z9 23
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0732-8893
EI 1879-0070
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD NOV
PY 1998
VL 32
IS 3
BP 211
EP 216
DI 10.1016/S0732-8893(98)00107-2
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA 152PW
UT WOS:000077786800012
PM 9884838
DA 2020-12-08
ER

PT J
AU Burattini, MN
   Massad, E
   Coutinho, FAB
   Azevedo-Neto, RS
   Menezes, RX
   Lopes, LF
AF Burattini, MN
   Massad, E
   Coutinho, FAB
   Azevedo-Neto, RS
   Menezes, RX
   Lopes, LF
TI A mathematical model of the impact of crack-cocaine use on the
   prevalence of HIV/AIDS among drug users
SO MATHEMATICAL AND COMPUTER MODELLING
LA English
DT Article
DE crack-cocaine; HIV/AIDS; mathematical modelling; nonlinear system
   dynamics
ID SAO-PAULO; VACCINATION STRATEGY; EPIDEMIC; RUBELLA; BRAZIL; ABUSE; HIV
AB We propose a dynamic model to study the impact of the introduction of crack-cocaine among illicit drug users, considering the population divided into susceptible to drug use, crack-cocaine users, intravenous drug users, and users of both types of drugs. With respect to HIV infection status each one of these classes can, in turn, be susceptible to or infected with HIV or have already developed full-blown AIDS. Simulations were performed considering different transmission intensities for both parenterally and sexually transmitted HN in each class of drug use. Differential mortality rates for each class of drug use and of HIV infection status was also considered. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Sao Paulo, Sch Med, BR-01246903 Sao Paulo, Brazil.
RP Burattini, MN (corresponding author), Univ Sao Paulo, Sch Med, Av Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
EM mnburatt@usp.br
RI Lopes, Luis Felipe Dias/I-5809-2012; Azevedo, Raymundo S/B-7593-2008;
   Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011; Coutinho, Francisco A B/H-5644-2011
OI Lopes, Luis Felipe Dias/0000-0002-2438-0226; Azevedo, Raymundo
   S/0000-0003-0660-2371; Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A B/0000-0003-3127-3071
CR ANDERSON R M, 1991
   Blank-Reid C, 1996, J Neurosci Nurs, V28, P19
   Cornish JW, 1996, ANNU REV PUBL HEALTH, V17, P259
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   HUNTER GM, 1995, ADDICTION, V90, P1397, DOI 10.1046/j.1360-0443.1995.9010139711.x
   Kandel DB, 1996, ARCH GEN PSYCHIAT, V53, P71
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   MASSAD E, 1995, INT J EPIDEMIOL, V24, P842, DOI 10.1093/ije/24.4.842
   MASSAD E, 1989, MATH COMPUT MODEL, V12, P89, DOI 10.1016/0895-7177(89)90448-2
   Massad E, 1996, M D COMPUT, V13, P147
   *MIN HLTH BRAZ NAT, 1997, AIDS EP B YEAR 10
   *MMWR, 1996, MMWR-MORBID MORTAL W, V45, P151
   Mollison D, 1995, EPIDEMIC MODELS THEI
   Nappo SA, 1996, SUBST USE MISUSE, V31, P565, DOI 10.3109/10826089609045827
   *UNAIDS WHO WORK G, 1997, REP GLOB HIV AIDS EP
   Weissman G, 1995, J PSYCHOACTIVE DRUGS, V27, P401, DOI 10.1080/02791072.1995.10471704
NR 17
TC 11
Z9 11
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-7177
EI 1872-9479
J9 MATH COMPUT MODEL
JI Math. Comput. Model.
PD AUG
PY 1998
VL 28
IS 3
BP 21
EP 29
DI 10.1016/S0895-7177(98)00095-8
PG 9
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA 116GY
UT WOS:000075717200003
DA 2020-12-08
ER

PT J
AU Rozman, M
   Massad, E
   Silveira, ASB
   Azevedo-Neto, RS
   Takey, K
   Yamamoto, YI
   Strazza, L
   Meneghin, P
   Ferreira, MMC
   Carvalho, HB
   Buchalla, CM
   Schechtman, M
   Burattini, M
AF Rozman, M
   Massad, E
   Silveira, ASB
   Azevedo-Neto, RS
   Takey, K
   Yamamoto, YI
   Strazza, L
   Meneghin, P
   Ferreira, MMC
   Carvalho, HB
   Buchalla, CM
   Schechtman, M
   Burattini, M
TI HIV/AIDS in a Brazilian prison
SO INTERNATIONAL JOURNAL OF STD & AIDS
LA English
DT Letter
C1 Univ Sao Paulo, NUPAIDS, BR-01246903 Sao Paulo, Brazil.
RP Rozman, M (corresponding author), Univ Sao Paulo, NUPAIDS, Ave Doutor Arnaldo 455, BR-01246903 Sao Paulo, Brazil.
RI Buchalla, Cassia Maria/D-3169-2013; Azevedo, Raymundo S/B-7593-2008;
   Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011; Massad,
   Eduardo/B-1169-2012; Carvalho, Heraclito/C-1334-2012
OI Azevedo, Raymundo S/0000-0003-0660-2371; Burattini, Marcelo
   N/0000-0002-5407-6890; Massad, Eduardo/0000-0002-7200-2916; Carvalho,
   Heraclito/0000-0002-7037-5655; Buchalla, Cassia
   Maria/0000-0001-5169-5533
CR CARVALHO HB, 1996, 11 INT C AIDS, V2, P454
   Carvalho Heraclito Barbosa De, 1996, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, V12, P84
   LORENCO R, 1992, THESIS ESCOLA PAULIS
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MASSAD E, 1996, 11 INT C AIDS, V2, P461
   PEIXINHO ZF, 1990, NAT IMMUN CELL GROW, V9, P133
   ROZMAN MA, 1996, 7 INT C INF DIS, P12
NR 7
TC 7
Z9 9
U1 0
U2 3
PU ROYAL SOC MEDICINE PRESS LTD
PI LONDON
PA 1 WIMPOLE STREET, LONDON W1M 8AE, ENGLAND
SN 0956-4624
J9 INT J STD AIDS
JI Int. J. STD AIDS
PD MAR
PY 1998
VL 9
IS 3
BP 183
EP 184
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA YZ553
UT WOS:000072265600016
PM 9530910
DA 2020-12-08
ER

PT J
AU Buratti, M
AF Buratti, M
TI Small quasimultiple affine and projective planes: Some improved bounds
SO JOURNAL OF COMBINATORIAL DESIGNS
LA English
DT Article
DE quasimultiple affine and projective planes; regular and 1-rotational
   designs; ordinary and relative difference families
ID DESIGNS; ORDER
AB We improve the known bounds on r(n):= min{lambda\ an (n(2), n, lambda)-RBIBD exists} in the case where n + 1 is a prime power. In such a case r(n) is proved to be at most n + 1. If, in addition, n - 1 is the product of twin prime powers, then r(n) less than or equal to n/2. We also improve the known bounds on p(n): = min{lambda\ an (n(2) + n + 1, n + 1, lambda)-BIBD exists} in the case where n(2) + n + 1 is a prime power. In such a case p(n) is bounded at worst by [n+1/2] but better bounds could be obtained exploiting the multiplicative structure of GF(n(2) + n + 1). Finally, we present an unpublished construction by M. Greig giving a quasidouble affine plane of order n for every positive integer n such that n - 1 and n + 1 are prime powers. (C) 1998 John Wiley & Sons, Inc.
C1 Univ Aquila, Dipartimento Ingn Elettr, I-67040 Poggio Di Roio, Aq, Italy.
RI Burattini, Marcelo Nascimento/J-9272-2014; Coutinho, Francisco Antonio
   Bezerra/H-5644-2011
OI Burattini, Marcelo Nascimento/0000-0002-5407-6890; Lopez,
   Luis/0000-0003-4097-6887; Coutinho, Francisco Antonio
   Bezerra/0000-0003-3127-3071
CR ABEL RJR, 1994, J COMB THEORY A, V65, P252, DOI 10.1016/0097-3165(94)90023-X
   ABEL RJR, 1996, CRC DISCR MATH APPL, P270
   Beth T., 1993, DESIGN THEORY
   Buratti M., 1995, Designs, Codes and Cryptography, V5, P13, DOI 10.1007/BF01388501
   BURATTI M, PAIRWISE BALANCED DE
   BURATTI M, J COMBIN DESIGNS
   Colbourn C. J., 1996, Designs, Codes and Cryptography, V9, P61, DOI 10.1023/A:1027389907339
   Colbourn CJ, 1996, EUR J COMBIN, V17, P1, DOI 10.1006/eujc.1996.0001
   DILLON JF, 1995, FINITE FIELDS THEIR, V1, P232
   Greig M., 1990, C NUMER, V77, P121
   GREIG M, COMMUNICATION
   JUNGNICKEL D, 1990, DISCRETE MATH, V85, P177, DOI 10.1016/0012-365X(90)90020-I
   JUNGNICKEL D, 1995, J COMB DES, V3, P427
   LING A, MORE EXISTENCE SMALL
   MAVRON VC, 1984, J STAT PLAN INFER, V10, P59, DOI 10.1016/0378-3758(84)90032-6
   Shrikhande S.S., 1972, UTILITAS MATHEMATICA, V1, P191
   Stanton R. G., 1958, CAN J MATH, V10, P73
   VANLINT JH, 1993, J COMB THEORY A, V62, P252, DOI 10.1016/0097-3165(93)90047-C
   WERTHEIMER MA, 1991, J COMB THEORY A, V56, P166, DOI 10.1016/0097-3165(91)90029-G
   Wilson R.M., 1972, J NUMBER THEORY, V4, P17
NR 20
TC 41
Z9 41
U1 0
U2 2
PU JOHN WILEY & SONS INC
PI NEW YORK
PA 605 THIRD AVE, NEW YORK, NY 10158-0012 USA
SN 1063-8539
J9 J COMB DES
JI J. Comb Des.
PY 1998
VL 6
IS 5
BP 337
EP 345
DI 10.1002/(SICI)1520-6610(1998)6:5<337::AID-JCD3>3.3.CO;2-O
PG 9
WC Mathematics
SC Mathematics
GA 109NU
UT WOS:000075329600003
DA 2020-12-08
ER

PT J
AU deCarvalho, HB
   Mesquita, F
   Massad, E
   Bueno, RC
   Lopes, GT
   Ruiz, MA
   Burattini, MN
AF deCarvalho, HB
   Mesquita, F
   Massad, E
   Bueno, RC
   Lopes, GT
   Ruiz, MA
   Burattini, MN
TI HIV and infections of similar transmission patterns in a drug injectors
   community of Santos, Brazil
SO JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY
LA English
DT Article
DE HIV; HTLV (1 and 2); hepatitis B; hepatitis C; syphilis; injecting drug
   users; cocaine; Brazil
ID HEPATITIS-C VIRUS; BLOOD-DONORS; NON-A; ANTIBODIES
AB To study the prevalence of HIV and infections with related transmission patterns, we interviewed and obtained blood samples from 110 injecting drug users (IDUs), sampled by snowballing, from the city of Santos in the state of Sao Paulo, Brazil, where the estimated number of IDUs (10,000) comprises similar to 2% of the entire population. Seroprevalence of HIV, hepatitis B and C. syphilis, and HTLV (1 and 2) was assessed and compared with that in 197 blood donors from the same city, matched for age and gender. Risk behavior related to HIV was assessed by a standard questionnaire applied to the IDU sample. Univariate and multivariate analyses of the risk factors were performed. Seroprevalences found were 62% for HIV, 75% for HCV. 75% for HBV, 34% for syphilis, and 25% for HTLV (1 and 2) among IDUs, which compare with 0.0%, 2%, 23%, 12%, and 1% for blood donors, respectively. The risk for parenterally transmitted infections in this IDU community was higher than that for sexually transmitted infections (odds ratio for syphilis, 3.57; hepatitis B. 10.0: and hepatitis C, 100). The results of the multivariate risk analysis showed that daily rate of ID use >5 times/day (OR = 6.73), not changing behavior to avoid AIDS (OR = 3.28), ID use >15 days/month (OR = 2.72), and ID use in the last 2 months (OR = 2.23) were the risk behaviors significantly associated with HIV infection.
C1 UNIV SAO PAULO,NUPAIDS,BR-05508 SAO PAULO,BRAZIL.
   IEPAS,SANTOS,BRAZIL.
   SECRETARIA ESTADO SAUDE SAO PAULO,SAO PAULO,BRAZIL.
   ESCOLA PAULISTA MED,DISCIPLINA DOENCAS INFECC,SAO PAULO,BRAZIL.
RI Burattini, Marcelo N/J-9272-2014; Carvalho, Heraclito/C-1334-2012;
   Massad, Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Carvalho,
   Heraclito/0000-0002-7037-5655; Massad, Eduardo/0000-0002-7200-2916;
   Mesquita, Fabio/0000-0002-8297-0224
CR Andrade ALSS, 1989, REV SAUDE PUBL, V23, P20, DOI DOI 10.1590/S0034-89101989000100004
   BLOWER SM, 1994, SCIENCE, V265, P1451, DOI 10.1126/science.8073289
   CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562
   DAWSON GJ, 1991, J CLIN MICROBIOL, V29, P551, DOI 10.1128/JCM.29.3.551-556.1991
   DEAN AG, 1990, EPIINFO VERSION 5 WO
   Des Jarlais D. C., 1994, Scientific American, V270, P56
   Esteban JL, 1992, BLOOD SAFETY CURRENT, P45
   FOLLETT EAC, 1991, LANCET, V338, P1024, DOI 10.1016/0140-6736(91)91891-W
   HSU HH, 1991, GASTROENTEROLOGY, V101, P1724, DOI 10.1016/0016-5085(91)90413-F
   KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467
   LIMA ES, 1994, ADDICTION, V89, P689, DOI 10.1111/j.1360-0443.1994.tb00955.x
   LIMA VCP, 1992, 8 INT C AIDS AMST JU
   LONG S, 1990, GUARDIAN        0305
   LONGO MA, 1994, 6 INT C INF DIS PRAG, V1, P414
   Mann J, 1992, AIDS WORLD
   MASSAD E, 1994, MATH BIOSCI, V123, P227, DOI 10.1016/0025-5564(94)90013-2
   MESQUITA F, 1992, TEMPOS AIDS AIDS DRO
   *MIN HLTH BRAZ, 1994, EP B, V8
   Poshyachina V., 1993, Bulletin on Narcotics, V45, P77
   ROGGENDORF M, 1989, LANCET, V2, P324
   Sarkar S., 1993, Bulletin on Narcotics, V45, P91
   *SECR HLTH CIT SAN, 1984, EP B, V2
   *SECR HLTH CIT SAT, 1994, EP B, V14
   Stimson G. V., 1993, Bulletin on Narcotics, V45, P3
   Tramont EC, 1990, PRINCIPLES PRACTICE, P1794
   VANDERBORGHT BOM, 1993, VOX SANG, V65, P122, DOI 10.1111/j.1423-0410.1993.tb02128.x
   VAZ AJ, 1990, REV SAUDE PUBL, V24, P373, DOI 10.1590/S0034-89101990000500004
   *WHO, 1994, IN PRESS FIN REP WHO
   WILCOX RR, 1966, B WHO S, V35, P1
   1993, B NARCOTICS, V45, P19
NR 30
TC 54
Z9 62
U1 0
U2 5
PU LIPPINCOTT-RAVEN PUBL
PI PHILADELPHIA
PA 227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106
SN 1077-9450
J9 J ACQ IMMUN DEF SYND
JI J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.
PD MAY 1
PY 1996
VL 12
IS 1
BP 84
EP 92
DI 10.1097/00042560-199605010-00012
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA UK146
UT WOS:A1996UK14600012
PM 8624766
DA 2020-12-08
ER

PT J
AU MASSAD, E
   AZEVEDONETO, RS
   BURATTINI, MN
   ZANETTA, DMT
   COUTINHO, FAB
   YANG, HM
   MORAES, JC
   PANNUTI, CS
   SOUZA, VAUF
   SILVEIRA, ASB
   STRUCHINER, CJ
   OSELKA, GW
   CAMARGO, MCC
   OMOTO, TM
   PASSOS, SD
AF MASSAD, E
   AZEVEDONETO, RS
   BURATTINI, MN
   ZANETTA, DMT
   COUTINHO, FAB
   YANG, HM
   MORAES, JC
   PANNUTI, CS
   SOUZA, VAUF
   SILVEIRA, ASB
   STRUCHINER, CJ
   OSELKA, GW
   CAMARGO, MCC
   OMOTO, TM
   PASSOS, SD
TI ASSESSING THE EFFICACY OF A MIXED VACCINATION STRATEGY AGAINST RUBELLA
   IN SAO-PAULO, BRAZIL
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE RUBELLA; CRS; VACCINATION; SEROEPIDEMIOLOGY; CONTROL STRATEGIES
AB Background. In 1992 a major vaccination strategy against measles-mumps-rubella was introduced in the State of Sao Paulo, Brazil. This strategy was based on mathematical models and comprised a pulse vaccination covering all children aged 1-10 years, followed by the inclusion of this vaccine in the routine calendar at 15 months of age. The present work reports the evaluation of the efficacy of this mixed vaccination strategy.
   Methods. A rubella seroprevalence survey was carried out immediately and one year after the campaign, comprising 4953 children aged 1-15 years.
   Results. We show that average rubella seroprevalence increased from 0.40 to 0.97 and that the reported number of congenital rubella syndrome (CRS) cases dropped dramatically,
   Conclusions. The mixed vaccination strategy adopted against rubella has proved to be very effective in reducing the number of CRS cases in Sao Paulo.
C1 UNIV SAO PAULO,HCFM,BR-01246903 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,INST FIS,BR-01246903 SAO PAULO,BRAZIL.
   ESCOLA PAULISTA MED,BR-04023 SAO PAULO,BRAZIL.
   FAC CIENCIAS MED SANTA CASA,SAO PAULO,BRAZIL.
   SECRETARIA ESTADO SAUDE SAO PAULO,SAO PAULO,BRAZIL.
   FIOCRUZ MS,ESCOLA NACL SAUDE PUBL,RIO JANEIRO,BRAZIL.
RP MASSAD, E (corresponding author), UNIV SAO PAULO,FAC MED,AVE DOUTOR ARNALDO 455,BR-01246903 SAO PAULO,BRAZIL.
RI Azevedo, Raymundo S/B-7593-2008; Massad, Eduardo/B-1169-2012; Zanetta,
   Dirce M T/G-4950-2013; Pannuti, Claudio/B-7649-2012; Struchiner, Claudio
   J/M-9360-2013; Coutinho, Francisco A B/H-5644-2011; Yang, Hyun
   M/K-6873-2014; Burattini, Marcelo N/J-9272-2014; Passos, Saulo
   Duarte/C-5166-2012; Massad, Eduardo/H-6143-2011
OI Azevedo, Raymundo S/0000-0003-0660-2371; Massad,
   Eduardo/0000-0002-7200-2916; Struchiner, Claudio J/0000-0003-2114-847X;
   Coutinho, Francisco A B/0000-0003-3127-3071; Yang, Hyun
   M/0000-0002-1711-363X; Burattini, Marcelo N/0000-0002-5407-6890; Passos,
   Saulo Duarte/0000-0002-0908-2677; 
CR ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   BRUNET RC, 1993, MATH BIOSCI, V116, P111, DOI 10.1016/0025-5564(93)90063-G
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   FIELD PR, 1988, J CLIN MICROBIOL, V26, P990, DOI 10.1128/JCM.26.5.990-994.1988
   Francis T, 1955, AM J PUBLIC HEALTH N, V45, P1
   Greenwood M, 1915, Proc R Soc Med, V8, P113
   HALLORAN ME, 1994, STAT MED, V13, P357, DOI 10.1002/sim.4780130404
   HORSTMANN DM, 1989, VIRAL INFECTIONS HUM
   Kendrick P, 1939, AM J HYG, V29, P133, DOI 10.1093/oxfordjournals.aje.a118485
   KIRSH L, 1965, SURVEY SAMPLING
   LINDEGREN ML, 1991, EPIDEMIOL REV, V13, P341, DOI 10.1093/oxfordjournals.epirev.a036077
   Lwanga SK, 1991, SAMPLE SIZE DETERMIN
   MASSAD E, 1994, EPIDEMIOL INFECT, V112, P579, DOI 10.1017/S0950268800051281
   NETO RSD, 1994, EPIDEMIOL INFECT, V113, P161, DOI 10.1017/S095026880005158X
   PELISSERO C, 1993, EUR J EPIDEMIOL, V9, P322, DOI 10.1007/BF00146271
   Souza Vanda A. U. F., 1994, Revista do Instituto de Medicina Tropical de Sao Paulo, V36, P373, DOI 10.1590/S0036-46651994000400011
   SOUZA VAU, 1993, 29 P C BRAZ SOC TROP, P107
   SOUZA VAU, 1993, REV I MED TROPICAL S, V35, pS58
   WYLL SA, 1973, JAMA-J AM MED ASSOC, V225, P1472, DOI 10.1001/jama.225.12.1472
NR 19
TC 45
Z9 46
U1 0
U2 10
PU OXFORD UNIV PRESS UNITED KINGDOM
PI OXFORD
PA WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP
SN 0300-5771
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD AUG
PY 1995
VL 24
IS 4
BP 842
EP 850
DI 10.1093/ije/24.4.842
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA RQ192
UT WOS:A1995RQ19200025
PM 8550284
DA 2020-12-08
ER

PT B
AU Massad, E
   Neto, RSD
   Yang, HM
   Burattini, MN
   Coutinho, FAB
AF Massad, E
   Neto, RSD
   Yang, HM
   Burattini, MN
   Coutinho, FAB
BE Jean, RV
   Auger, PM
   Demongeot, J
TI Modelling age-dependent transmission rates for childhood infections
SO JOURNAL OF BIOLOGICAL SYSTEMS, VOL 3: SPECIAL ISSUE: 2ND ECMBM-LYON, PTS
   1-4
LA English
DT Proceedings Paper
CT 2nd European Conference on Mathematics Applied to Biology and Medicine
   (2nd ECMBM)
CY DEC 15-18, 1993
CL ECOLE NORMALE SUPERIEURE LYON, LYON, FRANCE
SP European Soc Math & Theoret Biol
HO ECOLE NORMALE SUPERIEURE LYON
DE epidemiology; rubella; age-dependent transmission; infections
C1 UNIV SAO PAULO, SCH MED, BR-01246903 SAO PAULO, BRAZIL.
RI Burattini, Marcelo N/J-9272-2014; Coutinho, Francisco A B/H-5644-2011;
   Azevedo, Raymundo S/B-7593-2008; Yang, Hyun M/K-6873-2014; Massad,
   Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Coutinho, Francisco A
   B/0000-0003-3127-3071; Azevedo, Raymundo S/0000-0003-0660-2371; Yang,
   Hyun M/0000-0002-1711-363X; Massad, Eduardo/0000-0002-7200-2916
NR 0
TC 0
Z9 0
U1 0
U2 3
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA PO BOX 128 FARRER RD, SINGAPORE 9128, SINGAPORE
PY 1995
BP 803
EP 812
PG 10
WC Biochemical Research Methods; Cell Biology; Mathematics, Applied;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Cell Biology; Mathematics;
   Pharmacology & Pharmacy
GA BF06V
UT WOS:A1995BF06V00072
DA 2020-12-08
ER

PT J
AU MASSAD, E
   COUTINHO, FAB
   YANG, HM
   DECARVALHO, HB
   MESQUITA, F
   BURATTINI, MN
AF MASSAD, E
   COUTINHO, FAB
   YANG, HM
   DECARVALHO, HB
   MESQUITA, F
   BURATTINI, MN
TI THE BASIC REPRODUCTION RATIO OF HIV AMONG INTRAVENOUS-DRUG-USERS
SO MATHEMATICAL BIOSCIENCES
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; PATHOGENESIS; NEEDLES; AIDS
AB A new approach for the estimation of the Basic Reproduction Ratio Ro for HIV among intravenous drug users (IVDU) is proposed. This approach is based in an adaptation of the models proposed by Ross and Macdonald for vector-borne infections. A straightforward adaptation of Macdonald's model is presented first: biological vectors are replaced by needles and syringes and we consider a homogeneous population of IVDUs; next we present a modified model where several heterogeneities are considered. Some of those heterogeneities are due to intrinsic differences between needles and syringes and biological vectors; others, such as those related to movements of individuals between communities, should apply to both biological vectors and injection apparatuses. An example of the calculations of R(0) for a real IVDUs community is presented.
C1 UNIV SAO PAULO, NUPAIDS, BR-01246903 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, SCH MED, SAO PAULO, BRAZIL.
   UNIV SAO PAULO, INST PHYS, BR-05508 SAO PAULO, BRAZIL.
RP MASSAD, E (corresponding author), UNIV SAO PAULO, SCH MED, LIM01HCFMUSP, AV DR ARNALDO 455, BR-01246903 SAO PAULO, BRAZIL.
RI Burattini, Marcelo N/J-9272-2014; Yang, Hyun M/K-6873-2014; Massad,
   Eduardo/B-1169-2012; Massad, Eduardo/H-6143-2011; Coutinho, Francisco A
   B/H-5644-2011; Carvalho, Heraclito/C-1334-2012
OI Burattini, Marcelo N/0000-0002-5407-6890; Yang, Hyun
   M/0000-0002-1711-363X; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071; Carvalho,
   Heraclito/0000-0002-7037-5655; Mesquita, Fabio/0000-0002-8297-0224
CR ANDERSON R M, 1991
   Anderson R.M., 1982, P67
   ANDERSON RM, 1992, SCI AM, V266, P58, DOI 10.1038/scientificamerican0592-58
   Bailey N. T. J., 1964, ELEMENTS STOCHASTIC
   BARATA LCB, 1990, REV SAUDE PUBL, V24, P321, DOI 10.1590/S0034-89101990000400011
   Brachman PS, 1990, PRINCIPLES PRACTICE, P155
   DOBKIN JF, 1990, PRINCIPLES PRACTICE, P2276
   DYE C, 1992, ANNU REV ENTOMOL, V37, P1, DOI 10.1146/annurev.en.37.010192.000245
   Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241
   HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401
   KAPLAN EH, 1989, REV INFECT DIS, V11, P289
   KAPLAN EH, 1993, INTERFACES, V23, P7, DOI 10.1287/inte.23.1.7
   KRASNOV ML, 1983, FUNCIONES VARIABLE C
   LAYNE SP, 1992, VIROLOGY, V189, P695, DOI 10.1016/0042-6822(92)90593-E
   LEVY JA, 1989, JAMA-J AM MED ASSOC, V261, P2997, DOI 10.1001/jama.261.20.2997
   LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037
   LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993
   LIFTON AR, 1992, AIDS ETHIOLOGY DIAGN, P111
   M.O.P.U. Direccion General de Puertos y Costas, 1991, TECHNICAL REPORT
   MACDONALD G, 1950, Trop Dis Bull, V47, P907
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Macdonald G., 1953, Tropical Diseases Bulletin, V50, P871
   MCKEGANY N, 1992, AIDS DRUGS SEXUAL RI
   Ross R, 1916, P R SOC LOND A-CONTA, V92, P204, DOI 10.1098/rspa.1916.0007
   Ross R, 1915, BRIT MED J, V1915, P546, DOI 10.1136/bmj.1.2830.546
   Ross R., 1911, PREVENTION MALARIA
   SYDEL R, 1988, EQUILIBRIUM CHAOS PR
   1983, TECHNICAL REPORT AID
NR 28
TC 34
Z9 35
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-5564
EI 1879-3134
J9 MATH BIOSCI
JI Math. Biosci.
PD OCT
PY 1994
VL 123
IS 2
BP 227
EP 247
DI 10.1016/0025-5564(94)90013-2
PG 21
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA PP586
UT WOS:A1994PP58600006
PM 7827421
DA 2020-12-08
ER

PT J
AU MASSAD, E
   BURATTINI, MN
   NETO, RSD
   YANG, HM
   COUTINHO, FAB
   ZANETTA, DMT
AF MASSAD, E
   BURATTINI, MN
   NETO, RSD
   YANG, HM
   COUTINHO, FAB
   ZANETTA, DMT
TI A MODEL-BASED DESIGN OF A VACCINATION STRATEGY AGAINST RUBELLA IN A
   NONIMMUNIZED COMMUNITY OF SAO-PAULO STATE, BRAZIL
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
ID MEASLES; INFECTION; PROGRAMS; RATES
AB A mixed vaccination strategy against rubella is proposed. We describe how the vaccination strategy was designed with the help of mathematical techniques. The strategy was designed for application in a non-immunized community of the State of Sao Paulo, Brazil, and was implemented by local health authorities in 1992. This strategy comprises a pulse vaccination campaign, covering the age interval between 1 and 10 years, followed by the introduction of the vaccine in the immunization calendar at 15 months of age. The expected impact of the proposed strategy is discussed.
C1 UNIV SAO PAULO, FAC MED, HOSP & CLIN, LIM-01, BR-01246903 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, INST PHYS, SAO PAULO, BRAZIL.
   ESCOLA PAULISTA MED, DISCIPLINE INFECT DIS, SAO PAULO, BRAZIL.
RP MASSAD, E (corresponding author), UNIV SAO PAULO, SCH MED, DISCIPLINE MED INFORMAT, SAO PAULO, BRAZIL.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/H-6143-2011; Azevedo,
   Raymundo S/B-7593-2008; Massad, Eduardo/B-1169-2012; Coutinho, Francisco
   A B/H-5644-2011; Zanetta, Dirce M T/G-4950-2013; Yang, Hyun
   Mo/K-6873-2014
OI Burattini, Marcelo N/0000-0002-5407-6890; Azevedo, Raymundo
   S/0000-0003-0660-2371; Massad, Eduardo/0000-0002-7200-2916; Coutinho,
   Francisco A B/0000-0003-3127-3071; Yang, Hyun Mo/0000-0002-1711-363X
CR Abramowitz M., 1970, HDB MATH FUNCTIONS
   ANDERSON R M, 1991
   Anderson R.M., 1982, POPULATION DYNAMICS, P1
   ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839
   ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X
   Bailey N.T.J., 1975, MATH THEORY INFECTIO
   COUTINHO FAB, 1993, IMA J MATH APPL MED, V10, P187
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859
   GRIFFEL DH, 1981, APPLIED FUNCTIONAL A
   Hethcote H. W., 1985, MATH COMPUTERS BIOME, P283
   HETHCOTE HW, 1988, MATH BIOSCI, V89, P29, DOI 10.1016/0025-5564(88)90111-3
   MASSAD E, 1990, MATH COMPUT MODEL, V13, P101, DOI 10.1016/0895-7177(90)90057-T
   Muench H, 1959, CATALYTIC MODELS EPI
   NETO RSA, 1993, UNPUB EPIDEMIOL INFE
   PANNUTI CS, 1991, B WORLD HEALTH ORGAN, V69, P557
   THACKER SB, 1991, AM J EPIDEMIOL, V133, P517, DOI 10.1093/oxfordjournals.aje.a115923
   1991, SNDIR003 MIN HLTH CT
NR 18
TC 52
Z9 52
U1 0
U2 9
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD JUN
PY 1994
VL 112
IS 3
BP 579
EP 594
DI 10.1017/S0950268800051281
PG 16
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NU193
UT WOS:A1994NU19300015
PM 8005224
OA Green Published
DA 2020-12-08
ER

PT J
AU COIMBRA, TLM
   NASSAR, ES
   BURATTINI, MN
   DESOUZA, LTM
   FERREIRA, IB
   ROCCO, IM
   DAROSA, APAT
   VASCONCELOS, PFC
   PINHEIRO, FP
   LEDUC, J
   RICOHESSE, R
   GONZALEZ, JP
   JAHRLING, PB
   TESH, RB
AF COIMBRA, TLM
   NASSAR, ES
   BURATTINI, MN
   DESOUZA, LTM
   FERREIRA, IB
   ROCCO, IM
   DAROSA, APAT
   VASCONCELOS, PFC
   PINHEIRO, FP
   LEDUC, J
   RICOHESSE, R
   GONZALEZ, JP
   JAHRLING, PB
   TESH, RB
TI NEW ARENAVIRUS ISOLATED IN BRAZIL
SO LANCET
LA English
DT Note
AB A new arenavirus, called Sabia, was isolated in Brazil from a fatal case of haemorrhagic fever initially thought to be yellow fever. Antigenic and molecular characterisation indicated that Sabia virus is a new member of the Tacaribe complex. A laboratory technician working with the agent was also infected and developed a prolonged, non-fatal influenza-like illness. Sabia virus is yet another arenavirus causing human disease in South America.
C1 YALE UNIV,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06520.
   ADOLFO LUTZ INST,VIRUS SERV,SAO PAULO,SP,BRAZIL.
   PAULISTA MED SCH,INFECT DIS CLIN,SAO PAULO,SP,BRAZIL.
   EVANDRO CHAGAS INST,DEPT ARBOVIRUS,BELEM,PARA,BRAZIL.
   PAN AMER HLTH ORG,COMMUNICABLE DIS PROGRAM,WASHINGTON,DC.
   WHO,MICROBIOL & IMMUNOL SUPPORT SECT,GENEVA,SWITZERLAND.
   USA,MED RES INST INFECT DIS,FREDERICK,MD.
RI Burattini, Marcelo N/J-9272-2014; Vasconcelos, Pedro/AAH-3142-2019;
   Gonzalez, J-P/C-3077-2013; Rico-Hesse, Rebeca/C-5294-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Gonzalez,
   J-P/0000-0003-3063-1770; Rico-Hesse, Rebeca/0000-0001-6216-1000
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [AI-10984, AI-01124, R01 AI042795-01,
   AI-33983] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI010984, R22AI010984,
   R37AI010984, R37AI010984, R37AI010984, R01AI010984, R37AI010984,
   R01AI042795, R01AI010984, R37AI010984, R01AI010984, R22AI010984,
   R37AI010984, R01AI010984, R37AI010984, R01AI010984, R37AI010984,
   R01AI010984, R01AI010984, R37AI010984] Funding Source: NIH RePORTER
CR BUCHMEIER MJ, 1991, CLASSIFICATION NOMEN, P284
   Childs J, 1993, ARENAVIRIDAE, P331, DOI DOI 10.1007/978-1-4615-3028-2_19
   CLEGG JCS, 1993, ARENAVIRIDAE, P175
   Fisher-Hoch S. P, 1993, ARENAVIRIDAE, P299
   JOHNSONKM, 1989, VIRAL INFECTIONS HUM, P133
   RICOHESSE R, 1987, VIROLOGY, V160, P311, DOI 10.1016/0042-6822(87)90001-8
   SALAS R, 1991, LANCET, V338, P1033, DOI 10.1016/0140-6736(91)91899-6
   VASCONCELOS PFC, IN PRESS REV I MED T
   WALKER DH, 1987, CURR TOP MICROBIOL, V133, P89
NR 9
TC 101
Z9 107
U1 0
U2 5
PU LANCET LTD
PI LONDON
PA 42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL
SN 0140-6736
J9 LANCET
JI Lancet
PD FEB 12
PY 1994
VL 343
IS 8894
BP 391
EP 392
DI 10.1016/S0140-6736(94)91226-2
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA MW283
UT WOS:A1994MW28300012
PM 7905555
OA Green Accepted
DA 2020-12-08
ER

PT J
AU BURATTINI, MN
   MASSAD, E
   COUTINHO, FAB
AF BURATTINI, MN
   MASSAD, E
   COUTINHO, FAB
TI MALARIA TRANSMISSION RATES ESTIMATED FROM SEROLOGICAL DATA
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
AB A mathematical model was used to estimate malaria transmission rates based on serological data. The model is minimally stochastic and assumes an age-dependent force of infection for malaria. The transmission rates estimated were applied to a simple compartmental model in order to mimic the malaria transmission.
   The model has shown a good retrieving capacity for serological and parasite prevalence data.
C1 HCFMUSP, SAO PAULO, BRAZIL.
   ESCOLA PAULISTA MED, BR-04023 SAO PAULO, BRAZIL.
   UNIV SAO PAULO, INST PHYS, BR-01498 SAO PAULO, BRAZIL.
RP BURATTINI, MN (corresponding author), UNIV SAO PAULO, SCH MED, AV DR ARNALDO 455, CEP 01246-903, SAO PAULO, BRAZIL.
RI Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Coutinho,
   Francisco A B/H-5644-2011; Massad, Eduardo/H-6143-2011
OI Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; 
CR Arfken G, 1970, MATH METHODS PHYSICI
   Aron J.L., 1982, P139
   ARON JL, 1988, MATH BIOSCI, V90, P385, DOI 10.1016/0025-5564(88)90076-4
   Bailey N.T.J., 1975, MATH THEORY INFECTIO
   Bruce-Chwatt L.J., 1985, ESSENTIAL MALARIOLOG
   BRUCECHWATT LJ, 1973, LANCET, V2, P547
   BURATTINI MN, 1993, EPIDEMIOL INFECT, V111, P525, DOI 10.1017/S0950268800057253
   BURATTINI MN, 1987, THESIS SAO PAULO
   BURATTINI MN, 1989, THESIS SAO PAULO
   BURATTINI MN, 1986, REV SOC BRAS MED T S, V19, P88
   BURATTINI MN, 1988, P INT C INFECTIOUS D, P153
   CARNEVALE P, 1978, B WORLD HEALTH ORGAN, V56, P147
   CLYDE DF, 1958, AM J TROP MED HYG, V7, P543, DOI 10.4269/ajtmh.1958.7.543
   COLLINS WE, 1968, AM J EPIDEMIOL, V87, P592, DOI 10.1093/oxfordjournals.aje.a120849
   Dietz K., 1988, P1091
   DIETZ K, 1974, B WORLD HEALTH ORGAN, V50, P347
   DRAGNA A, 1969, B WORLD HEALTH ORGAN, V40, P753
   DRAPER CC, 1972, AM J TROP MED HYG, V21, P696, DOI 10.4269/ajtmh.1972.21.696
   DYE C, 1986, T ROY SOC TROP MED H, V80, P69, DOI 10.1016/0035-9203(86)90199-9
   FEYNMAN RP, 1965, QUANTUM MECHANICS PA
   Garrett-Jones C., 1964, Bulletin of the World Health Organization, V30, P241
   LUBY JP, 1967, AM J TROP MED HYG, V16, P255, DOI 10.4269/ajtmh.1967.16.255
   MACDONALD G, 1950, Trop Dis Bull, V47, P907
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Macdonald G., 1953, Tropical Diseases Bulletin, V50, P871
   MERLIN M, 1986, B SOC PATHOL EXOT, V79, P707
   MEUWISSEN JHET, 1978, ISRAEL J MED SCI, V14, P687
   Molineaux L., 1988, P913
   MOLINEAUX L, 1985, T ROY SOC TROP MED H, V79, P743, DOI 10.1016/0035-9203(85)90107-5
   Molineaux L, 1980, THE GARKI PROJECT
   Morse P.M., 1953, METHODS THEORETICAL, V1
   MUIRHEADTHOMSON RC, 1951, BRIT MED J, V1, P1114, DOI 10.1136/bmj.1.4715.1114
   NEDELMAN J, 1985, MATH BIOSCI, V73, P159, DOI 10.1016/0025-5564(85)90010-0
   PAPOULIS A, 1981, PROBABILITY RANDOM V
   Ross R, 1917, P R SOC LOND A-CONTA, V93, P225, DOI 10.1098/rspa.1917.0015
   Ross R, 1916, P R SOC LOND A-CONTA, V92, P204, DOI 10.1098/rspa.1916.0007
   Ross R, 1915, BRIT MED J, V1915, P546, DOI 10.1136/bmj.1.2830.546
   Ross R., 1911, PREVENTION MALARIA
   VANDRUTEN JAM, 1981, THESIS KATHOLIEK U N
   1988, TDRIMMALFIELDMALSWG2
NR 40
TC 13
Z9 14
U1 0
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0950-2688
EI 1469-4409
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 1993
VL 111
IS 3
BP 503
EP 523
DI 10.1017/S0950268800057241
PG 21
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MQ156
UT WOS:A1993MQ15600011
PM 8270011
OA Green Published
DA 2020-12-08
ER

PT J
AU BURATTINI, MN
   MASSAD, E
   COUTINHO, FAB
   BARUZZI, RG
AF BURATTINI, MN
   MASSAD, E
   COUTINHO, FAB
   BARUZZI, RG
TI MALARIA PREVALENCE AMONGST BRAZILIAN INDIANS ASSESSED BY A NEW
   MATHEMATICAL-MODEL
SO EPIDEMIOLOGY AND INFECTION
LA English
DT Article
AB An alternative way to estimate the endemic level of malaria amongst Brazilian indians is proposed. This is achieved by estimating the age-related 'force of infection' of malaria (the effective inoculation rate), applying a mathematical model, described elsewhere, to serological data. In addition we present a way to estimate the Basic Reproductive Rate of malaria in the same area. The results have shown a good degree of accuracy in describing the endemic pattern of malaria in the area, and also indicate some relevant aspects of its age distribution related to the design of control strategies.
C1 ESCOLA PAULISTA MED,BR-04023 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,INST PHYS,SAO PAULO,BRAZIL.
   ESCOLA PAULISTA MED,DEPT PREVENT MED,BR-04023 SAO PAULO,BRAZIL.
RP BURATTINI, MN (corresponding author), UNIV SAO PAULO,SCH MED,SAO PAULO,BRAZIL.
RI Massad, Eduardo/B-1169-2012; Coutinho, Francisco A B/H-5644-2011;
   Massad, Eduardo/H-6143-2011; Burattini, Marcelo N/J-9272-2014
OI Massad, Eduardo/0000-0002-7200-2916; Coutinho, Francisco A
   B/0000-0003-3127-3071; Burattini, Marcelo N/0000-0002-5407-6890
CR Bruce-Chwatt L.J., 1985, ESSENTIAL MALARIOLOG
   BRUCECHA.LJ, 1969, T ROY SOC TROP MED H, V63, P131, DOI 10.1016/0035-9203(69)90100-X
   BURATTINI MN, 1993, EPIDEMIOL INFECT, V111, P503, DOI 10.1017/S0950268800057241
   BURATTINI MN, 1987, THESIS SAO PAULO
   BURATTINI MN, 1989, THESIS SAO PAULO
   BURATTINI MN, 1986, REV SOC BRAS MED T S, V19, P88
   BURATTINI MN, 1988, P INT C INFECTIOUS D, P153
   Dietz K., 1988, P1091
   DRAPER CC, 1972, AM J TROP MED HYG, V21, P696, DOI 10.4269/ajtmh.1972.21.696
   GUTHE T, 1964, B WORLD HEALTH ORGAN, V31, P87
   MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743
   Macdonald G., 1952, Tropical Diseases Bulletin, V49, P569
   MACDONALD G, 1952, Trop Dis Bull, V49, P813
   Macdonald G., 1953, Tropical Diseases Bulletin, V50, P871
   MACDONALD G, 1955, P ROY SOC MED, V48, P295, DOI 10.1177/003591575504800409
   Macdonald G., 1957, EPIDEMIOLOGY CONTROL
   MEETSELAAR D, 1959, TROP GEOGR MED, V11, P157
   Molineaux L., 1988, P999
   MOLINEAUX L, 1988, MALARIA PRINCIPLES P, P913
   MUENCH H, 1959, CATALYTIC MODELS CPI
   PAPOULIS A, 1981, PROBABILITY RANDOM V
   Picq J.J., 1982, Medecine Tropicale, V42, P365
   ROSS R, 1928, STUDIES MALARIA
   Ross R., 1911, PREVENTION MALARIA
   SULZER AJ, 1969, AM J TROP MED HYG, V18, P199, DOI 10.4269/ajtmh.1969.18.199
   TURNER PR, 1989, NUMERICAL ANAL
   VANDRUTEN JAM, 1981, THESIS KATHOLIEK U
   WERNSDORFER WH, 1988, MALARIA PRINCPILES P
   1979, 17640 ORG MUND SAL I
   1974, 16549 ORG MUND SAL I
   1951, WHOMAL38 COMM EXP MA
NR 31
TC 6
Z9 6
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 40 WEST 20TH STREET, NEW YORK, NY 10011-4211
SN 0950-2688
J9 EPIDEMIOL INFECT
JI Epidemiol. Infect.
PD DEC
PY 1993
VL 111
IS 3
BP 525
EP 537
DI 10.1017/S0950268800057253
PG 13
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA MQ156
UT WOS:A1993MQ15600012
PM 8270012
OA Green Published
DA 2020-12-08
ER

PT J
AU SADER, HS
   PIGNATARI, AC
   LEME, IL
   BURATTINI, MN
   TANCRESI, R
   HOLLIS, RJ
   JONES, RN
AF SADER, HS
   PIGNATARI, AC
   LEME, IL
   BURATTINI, MN
   TANCRESI, R
   HOLLIS, RJ
   JONES, RN
TI EPIDEMIOLOGIC TYPING OF MULTIPLY DRUG-RESISTANT PSEUDOMONAS-AERUGINOSA
   ISOLATED FROM AN OUTBREAK IN AN INTENSIVE-CARE UNIT
SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
LA English
DT Article
ID NOSOCOMIAL PNEUMONIA; CROSS-RESISTANCE; CYSTIC-FIBROSIS; CIPROFLOXACIN;
   IMIPENEM; THERAPY; STRAINS; COLONIZATION; FIELD
AB From June to August 1991, there was an outbreak of Pseudomonas aeruginosa infections in an intensive care unit in a general hospital in Sao Paulo, Brazil. We obtained 14 isolates from 14 patients, 11 from tracheal aspirate, and 3 from surgical wound exudates. These strains were typed by serotyping, pyocin typing, and pulsed-field electrophoresis (CHEF) of chromosomal DNA (chrDNA), and the different typing methods were analyzed, These three methods demonstrated seven identical strains. We also performed an extensive antibiogram (33 drugs) in all 14 isolates. The incidence of resistance to aminoglycosides, extended-spectrum beta-lactams, and quinolones was very high among the seven identical isolates; however, the antibiogram profile differed significantly among the isolates. Our results suggest that a unique strain caused several cross-transmitted infections during this period of time, and the emergence of antimicrobial resistance has been occurring before and after the establishment of the epidemic strain by selective drug use. The chrDNA fingerprinting proved to be versatile and precise for epidemiologic investigations of P. aeruginosa infections.
C1 PAULIST SCH MED,DEPT INFECT DIS,SAO PAULO,BRAZIL.
   NINTH JULY HOSP,FOCO INFECT DIS CTR,SAO PAULO,BRAZIL.
RP SADER, HS (corresponding author), UNIV IOWA,COLL MED,COLL MED,DEPT PATHOL,273 MRC,IOWA CITY,IA 52242, USA.
RI Pignatari, Antonio CC/C-8427-2012; Burattini, Marcelo N/J-9272-2014
OI Burattini, Marcelo N/0000-0002-5407-6890; Pignatari,
   Antonio/0000-0002-2146-8476
CR ALLARDETSERVENT A, 1989, J CLIN MICROBIOL, V27, P2957
   BAYER AS, 1988, ANTIMICROB AGENTS CH, V32, P231, DOI 10.1128/AAC.32.2.231
   BOUKADIDA J, 1991, J CLIN MICROBIOL, V29, P2068, DOI 10.1128/JCM.29.9.2068-2071.1991
   CARLE GF, 1986, SCIENCE, V232, P65, DOI 10.1126/science.3952500
   CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318
   CHOW AW, 1989, ANTIMICROB AGENTS CH, V33, P1368, DOI 10.1128/AAC.33.8.1368
   GROTHUES D, 1988, J CLIN MICROBIOL, V26, P1973, DOI 10.1128/JCM.26.10.1973-1977.1988
   JACOBY GA, 1990, ANTIMICROB AGENTS CH, V34, P2381, DOI 10.1128/AAC.34.12.2381
   JONES LF, 1974, APPL MICROBIOL, V27, P400, DOI 10.1128/AEM.27.2.400-406.1974
   JONES RN, 1992, DIAGN MICR INFEC DIS, V15, P73, DOI 10.1016/0732-8893(92)90059-3
   JONES RN, 1992, DIAGN MICR INFEC DIS, V15, pS3
   LEVINE SA, 1991, CLIN CHEST MED, V12, P523
   MORRISON AJ, 1984, REV INFECT DIS S3, V6, P627
   OGLE JW, 1988, J INFECT DIS, V157, P743, DOI 10.1093/infdis/157.4.743
   PITT TL, 1986, J MED MICROBIOL, V21, P179, DOI 10.1099/00222615-21-2-179
   PITT TL, 1988, EUR J CLIN MICROBIOL, V7, P238, DOI 10.1007/BF01963095
   PLESIAT P, 1988, EUR J CLIN MICROBIOL, V7, P261, DOI 10.1007/BF01963098
   RADBERG G, 1990, ANTIMICROB AGENTS CH, V34, P2142, DOI 10.1128/AAC.34.11.2142
   SABATH LD, 1984, REV INFECT DIS S3, V6, P643
   STRATTON CW, 1987, J ANTIMICROB CHEMOTH, V19, P413, DOI 10.1093/jac/19.4.413
   VURMARAPP U, 1990, EUR J CLIN MICROBIOL, V9, P580, DOI 10.1007/BF01967212
   1986, MMWR, V35
   1990, APPROVED STANDARD M7
NR 23
TC 37
Z9 39
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010
SN 0732-8893
J9 DIAGN MICR INFEC DIS
JI Diagn. Microbiol. Infect. Dis.
PD JUL
PY 1993
VL 17
IS 1
BP 13
EP 18
DI 10.1016/0732-8893(93)90063-D
PG 6
WC Infectious Diseases; Microbiology
SC Infectious Diseases; Microbiology
GA LK269
UT WOS:A1993LK26900003
PM 8359000
DA 2020-12-08
ER

PT J
AU MASSAD, E
   BURATTINI, MN
   COUTINHO, FAB
   YANG, HM
   RAIMUNDO, SM
AF MASSAD, E
   BURATTINI, MN
   COUTINHO, FAB
   YANG, HM
   RAIMUNDO, SM
TI MODELING THE INTERACTION BETWEEN AIDS AND TUBERCULOSIS
SO MATHEMATICAL AND COMPUTER MODELLING
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS-INFECTION; HIV INFECTION; EPIDEMIOLOGY;
   POPULATION; INCUBATION; DISEASES; PERIODS; IMPACT
AB A deterministic model is proposed for the study of the dynamics of acquired immunodeficiency syndrome (AIDS) and tuberculosis (TB) co-infection. The model is comprised by a set of sixteen ordinary differential equations representing different states of both diseases, and it is intended to provide a theoretical framework for the study of the interaction between both infections. Numerical simulations of the model resulted in three striking outcomes: first, the pathogenicity of Human Immunodeficiency Virus (HIV) is enhanced by the presence of TB, and vice-versa; second, the prevalence of AIDS is higher in the presence of TB; and third, relative risk analysis demonstrated a much stronger influence of AIDS on TB than the other way around.
C1 ESCOLA PAULISTA MED,BR-04023 SAO PAULO,BRAZIL.
   UNIV SAO PAULO,INST PHYS,SAO PAULO,BRAZIL.
   HCFMUSP,BR-01246 SAO PAULO,BRAZIL.
RP MASSAD, E (corresponding author), UNIV SAO PAULO,SCH MED,BR-01246 SAO PAULO,BRAZIL.
RI Coutinho, Francisco A B/H-5644-2011; Raimundo, Silvia
   Martorano/D-4624-2012; Yang, Hyun M/K-6873-2014; Massad,
   Eduardo/H-6143-2011; Massad, Eduardo/B-1169-2012; Burattini, Marcelo
   N/J-9272-2014
OI Coutinho, Francisco A B/0000-0003-3127-3071; Raimundo, Silvia
   Martorano/0000-0002-9960-7341; Yang, Hyun M/0000-0002-1711-363X; Massad,
   Eduardo/0000-0002-7200-2916; Burattini, Marcelo N/0000-0002-5407-6890
CR ANDERSON RM, 1988, J ROY STAT SOC A STA, V151, P66, DOI 10.2307/2982185
   ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   ANDERSON RM, 1991, NATURE, V352, P581, DOI 10.1038/352581a0
   AZUMA Y, 1975, B WORLD HEALTH ORGAN, V52, P313
   BAILEY NTJ, 1982, BIOMATHEMATICS MALAR, P178
   BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307
   BLACK S, 1989, 5TH AIDS INT C MONTR
   BLYTHE SP, 1988, IMA J MATH APPL MED, V5, P1
   CHAISSON RE, 1989, J INFECT DIS, V159, P96, DOI 10.1093/infdis/159.1.96
   FITZGERALD JM, 1991, CHEST, V100, P191, DOI 10.1378/chest.100.1.191
   KAULT DA, 1991, MATH BIOSCI, V103, P17, DOI 10.1016/0025-5564(91)90088-Z
   KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P140
   MASSAD E, 1989, MATH COMPUT MODEL, V12, P89, DOI 10.1016/0895-7177(89)90448-2
   MAY RM, 1974, STABILITY COMPLEXITY, P19
   MORGENSTERN H, 1980, INT J EPIDEMIOL, V9, P97, DOI 10.1093/ije/9.1.97
   PEPIN J, 1989, AIDS, V3, P3, DOI 10.1097/00002030-198903010-00002
   PILZ L, 1988, METHOD INFORM MED, V27, P153
   PRESS WH, 1989, NUMERICAL RECIPES AR, P254
   REVELLE CS, 1967, AM REV RESPIR DIS, V96, P893
   RIEDER HL, 1989, ARCH INTERN MED, V149, P1268, DOI 10.1001/archinte.149.6.1268
   RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046
   RIEDER HL, 1989, JAMA-J AM MED ASSOC, V268, P3385
   SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901
   SMITH PG, 1988, INT J EPIDEMIOL, V17, P705, DOI 10.1093/ije/17.4.705
   STYBLO K, 1989, REV INFECT DIS, V11, pS339
   SUNDERAM G, 1986, JAMA-J AM MED ASSOC, V256, P362, DOI 10.1001/jama.256.3.362
   THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8
   WAALER HANS, 1962, AMER JOUR PUBL HEALTH, V52, P1002, DOI 10.2105/AJPH.52.6.1002
   WAALER HT, 1969, B WORLD HEALTH ORGAN, V41, P75
   WAALER HT, 1968, AM REV RESPIR DIS, V98, P591
   1989, 1988 TECHN ADV M AID
   1987, MMWR S15, V36, P35
   1991, MMWR, V39, P944
   1989, WHOGPAINF894
   1985, 1984 TUBERCULOSIS ST, P85
   1990, MMWR, V39, P153
NR 36
TC 11
Z9 11
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB
SN 0895-7177
J9 MATH COMPUT MODEL
JI Math. Comput. Model.
PD MAY
PY 1993
VL 17
IS 9
BP 7
EP 21
DI 10.1016/0895-7177(93)90013-O
PG 15
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
SC Computer Science; Mathematics
GA LL848
UT WOS:A1993LL84800002
OA Green Published
DA 2020-12-08
ER

PT J
AU COUTINHO, FAB
   MASSAD, E
   BURATTINI, MN
   YANG, HM
   NETO, RSD
AF COUTINHO, FAB
   MASSAD, E
   BURATTINI, MN
   YANG, HM
   NETO, RSD
TI EFFECTS OF VACCINATION PROGRAMS ON TRANSMISSION RATES OF INFECTIONS AND
   RELATED THRESHOLD CONDITIONS FOR CONTROL
SO IMA JOURNAL OF MATHEMATICS APPLIED IN MEDICINE AND BIOLOGY
LA English
DT Article
DE EPIDEMIOLOGY; CHILDHOOD INFECTIONS; VACCINATION; THRESHOLD THEOREMS;
   CONTRACTION MAPPING THEOREM; FUNCTIONAL ANALYSIS
ID ZAGREB MEASLES-VACCINE; EDMONSTON-ZAGREB; RUBELLA; MODEL; IMMUNIZATION;
   STRATEGIES; AGES
AB This study addresses the problem of the existence of conditions for persistence or eradication of age-dependent directly transmitted infections. The usual system of differential equations describing the dynamics of the disease is transformed into integral equations. The authors show how to solve these equations and, by applying the contraction mapping theorem, give conditions for the persistence or eradication of the infection. A practical illustration of the application of the methods proposed is sketched, using data for rubella collected from a small Brazilian community.
C1 UNIV SAO PAULO, SCH MED, DISCIPLINE MED INFORMAT, BR-01246 SAO PAULO, BRAZIL.
RI Coutinho, Francisco A B/H-5644-2011; Azevedo, Raymundo S/B-7593-2008;
   Burattini, Marcelo N/J-9272-2014; Massad, Eduardo/B-1169-2012; Massad,
   Eduardo/H-6143-2011
OI Coutinho, Francisco A B/0000-0003-3127-3071; Azevedo, Raymundo
   S/0000-0003-0660-2371; Burattini, Marcelo N/0000-0002-5407-6890; Massad,
   Eduardo/0000-0002-7200-2916; 
CR AABY P, 1988, LANCET, V2, P809
   Abramowitz M., 1970, HDB MATH FUNCTIONS
   ANDERSON R M, 1991
   Anderson R.M., 1982, POPULATION DYNAMICS, P1
   ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X
   ANDERSON RM, 1982, SCIENCE, V215, P1053, DOI 10.1126/science.7063839
   ANDERSON RM, 1985, J HYG-CAMBRIDGE, V94, P365, DOI 10.1017/S002217240006160X
   AZEVEDO RSN, 1992, THESIS U SAO PAULO
   Bailey N.T.J., 1975, MATH THEORY INFECTIO
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859
   GRIFFEL DH, 1981, APPLIED FUNCTIONAL A
   Hethcote H. W., 1985, MATH COMPUTERS BIOME, P283
   HETHCOTE HW, 1988, MATH BIOSCI, V89, P29, DOI 10.1016/0025-5564(88)90111-3
   HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511
   INABA H, 1990, J MATH BIOL, V28, P411
   KATZMANN W, 1984, THEOR POPUL BIOL, V25, P125, DOI 10.1016/0040-5809(84)90016-9
   Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118
   KNOX EG, 1980, INT J EPIDEMIOL, V9, P13, DOI 10.1093/ije/9.1.13
   MARKOWITZ LE, 1987, PEDIATR INFECT DIS J, V6, P809, DOI 10.1097/00006454-198709000-00001
   MASSAD E, 1990, MATH COMPUT MODEL, V13, P101, DOI 10.1016/0895-7177(90)90057-T
   MCLEAN AR, 1985, LECTURE NOTES BIOMAT, V65
   Muench H, 1959, CATALYTIC MODELS EPI
   NOKES DJ, 1990, INT J EPIDEMIOL, V19, P703, DOI 10.1093/ije/19.3.703
   TIDJANI O, 1989, LANCET, V2, P1357
   VLADIMIROV VS, 1971, EQUATIONS MATH PHYSI
   WALTMAN P, 1974, LECTURE NOTES BIOMAT, V1
   WHITTLE H, 1988, LANCET, V2, P811
NR 28
TC 24
Z9 24
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0265-0746
J9 IMA J MATH APPL MED
JI IMA J. Math. Appl. Med. Biol.
PY 1993
VL 10
IS 3
BP 187
EP 206
PG 20
WC Mathematics, Interdisciplinary Applications
SC Mathematics
GA MG610
UT WOS:A1993MG61000004
PM 8263359
DA 2020-12-08
ER

PT J
AU VITARELLI, A
   DADDIO, AP
   GENTILE, R
   BURATTINI, M
AF VITARELLI, A
   DADDIO, AP
   GENTILE, R
   BURATTINI, M
TI ECHOCARDIOGRAPHIC EVALUATION OF LEFT-VENTRICULAR OUTFLOW TRACT
   OBSTRUCTION IN COMPLETE TRANSPOSITION OF THE GREAT-ARTERIES
SO AMERICAN HEART JOURNAL
LA English
DT Article
C1 UNIV ROME,SCH MED,DEPT PEDIAT,I-00198 ROME,ITALY.
   UNIV ROME,SCH MED,DEPT MED,I-00198 ROME,ITALY.
RP VITARELLI, A (corresponding author), UNIV ROME,SCH MED,DEPT CARDIOL,I-00198 ROME,ITALY.
CR AZIZ KU, 1977, AM J CARDIOL, V40, P775, DOI 10.1016/0002-9149(77)90196-5
   AZIZ KU, 1979, AM J CARDIOL, V44, P290, DOI 10.1016/0002-9149(79)90319-9
   AZIZ KU, 1976, AM J CARDIOL, V38, P452, DOI 10.1016/0002-9149(76)90462-8
   AZIZ KU, 1978, AM J CARDIOL, V41, P543, DOI 10.1016/0002-9149(78)90013-9
   BIERMAN FZ, 1979, CIRCULATION, V60, P1496, DOI 10.1161/01.CIR.60.7.1496
   CRUPI G, 1979, J THORAC CARDIOV SUR, V78, P730
   EDWARDS JE, 1965, CIRCULATION, V31, P586, DOI 10.1161/01.CIR.31.4.586
   GARDIN JM, 1981, CIRCULATION, V63, P181, DOI 10.1161/01.CIR.63.1.181
   HATLE L, 1981, CIRCULATION, V64, P381, DOI 10.1161/01.CIR.64.2.381
   IDRISS FS, 1977, J THORAC CARDIOV SUR, V74, P343
   JATENE AD, 1982, J THORAC CARDIOV SUR, V83, P20
   JOHNSON GL, 1982, AM J CARDIOL, V49, P1984, DOI 10.1016/0002-9149(82)90219-3
   KEITH JD, 1978, HEART DISEASE INFANC, P593
   LUNDSTROM NR, 1978, ECHOCARDIOGRAPHY CON, P280
   NANDA NC, 1975, CIRCULATION, V51, P515, DOI 10.1161/01.CIR.51.3.515
   PARK SC, 1978, CIRCULATION, V57, P291, DOI 10.1161/01.CIR.57.2.291
   QUEROJIMENEZ M, 1974, CHEST, V66, P411
   RASTELLI GC, 1969, MAYO CLIN PROC, V44, P1
   RIEMENSCHNEIDER TA, 1969, CIRCULATION, V39, P603, DOI 10.1161/01.CIR.39.5.603
   SANSA M, 1979, AM J CARDIOL, V44, P88, DOI 10.1016/0002-9149(79)90255-8
   SEWARD JB, 1976, CIRCULATION, V54, P161, DOI 10.1161/circ.54.1.1277422
   SEWARD JB, 1980, PEDIATRIC ECHOCARDIO, P19
   SHAHER RM, 1967, AM J CARDIOL, V19, P658, DOI 10.1016/0002-9149(67)90470-5
   SHRIVASTAVA S, 1976, CIRCULATION, V54, P154, DOI 10.1161/01.CIR.54.1.154
   Silove E D, 1973, Pediatr Radiol, V1, P87, DOI 10.1007/BF00973220
   SINGH AK, 1976, BRIT HEART J, V38, P1213
   TONKIN IL, 1980, RADIOLOGY, V134, P53, DOI 10.1148/radiology.134.1.7188646
   VANGILS FAW, 1978, BRIT HEART J, V40, P494
   VIDNE BA, 1976, CIRCULATION, V53, P157, DOI 10.1161/01.CIR.53.1.157
   VITARELLI A, 1978, Giornale Italiano di Cardiologia, V8, P292
NR 30
TC 3
Z9 3
U1 0
U2 0
PU MOSBY-YEAR BOOK INC
PI ST LOUIS
PA 11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PY 1984
VL 108
IS 3
BP 531
EP 538
DI 10.1016/0002-8703(84)90419-8
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA TJ437
UT WOS:A1984TJ43700016
PM 6540977
DA 2020-12-08
ER

EF